assay_id,tissue_id,assay_cell_type,assay_tissue,assay_organism,src_assay_id,assay_type,assay_subcellular_fraction,cell_id,relationship_type,doc_id,bao_format,chembl_id,tid,assay_category,curated_by,description,assay_test_type,assay_tax_id
1,,,,,,B,,,H,11087,BAO_0000019,CHEMBL615117,12052,,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,
2,,,,,,F,,,U,684,BAO_0000219,CHEMBL615118,22226,,Autocuration,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,
3,,,,,,B,,,U,15453,BAO_0000019,CHEMBL615119,22226,,Autocuration,,,
4,,,,Bos taurus,,B,,,H,17841,BAO_0000249,CHEMBL615120,104729,,Autocuration,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,9913.0
5,,143B,,Homo sapiens,,F,,163.0,N,17430,BAO_0000219,CHEMBL615121,80001,,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,9606.0
6,,143B,,Homo sapiens,,F,,163.0,N,17430,BAO_0000219,CHEMBL615122,80001,,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,9606.0
7,,143B,,Mus musculus,,F,,163.0,N,13799,BAO_0000219,CHEMBL615123,80001,,Intermediate,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,10090.0
8,,143B,,Homo sapiens,,F,,163.0,N,17774,BAO_0000219,CHEMBL615124,80001,,Expert,In vitro cell cytotoxicity was determined against 143B cell line,,9606.0
9,,143B,,Homo sapiens,,F,,163.0,N,3801,BAO_0000219,CHEMBL615125,80001,,Intermediate,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,9606.0
10,,143B,,Homo sapiens,,F,,163.0,N,17430,BAO_0000219,CHEMBL615126,80001,,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,9606.0
11,,143B,,Homo sapiens,,F,,163.0,N,17430,BAO_0000219,CHEMBL615127,80001,,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,9606.0
12,,143B,,Homo sapiens,,F,,163.0,N,17774,BAO_0000219,CHEMBL615128,80001,,Expert,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,9606.0
13,,,,Staphylococcus aureus,,F,,,N,11324,BAO_0000218,CHEMBL857900,50185,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1280.0
14,,,,Staphylococcus aureus,,F,,,N,11324,BAO_0000218,CHEMBL615129,50185,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1280.0
15,,,,Staphylococcus aureus,,F,,,N,11324,BAO_0000218,CHEMBL615130,50185,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1280.0
16,,,,Staphylococcus aureus,,F,,,N,11324,BAO_0000218,CHEMBL615131,50185,,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,1280.0
17,,,,Rattus norvegicus,,A,,,D,11347,BAO_0000357,CHEMBL884521,100122,,Expert,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,10116.0
18,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615132,12054,,Autocuration,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,
19,,,,,,B,,,H,10091,BAO_0000019,CHEMBL615133,12054,,Autocuration,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,
20,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615134,12054,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
21,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615135,12054,,Autocuration,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,
22,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615136,12054,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
23,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615137,12054,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
24,,,,,,B,,,H,16474,BAO_0000357,CHEMBL615138,12054,,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
25,,,,,,B,,,U,14352,BAO_0000219,CHEMBL836324,22226,,Autocuration,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,
26,,,,Oryctolagus cuniculus,,B,,,H,5646,BAO_0000357,CHEMBL615139,12054,,Autocuration,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,9986.0
27,,,,Oryctolagus cuniculus,,B,,,H,5646,BAO_0000357,CHEMBL615140,12054,,Autocuration,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,9986.0
28,,,,,,B,,,H,10997,BAO_0000219,CHEMBL615141,12426,,Autocuration,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,
29,,,,soya bean,,B,,,H,6309,BAO_0000357,CHEMBL615142,12054,,Autocuration,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,3847.0
30,,,,Glycine max,,B,,,H,167,BAO_0000357,CHEMBL615143,12054,,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,3847.0
31,,,,Glycine max,,B,,,H,167,BAO_0000357,CHEMBL615144,12054,,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,3847.0
32,,,,Glycine max,,B,,,H,11087,BAO_0000357,CHEMBL872867,12054,,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,3847.0
33,,,,Glycine max,,B,,,H,11087,BAO_0000357,CHEMBL615145,12054,,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,3847.0
34,,,,Glycine max,,B,,,H,13622,BAO_0000357,CHEMBL615146,12054,,Autocuration,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,3847.0
35,,,,Glycine max,,B,,,H,13622,BAO_0000357,CHEMBL615147,12054,,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,3847.0
36,,,,Rattus norvegicus,,A,,,U,11347,BAO_0000019,CHEMBL615148,22226,,Autocuration,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,10116.0
37,,,,Escherichia coli,,B,,,U,5926,BAO_0000019,CHEMBL615149,22226,,Autocuration,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,562.0
38,,,,,,B,,,U,4567,BAO_0000019,CHEMBL615150,22226,,Autocuration,Dissociation constant with dimeric 16S rRNA RNA construct B,,
39,,,,,,B,,,M,3782,BAO_0000225,CHEMBL615151,22222,,Intermediate,Dissociation constant towards 16S rRNA construct A,,
40,,,,,,B,,,M,3782,BAO_0000225,CHEMBL615152,22222,,Intermediate,Dissociation constant towards 16S rRNA construct B,,
41,,,,Escherichia coli,,B,,,M,4466,BAO_0000225,CHEMBL615153,100263,,Expert,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,562.0
42,,,,Escherichia coli,,B,,,M,6592,BAO_0000225,CHEMBL615154,100263,,Expert,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,562.0
43,,,,,,B,,,H,898,BAO_0000019,CHEMBL615155,13053,,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
44,,,,,,B,,,H,898,BAO_0000019,CHEMBL615156,13053,,Autocuration,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
45,,,,Homo sapiens,,B,,,H,13163,BAO_0000019,CHEMBL615157,20001,,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,9606.0
46,,,,Homo sapiens,,B,,,H,13163,BAO_0000019,CHEMBL615158,20001,,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,9606.0
47,,,,Rattus norvegicus,,B,,,D,10691,BAO_0000019,CHEMBL615159,12971,,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10116.0
48,,,,Rattus norvegicus,,B,,,D,10691,BAO_0000019,CHEMBL615172,12971,,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10116.0
49,,,,Rattus norvegicus,,B,,,D,10691,BAO_0000019,CHEMBL615173,12971,,Expert,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10116.0
50,,,,Rattus norvegicus,,B,,,D,10691,BAO_0000019,CHEMBL615174,12971,,Expert,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10116.0
51,,,,,,B,,,H,898,BAO_0000019,CHEMBL884518,13053,,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
52,,,,,,B,,,H,912,BAO_0000357,CHEMBL615175,11512,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,
53,,,,,,B,,,H,912,BAO_0000357,CHEMBL615176,11512,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,
54,,,,,,B,,,H,912,BAO_0000357,CHEMBL615177,11512,,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,
55,,,,Rattus norvegicus,,B,Membranes,,D,15103,BAO_0000249,CHEMBL615178,104740,,Autocuration,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,10116.0
56,,1A9,,Homo sapiens,,F,,506.0,N,5116,BAO_0000219,CHEMBL615179,80002,,Intermediate,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,9606.0
57,,Oocytes,,Rattus norvegicus,,F,,,D,14578,BAO_0000219,CHEMBL615180,104835,,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,10116.0
58,,Oocytes,,Rattus norvegicus,,F,,,D,14578,BAO_0000219,CHEMBL615181,104821,,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,10116.0
59,,Oocytes,,Rattus norvegicus,,F,,,D,14578,BAO_0000219,CHEMBL615182,104848,,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,10116.0
60,,1A9,,Homo sapiens,,F,,506.0,N,4787,BAO_0000219,CHEMBL615183,80002,,Expert,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,9606.0
61,,1A9,,Homo sapiens,,F,,506.0,N,4787,BAO_0000219,CHEMBL615184,80002,,Intermediate,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,9606.0
62,,1A9,,Homo sapiens,,F,,506.0,N,3547,BAO_0000219,CHEMBL615185,80002,,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line,,9606.0
63,,1A9,,Homo sapiens,,F,,506.0,N,3547,BAO_0000219,CHEMBL615186,80002,,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,9606.0
64,,1A9,,Homo sapiens,,F,,506.0,N,6726,BAO_0000219,CHEMBL615187,80002,,Intermediate,Effective dose of compound against replication of 1A9 cell line was evaluated,,9606.0
65,,1A9,,Homo sapiens,,F,,506.0,N,3455,BAO_0000219,CHEMBL885343,80002,,Expert,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,9606.0
66,,1A9,,Homo sapiens,,F,,506.0,N,5726,BAO_0000219,CHEMBL615188,80002,,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,9606.0
67,,1A9,,Homo sapiens,,F,,506.0,N,5726,BAO_0000219,CHEMBL615189,80002,,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,9606.0
68,,1A9,,Homo sapiens,,F,,506.0,N,5726,BAO_0000219,CHEMBL615190,80002,,Intermediate,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,9606.0
69,,1A9,,Homo sapiens,,F,,506.0,N,3395,BAO_0000219,CHEMBL615191,80002,,Intermediate,Inhibitory activity against Taxol resistant 1A9 cell lines,,9606.0
70,,1A9,,Homo sapiens,,F,,506.0,N,3415,BAO_0000219,CHEMBL615192,80002,,Expert,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,9606.0
71,,1A9,,Homo sapiens,,F,,506.0,N,3415,BAO_0000219,CHEMBL827083,80002,,Expert,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,9606.0
72,,1A9,,Homo sapiens,,F,,506.0,N,17099,BAO_0000219,CHEMBL615193,80002,,Expert,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,9606.0
73,,1A9,,Homo sapiens,,F,,506.0,N,17099,BAO_0000219,CHEMBL615194,80002,,Intermediate,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,9606.0
74,,1A9,,Homo sapiens,,F,,506.0,N,17099,BAO_0000219,CHEMBL615195,80002,,Intermediate,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,9606.0
75,,1A9,,Homo sapiens,,F,,506.0,N,17099,BAO_0000219,CHEMBL615196,80002,,Intermediate,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,9606.0
76,,Jurkat,,Homo sapiens,,F,,503.0,N,17721,BAO_0000219,CHEMBL615197,81072,,Intermediate,Inhibitory concentration against Jurkat cells,,9606.0
77,,,,,,F,,,U,1229,BAO_0000019,CHEMBL615198,22226,,Intermediate,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,
78,,,,Rattus norvegicus,,A,,,D,11347,BAO_0000357,CHEMBL615199,100121,,Expert,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,10116.0
79,,,,,,B,,,H,17117,BAO_0000357,CHEMBL615200,11231,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
80,,,,,,B,,,H,17117,BAO_0000357,CHEMBL615201,11231,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
81,,,,,,B,,,H,17117,BAO_0000357,CHEMBL615202,11231,,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,
82,,,,Candida albicans,,B,Microsomes,,H,11375,BAO_0000251,CHEMBL615203,11231,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,5476.0
83,,,,Candida albicans,,B,Microsomes,,H,11375,BAO_0000251,CHEMBL615204,11231,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,5476.0
84,,,,Saccharomyces cerevisiae,,B,Microsomes,,H,11375,BAO_0000251,CHEMBL615205,11231,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,4932.0
85,,,,Saccharomyces cerevisiae,,B,Microsomes,,H,11375,BAO_0000251,CHEMBL615206,11231,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,4932.0
86,2107.0,,Liver,Sus scrofa,,B,Microsomes,,H,11375,BAO_0000251,CHEMBL615207,12083,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,9823.0
87,,,,Rattus norvegicus,,B,,,H,791,BAO_0000019,CHEMBL827084,11231,,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,10116.0
88,,,,Rattus norvegicus,,B,,,H,791,BAO_0000019,CHEMBL615208,11231,,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,10116.0
89,,,,Rattus norvegicus,,B,,,H,791,BAO_0000019,CHEMBL615209,11231,,Autocuration,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,10116.0
90,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,11375,BAO_0000251,CHEMBL615210,12083,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,10116.0
91,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,11375,BAO_0000251,CHEMBL615211,12083,,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,10116.0
92,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,153,BAO_0000251,CHEMBL615212,12083,,Autocuration,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,10116.0
93,,,,,,B,,,H,8269,BAO_0000357,CHEMBL615213,11377,,Expert,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,
94,,,,,,B,,,H,8269,BAO_0000357,CHEMBL615273,11377,,Expert,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,
95,,HepG2,,Homo sapiens,,F,,726.0,N,17653,BAO_0000219,CHEMBL615274,81020,,Expert,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,9606.0
96,,HepG2,,Homo sapiens,,F,,726.0,N,14277,BAO_0000219,CHEMBL615275,81020,,Intermediate,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,9606.0
97,,HepG2,,Homo sapiens,,F,,726.0,N,1717,BAO_0000219,CHEMBL615276,81020,,Intermediate,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,9606.0
98,,HepG2,,Homo sapiens,,F,,726.0,N,14091,BAO_0000219,CHEMBL615277,81020,,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,9606.0
99,,HepG2,,Homo sapiens,,F,,726.0,N,14091,BAO_0000219,CHEMBL615326,81020,,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,9606.0
100,,,,Hepatitis B virus,,F,,,N,17653,BAO_0000218,CHEMBL883130,50606,,Expert,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,10407.0
101,,HepG2,,Homo sapiens,,F,,726.0,N,13105,BAO_0000219,CHEMBL884519,81020,,Intermediate,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,9606.0
102,,HepG2,,Homo sapiens,,F,,726.0,N,1717,BAO_0000219,CHEMBL615327,81020,,Intermediate,Concentration required to inhibit 50% of 2.2.15 cell line,,9606.0
103,,HepG2,,Homo sapiens,,A,,726.0,N,13105,BAO_0000219,CHEMBL615328,81020,,Intermediate,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,9606.0
104,,2.2.15,,Homo sapiens,,F,,,N,13600,BAO_0000218,CHEMBL615329,50587,,Intermediate,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,9606.0
105,,2.2.15,,Homo sapiens,,F,,,N,13467,BAO_0000218,CHEMBL615330,50587,,Intermediate,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,9606.0
106,,2.2.15,,Hepatitis B virus,,F,,,N,17477,BAO_0000218,CHEMBL615331,50606,,Expert,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,10407.0
107,,2.2.15,,Homo sapiens,,F,,,N,1593,BAO_0000218,CHEMBL615332,50587,,Intermediate,In vitro anti-HBV activity in 2.2.15 cells,,9606.0
108,,2.2.15,,Homo sapiens,,F,,,N,1593,BAO_0000218,CHEMBL615333,50587,,Intermediate,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,9606.0
109,,2.2.15,,Homo sapiens,,F,,,N,15089,BAO_0000218,CHEMBL615334,50587,,Intermediate,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,9606.0
110,,2.2.15,,Homo sapiens,,F,,,N,15089,BAO_0000218,CHEMBL615335,50587,,Intermediate,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,9606.0
111,,2.2.15,,Homo sapiens,,F,,,N,1593,BAO_0000218,CHEMBL615336,50587,,Intermediate,Cytotoxicity in 2.2.15 cells,,9606.0
112,,2.2.15,,Homo sapiens,,F,,,N,1593,BAO_0000218,CHEMBL615337,50587,,Intermediate,Cytotoxicity in 2.2.15 cells; Not determined,,9606.0
113,,2.2.15,,Homo sapiens,,F,,,N,13600,BAO_0000218,CHEMBL615338,50587,,Intermediate,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,9606.0
114,,2.2.15,,Homo sapiens,,F,,,N,13467,BAO_0000218,CHEMBL615339,50587,,Intermediate,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,9606.0
115,,2.2.15,,Homo sapiens,,F,,,N,13467,BAO_0000218,CHEMBL615340,50587,,Intermediate,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,9606.0
116,,HepG2,,Homo sapiens,,F,,726.0,N,14764,BAO_0000219,CHEMBL615341,81020,,Intermediate,Antiviral activity against HBV was determined in 2.215 cell line,,9606.0
117,,,,Homo sapiens,,B,Microsomes,,U,6531,BAO_0000251,CHEMBL615342,22226,,Autocuration,Inhibition of 20-HETE synthesis in human renal microsomes,,9606.0
118,,,,,,B,,,U,17322,BAO_0000019,CHEMBL615343,22226,,Autocuration,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,
119,,2008,,Homo sapiens,,F,,388.0,N,17072,BAO_0000219,CHEMBL615344,80612,,Intermediate,Inhibitory concentration against 2008 (ovarian) cells,,9606.0
120,,2008,,Homo sapiens,,F,,388.0,N,16936,BAO_0000219,CHEMBL615345,80612,,Intermediate,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,9606.0
121,,2008,,Homo sapiens,,F,,388.0,N,16936,BAO_0000219,CHEMBL615346,80612,,Intermediate,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,9606.0
122,,2008,,Homo sapiens,,F,,388.0,N,17146,BAO_0000219,CHEMBL615347,80612,,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,9606.0
123,,2008,,Homo sapiens,,F,,388.0,N,17146,BAO_0000219,CHEMBL615348,80612,,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,9606.0
124,,2008/R,,Homo sapiens,,F,,561.0,N,10797,BAO_0000219,CHEMBL827085,80613,,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line,,9606.0
125,,2008/R,,Homo sapiens,,F,,561.0,N,10797,BAO_0000219,CHEMBL615349,80613,,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,9606.0
126,,2008/S,,Homo sapiens,,F,,389.0,N,10797,BAO_0000219,CHEMBL615350,80614,,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line,,9606.0
127,,2008/S,,Homo sapiens,,F,,389.0,N,10797,BAO_0000219,CHEMBL615351,80614,,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,9606.0
128,,,,Homo sapiens,,B,,,S,4823,BAO_0000220,CHEMBL615352,100256,,Expert,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,9606.0
129,,,,Homo sapiens,,B,,,S,12912,BAO_0000220,CHEMBL615353,100256,,Intermediate,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,9606.0
130,,,,,,B,,,S,2957,BAO_0000220,CHEMBL615354,100256,,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome,,
131,,,,,,B,,,S,2957,BAO_0000220,CHEMBL615355,100256,,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,
132,,,,,,B,,,S,3260,BAO_0000220,CHEMBL615356,100256,,Intermediate,Inhibitory activity against 20S proteosome,,
133,,,,Homo sapiens,,B,,,U,3451,BAO_0000019,CHEMBL615357,22226,,Autocuration,Compound was tested for inhibitory activity against tryptase,,9606.0
134,,HepG2,,Homo sapiens,,F,,726.0,N,13885,BAO_0000219,CHEMBL615358,81020,,Intermediate,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,9606.0
135,,HepG2,,Homo sapiens,,F,,726.0,N,13885,BAO_0000219,CHEMBL827086,81020,,Intermediate,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,9606.0
136,,,,,,B,,,U,3676,BAO_0000019,CHEMBL615359,22226,,Autocuration,Compound was tested for the inhibition of Alpha-glucosidase,,
137,,,,,,B,,,H,6043,BAO_0000357,CHEMBL615360,235,,Autocuration,Inhibitory concentration against human neutrophil elastase (HNE),,
138,948.0,,Heart,Rattus norvegicus,,F,,,U,11140,BAO_0000218,CHEMBL615361,22226,,Autocuration,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,10116.0
139,,,,,,F,,,H,10543,BAO_0000019,CHEMBL615362,19640,,Autocuration,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
140,,,,,,F,,,H,10543,BAO_0000019,CHEMBL615363,19640,,Expert,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
141,,,,,,B,,,H,10543,BAO_0000357,CHEMBL615364,19640,,Autocuration,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
142,,,,,,F,,,H,10543,BAO_0000019,CHEMBL615365,19640,,Expert,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
143,,P338,,Mus musculus,,F,,524.0,N,11365,BAO_0000219,CHEMBL615366,80360,,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,10090.0
144,,P338,,Mus musculus,,F,,524.0,N,11365,BAO_0000219,CHEMBL615367,80360,,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,10090.0
145,,PBL,,Homo sapiens,,F,,554.0,N,11803,BAO_0000219,CHEMBL615368,80384,,Intermediate,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,9606.0
146,,,,Ovis aries,,F,,,U,11803,BAO_0000019,CHEMBL615369,22226,,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,9940.0
147,,,,Ovis aries,,F,,,U,11803,BAO_0000019,CHEMBL615370,22226,,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,9940.0
148,,,,,,B,,,H,12278,BAO_0000357,CHEMBL615673,191,,Autocuration,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,
149,,,,Homo sapiens,,F,,,U,8249,BAO_0000019,CHEMBL615674,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,9606.0
150,,,,Homo sapiens,,F,,,U,8249,BAO_0000019,CHEMBL615675,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,9606.0
151,,CCRF-CEM,,Homo sapiens,,F,,635.0,U,8249,BAO_0000219,CHEMBL615676,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,9606.0
152,,CCRF-CEM,,Homo sapiens,,F,,635.0,U,8249,BAO_0000219,CHEMBL615677,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,9606.0
153,,CCRF-CEM,,Homo sapiens,,F,,635.0,U,8249,BAO_0000219,CHEMBL615678,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,9606.0
154,,CCRF-CEM,,Homo sapiens,,F,,635.0,U,8249,BAO_0000219,CHEMBL615679,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,9606.0
155,,,,Homo sapiens,,F,,,U,8249,BAO_0000019,CHEMBL615680,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,9606.0
156,,,,Homo sapiens,,F,,,U,8249,BAO_0000019,CHEMBL615681,22226,,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,9606.0
157,,,,,,B,,,H,16992,BAO_0000249,CHEMBL857972,104290,,Autocuration,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,
158,,,,Streptococcus pyogenes,,F,,,N,10543,BAO_0000218,CHEMBL857899,50264,,Intermediate,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,1314.0
159,,,,Human herpesvirus 3,,F,,,N,17833,BAO_0000218,CHEMBL615371,50527,,Intermediate,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,10335.0
160,,HEL,,vericilla zoster virus,,F,,468.0,N,17290,BAO_0000218,CHEMBL615372,50527,,Expert,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,10335.0
161,,,,vericilla zoster virus,,F,,,N,17290,BAO_0000218,CHEMBL615373,50527,,Intermediate,Antiviral activity against 07/1 strain of VZV; ND: No data,,10335.0
162,,,,vericilla zoster virus,,F,,,N,17290,BAO_0000218,CHEMBL615374,50527,,Intermediate,Antiviral activity against 07/1 strain of VZV; ND=No data,,10335.0
163,,,,escherichia cloac,,F,,,N,10932,BAO_0000218,CHEMBL615375,50145,,Intermediate,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,561.0
164,,,,,,B,,,U,9707,BAO_0000019,CHEMBL615376,22226,,Autocuration,Ratio of Ki at A2 to Ki at A1 receptors,,
165,,,,Candida albicans,,B,,,H,2346,BAO_0000249,CHEMBL615377,11143,,Expert,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,5476.0
166,,,,Candida glabrata CBS 138,,B,,,H,2205,BAO_0000357,CHEMBL615378,18077,,Expert,"Inhibition of 1,3-beta-glucan synthase",,284593.0
167,,1-87 tumor cell line,,Homo sapiens,,F,,832.0,N,11900,BAO_0000219,CHEMBL615379,80609,,Intermediate,Inhibition of growth of 1-87 human tumor cell line,,9606.0
168,,,,Rattus norvegicus,,B,,,D,14864,BAO_0000219,CHEMBL615380,12166,,Expert,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,10116.0
169,,,,Glycine max,,B,,,D,16474,BAO_0000357,CHEMBL615381,100171,,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO),,3847.0
170,,,,Glycine max,,B,,,D,16474,BAO_0000357,CHEMBL615382,100171,,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,3847.0
171,,,,Glycine max,,B,,,D,16474,BAO_0000357,CHEMBL615383,100171,,Autocuration,% inhibition against soybean 1-lipoxygenase (SLO),,3847.0
172,,,,Glycine max,,B,,,D,16474,BAO_0000357,CHEMBL615384,100171,,Autocuration,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,3847.0
173,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615385,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,3847.0
174,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615386,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,3847.0
175,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615387,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,3847.0
176,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615388,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,3847.0
177,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615214,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,3847.0
178,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL827087,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,3847.0
179,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615215,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,3847.0
180,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615216,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,3847.0
181,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615217,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,3847.0
182,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615218,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,3847.0
183,,,,Glycine max,,B,,,D,3094,BAO_0000357,CHEMBL615219,100171,,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,3847.0
184,,,,Mus musculus,,B,,,U,10413,BAO_0000019,CHEMBL615220,22226,,Autocuration,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,10090.0
185,,C3H 10T1/2,,Mus musculus,,F,,294.0,N,16929,BAO_0000219,CHEMBL615221,80049,,Intermediate,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,10090.0
186,,,,,,F,,,U,1229,BAO_0000019,CHEMBL615222,22226,,Intermediate,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,
187,,,,,,B,,,H,16587,BAO_0000357,CHEMBL615223,11489,,Autocuration,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
188,,,,,,B,,,H,16587,BAO_0000357,CHEMBL615224,11862,,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
189,,,,,,B,,,H,16587,BAO_0000357,CHEMBL615225,11862,,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,
190,,,,,,B,,,H,16587,BAO_0000357,CHEMBL615226,11489,,Autocuration,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,
191,,,,,,B,,,H,16587,BAO_0000357,CHEMBL615227,11862,,Autocuration,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,
192,,,,Bos taurus,,F,,,D,8058,BAO_0000019,CHEMBL615228,12347,,Expert,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,9913.0
193,,,,Rattus norvegicus,,B,,,D,9065,BAO_0000357,CHEMBL615229,100120,,Expert,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,10116.0
194,2369.0,,Adrenal gland,Rattus norvegicus,,B,,,D,8865,BAO_0000357,CHEMBL615230,100120,,Expert,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,10116.0
195,,,,Rattus norvegicus,,B,,,D,9066,BAO_0000357,CHEMBL615231,100120,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,,10116.0
196,,,,Rattus norvegicus,,B,,,D,8394,BAO_0000357,CHEMBL884520,100120,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,,10116.0
197,,,,Rattus norvegicus,,B,,,D,8394,BAO_0000357,CHEMBL615232,100120,,Expert,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,10116.0
198,,,,,,B,,,H,6431,BAO_0000019,CHEMBL615233,10328,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,
199,,,,,,B,,,H,6431,BAO_0000357,CHEMBL827088,11490,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
200,,,,,,B,,,H,6431,BAO_0000357,CHEMBL615234,11490,,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
201,,,,,,F,,,H,9295,BAO_0000019,CHEMBL615235,11134,,Autocuration,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,
202,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615236,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
203,,,,,,B,,,H,13622,BAO_0000019,CHEMBL615237,11134,,Autocuration,Compound was tested in vitro for inhibition of 12-LO human platelet,,
204,,,,,,F,,,H,12079,BAO_0000019,CHEMBL615238,11134,,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,,
205,,,,,,B,,,H,13622,BAO_0000019,CHEMBL615239,11134,,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,
206,,,,Homo sapiens,,F,,,D,12079,BAO_0000019,CHEMBL615240,11134,,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,,9606.0
207,,,,,,B,,,H,13500,BAO_0000019,CHEMBL615241,11835,,Expert,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,
208,,,,,,B,,,H,13723,BAO_0000357,CHEMBL615242,11601,,Expert,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,
209,,,,,,B,,,H,16474,BAO_0000019,CHEMBL615243,11134,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,
210,,,,,,B,,,H,1630,BAO_0000019,CHEMBL615244,11134,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase,,
211,,,,,,B,,,H,167,BAO_0000019,CHEMBL615245,11134,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,
212,,,,,,B,,,H,16474,BAO_0000019,CHEMBL615246,11134,,Autocuration,% inhibition against human platelet 12-lipoxygenase (12-HLO),,
213,,,,,,B,,,H,167,BAO_0000019,CHEMBL615247,11134,,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,
214,,,,,,B,,,H,16474,BAO_0000019,CHEMBL615248,11134,,Autocuration,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,
215,,,,,,B,,,H,10091,BAO_0000357,CHEMBL615249,11601,,Autocuration,Inhibitory activity towards porcine 12-lipoxygenase,,
216,,,,,,B,,,H,11966,BAO_0000357,CHEMBL615250,11601,,Autocuration,Tested for inhibition against porcine 12-LO,,
217,,,,,,B,,,H,951,BAO_0000019,CHEMBL615251,12052,,Autocuration,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,
218,,,,,,B,,,H,10997,BAO_0000019,CHEMBL615252,12052,,Autocuration,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,
219,,,,,,B,,,H,10193,BAO_0000019,CHEMBL828340,12052,,Expert,In vitro inhibition of rat platelet 12-lipoxygenase,,
220,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615253,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
221,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615254,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,
222,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615255,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,
223,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615256,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
224,,,,,,B,,,H,10193,BAO_0000019,CHEMBL615257,12052,,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,
225,,,,,,B,,,H,11087,BAO_0000019,CHEMBL615258,12052,,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,
226,,41M,,Homo sapiens,,F,,621.0,N,15569,BAO_0000219,CHEMBL615259,80007,,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,9606.0
227,,41M,,Homo sapiens,,F,,621.0,N,12989,BAO_0000219,CHEMBL615260,80007,,Expert,In vitro antitumor activity against 41M cell line.,,9606.0
228,,41M,,Homo sapiens,,F,,621.0,N,16745,BAO_0000219,CHEMBL615261,80007,,Intermediate,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,9606.0
229,,41M,,Homo sapiens,,F,,621.0,N,15569,BAO_0000219,CHEMBL615262,80007,,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,9606.0
230,,41M,,Homo sapiens,,F,,621.0,N,12989,BAO_0000219,CHEMBL615263,80007,,Expert,In vitro antitumor activity against 41McisR cell line.,,9606.0
231,,41M,,Homo sapiens,,F,,621.0,N,12989,BAO_0000219,CHEMBL838393,80007,,Expert,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,9606.0
232,,41M,,Homo sapiens,,F,,621.0,N,16745,BAO_0000219,CHEMBL615264,80007,,Intermediate,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,9606.0
233,,,,Homo sapiens,,B,,,D,6210,BAO_0000357,CHEMBL615265,84,,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,9606.0
234,,,,Homo sapiens,,B,,,D,6210,BAO_0000357,CHEMBL615266,68,,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,9606.0
235,,,,,,B,,,H,6226,BAO_0000357,CHEMBL615267,68,,Expert,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,
236,,,,,,B,,,H,17855,BAO_0000357,CHEMBL615268,10201,,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
237,,,,,,B,,,H,17855,BAO_0000357,CHEMBL615269,10201,,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,
238,,,,,,B,,,H,17855,BAO_0000357,CHEMBL615270,10201,,Expert,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
239,,,,,,B,,,H,10413,BAO_0000357,CHEMBL615271,12220,,Autocuration,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
240,,,,Escherichia coli,,B,,,H,10413,BAO_0000357,CHEMBL615272,11303,,Autocuration,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,562.0
241,,,,Escherichia coli,,B,,,H,10413,BAO_0000357,CHEMBL615103,11303,,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,562.0
242,,,,Escherichia coli,,B,,,H,10413,BAO_0000357,CHEMBL615104,11303,,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,562.0
243,,,,,,B,,,H,10413,BAO_0000357,CHEMBL615105,12220,,Autocuration,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
244,,,,,,B,,,H,10413,BAO_0000357,CHEMBL872866,12220,,Autocuration,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,
245,,,,Sus scrofa,,B,,,H,7587,BAO_0000357,CHEMBL615106,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,9823.0
246,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615107,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,9823.0
247,,,,Sus scrofa,,B,,,H,7587,BAO_0000357,CHEMBL615108,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,9823.0
248,,,,Sus scrofa,,B,,,H,7587,BAO_0000357,CHEMBL615109,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,9823.0
249,,,,Sus scrofa,,B,,,H,7587,BAO_0000357,CHEMBL615110,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,9823.0
250,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL840105,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,9823.0
251,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615111,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,9823.0
252,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615112,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,9823.0
253,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615113,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,9823.0
254,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615114,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,9823.0
255,,,,Sus scrofa,,B,,,H,7587,BAO_0000357,CHEMBL615115,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,9823.0
256,,,,Sus scrofa,,B,,,H,7587,BAO_0000019,CHEMBL615116,11303,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,9823.0
257,,,,,,B,,,H,7323,BAO_0000357,CHEMBL615698,11303,,Autocuration,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,
258,,,,Sus scrofa,,B,,,U,7587,BAO_0000019,CHEMBL615699,22226,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,9823.0
259,,,,Sus scrofa,,B,,,U,7587,BAO_0000019,CHEMBL615700,22226,,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,9823.0
260,,,,Saccharomyces cerevisiae,,B,,,H,13750,BAO_0000357,CHEMBL615701,100249,,Expert,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,4932.0
261,,,,Rattus norvegicus,,B,,,U,7662,BAO_0000019,CHEMBL615702,22226,,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,10116.0
262,,,,Rattus norvegicus,,B,,,U,7662,BAO_0000019,CHEMBL615703,22226,,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,10116.0
263,,,,Rattus norvegicus,,B,,,U,7662,BAO_0000019,CHEMBL615704,22226,,Autocuration,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,10116.0
264,,,,,,F,,,H,12211,BAO_0000019,CHEMBL615705,104698,,Autocuration,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
265,,,,,,F,,,H,12211,BAO_0000019,CHEMBL615706,104698,,Autocuration,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
266,2116.0,,Ileum,Cavia porcellus,,F,,,D,12211,BAO_0000221,CHEMBL615707,20033,,Intermediate,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,10141.0
267,,,,,,F,,,H,12211,BAO_0000019,CHEMBL615708,10623,,Expert,Stimulatory activity of intragastric pressure was tested in the rat,,
268,,,,,,B,,,H,15453,BAO_0000357,CHEMBL615709,121,,Autocuration,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,
269,,,,Rattus norvegicus,,F,,,U,11884,BAO_0000218,CHEMBL615710,22226,,Autocuration,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,10116.0
270,,,,,,F,,,H,7185,BAO_0000019,CHEMBL615711,12688,,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
271,,,,Homo sapiens,,B,,,D,6876,BAO_0000357,CHEMBL615712,121,,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,9606.0
272,,,,Homo sapiens,,B,,,D,6876,BAO_0000357,CHEMBL836325,121,,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,9606.0
273,,,,,,F,,,H,11863,BAO_0000019,CHEMBL615713,12198,,Autocuration,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,
274,,,,,,B,,,H,11863,BAO_0000357,CHEMBL615714,12198,,Autocuration,Inhibition constant of high-affinity 5-HT uptake,,
275,,,,,,F,,,H,11863,BAO_0000019,CHEMBL615715,12198,,Autocuration,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,
276,,,,,,F,,,H,11863,BAO_0000019,CHEMBL615716,12198,,Autocuration,Maximum rate was determined for high affinity transport of 5-HT,,
277,,,,,,F,,,H,4639,BAO_0000019,CHEMBL615717,104714,,Autocuration,Compound was tested for agonistic activity against 5-HT uptake,,
278,,,,,,B,,,H,15796,BAO_0000019,CHEMBL881818,10577,,Expert,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,
279,,,,Bos taurus,,B,,,H,15796,BAO_0000357,CHEMBL884540,105,,Expert,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,9913.0
280,,,,Rattus norvegicus,,B,,,D,12801,BAO_0000224,CHEMBL615718,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,10116.0
281,,,,,,B,,,H,12801,BAO_0000224,CHEMBL615719,104744,,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,
282,,,,,,B,Membranes,,H,12120,BAO_0000249,CHEMBL615720,104744,,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,
283,,,,,,B,Membranes,,H,12120,BAO_0000249,CHEMBL615721,104744,,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,
284,,,,,,B,,,H,11963,BAO_0000019,CHEMBL615722,104744,,Autocuration,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
285,,,,,,F,,,H,11701,BAO_0000019,CHEMBL615723,51,,Autocuration,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,
286,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615724,51,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
287,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615725,51,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
288,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615726,51,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
289,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615727,10576,,Autocuration,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,
290,,,,Cavia porcellus,,F,,,D,11574,BAO_0000019,CHEMBL615728,105570,,Intermediate,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,10141.0
291,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL857971,279,,Autocuration,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
292,,,,,,B,,,H,15363,BAO_0000357,CHEMBL615729,107,,Autocuration,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,
293,,,,Rattus norvegicus,,F,,,D,15363,BAO_0000019,CHEMBL615730,12687,,Expert,Efficacy against 5-hydroxytryptamine 2A receptor,,10116.0
294,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615731,12687,,Expert,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,
295,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615732,12687,,Expert,Relative potency towards 5-HT2A receptor of rat tail artery,,
296,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615733,12687,,Expert,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
297,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615734,12687,,Expert,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,
298,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615735,12687,,Autocuration,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,
299,,,,,,F,,,H,15329,BAO_0000019,CHEMBL615736,12687,,Expert,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
300,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL615737,20033,,Intermediate,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,10141.0
301,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL615738,20033,,Intermediate,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,10141.0
302,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL615739,20033,,Intermediate,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,10141.0
303,,,,,,B,,,H,12092,BAO_0000357,CHEMBL615278,10623,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,
304,,,,Rattus norvegicus,,F,,,D,1317,BAO_0000019,CHEMBL615279,10623,,Expert,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10116.0
305,,,,,,B,,,H,12409,BAO_0000357,CHEMBL615280,168,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,,
306,,,,Gallus gallus,,B,,,U,11126,BAO_0000019,CHEMBL615281,22226,,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,9031.0
307,,,,Homo sapiens,,F,,,U,11126,BAO_0000019,CHEMBL615282,22226,,Autocuration,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,9606.0
308,,,,Homo sapiens,,F,,,U,11126,BAO_0000019,CHEMBL615283,22226,,Autocuration,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,9606.0
309,,HL-60,,Homo sapiens,,B,,649.0,N,11126,BAO_0000219,CHEMBL615284,80156,,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,9606.0
310,,,,Homo sapiens,,B,,,U,11126,BAO_0000019,CHEMBL615285,22226,,Autocuration,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,9606.0
311,,,,Homo sapiens,,B,,,U,11126,BAO_0000019,CHEMBL615286,22226,,Autocuration,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,9606.0
312,,Oocytes,,Homo sapiens,,B,,,D,17807,BAO_0000219,CHEMBL615287,104703,,Autocuration,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,9606.0
313,,,,,,F,,,S,16575,BAO_0000220,CHEMBL615288,100256,,Intermediate,Chymotryptic inhibitory activity against 26S proteasome,,
314,,,,,,B,,,S,15407,BAO_0000220,CHEMBL615289,100256,,Intermediate,Inhibitory activity against 26S proteasome degradation of IkB,,
315,,A2780,,Homo sapiens,,F,,478.0,N,10797,BAO_0000219,CHEMBL615290,81034,,Intermediate,In vitro inhibition of 2780/DOX ovarian cancer cell line,,9606.0
316,,A2780,,Homo sapiens,,F,,478.0,N,10797,BAO_0000219,CHEMBL884522,81034,,Intermediate,In vitro inhibition of 2780/S ovarian cancer cell line,,9606.0
317,,,,Homo sapiens,,F,,,U,3469,BAO_0000019,CHEMBL615291,22226,,Autocuration,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,9606.0
318,,,,,,B,,,M,16037,BAO_0000225,CHEMBL615292,22222,,Intermediate,Association constant for binding to AATT 28-mer AATT hairpin,,
319,,,,,,B,,,M,16037,BAO_0000225,CHEMBL615293,22222,,Intermediate,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,
320,,,,,,B,,,M,16037,BAO_0000225,CHEMBL615294,22222,,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,,
321,,,,,,B,,,M,16037,BAO_0000225,CHEMBL615295,22222,,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,,
322,,,,Homo sapiens,,F,,,U,16524,BAO_0000019,CHEMBL825021,22226,,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,9606.0
323,,,,Homo sapiens,,F,,,U,16524,BAO_0000019,CHEMBL615296,22226,,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,9606.0
324,,,,Homo sapiens,,F,,,U,16524,BAO_0000019,CHEMBL615297,22226,,Autocuration,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,9606.0
325,,,,Cricetulus griseus,,F,,,U,16758,BAO_0000019,CHEMBL615298,22226,,Autocuration,Cytotoxicity against cell line 2SC/20 determined by MTT test,,10029.0
326,,,,Cricetulus griseus,,F,,,U,16758,BAO_0000019,CHEMBL615299,22226,,Autocuration,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,10029.0
327,,,,Cricetulus griseus,,F,,,U,16758,BAO_0000019,CHEMBL615300,22226,,Autocuration,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,10029.0
328,,,,,,B,,,H,14360,BAO_0000357,CHEMBL615301,241,,Autocuration,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,
329,,,,Homo sapiens,,B,,,D,14360,BAO_0000357,CHEMBL615302,241,,Expert,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,9606.0
330,,,,Rattus norvegicus,,B,,,U,9964,BAO_0000019,CHEMBL615303,22226,,Autocuration,Selectivity ratio of ID50 in liver and heart,,10116.0
331,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615304,12132,,Autocuration,"Selectivity, ratio of relative ID50 in liver and heart",,
332,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615305,12132,,Autocuration,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,
333,,,,,,B,,,H,9964,BAO_0000218,CHEMBL615306,12132,,Autocuration,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
334,,,,,,B,,,H,9964,BAO_0000218,CHEMBL615307,12132,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
335,,,,,,B,,,H,9964,BAO_0000218,CHEMBL615308,12132,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,
336,,,,,,F,,,H,9964,BAO_0000218,CHEMBL615309,12132,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,
337,,,,,,B,,,U,9964,BAO_0000019,CHEMBL615310,22226,,Autocuration,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,
338,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615311,12132,,Autocuration,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,
339,,,,Homo sapiens,,B,,,U,9964,BAO_0000019,CHEMBL615312,22226,,Autocuration,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,9606.0
340,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615313,12132,,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
341,,,,,,F,,,H,9964,BAO_0000019,CHEMBL615314,12132,,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
342,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615315,12132,,Autocuration,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,
343,,,,Rattus norvegicus,,B,,,U,9964,BAO_0000218,CHEMBL615316,22226,,Autocuration,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,10116.0
344,,,,,,B,,,H,9964,BAO_0000218,CHEMBL615317,12132,,Autocuration,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,
345,,,,,,B,,,H,9964,BAO_0000218,CHEMBL615318,12132,,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
346,,,,Rattus norvegicus,,B,,,U,9964,BAO_0000218,CHEMBL615319,22226,,Autocuration,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,10116.0
347,,,,,,B,,,H,9964,BAO_0000019,CHEMBL615320,12132,,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
348,,,,,,F,,,H,9964,BAO_0000019,CHEMBL615321,12132,,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
349,,,,Rattus norvegicus,,B,,,U,3796,BAO_0000019,CHEMBL615322,22226,,Autocuration,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,10116.0
350,,,,Escherichia coli,,B,,,H,4251,BAO_0000357,CHEMBL615323,19690,,Autocuration,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,562.0
351,,,,Escherichia coli,,B,,,H,4251,BAO_0000357,CHEMBL615407,19690,,Autocuration,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,562.0
352,,,,Escherichia coli,,B,,,H,4251,BAO_0000357,CHEMBL857267,19690,,Autocuration,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,562.0
353,,,,Escherichia coli,,B,,,H,4251,BAO_0000357,CHEMBL615408,19690,,Autocuration,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,562.0
354,,,,,,B,,,H,166,BAO_0000357,CHEMBL615409,19690,,Autocuration,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,
355,,,,,,B,,,H,17861,BAO_0000357,CHEMBL615410,19690,,Autocuration,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,
356,,,,,,B,,,H,166,BAO_0000357,CHEMBL615411,19690,,Autocuration,Inhibition constant against 3-dehydroquinate synthase,,
357,,,,,,B,,,H,166,BAO_0000357,CHEMBL615412,19690,,Autocuration,Association rate constant against 3-dehydroquinate synthase,,
358,,,,,,B,,,H,166,BAO_0000357,CHEMBL615413,19690,,Autocuration,Rate constant against 3-dehydroquinate synthase,,
359,,,,,,B,,,U,3548,BAO_0000019,CHEMBL615414,22226,,Autocuration,Inhibitory activity against fuc-TVII,,
360,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615415,12236,,Autocuration,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,10116.0
361,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615416,12236,,Autocuration,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,10116.0
362,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615417,12236,,Autocuration,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,10116.0
363,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615418,12236,,Autocuration,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,10116.0
364,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615419,12236,,Autocuration,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,10116.0
365,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615420,12236,,Autocuration,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,10116.0
366,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615421,12236,,Autocuration,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,10116.0
367,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615422,12236,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,10116.0
368,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615423,12236,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,10116.0
369,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL872868,12236,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,10116.0
370,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,D,9877,BAO_0000251,CHEMBL615424,12236,,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,10116.0
371,,,,,,B,,,H,3003,BAO_0000224,CHEMBL825022,104832,,Autocuration,Inhibitory activity against 3-phosphoglycerate kinase.,,
372,,,,,,B,,,H,3003,BAO_0000224,CHEMBL615425,104832,,Autocuration,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,
373,,,,,,B,,,H,3003,BAO_0000224,CHEMBL615426,104832,,Autocuration,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,
374,,,,Homo sapiens,,B,,,D,17185,BAO_0000357,CHEMBL615427,10612,,Expert,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,9606.0
375,,3677 melanoma cell line,,Homo sapiens,,F,,844.0,N,6072,BAO_0000219,CHEMBL615428,80616,,Intermediate,Cytotoxicity on 3677 melanoma cells,,9606.0
376,,3677 melanoma cell line,,Homo sapiens,,F,,844.0,N,6072,BAO_0000219,CHEMBL615429,80616,,Intermediate,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,9606.0
377,,MC-38,,Mus musculus,,F,,700.0,N,5018,BAO_0000219,CHEMBL615430,80617,,Intermediate,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,10090.0
378,,,,Homo sapiens,,F,,,U,2852,BAO_0000019,CHEMBL615431,22226,,Intermediate,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,9606.0
379,,B16,,,,F,,798.0,U,8663,BAO_0000218,CHEMBL615432,22226,,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,
380,,B16,,,,F,,798.0,U,8663,BAO_0000218,CHEMBL615433,22226,,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,
381,,,,Human rhinovirus 14,,F,,,D,3245,BAO_0000019,CHEMBL615434,12464,,Expert,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,12131.0
382,,,,Human rhinovirus sp.,,F,,,N,3245,BAO_0000218,CHEMBL615435,50085,,Intermediate,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,169066.0
383,,,,human rhinovirus type 14,,F,,,N,3877,BAO_0000218,CHEMBL615436,50679,,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,169066.0
384,,,,human rhinovirus type 14,,F,,,N,3877,BAO_0000218,CHEMBL615437,50679,,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,169066.0
385,,,,Human rhinovirus 14,,F,,,D,5861,BAO_0000019,CHEMBL615438,12464,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12131.0
386,,,,Human rhinovirus 14,,F,,,D,5861,BAO_0000019,CHEMBL615439,12464,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12131.0
387,,,,Human rhinovirus 14,,F,,,D,5861,BAO_0000019,CHEMBL615440,12464,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,12131.0
388,,,,Human rhinovirus 14,,F,,,D,5861,BAO_0000019,CHEMBL615441,12464,,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,12131.0
389,,,,Enterovirus,,F,,,N,13748,BAO_0000218,CHEMBL615641,50665,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,12059.0
390,,,,Enterovirus,,F,,,N,13748,BAO_0000218,CHEMBL872065,50665,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,12059.0
391,,,,Enterovirus,,F,,,N,13748,BAO_0000218,CHEMBL825023,50665,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,12059.0
392,,,,Enterovirus,,F,,,N,13748,BAO_0000218,CHEMBL615642,50665,,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,12059.0
393,,,,Human rhinovirus B,,B,,,H,13748,BAO_0000357,CHEMBL615643,12464,,Expert,Inhibition of human rhinovirus 3C protease,,147712.0
394,,,,Homo sapiens,,B,,,U,17699,BAO_0000019,CHEMBL615644,22226,,Autocuration,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,9606.0
395,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615645,80619,,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,10090.0
396,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615646,80619,,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,10090.0
397,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615647,80619,,Intermediate,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,10090.0
398,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615648,80619,,Intermediate,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,10090.0
399,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615649,80619,,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,10090.0
400,,3EM 37,,Mus musculus,,F,,833.0,N,7145,BAO_0000218,CHEMBL615650,80619,,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,10090.0
401,,3LL cell line,,Mus musculus,,F,,847.0,N,5325,BAO_0000218,CHEMBL615651,80620,,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,10090.0
402,,3LL cell line,,Mus musculus,,F,,847.0,N,5325,BAO_0000218,CHEMBL615652,80620,,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,10090.0
403,,3LL cell line,,Mus musculus,,F,,847.0,N,5325,BAO_0000218,CHEMBL615653,80620,,Expert,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,10090.0
404,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615654,80620,,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,10090.0
405,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615655,80620,,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,10090.0
406,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL825024,80620,,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,10090.0
407,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615656,80620,,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,10090.0
408,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615657,80620,,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,10090.0
409,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615658,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,10090.0
410,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615659,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,10090.0
411,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615660,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,10090.0
412,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615661,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,10090.0
413,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615662,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,10090.0
414,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615663,80620,,Intermediate,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,10090.0
415,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615664,80620,,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,10090.0
416,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615665,80620,,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,10090.0
417,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615666,80620,,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,10090.0
418,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615667,80620,,Intermediate,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,10090.0
419,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615668,80620,,Intermediate,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,10090.0
420,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615669,80620,,Intermediate,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,10090.0
421,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615670,80620,,Intermediate,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,10090.0
422,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL836739,80620,,Intermediate,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,10090.0
423,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615671,80620,,Intermediate,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,10090.0
424,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615672,80620,,Intermediate,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,10090.0
425,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615791,80620,,Intermediate,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,10090.0
426,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615792,80620,,Intermediate,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,10090.0
427,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615793,80620,,Intermediate,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,10090.0
428,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615794,80620,,Intermediate,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,10090.0
429,,3LL cell line,,Mus musculus,,F,,847.0,N,16169,BAO_0000219,CHEMBL615795,80620,,Intermediate,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,10090.0
430,,3LLD122,,Homo sapiens,,F,,971.0,N,15547,BAO_0000219,CHEMBL615590,80621,,Intermediate,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,9606.0
431,,,,,,F,,,U,8663,BAO_0000218,CHEMBL615591,22226,,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,
432,,,,,,F,,,U,8663,BAO_0000218,CHEMBL615592,22226,,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,
433,,,,,,F,,,U,8663,BAO_0000218,CHEMBL615593,22226,,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,
434,,,,,,F,,,U,8663,BAO_0000218,CHEMBL615594,22226,,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,
435,,NIH3T3,,Mus musculus,,F,,723.0,N,4504,BAO_0000219,CHEMBL615595,80951,,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,10090.0
436,,NIH3T3,,Mus musculus,,F,,723.0,N,4504,BAO_0000219,CHEMBL615596,80951,,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,10090.0
437,,NIH3T3,,,,F,,723.0,H,12695,BAO_0000219,CHEMBL615597,11169,,Expert,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,
438,,NIH3T3,,Mus musculus,,F,,723.0,N,12695,BAO_0000219,CHEMBL615598,80951,,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,10090.0
439,,NIH3T3,,Mus musculus,,F,,723.0,N,12695,BAO_0000219,CHEMBL615599,80951,,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,10090.0
440,,NIH3T3,,Mus musculus,,F,,723.0,N,17642,BAO_0000219,CHEMBL615600,80951,,Expert,Effective dose against murine 3T3 fibroblasts cells,,10090.0
441,,NIH3T3,,Mus musculus,,F,,723.0,N,17642,BAO_0000219,CHEMBL615601,80951,,Expert,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,10090.0
442,,NIH3T3,,Mus musculus,,F,,723.0,N,12340,BAO_0000219,CHEMBL615602,80951,,Expert,Cytotoxic effect on 3T3 cells,,10090.0
443,,NIH3T3,,Mus musculus,,F,,723.0,N,12340,BAO_0000219,CHEMBL615603,80951,,Expert,Cytotoxic effect on 3T3 cells,,10090.0
444,,NIH3T3,,Mus musculus,,F,,723.0,N,12716,BAO_0000219,CHEMBL615604,80951,,Intermediate,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,10090.0
445,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615605,80951,,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,10090.0
446,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615606,80951,,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,10090.0
447,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL884526,80951,,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,10090.0
448,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615607,80951,,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,10090.0
449,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615608,80951,,Intermediate,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,10090.0
450,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615609,80951,,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,10090.0
451,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615682,80951,,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,10090.0
452,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615683,80951,,Intermediate,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,10090.0
453,,NIH3T3,,Mus musculus,,F,,723.0,N,17780,BAO_0000218,CHEMBL615684,80951,,Expert,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,10090.0
454,,,,Mus musculus,,F,,,D,12751,BAO_0000219,CHEMBL615685,104860,,Autocuration,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,10090.0
455,,NIH3T3,,Mus musculus,,F,,723.0,N,12380,BAO_0000219,CHEMBL615686,80951,,Expert,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,10090.0
456,,NIH3T3,,Mus musculus,,F,,723.0,N,14892,BAO_0000219,CHEMBL615687,80951,,Intermediate,Inhibitory activity against 3T3 cell line,,10090.0
457,,NIH3T3,,Mus musculus,,F,,723.0,N,12695,BAO_0000219,CHEMBL884523,80951,,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,10090.0
458,,,,,,F,,,H,12695,BAO_0000019,CHEMBL615688,11169,,Expert,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,
459,,NIH3T3,,Mus musculus,,F,,723.0,N,12695,BAO_0000219,CHEMBL615689,80951,,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,10090.0
460,,NIH3T3,,Mus musculus,,F,,723.0,N,12695,BAO_0000219,CHEMBL615690,80951,,Intermediate,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,10090.0
461,,,,,,F,,,H,12695,BAO_0000019,CHEMBL615691,11169,,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,
462,,,,,,F,,,H,12695,BAO_0000019,CHEMBL615692,11169,,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,
463,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615693,80951,,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,10090.0
464,,NIH3T3,,Mus musculus,,F,,723.0,N,6277,BAO_0000219,CHEMBL615324,80951,,Expert,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,10090.0
465,,NIH3T3,,Homo sapiens,,F,,723.0,D,4959,BAO_0000219,CHEMBL615325,9,,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,9606.0
466,,NIH3T3,,Homo sapiens,,F,,723.0,D,4959,BAO_0000219,CHEMBL615490,9,,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,9606.0
467,,NIH3T3,,Homo sapiens,,F,,723.0,D,4959,BAO_0000219,CHEMBL615491,188,,Expert,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,9606.0
468,,NIH3T3,,Homo sapiens,,F,,723.0,D,4959,BAO_0000219,CHEMBL615492,188,,Expert,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,9606.0
469,,NIH3T3,,Mus musculus,,F,,723.0,N,12082,BAO_0000219,CHEMBL615493,80951,,Intermediate,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,10090.0
470,,NIH3T3,,Mus musculus,,F,,723.0,N,12082,BAO_0000219,CHEMBL615494,80951,,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,10090.0
471,,NIH3T3,,Mus musculus,,F,,723.0,N,12082,BAO_0000219,CHEMBL615495,80951,,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,10090.0
472,,NIH3T3,,Mus musculus,,F,,723.0,N,12082,BAO_0000219,CHEMBL615496,80951,,Intermediate,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,10090.0
473,,NIH3T3,,Mus musculus,,F,,723.0,N,2643,BAO_0000219,CHEMBL615497,80951,,Intermediate,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,10090.0
474,,NIH3T3,,Mus musculus,,F,,723.0,N,11926,BAO_0000219,CHEMBL615498,80951,,Expert,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,10090.0
475,,NIH3T3,,Mus musculus,,A,,723.0,N,15204,BAO_0000219,CHEMBL615499,80951,,Intermediate,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,10090.0
476,,NIH3T3,,Mus musculus,,F,,723.0,N,15992,BAO_0000219,CHEMBL835522,80951,,Expert,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,10090.0
477,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615500,80951,,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,10090.0
478,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615501,80951,,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,10090.0
479,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615502,80951,,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,10090.0
480,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615503,80951,,Intermediate,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,10090.0
481,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615504,80951,,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,10090.0
482,,NIH3T3,,Mus musculus,,F,,723.0,N,16279,BAO_0000219,CHEMBL615505,80951,,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,10090.0
483,,NIH3T3,,Mus musculus,,F,,723.0,N,12831,BAO_0000219,CHEMBL615506,80951,,Expert,Inhibition of swiss 3T3 mouse fibroblast proliferation,,10090.0
484,,NIH3T3,,Mus musculus,,F,,723.0,N,13497,BAO_0000219,CHEMBL615507,80951,,Intermediate,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,10090.0
485,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615508,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
486,,3T3-L1,,Mus musculus,,F,,620.0,N,13618,BAO_0000219,CHEMBL615509,80006,,Intermediate,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,10090.0
487,,3T3-L1,,Mus musculus,,F,,620.0,N,11902,BAO_0000219,CHEMBL615510,80006,,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,10090.0
488,,3T3-L1,,Mus musculus,,F,,620.0,N,11902,BAO_0000219,CHEMBL615511,80006,,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,10090.0
489,,3T3-L1,,Mus musculus,,F,,620.0,N,11902,BAO_0000219,CHEMBL615512,80006,,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,10090.0
490,,3T3-L1,,Mus musculus,,F,,620.0,N,14840,BAO_0000218,CHEMBL615513,80006,,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,10090.0
491,,3T3-L1,,Mus musculus,,F,,620.0,N,14840,BAO_0000218,CHEMBL615514,80006,,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,10090.0
492,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615515,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,
493,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615516,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
494,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615517,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
495,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615518,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
496,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615519,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
497,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615520,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,
498,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615521,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,
499,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615522,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
500,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615523,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
501,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615524,80006,,Expert,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
502,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615525,80006,,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
503,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615526,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
504,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615527,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
505,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615528,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,
506,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615529,80006,,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
507,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615530,80006,,Expert,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
508,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615531,80006,,Expert,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
509,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615532,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
510,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615533,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
511,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000219,CHEMBL615534,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
512,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615535,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
513,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615536,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
514,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615537,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
515,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL615538,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
516,,3T3-L1,,,,F,,620.0,N,13715,BAO_0000218,CHEMBL836166,80006,,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
517,,3T3-L1,,,,F,,620.0,H,6411,BAO_0000219,CHEMBL615539,11214,,Expert,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,
518,,3T3-L1,,Mus musculus,,F,,620.0,N,6411,BAO_0000219,CHEMBL615540,80006,,Intermediate,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,10090.0
519,,3T3-L1,,,,F,,620.0,H,6411,BAO_0000219,CHEMBL615541,11214,,Expert,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,
520,,3T3-L1,,Mus musculus,,F,,620.0,N,3966,BAO_0000219,CHEMBL615542,80006,,Expert,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,10090.0
521,,3T3-L1,,Mus musculus,,F,,620.0,N,3966,BAO_0000219,CHEMBL615543,80006,,Intermediate,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,10090.0
522,,3T3-L1,,Mus musculus,,F,,620.0,N,15556,BAO_0000219,CHEMBL615544,80006,,Expert,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,10090.0
523,,3T3-L1,,Mus musculus,,F,,620.0,N,5845,BAO_0000219,CHEMBL615545,80006,,Expert,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,10090.0
524,,3T3-L1,,Mus musculus,,F,,620.0,N,14422,BAO_0000219,CHEMBL615546,80006,,Expert,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,10090.0
525,,3T3-L1,,Mus musculus,,F,,620.0,N,5845,BAO_0000219,CHEMBL615547,80006,,Expert,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,10090.0
526,,3T3-L1,,Mus musculus,,F,,620.0,N,14508,BAO_0000219,CHEMBL615548,80006,,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,10090.0
527,,3T3-L1,,Mus musculus,,F,,620.0,N,14508,BAO_0000219,CHEMBL615549,80006,,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,10090.0
528,,3T3-L1,,Mus musculus,,F,,620.0,N,14508,BAO_0000219,CHEMBL615550,80006,,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,10090.0
529,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,6349,BAO_0000219,CHEMBL615551,80622,,Intermediate,Inhibitory activity against rat fibroblast (3Y1) cell line,,10116.0
530,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,15899,BAO_0000219,CHEMBL615552,80622,,Expert,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,10116.0
531,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,15899,BAO_0000219,CHEMBL615553,80622,,Expert,Cytotoxicity in 3Y1 cells.,,10116.0
532,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,15899,BAO_0000219,CHEMBL615554,80622,,Expert,Cytostatic effect in 3Y1 cells.,,10116.0
533,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,15899,BAO_0000219,CHEMBL615555,80622,,Intermediate,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,10116.0
534,,3Y1 cell line,,Rattus norvegicus,,F,,1118.0,N,17038,BAO_0000219,CHEMBL615556,80622,,Expert,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,10116.0
535,,,,,,B,,,U,12421,BAO_0000019,CHEMBL615557,22226,,Autocuration,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,
536,,,,,,B,,,U,12947,BAO_0000019,CHEMBL615558,22226,,Autocuration,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
537,,,,,,B,,,U,12947,BAO_0000019,CHEMBL872066,22226,,Autocuration,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
538,,,,Sus scrofa,,B,,,D,4896,BAO_0000019,CHEMBL615559,11607,,Expert,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,9823.0
539,,,,,,B,,,H,6148,BAO_0000019,CHEMBL615560,11607,,Autocuration,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,
540,,,,,,B,,,H,16432,BAO_0000019,CHEMBL615561,11607,,Autocuration,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,
541,,,,,,B,,,H,4978,BAO_0000019,CHEMBL857062,11607,,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,
542,,,,,,B,,,H,4978,BAO_0000019,CHEMBL615562,11607,,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,
543,,,,,,B,,,H,3723,BAO_0000019,CHEMBL615563,11607,,Autocuration,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,
544,,,,,,B,,,H,3518,BAO_0000357,CHEMBL615564,11607,,Autocuration,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,
545,,,,,,B,,,H,4164,BAO_0000019,CHEMBL615565,11607,,Autocuration,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,
546,,,,,,B,,,H,3518,BAO_0000019,CHEMBL615566,11607,,Autocuration,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,
547,,,,Sus scrofa,,B,,,D,4164,BAO_0000019,CHEMBL615567,11607,,Expert,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,9823.0
548,,,,,,B,,,H,3518,BAO_0000019,CHEMBL615568,11607,,Autocuration,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,
549,,,,,,B,,,H,3518,BAO_0000357,CHEMBL615569,11607,,Autocuration,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,
550,,,,,,B,,,H,4978,BAO_0000019,CHEMBL615570,11607,,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,
551,,,,,,B,,,H,4978,BAO_0000019,CHEMBL615571,11607,,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,
552,,,,,,B,,,H,6455,BAO_0000224,CHEMBL615572,104733,,Autocuration,Binding affinity against melatonin (MT1) receptor (pC1),,
553,,,,,,B,,,U,2222,BAO_0000019,CHEMBL615573,22226,,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,
554,,,,,,B,,,U,13020,BAO_0000019,CHEMBL615574,22226,,Autocuration,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,
555,,,,,,B,,,U,13021,BAO_0000019,CHEMBL615575,22226,,Autocuration,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,
556,,,,,,B,,,H,14532,BAO_0000357,CHEMBL615576,10619,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,
557,,,,,,B,,,H,14118,BAO_0000357,CHEMBL615577,10619,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,
558,10000000.0,,Hippocampus,,,B,,,H,11884,BAO_0000221,CHEMBL615578,51,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,
559,,,,,,B,,,H,13969,BAO_0000357,CHEMBL615579,51,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,
560,,,,,,B,,,H,13392,BAO_0000357,CHEMBL615580,51,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,,
561,,,,,,B,,,H,14430,BAO_0000019,CHEMBL615581,51,,Expert,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,
562,10000000.0,,Hippocampus,,,B,,,H,12248,BAO_0000221,CHEMBL615582,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
563,10000000.0,,Hippocampus,,,B,,,H,12249,BAO_0000221,CHEMBL615583,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
564,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615584,51,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
565,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL833691,51,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
566,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615585,51,,Autocuration,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
567,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615586,51,,Autocuration,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
568,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL884524,51,,Autocuration,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
569,10000000.0,,Hippocampus,,,B,,,H,12249,BAO_0000221,CHEMBL615587,51,,Autocuration,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
570,10000000.0,,Hippocampus,,,B,,,H,11799,BAO_0000221,CHEMBL615588,51,,Autocuration,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
571,,,,Rattus norvegicus,,B,Membranes,,D,14331,BAO_0000249,CHEMBL615589,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,10116.0
572,10000000.0,,Hippocampus,Bos taurus,,B,,,H,11884,BAO_0000221,CHEMBL615442,51,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,9913.0
573,10000000.0,,Hippocampus,,,B,,,H,14331,BAO_0000221,CHEMBL615443,51,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,
574,10000000.0,,Hippocampus,,,B,,,H,11701,BAO_0000221,CHEMBL615444,51,,Autocuration,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,
575,10000000.0,,Hippocampus,,,B,,,H,11701,BAO_0000221,CHEMBL615445,51,,Expert,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,
576,10000000.0,,Hippocampus,,,B,,,H,12248,BAO_0000221,CHEMBL615446,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,
577,,CHO,,,,B,,449.0,H,12248,BAO_0000219,CHEMBL615447,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,
578,10000000.0,,Hippocampus,,,B,,,H,12248,BAO_0000221,CHEMBL615448,51,,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
579,10000000.0,,Hippocampus,,,B,,,H,12249,BAO_0000221,CHEMBL615449,51,,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
580,,CHO,,,,B,,449.0,H,12248,BAO_0000219,CHEMBL615450,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
581,10000000.0,,Hippocampus,,,B,,,H,11799,BAO_0000221,CHEMBL615451,51,,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
582,,,,,,B,,,H,634,BAO_0000357,CHEMBL615452,51,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
583,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615453,51,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
584,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615454,51,,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
585,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615455,51,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
586,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615456,51,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
587,10000000.0,,Hippocampus,,,B,,,H,9995,BAO_0000221,CHEMBL615457,51,,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
588,10000000.0,,Hippocampus,,,B,,,H,12210,BAO_0000218,CHEMBL615458,51,,Expert,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,
589,10000000.0,,Hippocampus,,,B,,,H,13311,BAO_0000221,CHEMBL615459,51,,Expert,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
590,,CHO,,Homo sapiens,,B,,449.0,D,2331,BAO_0000219,CHEMBL615460,51,,Expert,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,9606.0
591,,,,Cavia porcellus,,F,,,H,1375,BAO_0000019,CHEMBL615461,51,,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,10141.0
592,,,,Cavia porcellus,,F,,,H,1375,BAO_0000019,CHEMBL615462,51,,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,10141.0
593,10000000.0,,Hippocampus,Cavia porcellus,,F,,,H,11574,BAO_0000221,CHEMBL615463,51,,Autocuration,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,10141.0
594,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615464,51,,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,10141.0
595,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615465,51,,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,10141.0
596,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615466,51,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,10141.0
597,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615467,51,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,10141.0
598,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615468,51,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,10141.0
599,2116.0,,Ileum,Cavia porcellus,,B,,,H,12867,BAO_0000221,CHEMBL615469,51,,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,10141.0
600,,,,Cavia porcellus,,B,,,H,11574,BAO_0000357,CHEMBL615470,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,10141.0
601,,,,Cavia porcellus,,B,,,H,13114,BAO_0000357,CHEMBL615471,51,,Autocuration,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,10141.0
602,,,,Cavia porcellus,,B,,,H,13181,BAO_0000357,CHEMBL615472,51,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,10141.0
603,10000000.0,,Hippocampus,Cavia porcellus,,B,,,H,10639,BAO_0000221,CHEMBL883242,106,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10141.0
604,10000000.0,,Hippocampus,Cavia porcellus,,F,,,H,10639,BAO_0000221,CHEMBL615473,106,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10141.0
605,,CHO,,Cricetulus griseus,,B,,449.0,H,11883,BAO_0000218,CHEMBL615474,11863,,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,10029.0
606,,,,,,B,,,H,17785,BAO_0000357,CHEMBL615475,51,,Autocuration,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,
607,,HeLa,,,,F,,308.0,H,1558,BAO_0000219,CHEMBL615476,51,,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,
608,,HeLa,,,,F,,308.0,H,1558,BAO_0000219,CHEMBL615477,51,,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,
609,,,,,,F,,,H,15740,BAO_0000019,CHEMBL615478,51,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
610,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615160,51,,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
611,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615161,51,,Expert,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
612,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615162,51,,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,
613,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615163,51,,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,
614,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615164,51,,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
615,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615165,51,,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
616,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615166,51,,Autocuration,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,
617,,,,,,F,,,H,14256,BAO_0000219,CHEMBL615167,51,,Autocuration,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,
618,,HeLa,,Homo sapiens,,B,,308.0,D,3445,BAO_0000219,CHEMBL615168,51,,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,9606.0
619,,HeLa,,Homo sapiens,,B,,308.0,D,3445,BAO_0000219,CHEMBL615169,51,,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,9606.0
620,,CHO,,Homo sapiens,,B,,449.0,D,17200,BAO_0000219,CHEMBL615170,51,,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,9606.0
621,,CHO,,Homo sapiens,,B,,449.0,D,17200,BAO_0000219,CHEMBL615171,51,,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,9606.0
622,,,,,,F,,,H,15180,BAO_0000019,CHEMBL615694,51,,Autocuration,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
623,,,,,,F,,,H,15180,BAO_0000019,CHEMBL615695,51,,Autocuration,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
624,,,,,,F,,,H,16026,BAO_0000019,CHEMBL615696,51,,Autocuration,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
625,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL615697,51,,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
626,,CHO,,Homo sapiens,,F,,449.0,D,2759,BAO_0000219,CHEMBL859410,51,,Expert,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,9606.0
627,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL615841,51,,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
628,,CHO,,Homo sapiens,,F,,449.0,D,2759,BAO_0000219,CHEMBL615842,51,,Expert,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,9606.0
629,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL835003,51,,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
630,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL615843,51,,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,
631,,CHO,,Homo sapiens,,F,,449.0,D,2759,BAO_0000219,CHEMBL615979,51,,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,9606.0
632,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL615980,51,,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
633,,CHO,,Homo sapiens,,F,,449.0,D,2759,BAO_0000219,CHEMBL615981,51,,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,9606.0
634,,,,Homo sapiens,,F,,,D,3445,BAO_0000019,CHEMBL615982,51,,Expert,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,9606.0
635,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL615983,51,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9606.0
636,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL615984,51,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,9606.0
637,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL615985,51,,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,9606.0
638,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615986,51,,Autocuration,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
639,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615987,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
640,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615988,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
641,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615989,51,,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
642,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615990,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
643,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615991,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,
644,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615992,51,,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
645,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615993,51,,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
646,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615994,51,,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
647,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615995,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,
648,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615996,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
649,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615997,51,,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
650,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615998,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
651,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615999,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
652,,,,,,F,,,H,6563,BAO_0000019,CHEMBL616000,51,,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
653,,HEK293,,,,F,,722.0,H,17296,BAO_0000219,CHEMBL616001,51,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
654,,,,Homo sapiens,,F,,,D,6876,BAO_0000019,CHEMBL616002,51,,Expert,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,9606.0
655,,,,,,F,,,H,6876,BAO_0000019,CHEMBL616003,51,,Expert,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,
656,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616004,51,,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,9606.0
657,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616005,51,,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,9606.0
658,,,,,,F,,,H,5548,BAO_0000019,CHEMBL616006,51,,Autocuration,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
659,,,,,,F,,,H,5548,BAO_0000019,CHEMBL616007,51,,Expert,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,
660,,,,,,F,,,H,5548,BAO_0000019,CHEMBL616008,51,,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
661,,,,,,F,,,H,5548,BAO_0000019,CHEMBL616009,51,,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
662,,,,,,F,,,H,5929,BAO_0000019,CHEMBL616010,51,,Expert,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,
663,,,,Homo sapiens,,F,,,D,5929,BAO_0000019,CHEMBL616011,51,,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,9606.0
664,,,,Homo sapiens,,F,,,D,5929,BAO_0000019,CHEMBL615740,51,,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,9606.0
665,,,,,,F,,,H,16245,BAO_0000019,CHEMBL615741,51,,Autocuration,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,
666,,,,,,F,,,H,5640,BAO_0000019,CHEMBL615742,51,,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
667,,,,,,F,,,H,5640,BAO_0000019,CHEMBL615743,51,,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,
668,,CHO,,,,F,,449.0,H,14509,BAO_0000219,CHEMBL615744,51,,Autocuration,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,
669,,CHO,,,,F,,449.0,H,14509,BAO_0000219,CHEMBL615745,51,,Expert,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,
670,,,,,,B,,,H,15331,BAO_0000357,CHEMBL615746,51,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
671,,,,,,B,,,H,15331,BAO_0000357,CHEMBL615747,51,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
672,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615748,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
673,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615749,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,
674,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615750,51,,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
675,,,,Homo sapiens,,F,,,D,6563,BAO_0000019,CHEMBL616259,51,,Expert,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,9606.0
676,,,,,,F,,,H,6563,BAO_0000019,CHEMBL616260,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
677,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616261,51,,Expert,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,9606.0
678,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616262,51,,Expert,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9606.0
679,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616263,51,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,9606.0
680,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616264,51,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,9606.0
681,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616265,51,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,9606.0
682,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616266,51,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,9606.0
683,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616267,51,,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,9606.0
684,,,,Homo sapiens,,F,,,D,5272,BAO_0000019,CHEMBL616268,51,,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,9606.0
685,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL616269,51,,Expert,Inhibition of human 5-hydroxytryptamine 1A receptor,,9606.0
686,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL884528,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
687,,HEK293,,,,B,,722.0,D,13706,BAO_0000219,CHEMBL616270,105,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,
688,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616271,51,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,
689,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL616272,51,,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
690,,,,,,B,,,H,6861,BAO_0000357,CHEMBL616273,51,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,
691,,,,Homo sapiens,,B,,,D,17200,BAO_0000357,CHEMBL616274,51,,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,9606.0
692,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL616275,51,,Autocuration,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,
693,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL616276,51,,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
694,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616277,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,10116.0
695,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616278,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,10116.0
696,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616279,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,10116.0
697,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616280,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,10116.0
698,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616281,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,10116.0
699,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616282,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,10116.0
700,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616283,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,10116.0
701,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616284,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,10116.0
702,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616285,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,10116.0
703,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616286,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,10116.0
704,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616287,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,10116.0
705,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616288,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,10116.0
706,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL616289,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,10116.0
707,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615610,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,10116.0
708,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615611,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,10116.0
709,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615612,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,10116.0
710,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615613,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,10116.0
711,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615614,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,10116.0
712,,,,Rattus norvegicus,,F,,,U,12058,BAO_0000218,CHEMBL615615,22226,,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,10116.0
713,,,,,,B,,,H,11440,BAO_0000019,CHEMBL615616,105093,,Autocuration,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,
714,1898.0,,Hypothalamus,,,B,,,H,6238,BAO_0000249,CHEMBL615617,11923,,Autocuration,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,
715,,,,,,B,,,H,10046,BAO_0000019,CHEMBL615618,10577,,Autocuration,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,
716,,,,,,B,,,H,10046,BAO_0000019,CHEMBL615619,10577,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,
717,,,,,,B,,,H,10046,BAO_0000019,CHEMBL615620,10577,,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
718,,,,,,B,,,H,167,BAO_0000357,CHEMBL615621,55,,Autocuration,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,
719,,,,,,B,,,H,167,BAO_0000357,CHEMBL615622,55,,Autocuration,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,
720,,,,,,F,,,H,11520,BAO_0000019,CHEMBL615623,12166,,Autocuration,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,
721,,,,,,F,,,H,11520,BAO_0000019,CHEMBL615624,12166,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
722,,,,,,F,,,H,11520,BAO_0000019,CHEMBL615625,12166,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
723,,,,,,F,,,H,11520,BAO_0000019,CHEMBL767045,12166,,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
724,,,,Cavia porcellus,,F,,,H,135,BAO_0000019,CHEMBL615626,55,,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,10141.0
725,,,,Cavia porcellus,,F,,,H,135,BAO_0000019,CHEMBL615627,55,,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,10141.0
726,,,,Cavia porcellus,,B,,,H,11311,BAO_0000019,CHEMBL615628,55,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,10141.0
727,,,,Cavia porcellus,,B,,,H,10193,BAO_0000357,CHEMBL615629,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10141.0
728,,,,Homo sapiens,,B,,,D,12281,BAO_0000357,CHEMBL615630,55,,Expert,Inhibitory concentration against 5-lipoxygenase from human whole blood,,9606.0
729,,,,,,B,,,H,11311,BAO_0000219,CHEMBL615631,55,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
730,,,,,,F,,,H,12576,BAO_0000218,CHEMBL615632,17087,,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
731,,,,,,B,,,H,12281,BAO_0000357,CHEMBL615633,17087,,Autocuration,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,
732,,,,,,F,,,H,12576,BAO_0000218,CHEMBL615634,17087,,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
733,,,,Sus scrofa,,B,,,H,11089,BAO_0000019,CHEMBL615635,55,,Expert,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,9823.0
734,,,,,,B,,,H,11006,BAO_0000357,CHEMBL615636,12166,,Expert,In vitro inhibition of rat 5-Lipoxygenase,,
735,,,,Rattus norvegicus,,B,,,D,11481,BAO_0000357,CHEMBL615637,12166,,Expert,Inhibitory activity against 5-Lipoxygenase,,10116.0
736,,RBL-1,,,,B,,702.0,H,10864,BAO_0000219,CHEMBL615638,12166,,Expert,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,
737,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL615639,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
738,,RBL-1,,,,B,,702.0,H,11311,BAO_0000219,CHEMBL615640,12166,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,
739,,,,,,B,,,H,11311,BAO_0000019,CHEMBL615796,12166,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,
740,,,,,,B,,,H,11311,BAO_0000219,CHEMBL615845,12166,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,
741,,,,,,B,,,H,11006,BAO_0000357,CHEMBL615846,12166,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
742,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL615847,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
743,,,,,,B,,,H,11311,BAO_0000357,CHEMBL615848,12166,,Autocuration,The compound was tested for inhibition of isolated 5-Lipoxygenase,,
744,,,,Rattus norvegicus,,B,,,U,11481,BAO_0000019,CHEMBL615849,22226,,Autocuration,Ratio of IC50 against 5-LO and COX,,10116.0
745,,,,,,B,,,H,11006,BAO_0000357,CHEMBL615850,12166,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
746,,,,,,B,,,H,11006,BAO_0000357,CHEMBL615851,12166,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,
747,,,,,,B,,,H,11311,BAO_0000219,CHEMBL615852,12166,,Autocuration,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,
748,,,,,,F,,,H,11006,BAO_0000019,CHEMBL615853,12166,,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,
749,2367.0,,Prostate gland,,,B,,,H,4288,BAO_0000357,CHEMBL884527,120,,Autocuration,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,
750,,,,Columba livia,,B,,,U,7587,BAO_0000019,CHEMBL872871,22226,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,8932.0
751,,,,Columba livia,,B,,,U,7587,BAO_0000019,CHEMBL615854,22226,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,8932.0
752,,,,Columba livia,,B,,,U,7587,BAO_0000019,CHEMBL767046,22226,,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,8932.0
753,,,,,,B,,,H,11249,BAO_0000357,CHEMBL615855,10732,,Autocuration,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,
754,,,,Rattus norvegicus,,F,,,D,8003,BAO_0000019,CHEMBL615856,12198,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,10116.0
755,,,,Rattus norvegicus,,F,,,D,8003,BAO_0000019,CHEMBL615857,12198,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,10116.0
756,,,,Rattus norvegicus,,F,,,D,8003,BAO_0000019,CHEMBL615858,12198,,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,10116.0
757,10000000.0,,Hippocampus,,,B,,,H,12416,BAO_0000221,CHEMBL615859,10576,,Expert,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
758,,,,,,B,,,H,16293,BAO_0000357,CHEMBL615860,51,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,
759,,,,Oryctolagus cuniculus,,B,,,U,13047,BAO_0000019,CHEMBL615861,22226,,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,9986.0
760,,,,Oryctolagus cuniculus,,B,,,U,13047,BAO_0000019,CHEMBL615862,22226,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,9986.0
761,,,,Oryctolagus cuniculus,,B,,,U,13047,BAO_0000019,CHEMBL615863,22226,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,9986.0
762,,,,Oryctolagus cuniculus,,B,,,U,13047,BAO_0000019,CHEMBL615864,22226,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,9986.0
763,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL615865,104744,,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
764,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL615866,104744,,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
765,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL615867,104744,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
766,,,,,,B,Membranes,,H,9841,BAO_0000249,CHEMBL615868,104744,,Autocuration,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,
767,,,,Rattus norvegicus,,B,,,D,8822,BAO_0000249,CHEMBL615869,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,10116.0
768,,,,Rattus norvegicus,,B,,,D,9806,BAO_0000019,CHEMBL615870,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,10116.0
769,,,,Rattus norvegicus,,B,,,D,9806,BAO_0000019,CHEMBL615871,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,10116.0
770,,,,,,B,,,H,8868,BAO_0000224,CHEMBL615872,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,
771,10000000.0,,Hippocampus,,,B,,,H,9036,BAO_0000221,CHEMBL833492,104744,,Autocuration,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,
772,10000000.0,,Hippocampus,,,B,,,H,11374,BAO_0000221,CHEMBL615873,104744,,Autocuration,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,
773,,,,,,B,,,H,10881,BAO_0000224,CHEMBL615479,104744,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,
774,,,,,,B,,,H,8822,BAO_0000019,CHEMBL615480,104744,,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,
775,,,,Rattus norvegicus,,B,,,D,9806,BAO_0000249,CHEMBL615481,104744,,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,10116.0
776,,,,,,B,,,H,15463,BAO_0000019,CHEMBL872869,104744,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
777,,,,,,B,,,H,15463,BAO_0000019,CHEMBL615482,104744,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
778,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL615483,104744,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
779,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL615484,104744,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
780,,,,,,B,,,H,8569,BAO_0000019,CHEMBL615485,104744,,Autocuration,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,
781,,,,Rattus norvegicus,,B,,,D,10062,BAO_0000224,CHEMBL615486,104744,,Autocuration,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,10116.0
782,,,,,,B,,,H,4771,BAO_0000224,CHEMBL615487,104744,,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,
783,,,,,,B,,,H,10062,BAO_0000224,CHEMBL615488,104744,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
784,,,,,,B,,,H,10062,BAO_0000224,CHEMBL615489,104744,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
785,,,,,,B,,,H,10062,BAO_0000224,CHEMBL615389,104744,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
786,,,,,,B,,,H,15463,BAO_0000019,CHEMBL615390,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
787,,,,,,B,,,H,15463,BAO_0000019,CHEMBL615391,104744,,Autocuration,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
788,,,,,,B,,,H,9098,BAO_0000224,CHEMBL615392,104744,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,
789,,,,Rattus norvegicus,,B,,,U,3070,BAO_0000019,CHEMBL615393,22226,,Autocuration,Affinity for 5-hydroxytryptamine 1 receptor,,10116.0
790,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL615394,104744,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,
791,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL615395,104744,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
792,,,,,,B,,,H,6398,BAO_0000224,CHEMBL615396,104744,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,
793,955.0,,Brain,,,B,,,H,1344,BAO_0000221,CHEMBL615397,104744,,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,
794,,,,,,B,,,H,11963,BAO_0000019,CHEMBL615398,104744,,Autocuration,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
795,,,,Rattus norvegicus,,B,,,U,8908,BAO_0000019,CHEMBL615399,22226,,Autocuration,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,10116.0
796,,,,,,B,,,H,9098,BAO_0000019,CHEMBL615400,104744,,Autocuration,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,
797,,,,Rattus norvegicus,,B,,,D,8841,BAO_0000019,CHEMBL615401,104744,,Autocuration,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,10116.0
798,,,,Rattus norvegicus,,B,,,U,8814,BAO_0000019,CHEMBL615402,22226,,Autocuration,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,10116.0
799,,,,,,B,,,H,11752,BAO_0000019,CHEMBL615403,104744,,Autocuration,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,
800,955.0,,Brain,,,B,,,H,11642,BAO_0000221,CHEMBL615404,104744,,Autocuration,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,
801,,,,,,B,,,H,11642,BAO_0000019,CHEMBL615781,104744,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,
802,955.0,,Brain,,,B,,,H,9231,BAO_0000220,CHEMBL615782,104744,,Autocuration,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,
803,955.0,,Brain,,,B,,,H,11351,BAO_0000221,CHEMBL615783,104744,,Autocuration,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,
804,,,,,,B,,,U,4639,BAO_0000019,CHEMBL873481,22226,,Autocuration,Compound was tested for binding affinity against 5-HT1 receptor,,
805,,,,,,B,,,U,1205,BAO_0000019,CHEMBL615784,22226,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,
806,,,,,,B,,,H,10025,BAO_0000357,CHEMBL615785,10576,,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
807,,,,,,F,,,H,13241,BAO_0000249,CHEMBL615786,10576,,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
808,,,,,,F,,,H,16245,BAO_0000218,CHEMBL615787,10576,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,
809,,,,,,F,,,H,16245,BAO_0000218,CHEMBL615788,10576,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,
810,,,,,,F,,,H,12438,BAO_0000019,CHEMBL767044,10576,,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,
811,,,,,,F,,,H,16245,BAO_0000218,CHEMBL615789,10576,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,
812,,,,,,F,,,H,16245,BAO_0000218,CHEMBL615790,10576,,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,
813,,,,,,F,,,H,15740,BAO_0000019,CHEMBL615813,10576,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,
814,,,,,,F,,,H,15535,BAO_0000219,CHEMBL615814,10576,,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,
815,,,,,,F,,,H,15535,BAO_0000219,CHEMBL615815,51,,Expert,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,
816,,,,,,F,,,H,15535,BAO_0000219,CHEMBL615816,10576,,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,
817,,,,,,B,,,H,9888,BAO_0000249,CHEMBL615817,10576,,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,
818,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL615818,10576,,Autocuration,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,
819,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL615819,10576,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,
820,,,,,,B,Membranes,,H,17331,BAO_0000249,CHEMBL615820,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,
821,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,10845,BAO_0000221,CHEMBL615821,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,10116.0
822,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,10845,BAO_0000221,CHEMBL615822,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10116.0
823,10000000.0,,Hippocampus,,,B,,,H,10845,BAO_0000221,CHEMBL615823,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,
824,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,10845,BAO_0000221,CHEMBL615824,10576,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,10116.0
825,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,10845,BAO_0000221,CHEMBL615825,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10116.0
826,,,,,,B,,,H,13730,BAO_0000357,CHEMBL615826,10576,,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,
827,,,,,,B,,,H,13508,BAO_0000249,CHEMBL615827,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,
828,10000000.0,,Hippocampus,,,B,,,H,13508,BAO_0000249,CHEMBL615828,10576,,Expert,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,
829,10000000.0,,Hippocampus,,,B,,,H,12073,BAO_0000221,CHEMBL615829,10576,,Expert,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
830,10000000.0,,Hippocampus,,,B,,,H,4671,BAO_0000221,CHEMBL615830,10576,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,
831,10000000.0,,Hippocampus,,,B,,,H,13631,BAO_0000221,CHEMBL615831,10576,,Expert,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,
832,,,,,,B,,,H,12438,BAO_0000357,CHEMBL615832,10576,,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,
833,,,,,,B,,,H,10483,BAO_0000019,CHEMBL615833,10576,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,
834,10000000.0,,Hippocampus,,,B,,,H,10483,BAO_0000221,CHEMBL615834,10576,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,
835,,,,,,B,,,H,12352,BAO_0000249,CHEMBL615835,10576,,Intermediate,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,
836,10000000.0,,Hippocampus,,,B,,,H,14732,BAO_0000249,CHEMBL615836,10576,,Autocuration,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,
837,,,,Rattus norvegicus,,B,,,D,11049,BAO_0000019,CHEMBL615837,10576,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,10116.0
838,,,,Rattus norvegicus,,B,,,D,11049,BAO_0000019,CHEMBL615838,10576,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,10116.0
839,,,,,,B,,,H,13657,BAO_0000249,CHEMBL615839,10576,,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,
840,,,,,,B,,,H,11473,BAO_0000019,CHEMBL884525,10576,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,
841,,,,,,B,,,H,2014,BAO_0000249,CHEMBL615840,10576,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
842,10000000.0,,Hippocampus,,,B,,,H,3086,BAO_0000221,CHEMBL615405,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
843,,,,,,B,,,H,15854,BAO_0000019,CHEMBL615406,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
844,10000000.0,,Hippocampus,,,B,,,H,10922,BAO_0000221,CHEMBL615900,10576,,Expert,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
845,10000000.0,,Hippocampus,,,B,,,H,13346,BAO_0000221,CHEMBL615901,10576,,Expert,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,
846,,,,,,B,,,H,15311,BAO_0000357,CHEMBL615902,10576,,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,
847,10000000.0,,Hippocampus,,,B,,,H,10922,BAO_0000221,CHEMBL615903,10576,,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
848,,,,,,B,,,H,10025,BAO_0000357,CHEMBL615904,10576,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,
849,,,,,,B,,,H,10025,BAO_0000357,CHEMBL615905,10576,,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
850,,,,,,B,,,H,9742,BAO_0000019,CHEMBL615906,10576,,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
851,,,,,,F,,,H,9742,BAO_0000019,CHEMBL615907,10576,,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
852,,,,,,B,,,H,12304,BAO_0000019,CHEMBL615908,10576,,Expert,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
853,10000000.0,,Hippocampus,,,B,,,H,15789,BAO_0000221,CHEMBL615909,10576,,Autocuration,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,
854,,,,,,B,,,H,9912,BAO_0000019,CHEMBL615910,10576,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,
855,,,,,,B,,,H,9912,BAO_0000019,CHEMBL615911,10576,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,
856,,,,,,B,,,H,9912,BAO_0000019,CHEMBL615912,10576,,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,
857,,,,,,B,,,H,16693,BAO_0000019,CHEMBL615913,10576,,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
858,,,,,,B,,,H,13276,BAO_0000357,CHEMBL615914,10576,,Expert,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
859,10000000.0,,Hippocampus,,,B,,,H,12678,BAO_0000221,CHEMBL615915,10576,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
860,,,,,,B,,,H,11825,BAO_0000357,CHEMBL615916,10576,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,
861,,,,,,B,,,H,12443,BAO_0000357,CHEMBL615917,10576,,Expert,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,
862,,,,,,B,,,H,13830,BAO_0000357,CHEMBL615918,10576,,Expert,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
863,10000000.0,,Hippocampus,,,B,,,H,14286,BAO_0000249,CHEMBL615919,10576,,Expert,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,
864,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,14356,BAO_0000221,CHEMBL615920,10576,,Expert,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10116.0
865,,,,,,B,,,H,15306,BAO_0000357,CHEMBL615921,10576,,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,
866,,,,,,B,,,H,15306,BAO_0000357,CHEMBL615922,10576,,Expert,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,
867,,,,Rattus norvegicus,,F,,,D,16616,BAO_0000249,CHEMBL881290,10576,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10116.0
868,10000000.0,,Hippocampus,,,B,,,H,3651,BAO_0000221,CHEMBL615923,10576,,Autocuration,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,
869,10000000.0,,Hippocampus,,,F,,,H,14331,BAO_0000221,CHEMBL615924,10576,,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
870,10000000.0,,Hippocampus,,,F,,,H,14331,BAO_0000221,CHEMBL615925,10576,,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
871,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL615926,10576,,Expert,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,10116.0
872,,,,Rattus norvegicus,,B,,,D,10639,BAO_0000019,CHEMBL615927,10576,,Expert,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,10116.0
873,10000000.0,,Hippocampus,,,B,,,H,12306,BAO_0000221,CHEMBL615928,10576,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
874,,,,Rattus norvegicus,,B,,,D,1348,BAO_0000357,CHEMBL615929,10576,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,10116.0
875,10000000.0,,Hippocampus,,,B,,,H,13605,BAO_0000221,CHEMBL615930,10576,,Autocuration,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,
876,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615931,51,,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
877,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615932,51,,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
878,,CHO,,,,F,,449.0,H,17624,BAO_0000219,CHEMBL615933,51,,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
879,,,,,,B,,,H,15267,BAO_0000357,CHEMBL615934,51,,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
880,,,,,,B,,,H,16532,BAO_0000357,CHEMBL615935,51,,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,
881,,,,,,F,,,H,6563,BAO_0000019,CHEMBL615936,51,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
882,,CHO,,,,B,,449.0,H,4751,BAO_0000219,CHEMBL615937,51,,Autocuration,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,
883,,,,,,B,,,H,15463,BAO_0000357,CHEMBL615938,51,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,
884,,,,,,B,,,H,3805,BAO_0000357,CHEMBL615797,51,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,
885,,,,,,B,,,H,5640,BAO_0000357,CHEMBL615798,51,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
886,,,,,,B,,,H,6563,BAO_0000357,CHEMBL872870,51,,Autocuration,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,
887,,,,,,B,,,H,5548,BAO_0000357,CHEMBL615799,51,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,
888,,,,,,B,,,H,6347,BAO_0000357,CHEMBL615800,51,,Autocuration,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,
889,,HEK293,,,,F,,722.0,H,17296,BAO_0000219,CHEMBL615801,51,,Autocuration,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
890,,,,,,B,,,H,13047,BAO_0000019,CHEMBL615802,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,
891,,,,,,B,,,H,15740,BAO_0000357,CHEMBL615803,51,,Autocuration,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,
892,,,,,,F,,,H,5640,BAO_0000019,CHEMBL835002,51,,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
893,,,,,,F,,,H,5640,BAO_0000019,CHEMBL615804,51,,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,
894,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL615805,51,,Expert,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,
895,,CHO,,,,B,,449.0,H,4751,BAO_0000219,CHEMBL615806,51,,Autocuration,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,
896,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL615807,51,,Expert,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,9606.0
897,,,,,,B,,,H,4707,BAO_0000357,CHEMBL615808,51,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,
898,,,,Homo sapiens,,B,,,D,13910,BAO_0000357,CHEMBL615809,51,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,,9606.0
899,,HeLa,,,,B,,308.0,H,16190,BAO_0000219,CHEMBL615810,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,
900,,,,,,B,,,H,16633,BAO_0000357,CHEMBL615811,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
901,,CHO,,,,B,,449.0,H,11898,BAO_0000219,CHEMBL615812,51,,Autocuration,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,
902,,CHO,,,,B,,449.0,H,11898,BAO_0000219,CHEMBL615751,51,,Autocuration,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
903,,,,,,B,,,H,14331,BAO_0000357,CHEMBL615752,51,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor,,
904,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615753,51,,Expert,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,
905,,CHO,,,,B,,449.0,H,17624,BAO_0000219,CHEMBL615754,51,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,
906,,,,,,B,,,H,3307,BAO_0000357,CHEMBL615755,51,,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,
907,,CHO,,Homo sapiens,,B,,449.0,D,6563,BAO_0000219,CHEMBL615756,51,,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,9606.0
908,,,,,,B,,,H,14165,BAO_0000019,CHEMBL615757,51,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,
909,,,,,,B,,,H,5732,BAO_0000357,CHEMBL615758,51,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
910,,,,,,B,,,H,13366,BAO_0000357,CHEMBL615759,51,,Expert,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
911,,,,,,B,,,H,17626,BAO_0000357,CHEMBL615760,51,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,
912,,HeLa,,,,B,,308.0,H,6588,BAO_0000219,CHEMBL615761,51,,Expert,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,
913,,,,,,B,,,H,16209,BAO_0000357,CHEMBL872104,51,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,
914,,,,,,B,,,H,15463,BAO_0000357,CHEMBL615762,51,,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
915,,,,,,B,,,H,15463,BAO_0000357,CHEMBL615763,51,,Autocuration,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
916,,,,,,B,,,H,14770,BAO_0000357,CHEMBL615764,51,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,
917,,Cell line,,,,B,,1167.0,H,16245,BAO_0000219,CHEMBL615765,51,,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,
918,,,,,,B,,,H,16245,BAO_0000019,CHEMBL615766,51,,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,
919,,,,,,B,,,H,5548,BAO_0000357,CHEMBL615767,51,,Autocuration,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,
920,,,,,,B,,,H,5548,BAO_0000357,CHEMBL615768,51,,Expert,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
921,,,,,,B,,,H,5548,BAO_0000357,CHEMBL615769,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
922,,,,,,B,,,H,6876,BAO_0000357,CHEMBL615770,51,,Expert,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,
923,,,,,,B,,,H,2598,BAO_0000357,CHEMBL615771,51,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
924,,,,,,B,,,H,17785,BAO_0000357,CHEMBL615772,51,,Expert,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,
925,,,,,,B,,,H,6013,BAO_0000357,CHEMBL615773,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
926,,,,,,B,,,H,5929,BAO_0000357,CHEMBL615774,51,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
927,,,,,,B,,,H,16633,BAO_0000357,CHEMBL615775,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
928,,,,,,B,,,H,1558,BAO_0000357,CHEMBL615776,51,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
929,,,,,,B,,,H,16026,BAO_0000357,CHEMBL615777,51,,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
930,,,,,,B,,,H,12469,BAO_0000219,CHEMBL615778,51,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,
931,,,,Homo sapiens,,B,,,D,15874,BAO_0000357,CHEMBL615779,51,,Expert,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,9606.0
932,,,,,,B,,,H,15874,BAO_0000357,CHEMBL615780,51,,Autocuration,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
933,,,,,,B,,,H,3935,BAO_0000357,CHEMBL616298,51,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,
934,,,,,,B,,,H,15818,BAO_0000357,CHEMBL616299,51,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,
935,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL616300,51,,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,
936,,CHO-K1,,,,F,,485.0,H,13729,BAO_0000219,CHEMBL616301,51,,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,
937,,,,,,B,,,H,15413,BAO_0000019,CHEMBL616302,51,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,
938,,,,,,B,,,H,15413,BAO_0000019,CHEMBL616117,51,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,
939,,,,,,B,,,H,15413,BAO_0000019,CHEMBL616118,51,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,
940,,,,,,B,,,H,15413,BAO_0000019,CHEMBL616119,51,,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,
941,,HeLa,,Homo sapiens,,B,,308.0,D,3445,BAO_0000219,CHEMBL616120,51,,Expert,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,9606.0
942,,,,,,B,,,H,15740,BAO_0000357,CHEMBL616121,51,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
943,,,,,,B,,,H,15740,BAO_0000357,CHEMBL616122,51,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,
944,,,,,,B,,,H,17626,BAO_0000357,CHEMBL616123,51,,Autocuration,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,
945,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL616124,51,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,9606.0
946,,,,,,B,,,H,5640,BAO_0000357,CHEMBL616125,51,,Expert,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
947,,,,Rattus norvegicus,,B,,,H,5272,BAO_0000357,CHEMBL616126,51,,Expert,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,10116.0
948,,CHO,,,,B,,449.0,H,4622,BAO_0000219,CHEMBL616127,51,,Autocuration,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,
949,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616128,51,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,
950,,,,,,B,,,H,3025,BAO_0000357,CHEMBL616129,51,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
951,,,,,,B,,,H,15315,BAO_0000357,CHEMBL616130,51,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,
952,,,,,,B,,,H,15267,BAO_0000357,CHEMBL616131,51,,Autocuration,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,
953,,HeLa,,,,B,,308.0,H,17158,BAO_0000219,CHEMBL616132,51,,Autocuration,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,
954,,HeLa,,Homo sapiens,,B,,308.0,D,14214,BAO_0000219,CHEMBL616133,51,,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,9606.0
955,,,,,,B,,,H,17133,BAO_0000357,CHEMBL616134,51,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
956,,,,,,B,,,H,16532,BAO_0000357,CHEMBL616135,51,,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,
957,,,,Homo sapiens,,B,,,D,2391,BAO_0000357,CHEMBL616136,51,,Expert,Affinity for 5-hydroxytryptamine 1A receptor subtype,,9606.0
958,,,,,,B,,,H,14447,BAO_0000019,CHEMBL616137,51,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,
959,,,,,,B,,,H,14447,BAO_0000019,CHEMBL872105,51,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,
960,,,,,,B,,,H,15086,BAO_0000357,CHEMBL616138,51,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,
961,,,,Homo sapiens,,B,,,D,13051,BAO_0000357,CHEMBL616139,51,,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,9606.0
962,,,,,,F,,,H,16026,BAO_0000019,CHEMBL616140,51,,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,
963,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616141,51,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,
964,,,,,,B,,,H,17133,BAO_0000357,CHEMBL616142,51,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
965,,,,,,B,,,H,17133,BAO_0000357,CHEMBL616143,51,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,
966,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616144,51,,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
967,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616145,51,,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,
968,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616012,51,,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
969,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616013,51,,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
970,,,,,,F,,,H,16394,BAO_0000019,CHEMBL616014,51,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
971,,,,,,F,,,H,16394,BAO_0000019,CHEMBL616015,51,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
972,,,,,,F,,,H,16394,BAO_0000019,CHEMBL616016,51,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
973,,,,,,F,,,H,16394,BAO_0000218,CHEMBL616017,51,,Autocuration,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,
974,,,,,,B,,,H,16394,BAO_0000019,CHEMBL616018,51,,Autocuration,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,
975,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616019,51,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,
976,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616020,51,,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,
977,,,,,,B,,,H,15740,BAO_0000357,CHEMBL858018,51,,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
978,,HEK293,,,,F,,722.0,H,17296,BAO_0000219,CHEMBL616021,51,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
979,,,,,,F,,,H,5640,BAO_0000019,CHEMBL616022,51,,Expert,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,
980,,,,,,F,,,H,5640,BAO_0000019,CHEMBL616023,51,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,
981,,,,,,F,,,H,5640,BAO_0000019,CHEMBL616024,51,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,
982,,,,,,F,,,H,5640,BAO_0000019,CHEMBL616025,51,,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,
983,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL616026,51,,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
984,,,,,,F,,,H,16394,BAO_0000019,CHEMBL616027,51,,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,
985,,,,Homo sapiens,,F,,,D,16394,BAO_0000019,CHEMBL616028,51,,Expert,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,9606.0
986,,,,Homo sapiens,,F,,,D,3445,BAO_0000019,CHEMBL616029,51,,Expert,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,9606.0
987,,CHO,,,,B,,449.0,H,4316,BAO_0000219,CHEMBL616030,51,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,
988,,,,,,B,,,H,4316,BAO_0000019,CHEMBL616031,51,,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,
989,,,,Homo sapiens,,F,,,D,15180,BAO_0000019,CHEMBL616032,51,,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,9606.0
990,,,,Homo sapiens,,F,,,D,15180,BAO_0000019,CHEMBL616033,51,,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,9606.0
991,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616034,51,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
992,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616035,51,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
993,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616036,51,,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
994,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616037,51,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
995,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616038,51,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
996,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616039,51,,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
997,,,,,,F,,,H,15042,BAO_0000019,CHEMBL616040,51,,Autocuration,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
998,,HeLa,,Homo sapiens,,F,,308.0,D,15180,BAO_0000219,CHEMBL616041,51,,Expert,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9606.0
999,,HeLa,,Homo sapiens,,F,,308.0,D,15180,BAO_0000219,CHEMBL616042,51,,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9606.0
1000,,HeLa,,Homo sapiens,,F,,308.0,D,15180,BAO_0000219,CHEMBL616043,51,,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,9606.0
1001,,,,,,F,,,H,16245,BAO_0000019,CHEMBL616044,51,,Autocuration,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,
1002,,,,,,F,,,H,16026,BAO_0000019,CHEMBL616045,51,,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1003,,HEK293,,,,F,,722.0,H,17296,BAO_0000219,CHEMBL616046,51,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
1004,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL616047,51,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1005,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL616048,51,,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
1006,,CHO,,Homo sapiens,,F,,449.0,D,2759,BAO_0000219,CHEMBL616049,51,,Expert,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,9606.0
1007,,CHO,,,,F,,449.0,H,2759,BAO_0000219,CHEMBL616050,51,,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1008,,,,,,F,,,H,15419,BAO_0000219,CHEMBL616051,51,,Expert,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,
1009,,,,,,F,,,H,15419,BAO_0000219,CHEMBL616212,51,,Autocuration,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,
1010,,,,,,F,,,H,16026,BAO_0000019,CHEMBL616213,51,,Autocuration,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1011,,,,,,B,,,H,1414,BAO_0000219,CHEMBL616214,51,,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,
1012,,,,,,B,,,H,1414,BAO_0000219,CHEMBL616215,51,,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,
1013,,,,,,B,,,H,12861,BAO_0000357,CHEMBL616216,51,,Autocuration,Binding activity radioligand.,,
1014,,,,,,B,,,H,12861,BAO_0000019,CHEMBL616217,51,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1015,,,,,,B,,,H,5104,BAO_0000357,CHEMBL616218,51,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1016,,,,,,B,,,H,5105,BAO_0000357,CHEMBL616219,51,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1017,,,,,,B,,,H,16312,BAO_0000357,CHEMBL616220,51,,Autocuration,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,
1018,,,,Homo sapiens,,B,,,D,15180,BAO_0000357,CHEMBL833493,51,,Expert,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,9606.0
1019,,,,,,B,,,H,5033,BAO_0000357,CHEMBL616221,51,,Autocuration,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,
1020,,CHO,,Homo sapiens,,B,,449.0,D,16909,BAO_0000219,CHEMBL616222,51,,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,9606.0
1021,,,,,,F,,,H,2590,BAO_0000019,CHEMBL616223,51,,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,
1022,,,,,,F,,,H,2590,BAO_0000019,CHEMBL616224,51,,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,
1023,,,,,,B,,,H,16394,BAO_0000019,CHEMBL616225,51,,Expert,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,
1024,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL616226,51,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,9606.0
1025,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL616227,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,
1026,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL616228,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,
1027,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL616229,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1028,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL616230,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,
1029,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL616231,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,
1030,,,,,,B,,,H,6166,BAO_0000357,CHEMBL616232,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
1031,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL616233,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1032,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL857973,51,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,
1033,,,,,,B,,,H,15316,BAO_0000219,CHEMBL616234,51,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,
1034,,,,,,B,,,H,14875,BAO_0000357,CHEMBL616235,51,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,
1035,,HeLa,,,,B,,308.0,H,14727,BAO_0000219,CHEMBL616236,51,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1036,,,,,,B,,,H,14727,BAO_0000019,CHEMBL616237,51,,Expert,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1037,,HEK293,,,,B,,722.0,H,15146,BAO_0000219,CHEMBL616238,51,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,
1038,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL616239,51,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,
1039,,,,,,B,,,H,16429,BAO_0000219,CHEMBL616240,51,,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,
1040,,HeLa,,Homo sapiens,,B,,308.0,D,15042,BAO_0000219,CHEMBL616241,51,,Expert,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,9606.0
1041,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL616242,51,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,
1042,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL616243,51,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,
1043,,,,,,B,,,D,17200,BAO_0000357,CHEMBL616244,51,,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,
1044,,,,Homo sapiens,,B,,,D,13051,BAO_0000357,CHEMBL616245,51,,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,9606.0
1045,,,,,,B,,,H,5486,BAO_0000357,CHEMBL616246,106,,Autocuration,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
1046,,,,,,B,,,H,5254,BAO_0000357,CHEMBL616247,105,,Autocuration,Binding affinity against 5-HT1D receptor,,
1047,,,,,,B,,,H,5254,BAO_0000357,CHEMBL616248,105,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1048,,,,,,B,,,H,15331,BAO_0000357,CHEMBL616249,107,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
1049,,,,Homo sapiens,,B,,,H,13506,BAO_0000357,CHEMBL616250,10576,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,9606.0
1050,,,,,,B,,,H,15267,BAO_0000357,CHEMBL616251,51,,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
1051,,,,,,F,,,H,16616,BAO_0000218,CHEMBL616252,11863,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,
1052,,,,,,F,,,H,16616,BAO_0000218,CHEMBL616253,11863,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,
1053,,,,,,F,,,H,16616,BAO_0000218,CHEMBL616254,11863,,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,
1054,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL616255,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,10090.0
1055,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL832872,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,10090.0
1056,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL616256,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,10090.0
1057,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL616257,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,10090.0
1058,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL616258,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,10090.0
1059,,,,Mus musculus,,F,,,D,16616,BAO_0000218,CHEMBL616384,11863,,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,10090.0
1060,10000000.0,,Hippocampus,,,B,,,H,10297,BAO_0000221,CHEMBL616385,11863,,Autocuration,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,
1061,,,,,,B,,,H,13704,BAO_0000357,CHEMBL616386,11863,,Expert,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,
1062,10000000.0,,Hippocampus,Mus musculus,,B,,,D,10297,BAO_0000221,CHEMBL616387,11863,,Expert,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10090.0
1063,10000000.0,,Hippocampus,,,B,,,H,10297,BAO_0000221,CHEMBL616388,11863,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1064,10000000.0,,Hippocampus,Mus musculus,,B,,,D,10297,BAO_0000221,CHEMBL616389,11863,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10090.0
1065,10000000.0,,Hippocampus,,,B,,,H,10297,BAO_0000221,CHEMBL616390,11863,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1066,,,,,,B,,,H,217,BAO_0000357,CHEMBL616391,11863,,Autocuration,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,
1067,10000000.0,,Hippocampus,Mus musculus,,B,,,D,10297,BAO_0000221,CHEMBL616392,11863,,Expert,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,10090.0
1068,,,,Sus scrofa,,B,,,H,4921,BAO_0000357,CHEMBL616393,51,,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,9823.0
1069,,,,Sus scrofa,,B,,,H,4921,BAO_0000357,CHEMBL616394,51,,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,9823.0
1070,,,,Sus scrofa,,B,,,H,4996,BAO_0000019,CHEMBL616395,51,,Autocuration,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,9823.0
1071,,,,Sus scrofa,,B,,,H,12918,BAO_0000357,CHEMBL616396,51,,Autocuration,Compound was evaluated for the binding affinity at 5- HT1A receptor,,9823.0
1072,,,,Sus scrofa,,B,,,H,5333,BAO_0000019,CHEMBL872907,51,,Autocuration,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,9823.0
1073,,,,Sus scrofa,,B,,,H,4437,BAO_0000019,CHEMBL616397,51,,Autocuration,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,9823.0
1074,,,,Sus scrofa,,B,,,H,1742,BAO_0000019,CHEMBL616398,51,,Autocuration,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,9823.0
1075,,,,Sus scrofa,,B,,,H,16688,BAO_0000357,CHEMBL616399,51,,Expert,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,9823.0
1076,,,,Sus scrofa,,B,,,H,12861,BAO_0000357,CHEMBL857065,51,,Autocuration,Binding activity radioligand.,,9823.0
1077,,,,Sus scrofa,,B,,,H,12861,BAO_0000019,CHEMBL616400,51,,Expert,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,9823.0
1078,,,,Sus scrofa,,B,,,H,12861,BAO_0000019,CHEMBL616401,51,,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,9823.0
1079,,,,,,B,,,H,12490,BAO_0000019,CHEMBL616402,10624,,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,
1080,,,,Sus scrofa,,B,,,H,11828,BAO_0000019,CHEMBL616403,51,,Expert,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,9823.0
1081,10000000.0,,Hippocampus,Sus scrofa,,B,,,H,11866,BAO_0000221,CHEMBL616404,51,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,9823.0
1082,,,,Sus scrofa,,B,,,H,12827,BAO_0000249,CHEMBL616405,51,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,9823.0
1083,,,,Sus scrofa,,B,,,H,12918,BAO_0000019,CHEMBL616406,51,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,9823.0
1084,,,,Sus scrofa,,F,,,H,12919,BAO_0000019,CHEMBL616407,51,,Expert,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,9823.0
1085,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL616408,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,9986.0
1086,,,,Rattus norvegicus,,B,,,D,15796,BAO_0000249,CHEMBL616409,10576,,Expert,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,10116.0
1087,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,3651,BAO_0000221,CHEMBL616410,10576,,Expert,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,10116.0
1088,,,,,,B,,,H,188,BAO_0000357,CHEMBL616411,10576,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,
1089,,,,Rattus norvegicus,,F,Membranes,,D,16616,BAO_0000249,CHEMBL616412,10576,,Expert,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10116.0
1090,10000000.0,,Hippocampus,Rattus norvegicus,,F,Membranes,,D,16616,BAO_0000249,CHEMBL616413,10576,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10116.0
1091,10000000.0,,Hippocampus,,,B,,,H,12306,BAO_0000221,CHEMBL616414,10576,,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1092,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,17167,BAO_0000221,CHEMBL616415,10576,,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,10116.0
1093,,,,,,B,,,H,14776,BAO_0000019,CHEMBL616416,10576,,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,
1094,,,,,,B,,,H,12158,BAO_0000357,CHEMBL616417,10576,,Expert,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,
1095,,,,,,B,,,H,13481,BAO_0000357,CHEMBL616418,10576,,Autocuration,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1096,,,,,,B,,,H,13427,BAO_0000219,CHEMBL616419,10576,,Autocuration,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
1097,,,,,,B,,,H,10210,BAO_0000357,CHEMBL616420,10576,,Autocuration,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,
1098,,,,,,B,Membranes,,H,10205,BAO_0000249,CHEMBL616421,10576,,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1099,,,,,,B,Membranes,,H,10205,BAO_0000249,CHEMBL616422,10576,,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1100,,,,,,B,Membranes,,H,10205,BAO_0000249,CHEMBL616423,10576,,Expert,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,
1101,,,,Rattus norvegicus,,B,,,D,12280,BAO_0000357,CHEMBL616424,10576,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,10116.0
1102,,,,,,B,,,H,17386,BAO_0000357,CHEMBL616425,10576,,Expert,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,
1103,,,,,,B,,,H,13654,BAO_0000357,CHEMBL616426,10576,,Expert,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,
1104,10000000.0,,Hippocampus,,,B,,,H,14423,BAO_0000221,CHEMBL616427,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,
1105,10000000.0,,Hippocampus,,,B,,,H,15412,BAO_0000221,CHEMBL616428,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,
1106,10000000.0,,Hippocampus,,,B,,,H,12073,BAO_0000221,CHEMBL616290,10576,,Autocuration,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1107,,,,Rattus norvegicus,,B,,,D,4101,BAO_0000357,CHEMBL616052,10576,,Expert,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,10116.0
1108,,,,,,B,,,H,10062,BAO_0000357,CHEMBL616053,10576,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,
1109,,,,,,B,,,H,6238,BAO_0000249,CHEMBL616054,10576,,Autocuration,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,
1110,,,,,,B,,,H,16273,BAO_0000357,CHEMBL616055,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1111,,,,,,B,,,H,11139,BAO_0000357,CHEMBL616056,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,
1112,,,,,,B,,,H,16796,BAO_0000019,CHEMBL616057,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1113,955.0,,Brain,Rattus norvegicus,,B,,,D,9548,BAO_0000221,CHEMBL616058,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10116.0
1114,955.0,,Brain,,,B,,,H,10381,BAO_0000221,CHEMBL616059,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1115,,,,,,B,,,H,13408,BAO_0000249,CHEMBL616060,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,
1116,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,13825,BAO_0000221,CHEMBL616061,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,10116.0
1117,10000000.0,,Hippocampus,,,B,,,H,11147,BAO_0000221,CHEMBL616062,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,
1118,,,,,,B,,,H,10552,BAO_0000249,CHEMBL616063,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,
1119,2435.0,,Striatum,,,B,,,H,10552,BAO_0000249,CHEMBL616064,10576,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1120,,,,Rattus norvegicus,,B,Membranes,,D,17136,BAO_0000249,CHEMBL616065,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,10116.0
1121,,,,Rattus norvegicus,,B,Membranes,,D,5778,BAO_0000249,CHEMBL616066,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,10116.0
1122,10000000.0,,Hippocampus,,,B,,,H,13481,BAO_0000221,CHEMBL616067,10576,,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1123,10000000.0,,Hippocampus,,,B,,,H,13481,BAO_0000221,CHEMBL616068,10576,,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,
1124,10000000.0,,Hippocampus,,,B,,,H,13630,BAO_0000221,CHEMBL616069,10576,,Intermediate,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,
1125,,,,,,B,,,H,16245,BAO_0000249,CHEMBL616070,10576,,Expert,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1126,10000000.0,,Hippocampus,,,B,,,H,14509,BAO_0000221,CHEMBL616071,10576,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1127,10000000.0,,Hippocampus,,,B,,,H,14509,BAO_0000221,CHEMBL616072,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1128,10000000.0,,Hippocampus,,,B,,,H,14509,BAO_0000221,CHEMBL616073,10576,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,
1129,10000000.0,,Hippocampus,,,B,,,H,14509,BAO_0000221,CHEMBL616074,10576,,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,
1130,,,,,,B,,,H,14256,BAO_0000019,CHEMBL616075,10576,,Expert,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,
1131,,,,,,B,,,H,11139,BAO_0000357,CHEMBL616076,10576,,Autocuration,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,
1132,,,,Rattus norvegicus,,B,,,D,11047,BAO_0000019,CHEMBL616077,10576,,Expert,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,10116.0
1133,,,,Rattus norvegicus,,B,,,D,11047,BAO_0000019,CHEMBL616078,10576,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,10116.0
1134,,,,Rattus norvegicus,,B,,,D,11047,BAO_0000019,CHEMBL616079,10576,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,10116.0
1135,,CHO-K1,,Rattus norvegicus,,B,,485.0,D,2395,BAO_0000219,CHEMBL616080,10576,,Expert,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,10116.0
1136,,,,,,B,,,H,9699,BAO_0000357,CHEMBL616081,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1137,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,12028,BAO_0000221,CHEMBL616082,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,10116.0
1138,10000000.0,,Hippocampus,,,B,,,H,12028,BAO_0000221,CHEMBL616083,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,
1139,,,,,,B,,,H,5815,BAO_0000019,CHEMBL616084,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1140,,,,,,B,,,H,16616,BAO_0000019,CHEMBL616085,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,
1141,,,,,,B,,,H,5815,BAO_0000019,CHEMBL616086,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,
1142,10000000.0,,Hippocampus,,,B,,,H,2761,BAO_0000221,CHEMBL616087,10576,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,
1143,,,,,,B,,,H,13133,BAO_0000357,CHEMBL616088,10576,,Expert,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,
1144,,,,,,B,,,H,10444,BAO_0000019,CHEMBL616089,10576,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,
1145,,,,Rattus norvegicus,,B,,,D,13278,BAO_0000357,CHEMBL616090,10576,,Expert,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,10116.0
1146,,,,,,B,,,H,15874,BAO_0000357,CHEMBL616091,10576,,Autocuration,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
1147,2435.0,,Striatum,,,B,Membranes,,H,10552,BAO_0000249,CHEMBL616092,10576,,Autocuration,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1148,,,,,,B,,,H,11130,BAO_0000357,CHEMBL616093,10576,,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,
1149,,,,,,B,,,H,11130,BAO_0000218,CHEMBL616094,10576,,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,
1150,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL616095,10576,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,
1151,,,,Rattus norvegicus,,B,,,D,13670,BAO_0000357,CHEMBL616096,10576,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10116.0
1152,,,,,,B,,,H,9888,BAO_0000249,CHEMBL616097,10576,,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,
1153,,,,Rattus norvegicus,,B,Membranes,,D,3678,BAO_0000249,CHEMBL616098,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,10116.0
1154,10000000.0,,Hippocampus,,,B,,,H,11332,BAO_0000221,CHEMBL616099,10576,,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1155,10000000.0,,Hippocampus,,,B,,,H,11332,BAO_0000221,CHEMBL616100,10576,,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1156,,,,,,B,,,H,1185,BAO_0000357,CHEMBL616101,10576,,Expert,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1157,,,,,,B,,,H,2014,BAO_0000249,CHEMBL616102,10576,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,
1158,,,,,,B,,,H,1185,BAO_0000357,CHEMBL616103,10576,,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1159,,,,,,B,,,H,14429,BAO_0000019,CHEMBL616104,10576,,Expert,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,
1160,,,,,,B,,,H,16288,BAO_0000019,CHEMBL616105,10576,,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,
1161,,,,Rattus norvegicus,,B,,,D,5432,BAO_0000019,CHEMBL616106,10576,,Expert,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,10116.0
1162,,,,,,B,,,H,14429,BAO_0000019,CHEMBL616107,10576,,Autocuration,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,
1163,,,,,,B,,,H,13672,BAO_0000357,CHEMBL616108,10576,,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,
1164,10000000.0,,Hippocampus,,,B,,,H,11296,BAO_0000221,CHEMBL616109,10576,,Expert,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1165,,,,,,B,,,H,11296,BAO_0000357,CHEMBL616110,10576,,Autocuration,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,
1166,,CHO,,,,B,,449.0,H,14749,BAO_0000219,CHEMBL616111,10576,,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,
1167,,,,,,B,,,H,15086,BAO_0000019,CHEMBL616112,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,
1168,10000000.0,,Hippocampus,,,B,,,H,13462,BAO_0000221,CHEMBL616113,10576,,Autocuration,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,
1169,,,,,,B,,,H,15363,BAO_0000019,CHEMBL616114,10576,,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1170,,,,,,B,,,H,15363,BAO_0000019,CHEMBL616115,10576,,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1171,,,,,,B,,,H,10796,BAO_0000357,CHEMBL616116,10576,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,
1172,955.0,,Brain,,,B,,,H,12816,BAO_0000221,CHEMBL615844,10576,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,
1173,10000000.0,,Hippocampus,,,B,,,H,13542,BAO_0000221,CHEMBL615939,10576,,Expert,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1174,,,,,,B,,,H,13308,BAO_0000019,CHEMBL615940,10576,,Expert,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,
1175,10000000.0,,Hippocampus,,,B,,,H,13541,BAO_0000221,CHEMBL615941,10576,,Expert,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,
1176,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615942,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,
1177,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615943,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1178,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615944,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,
1179,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615945,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,
1180,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615946,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,
1181,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615947,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,
1182,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615948,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,
1183,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615949,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,
1184,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615950,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,
1185,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615951,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,
1186,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615952,10576,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,
1187,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615953,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,
1188,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615954,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,
1189,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,10058,BAO_0000221,CHEMBL615955,10576,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10116.0
1190,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615956,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,
1191,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL615957,10576,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,
1192,,,,,,B,,,H,12879,BAO_0000019,CHEMBL615958,10576,,Expert,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,
1193,,,,,,B,,,H,11964,BAO_0000019,CHEMBL615959,10576,,Expert,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,
1194,,,,,,B,,,H,11964,BAO_0000019,CHEMBL615960,10576,,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,
1195,,,,,,B,,,H,11964,BAO_0000019,CHEMBL615961,10576,,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,
1196,955.0,,Brain,,,B,,,H,9548,BAO_0000221,CHEMBL615962,10576,,Expert,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1197,,,,,,B,,,H,9098,BAO_0000019,CHEMBL615963,10576,,Expert,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,
1198,,,,,,B,,,H,9098,BAO_0000019,CHEMBL615964,10576,,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,
1199,,,,,,B,,,H,9098,BAO_0000019,CHEMBL615965,10576,,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,
1200,,CHO,,,,B,,449.0,H,13248,BAO_0000219,CHEMBL615966,10576,,Expert,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,
1201,,,,,,B,,,H,3147,BAO_0000249,CHEMBL615967,10576,,Expert,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,
1202,,,,,,B,,,H,13949,BAO_0000019,CHEMBL615968,10576,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1203,,CHO,,,,B,,449.0,H,11883,BAO_0000218,CHEMBL615969,10576,,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,
1204,,,,,,B,,,H,11883,BAO_0000218,CHEMBL615970,10576,,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,
1205,,,,Rattus norvegicus,,B,,,D,11883,BAO_0000357,CHEMBL615971,10576,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,10116.0
1206,,,,,,B,Membranes,,H,15535,BAO_0000249,CHEMBL615972,10576,,Expert,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1207,,,,,,B,,,H,15535,BAO_0000249,CHEMBL615973,10576,,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,
1208,,,,,,B,,,H,15535,BAO_0000249,CHEMBL615974,10576,,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,
1209,,CHO,,Homo sapiens,,B,,449.0,D,16372,BAO_0000219,CHEMBL615975,51,,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,9606.0
1210,,,,,,B,,,H,14608,BAO_0000249,CHEMBL615976,10576,,Expert,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,
1211,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,4795,BAO_0000221,CHEMBL872106,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,10116.0
1212,,,,,,B,,,H,13863,BAO_0000357,CHEMBL615977,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1213,,,,,,B,,,H,13863,BAO_0000357,CHEMBL615978,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,
1214,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616166,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,
1215,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616167,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,
1216,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616168,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,
1217,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616169,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,
1218,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616170,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,
1219,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616171,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,
1220,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616172,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,
1221,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616173,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,
1222,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616174,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,
1223,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616175,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,
1224,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616176,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,
1225,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616177,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,
1226,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616178,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,
1227,,,,,,B,,,H,9742,BAO_0000019,CHEMBL616179,10576,,Autocuration,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,
1228,,,,,,B,,,H,12073,BAO_0000357,CHEMBL616180,10576,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,
1229,,,,,,B,,,H,4101,BAO_0000357,CHEMBL616181,10576,,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,
1230,,,,,,B,,,H,15360,BAO_0000019,CHEMBL616182,10576,,Autocuration,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,
1231,10000000.0,,Hippocampus,,,B,,,H,11576,BAO_0000221,CHEMBL616183,10576,,Autocuration,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1232,,,,,,B,,,H,5834,BAO_0000019,CHEMBL615874,10576,,Expert,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,
1233,,CHO-K1,,Rattus norvegicus,,B,,485.0,D,2395,BAO_0000219,CHEMBL615875,10576,,Expert,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,10116.0
1234,,,,,,B,,,H,1375,BAO_0000019,CHEMBL615876,10576,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,
1235,,,,,,B,,,H,1375,BAO_0000019,CHEMBL615877,10576,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,
1236,,,,,,B,,,H,3967,BAO_0000357,CHEMBL615878,10576,,Autocuration,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,
1237,,,,,,B,,,H,12884,BAO_0000357,CHEMBL615879,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,
1238,,,,,,B,,,H,2343,BAO_0000357,CHEMBL615880,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,
1239,,,,,,B,,,H,11511,BAO_0000019,CHEMBL615881,10576,,Autocuration,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,
1240,,,,Rattus norvegicus,,B,,,D,11511,BAO_0000019,CHEMBL615882,10576,,Expert,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10116.0
1241,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615883,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,
1242,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615884,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,
1243,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615885,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,
1244,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615886,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,
1245,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615887,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,
1246,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615888,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,
1247,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615889,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,
1248,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615890,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,
1249,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615891,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,
1250,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615892,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,
1251,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615893,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,
1252,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615894,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,
1253,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615895,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,
1254,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615896,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,
1255,,,,,,F,,,H,16394,BAO_0000218,CHEMBL615897,10576,,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,
1256,,,,Rattus norvegicus,,F,Membranes,,D,16616,BAO_0000249,CHEMBL615898,10576,,Expert,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,10116.0
1257,,,,,,B,,,H,16796,BAO_0000019,CHEMBL615899,10576,,Autocuration,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,
1258,,,,,,B,,,H,16796,BAO_0000019,CHEMBL616291,10576,,Autocuration,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1259,,,,,,B,,,H,15629,BAO_0000357,CHEMBL616292,10576,,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,
1260,,,,,,F,,,H,13241,BAO_0000249,CHEMBL616293,10576,,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
1261,10000000.0,,Hippocampus,,,B,,,H,12073,BAO_0000221,CHEMBL616294,10576,,Expert,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1262,10000000.0,,Hippocampus,,,B,,,H,14286,BAO_0000249,CHEMBL616295,10576,,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,
1263,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL616296,10576,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,
1264,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616297,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1265,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616605,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,
1266,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616606,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,
1267,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616607,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1268,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616608,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1269,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616609,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,
1270,,,,Rattus norvegicus,,F,,,D,13630,BAO_0000019,CHEMBL616610,10576,,Expert,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,10116.0
1271,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616611,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1272,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616612,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,
1273,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616613,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,
1274,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616614,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,
1275,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616615,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,
1276,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616616,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1277,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616617,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,
1278,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616618,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1279,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616619,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,
1280,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616620,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,
1281,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616621,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1282,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616622,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,
1283,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616146,10576,,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,
1284,,,,,,F,,,H,13630,BAO_0000019,CHEMBL832873,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,
1285,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616147,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,
1286,,,,,,F,,,H,13630,BAO_0000019,CHEMBL872872,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1287,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616148,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1288,10000000.0,,Hippocampus,,,B,,,H,9783,BAO_0000221,CHEMBL616149,10576,,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,
1289,10000000.0,,Hippocampus,,,B,,,H,9783,BAO_0000221,CHEMBL616150,10576,,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,
1290,,,,Rattus norvegicus,,B,Membranes,,D,14331,BAO_0000249,CHEMBL616151,10576,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,10116.0
1291,10000000.0,,Hippocampus,,,B,,,H,15260,BAO_0000221,CHEMBL872873,10576,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,
1292,10000000.0,,Hippocampus,,,B,,,H,15260,BAO_0000221,CHEMBL616670,10576,,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,
1293,10000000.0,,Hippocampus,,,B,,,H,15260,BAO_0000221,CHEMBL616671,10576,,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,
1294,,,,Rattus norvegicus,,F,,,D,16616,BAO_0000249,CHEMBL884861,10576,,Expert,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,10116.0
1295,,,,,,B,,,H,15629,BAO_0000357,CHEMBL616672,10576,,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,
1296,,,,,,B,,,H,15086,BAO_0000019,CHEMBL616673,10576,,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1297,,,,,,F,,,H,5717,BAO_0000019,CHEMBL616674,10576,,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1298,,,,,,B,,,H,12652,BAO_0000357,CHEMBL616675,10576,,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1299,10000000.0,,Hippocampus,,,B,,,H,14608,BAO_0000221,CHEMBL616676,10576,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,
1300,10000000.0,,Hippocampus,,,B,,,H,12306,BAO_0000221,CHEMBL616677,10576,,Autocuration,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1301,10000000.0,,Hippocampus,,,B,,,H,12306,BAO_0000221,CHEMBL616678,10576,,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1302,,,,Rattus norvegicus,,B,,,D,15247,BAO_0000357,CHEMBL616679,10576,,Expert,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10116.0
1303,10000000.0,,Hippocampus,,,B,,,H,17529,BAO_0000221,CHEMBL616680,10576,,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,
1304,10000000.0,,Hippocampus,,,B,,,H,14826,BAO_0000221,CHEMBL616681,10576,,Autocuration,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1305,10000000.0,,Hippocampus,,,B,,,H,14826,BAO_0000221,CHEMBL616682,10576,,Autocuration,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1306,10000000.0,,Hippocampus,,,B,,,H,13241,BAO_0000221,CHEMBL616683,10576,,Autocuration,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1307,10000000.0,,Hippocampus,,,B,,,H,14093,BAO_0000221,CHEMBL616684,10576,,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,
1308,10000000.0,,Hippocampus,,,B,,,H,14093,BAO_0000221,CHEMBL616685,10576,,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,
1309,955.0,,Brain,,,B,,,H,14442,BAO_0000221,CHEMBL616686,10576,,Autocuration,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,
1310,,,,,,B,,,H,9919,BAO_0000357,CHEMBL616687,10576,,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,,
1311,,,,,,B,,,H,9919,BAO_0000357,CHEMBL616688,10576,,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,,
1312,10000000.0,,Hippocampus,,,B,,,H,11440,BAO_0000221,CHEMBL616689,10576,,Autocuration,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,
1313,,,,,,B,,,H,11257,BAO_0000357,CHEMBL616690,10576,,Autocuration,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,
1314,,,,,,B,,,H,10330,BAO_0000357,CHEMBL616691,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,
1315,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,17331,BAO_0000221,CHEMBL616692,10576,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,10116.0
1316,,,,,,B,,,H,16567,BAO_0000249,CHEMBL616693,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,
1317,,,,Rattus norvegicus,,B,,,D,12058,BAO_0000019,CHEMBL616694,10576,,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10116.0
1318,10000000.0,,Hippocampus,,,B,,,H,9699,BAO_0000221,CHEMBL616695,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,
1319,,,,,,B,,,H,9547,BAO_0000357,CHEMBL616696,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,
1320,,,,,,B,,,H,10330,BAO_0000357,CHEMBL616697,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,
1321,,,,,,B,,,H,14331,BAO_0000357,CHEMBL616698,10576,,Autocuration,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,
1322,,,,Rattus norvegicus,,B,,,D,14060,BAO_0000019,CHEMBL616949,10576,,Expert,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,10116.0
1323,10000000.0,,Hippocampus,,,B,,,H,14744,BAO_0000221,CHEMBL616950,10576,,Autocuration,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,
1324,,,,,,B,,,H,13506,BAO_0000357,CHEMBL832875,10576,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,
1325,955.0,,Brain,,,B,,,H,10862,BAO_0000221,CHEMBL616951,10576,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1326,955.0,,Brain,,,B,,,H,10862,BAO_0000221,CHEMBL616952,10576,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1327,,,,,,B,,,H,10062,BAO_0000357,CHEMBL616953,10576,,Expert,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,
1328,,,,,,B,,,H,12073,BAO_0000357,CHEMBL616954,10576,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,
1329,,,,,,B,,,H,14875,BAO_0000357,CHEMBL616955,106,,Autocuration,GTPgammaS radioligand binding assay,,
1330,,,,,,B,,,H,2391,BAO_0000357,CHEMBL616956,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1331,,,,,,F,,,H,2391,BAO_0000019,CHEMBL616957,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,
1332,,,,,,F,,,H,2391,BAO_0000019,CHEMBL616958,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,
1333,,,,,,B,,,H,2391,BAO_0000357,CHEMBL616959,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1334,,,,,,B,,,H,2391,BAO_0000357,CHEMBL616960,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1335,,,,,,F,,,H,2391,BAO_0000019,CHEMBL616961,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,
1336,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616962,106,,Expert,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,
1337,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616963,106,,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,
1338,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL616524,106,,Expert,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,9606.0
1339,,CHO,,,,B,,449.0,H,16190,BAO_0000219,CHEMBL616525,106,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,
1340,,,,,,B,,,H,14165,BAO_0000019,CHEMBL872908,106,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,
1341,,,,,,B,,,H,14165,BAO_0000019,CHEMBL616526,106,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,
1342,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL616527,106,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,9606.0
1343,,,,,,B,,,H,6328,BAO_0000219,CHEMBL616528,106,,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1344,,,,,,B,,,H,14770,BAO_0000357,CHEMBL616529,106,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1345,,,,,,B,,,H,2598,BAO_0000357,CHEMBL616530,106,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,
1346,,,,,,B,,,H,6897,BAO_0000357,CHEMBL616531,106,,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1347,,,,,,B,,,H,6897,BAO_0000357,CHEMBL616532,106,,Autocuration,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1348,,,,,,B,,,H,6013,BAO_0000357,CHEMBL616533,106,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor,,
1349,,,,,,B,,,H,5843,BAO_0000357,CHEMBL616534,106,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,
1350,,,,,,B,,,H,14454,BAO_0000357,CHEMBL616535,106,,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,
1351,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616536,106,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,
1352,,,,,,B,,,H,3935,BAO_0000357,CHEMBL616537,106,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,
1353,,CHO-K1,,,,F,,485.0,H,13729,BAO_0000219,CHEMBL616538,106,,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,
1354,,,,,,F,,,H,14251,BAO_0000019,CHEMBL616539,106,,Expert,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,
1355,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616540,106,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,
1356,,,,,,B,,,H,3025,BAO_0000357,CHEMBL616429,106,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1357,,,,,,B,,,H,15315,BAO_0000357,CHEMBL616430,106,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,
1358,,,,Homo sapiens,,B,,,D,14214,BAO_0000219,CHEMBL616431,106,,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,9606.0
1359,,,,Homo sapiens,,B,,,D,3804,BAO_0000357,CHEMBL616432,106,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,9606.0
1360,,,,Homo sapiens,,B,,,D,2391,BAO_0000357,CHEMBL616433,106,,Expert,Affinity for 5-hydroxytryptamine 1B receptor subtype,,9606.0
1361,,,,Homo sapiens,,B,,,D,4175,BAO_0000357,CHEMBL616434,106,,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,,9606.0
1362,,CHO,,,,B,,449.0,H,17296,BAO_0000219,CHEMBL616435,106,,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,
1363,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616436,106,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,
1364,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616437,106,,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1365,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616438,106,,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,
1366,,HeLa,,,,B,,308.0,H,17211,BAO_0000219,CHEMBL616439,106,,Autocuration,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1367,,,,Homo sapiens,,B,,,D,15926,BAO_0000357,CHEMBL616440,106,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,9606.0
1368,,CHO-K1,,,,B,,485.0,H,16312,BAO_0000219,CHEMBL616441,106,,Autocuration,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,
1369,,,,,,B,,,H,5843,BAO_0000357,CHEMBL616442,106,,Expert,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,
1370,,,,,,B,,,H,5843,BAO_0000357,CHEMBL616443,106,,Autocuration,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,
1371,,CHO-K1,,,,B,,485.0,H,16312,BAO_0000219,CHEMBL616444,106,,Expert,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,
1372,,,,Homo sapiens,,B,,,D,15926,BAO_0000357,CHEMBL616445,106,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,,9606.0
1373,,,,Homo sapiens,,B,,,D,15926,BAO_0000357,CHEMBL616446,106,,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,,9606.0
1374,,CHO,,Homo sapiens,,B,,449.0,D,4540,BAO_0000219,CHEMBL616447,106,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,9606.0
1375,,,,,,B,,,H,6166,BAO_0000357,CHEMBL616448,106,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,
1376,,CHO,,,,B,,449.0,H,17296,BAO_0000219,CHEMBL616449,106,,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,
1377,,CHO,,,,B,,449.0,H,17296,BAO_0000219,CHEMBL616450,106,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,
1378,,CHO,,,,B,,449.0,H,17296,BAO_0000219,CHEMBL857974,106,,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,
1379,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616451,106,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1380,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616452,106,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1381,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616453,106,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
1382,,CHO,,,,B,,449.0,H,4199,BAO_0000219,CHEMBL616454,106,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,
1383,,,,Homo sapiens,,B,,,D,14875,BAO_0000357,CHEMBL616455,106,,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,,9606.0
1384,,CHO,,,,B,,449.0,H,15146,BAO_0000219,CHEMBL616456,106,,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1385,,,,,,B,,,H,5213,BAO_0000357,CHEMBL616457,106,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,
1386,,CHO,,,,B,,449.0,H,14818,BAO_0000219,CHEMBL616458,106,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1387,,CHO,,,,B,,449.0,H,4829,BAO_0000219,CHEMBL616459,106,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,
1388,,,,,,F,,,H,14454,BAO_0000019,CHEMBL616460,106,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,
1389,,,,,,F,,,H,14454,BAO_0000019,CHEMBL616461,106,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,
1390,,CHO,,,,F,,449.0,H,14875,BAO_0000219,CHEMBL616462,106,,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1391,,CHO,,,,F,,449.0,H,14875,BAO_0000219,CHEMBL616463,106,,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1392,,,,,,F,,,H,15250,BAO_0000019,CHEMBL616464,105,,Autocuration,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,
1393,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616465,105,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,
1394,,,,,,B,,,H,15086,BAO_0000357,CHEMBL832874,17105,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1395,,,,Oryctolagus cuniculus,,F,,,H,3025,BAO_0000019,CHEMBL616184,106,,Autocuration,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,9986.0
1396,,,,Oryctolagus cuniculus,,B,,,H,14998,BAO_0000019,CHEMBL616185,106,,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,9986.0
1397,,,,Oryctolagus cuniculus,,B,,,H,14998,BAO_0000019,CHEMBL616186,106,,Intermediate,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,9986.0
1398,,,,Oryctolagus cuniculus,,B,,,H,14998,BAO_0000019,CHEMBL616187,106,,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,9986.0
1399,,,,,,B,,,H,13969,BAO_0000357,CHEMBL616188,10577,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,
1400,,,,,,B,,,D,13392,BAO_0000357,CHEMBL873475,10577,,Intermediate,Binding affinity for 5-hydroxytryptamine 1B receptor,,
1401,2435.0,,Striatum,Rattus norvegicus,,B,,,D,3651,BAO_0000019,CHEMBL616189,10577,,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,10116.0
1402,,,,,,B,,,H,10025,BAO_0000357,CHEMBL616190,10577,,Expert,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1403,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616191,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,
1404,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616192,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,
1405,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616193,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,
1406,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616194,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,
1407,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616195,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,
1408,,,,,,B,,,H,13863,BAO_0000357,CHEMBL616196,10576,,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,
1409,10000000.0,,Hippocampus,,,B,,,H,4622,BAO_0000249,CHEMBL616197,10576,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,
1410,,,,,,B,,,H,14911,BAO_0000019,CHEMBL616198,10576,,Intermediate,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
1411,10000000.0,,Hippocampus,,,B,,,H,12678,BAO_0000221,CHEMBL616199,10576,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
1412,10000000.0,,Hippocampus,,,B,,,H,12678,BAO_0000221,CHEMBL616200,10576,,Expert,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,
1413,10000000.0,,Hippocampus,,,B,,,H,14235,BAO_0000221,CHEMBL616201,10576,,Expert,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1414,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616202,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1415,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616203,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1416,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616204,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,
1417,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616205,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,
1418,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616206,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,
1419,,,,,,B,,,H,16118,BAO_0000249,CHEMBL616207,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
1420,,,,,,B,,,H,3268,BAO_0000249,CHEMBL616208,10576,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,
1421,,,,,,B,,,H,3268,BAO_0000249,CHEMBL616209,10576,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,
1422,,,,,,B,,,H,16117,BAO_0000357,CHEMBL616210,10576,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,
1423,10000000.0,,Hippocampus,,,B,,,H,9783,BAO_0000221,CHEMBL616211,10576,,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,
1424,10000000.0,,Hippocampus,,,B,,,H,9783,BAO_0000221,CHEMBL616504,10576,,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,
1425,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,14356,BAO_0000221,CHEMBL616505,10576,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10116.0
1426,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616506,10576,,Autocuration,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
1427,10000000.0,,Hippocampus,,,B,,,H,12306,BAO_0000221,CHEMBL872107,10576,,Autocuration,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1428,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,13348,BAO_0000221,CHEMBL616507,10576,,Expert,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,10116.0
1429,,,,,,B,,,H,10394,BAO_0000249,CHEMBL616303,10576,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,
1430,10000000.0,,Hippocampus,,,B,,,H,15260,BAO_0000221,CHEMBL616304,10576,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,
1431,10000000.0,,Hippocampus,,,B,,,H,10046,BAO_0000221,CHEMBL616305,10576,,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
1432,10000000.0,,Hippocampus,,,F,,,H,15260,BAO_0000221,CHEMBL616306,10576,,Intermediate,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,
1433,,,,,,B,,,H,12851,BAO_0000357,CHEMBL616307,10576,,Autocuration,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,
1434,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,2148,BAO_0000221,CHEMBL881829,10576,,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,10116.0
1435,,,,,,B,,,H,13134,BAO_0000357,CHEMBL616308,10576,,Expert,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,
1436,,,,,,B,,,H,12462,BAO_0000019,CHEMBL616309,10576,,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,
1437,,,,,,B,,,H,12462,BAO_0000019,CHEMBL616310,10576,,Expert,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,
1438,,CHO,,,,B,,449.0,H,12462,BAO_0000219,CHEMBL616311,10576,,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,
1439,,,,,,B,,,H,11933,BAO_0000357,CHEMBL616312,10576,,Expert,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,
1440,,,,,,B,,,H,11933,BAO_0000357,CHEMBL616313,10576,,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,
1441,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,403,BAO_0000221,CHEMBL616314,10576,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,10116.0
1442,10000000.0,,Hippocampus,,,B,,,H,15538,BAO_0000221,CHEMBL616315,10576,,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1443,10000000.0,,Hippocampus,,,B,,,H,15538,BAO_0000221,CHEMBL616567,10576,,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,
1444,10000000.0,,Hippocampus,,,B,,,H,15538,BAO_0000221,CHEMBL616568,10576,,Autocuration,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,
1445,,,,,,B,,,H,12464,BAO_0000019,CHEMBL616569,10576,,Intermediate,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,
1446,,,,,,B,,,H,1455,BAO_0000357,CHEMBL616570,10576,,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,
1447,,,,,,B,,,H,12652,BAO_0000357,CHEMBL616571,10576,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1448,10000000.0,,Hippocampus,,,B,,,H,12639,BAO_0000221,CHEMBL616572,10576,,Autocuration,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,
1449,,,,,,B,,,H,13949,BAO_0000249,CHEMBL616573,10576,,Expert,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,
1450,,,,Rattus norvegicus,,B,,,D,12463,BAO_0000357,CHEMBL616574,10576,,Expert,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,10116.0
1451,10000000.0,,Hippocampus,,,B,,,H,14829,BAO_0000221,CHEMBL616575,10576,,Expert,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,
1452,10000000.0,,Hippocampus,,,B,,,H,14829,BAO_0000221,CHEMBL872108,10576,,Autocuration,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,
1453,,,,,,B,,,H,12092,BAO_0000357,CHEMBL616576,10576,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,
1454,,,,,,B,,,H,403,BAO_0000249,CHEMBL616577,10576,,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,
1455,,,,,,B,,,H,403,BAO_0000249,CHEMBL616578,10576,,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,
1456,,,,,,B,,,H,3967,BAO_0000357,CHEMBL616579,10576,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,
1457,,,,Rattus norvegicus,,B,,,D,12771,BAO_0000019,CHEMBL616580,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,10116.0
1458,,,,,,B,,,H,15086,BAO_0000019,CHEMBL616581,10576,,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1459,10000000.0,,Hippocampus,,,B,,,H,14909,BAO_0000221,CHEMBL616582,10576,,Autocuration,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1460,10000000.0,,Hippocampus,,,B,,,H,14949,BAO_0000221,CHEMBL616583,10576,,Expert,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1461,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,2309,BAO_0000221,CHEMBL616584,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,10116.0
1462,,,,,,B,,,H,4170,BAO_0000357,CHEMBL616585,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1463,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,11642,BAO_0000221,CHEMBL616586,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,10116.0
1464,10000000.0,,Hippocampus,,,B,,,H,11642,BAO_0000221,CHEMBL616587,10576,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,
1465,10000000.0,,Hippocampus,,,B,,,H,12953,BAO_0000221,CHEMBL616588,10576,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,
1466,10000000.0,,Hippocampus,,,B,,,H,12953,BAO_0000221,CHEMBL616589,10576,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1467,10000000.0,,Hippocampus,,,B,,,H,12953,BAO_0000221,CHEMBL616590,10576,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1468,,CHO,,,,B,,449.0,H,12903,BAO_0000219,CHEMBL616591,10576,,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,
1469,,,,,,B,,,H,12536,BAO_0000357,CHEMBL616592,10576,,Expert,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1470,,,,,,B,,,H,10058,BAO_0000357,CHEMBL616593,10576,,Autocuration,The inhibition activity of 5-HT1A at 1 uM,,
1471,,CHO-K1,,,,B,,485.0,H,12902,BAO_0000219,CHEMBL616594,10576,,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,
1472,,,,,,B,,,H,14057,BAO_0000249,CHEMBL616595,10576,,Expert,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,
1473,,,,,,B,,,H,11296,BAO_0000357,CHEMBL616596,10576,,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,
1474,10000000.0,,Hippocampus,,,B,,,H,11296,BAO_0000221,CHEMBL616597,10576,,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1475,10000000.0,,Hippocampus,,,B,,,H,11296,BAO_0000221,CHEMBL616598,10576,,Expert,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1476,,,,Rattus norvegicus,,F,Membranes,,D,16616,BAO_0000249,CHEMBL616599,10576,,Expert,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,10116.0
1477,10000000.0,,Hippocampus,Rattus norvegicus,,F,Membranes,,D,16616,BAO_0000249,CHEMBL616600,10576,,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,10116.0
1478,,,,,,B,,,H,16567,BAO_0000019,CHEMBL616601,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,
1479,,,,,,B,,,H,16567,BAO_0000019,CHEMBL616602,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,
1480,,,,,,B,,,H,16567,BAO_0000019,CHEMBL616603,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,
1481,,,,,,B,,,H,16567,BAO_0000019,CHEMBL616604,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,
1482,,,,,,B,,,H,17136,BAO_0000249,CHEMBL616316,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,
1483,,,,,,B,,,H,17136,BAO_0000249,CHEMBL616317,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,
1484,,,,Rattus norvegicus,,B,,,D,16616,BAO_0000019,CHEMBL616318,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,10116.0
1485,10000000.0,,Hippocampus,,,B,,,H,17331,BAO_0000221,CHEMBL616319,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,
1486,10000000.0,,Hippocampus,,,B,,,H,17331,BAO_0000221,CHEMBL616320,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,
1487,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,17167,BAO_0000221,CHEMBL616321,10576,,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,10116.0
1488,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616322,10576,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1489,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616323,10576,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,
1490,,,,,,B,,,H,4671,BAO_0000357,CHEMBL616324,10576,,Autocuration,Ratio of binding affinity to 5-HT 1A and D2 receptor,,
1491,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL616325,10576,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1492,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL616326,10576,,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1493,10000000.0,,Hippocampus,,,B,,,H,10058,BAO_0000221,CHEMBL616327,10576,,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,
1494,,,,,,B,,,H,12073,BAO_0000357,CHEMBL616328,10576,,Autocuration,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,
1495,,,,,,B,,,H,2759,BAO_0000249,CHEMBL858110,10576,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1496,,,,,,F,,,H,2759,BAO_0000249,CHEMBL616329,10576,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1497,,,,,,B,,,H,2759,BAO_0000249,CHEMBL616330,10576,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1498,,,,,,F,,,H,2759,BAO_0000249,CHEMBL616331,10576,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1499,,,,,,F,,,H,2759,BAO_0000249,CHEMBL616332,10576,,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1500,955.0,,Brain,,,B,,,H,9737,BAO_0000249,CHEMBL857063,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1501,,,,,,B,,,H,9737,BAO_0000019,CHEMBL616333,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,
1502,,,,,,F,,,H,5717,BAO_0000019,CHEMBL616334,10576,,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,
1503,10000000.0,,Hippocampus,,,B,,,H,12253,BAO_0000221,CHEMBL616335,10576,,Autocuration,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1504,,,,,,B,,,H,14025,BAO_0000019,CHEMBL616336,10576,,Autocuration,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,
1505,,,,,,B,,,H,10425,BAO_0000249,CHEMBL616337,10576,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,
1506,,,,,,B,,,H,14998,BAO_0000019,CHEMBL616338,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,
1507,10000000.0,,Hippocampus,,,B,,,H,13694,BAO_0000221,CHEMBL616339,10576,,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,
1508,10000000.0,,Hippocampus,,,B,,,H,13694,BAO_0000221,CHEMBL616340,10576,,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,
1509,,,,,,B,,,H,4342,BAO_0000357,CHEMBL616341,10576,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,
1510,,,,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL616342,10576,,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10116.0
1511,,,,Rattus norvegicus,,B,,,D,13144,BAO_0000019,CHEMBL616343,10576,,Expert,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,10116.0
1512,,,,,,B,,,H,13343,BAO_0000019,CHEMBL616344,10576,,Expert,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,
1513,,,,,,B,,,H,12132,BAO_0000357,CHEMBL616345,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1514,,,,,,B,,,H,15419,BAO_0000019,CHEMBL616346,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,
1515,10000000.0,,Hippocampus,,,B,,,H,1479,BAO_0000221,CHEMBL616347,10576,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1516,,,,,,B,,,H,14287,BAO_0000019,CHEMBL616348,10576,,Expert,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,
1517,,,,,,B,,,H,13116,BAO_0000357,CHEMBL616349,10576,,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1518,,,,Rattus norvegicus,,B,Membranes,,D,2759,BAO_0000249,CHEMBL616152,10576,,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,10116.0
1519,,,,,,B,,,H,2759,BAO_0000249,CHEMBL616153,10576,,Autocuration,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1520,,,,,,B,,,H,14748,BAO_0000019,CHEMBL616154,10576,,Expert,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,
1521,,,,,,B,,,H,12304,BAO_0000019,CHEMBL616155,10576,,Autocuration,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1522,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,12409,BAO_0000221,CHEMBL616156,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,10116.0
1523,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,12409,BAO_0000221,CHEMBL616157,10576,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,10116.0
1524,10000000.0,,Hippocampus,,,B,,,H,13267,BAO_0000221,CHEMBL616158,10576,,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,
1525,,,,,,B,,,H,15194,BAO_0000357,CHEMBL616159,10576,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1526,,,,,,B,,,H,14256,BAO_0000357,CHEMBL616160,10576,,Expert,pKi value against rat 5-hydroxytryptamine 1A receptor.,,
1527,,,,,,B,,,H,16567,BAO_0000019,CHEMBL616161,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,
1528,,,,,,F,,,H,15740,BAO_0000019,CHEMBL616162,10576,,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1529,,,,Rattus norvegicus,,B,,,D,13278,BAO_0000357,CHEMBL616163,12687,,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,10116.0
1530,,,,,,B,Membranes,,H,1970,BAO_0000249,CHEMBL616164,10626,,Expert,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1531,955.0,,Brain,,,B,,,H,10034,BAO_0000221,CHEMBL616165,10576,,Autocuration,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,
1532,,,,Rattus norvegicus,,B,,,H,13348,BAO_0000019,CHEMBL616355,51,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,10116.0
1533,,,,,,F,,,H,13630,BAO_0000019,CHEMBL616356,10576,,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1534,955.0,,Brain,,,B,,,H,10862,BAO_0000221,CHEMBL616357,10576,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1535,,,,,,B,,,H,12058,BAO_0000019,CHEMBL616358,10576,,Autocuration,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,
1536,,,,,,B,,,H,4639,BAO_0000357,CHEMBL616359,51,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,
1537,,,,,,B,,,H,15453,BAO_0000357,CHEMBL616360,51,,Expert,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,
1538,,,,,,B,,,H,4820,BAO_0000357,CHEMBL616361,51,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1539,,,,,,B,,,H,1089,BAO_0000357,CHEMBL616362,51,,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,
1540,,,,,,B,Brain membranes,,H,386,BAO_0000249,CHEMBL616363,51,,Autocuration,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,
1541,,,,,,B,,,H,6011,BAO_0000357,CHEMBL616364,51,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,
1542,,,,,,B,,,H,5014,BAO_0000357,CHEMBL616365,51,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,
1543,,,,,,B,,,H,4402,BAO_0000357,CHEMBL616366,51,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,
1544,,,,,,B,,,H,17066,BAO_0000357,CHEMBL872906,51,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1545,,,,,,B,,,H,17515,BAO_0000357,CHEMBL616367,51,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,
1546,,,,,,B,,,H,2474,BAO_0000357,CHEMBL616368,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1547,,,,,,B,,,H,4775,BAO_0000357,CHEMBL616369,51,,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,
1548,,,,Homo sapiens,,B,,,D,14294,BAO_0000357,CHEMBL616370,51,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,9606.0
1549,,,,Homo sapiens,,B,,,D,14294,BAO_0000357,CHEMBL616371,51,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,9606.0
1550,,CHO,,,,B,,449.0,H,12249,BAO_0000219,CHEMBL616372,51,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1551,,,,,,B,,,H,11376,BAO_0000219,CHEMBL616373,51,,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,
1552,,,,,,B,,,H,2474,BAO_0000218,CHEMBL616374,51,,Autocuration,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,
1553,10000000.0,,Hippocampus,,,B,,,H,13311,BAO_0000221,CHEMBL616375,51,,Autocuration,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
1554,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616376,51,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,
1555,,,,,,B,,,H,1633,BAO_0000357,CHEMBL857064,51,,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,
1556,,,,,,B,,,H,11866,BAO_0000357,CHEMBL616377,51,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1557,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616378,51,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1558,,,,,,B,,,H,4687,BAO_0000357,CHEMBL616379,51,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,
1559,,,,,,B,,,H,16946,BAO_0000357,CHEMBL616380,11863,,Autocuration,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1560,,,,,,B,,,H,13291,BAO_0000357,CHEMBL616381,11863,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,
1561,,,,,,B,,,H,14159,BAO_0000357,CHEMBL616382,11863,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,
1562,,,,,,B,,,H,10812,BAO_0000357,CHEMBL616383,11863,,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,
1563,,CHO,,Mus musculus,,B,,449.0,D,3032,BAO_0000219,CHEMBL616350,11863,,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,10090.0
1564,,,,,,B,,,H,16655,BAO_0000357,CHEMBL616351,11863,,Autocuration,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
1565,,,,,,B,,,H,14532,BAO_0000357,CHEMBL616352,11863,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,
1566,,,,,,B,,,H,13944,BAO_0000357,CHEMBL616353,11863,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1567,,,,,,B,,,H,13033,BAO_0000357,CHEMBL616354,11863,,Autocuration,Binding affinity against serotonergic 5-HT1a receptor,,
1568,,,,,,B,,,H,10321,BAO_0000357,CHEMBL616508,11863,,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,
1569,,,,Mus musculus,,B,,,D,2968,BAO_0000357,CHEMBL616559,11863,,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,,10090.0
1570,,,,,,B,,,H,13964,BAO_0000357,CHEMBL616560,11863,,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1571,,,,,,B,,,H,15527,BAO_0000357,CHEMBL616561,11863,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,
1572,,CHO,,,,B,,449.0,H,12248,BAO_0000219,CHEMBL616562,11863,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1573,,CHO,,,,B,,449.0,H,12249,BAO_0000219,CHEMBL616563,11863,,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1574,,,,,,B,,,H,15120,BAO_0000357,CHEMBL616564,11863,,Autocuration,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,
1575,,,,,,B,,,H,13313,BAO_0000357,CHEMBL616565,11863,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,
1576,,,,,,B,,,H,2613,BAO_0000218,CHEMBL616566,11863,,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,
1577,,,,,,B,,,H,16700,BAO_0000357,CHEMBL616989,11863,,Autocuration,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,
1578,,,,,,B,,,H,2201,BAO_0000357,CHEMBL857975,11863,,Autocuration,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,
1579,,,,Mus musculus,,B,,,D,1274,BAO_0000357,CHEMBL616990,11863,,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,,10090.0
1580,,,,,,B,,,H,1317,BAO_0000357,CHEMBL616991,11863,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1581,,,,,,B,,,H,12146,BAO_0000357,CHEMBL616992,11863,,Autocuration,Tested against 5-hydroxytryptamine 1A receptor,,
1582,,,,,,B,,,H,14059,BAO_0000357,CHEMBL616993,11863,,Autocuration,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,
1583,,,,Oryctolagus cuniculus,,B,,,H,14025,BAO_0000019,CHEMBL616994,106,,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,9986.0
1584,,,,Oryctolagus cuniculus,,B,,,H,14025,BAO_0000019,CHEMBL616995,106,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,9986.0
1585,,HEK293,,Gorilla gorilla,,B,,722.0,D,14447,BAO_0000219,CHEMBL616996,105571,,Intermediate,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,9593.0
1586,,,,Cavia porcellus,,F,,,H,3025,BAO_0000218,CHEMBL616997,106,,Autocuration,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,10141.0
1587,,,,Cavia porcellus,,F,,,H,3025,BAO_0000218,CHEMBL616998,106,,Autocuration,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,10141.0
1588,,,,Cavia porcellus,,F,,,H,15329,BAO_0000019,CHEMBL616999,106,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,10141.0
1589,,,,Cavia porcellus,,F,,,H,15329,BAO_0000019,CHEMBL617000,106,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,10141.0
1590,,,,Cavia porcellus,,F,,,H,15847,BAO_0000019,CHEMBL617001,106,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,10141.0
1591,,,,Cavia porcellus,,F,,,H,15847,BAO_0000019,CHEMBL858111,106,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,10141.0
1592,,,,,,F,,,H,14165,BAO_0000019,CHEMBL617002,106,,Autocuration,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,
1593,,,,,,F,,,H,14214,BAO_0000019,CHEMBL617003,106,,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,
1594,,,,,,F,,,H,14214,BAO_0000019,CHEMBL617004,106,,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,
1595,,,,Homo sapiens,,F,,,D,14214,BAO_0000019,CHEMBL617005,106,,Expert,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,9606.0
1596,,CHO-K1,,Homo sapiens,,F,,485.0,D,13729,BAO_0000219,CHEMBL616623,106,,Expert,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,9606.0
1597,,CHO,,,,F,,449.0,H,3025,BAO_0000219,CHEMBL616624,106,,Autocuration,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,
1598,,,,,,B,,,H,2391,BAO_0000357,CHEMBL883243,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1599,,,,,,F,,,H,2391,BAO_0000019,CHEMBL616625,106,,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,
1600,,CHO,,,,F,,449.0,H,14956,BAO_0000219,CHEMBL616626,106,,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,
1601,,CHO,,,,F,,449.0,H,2598,BAO_0000219,CHEMBL616627,106,,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,
1602,,CHO,,,,F,,449.0,H,2598,BAO_0000219,CHEMBL616628,106,,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,
1603,,CHO,,,,F,,449.0,H,2598,BAO_0000219,CHEMBL616629,106,,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,
1604,,CHO,,,,F,,449.0,H,2598,BAO_0000219,CHEMBL616630,106,,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,
1605,,,,,,F,,,H,14956,BAO_0000019,CHEMBL616631,106,,Expert,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,
1606,,,,,,F,,,H,14956,BAO_0000019,CHEMBL616632,106,,Autocuration,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,
1607,,,,Homo sapiens,,B,,,D,14214,BAO_0000357,CHEMBL616633,106,,Expert,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,9606.0
1608,,CHO,,,,B,,449.0,H,3463,BAO_0000219,CHEMBL616634,106,,Expert,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,
1609,,,,,,B,,,H,15331,BAO_0000357,CHEMBL616635,106,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,
1610,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL885358,106,,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor,,9606.0
1611,,CHO,,Homo sapiens,,B,,449.0,D,14159,BAO_0000219,CHEMBL616636,106,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,9606.0
1612,,CHO,,,,B,,449.0,H,14158,BAO_0000219,CHEMBL616637,106,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,
1613,,,,,,B,,,H,14159,BAO_0000357,CHEMBL616638,106,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,
1614,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616639,106,,Expert,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1615,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616640,106,,Expert,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1616,,CHO,,,,B,,449.0,H,15331,BAO_0000219,CHEMBL616641,106,,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1617,,CHO,,,,B,,449.0,H,15332,BAO_0000219,CHEMBL616642,106,,Expert,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,
1618,,CHO,,,,B,,449.0,H,14956,BAO_0000219,CHEMBL616643,106,,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,
1619,,,,,,B,,,H,3805,BAO_0000357,CHEMBL616644,106,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,
1620,,,,,,B,,,H,14875,BAO_0000357,CHEMBL616645,106,,Autocuration,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,
1621,,,,Oryctolagus cuniculus,,F,,,H,14454,BAO_0000019,CHEMBL616646,105,,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,9986.0
1622,,,,Oryctolagus cuniculus,,F,,,H,14454,BAO_0000019,CHEMBL616647,105,,Expert,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,9986.0
1623,,,,,,B,,,H,16288,BAO_0000357,CHEMBL616509,105,,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,
1624,,,,,,B,,,H,16288,BAO_0000357,CHEMBL616510,105,,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,
1625,,,,,,B,,,H,16312,BAO_0000357,CHEMBL616511,105,,Autocuration,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,
1626,,,,Bos taurus,,B,,,H,1348,BAO_0000357,CHEMBL616512,105,,Expert,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,9913.0
1627,,,,Bos taurus,,B,,,H,5834,BAO_0000357,CHEMBL616513,105,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,9913.0
1628,2435.0,,Striatum,Bos taurus,,B,,,H,13366,BAO_0000019,CHEMBL616514,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,9913.0
1629,,,,Bos taurus,,B,,,H,1414,BAO_0000357,CHEMBL616515,105,,Expert,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,9913.0
1630,,,,Bos taurus,,B,,,H,14998,BAO_0000019,CHEMBL616516,105,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,9913.0
1631,,,,Bos taurus,,B,,,H,11473,BAO_0000357,CHEMBL616517,105,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,9913.0
1632,,,,Bos taurus,,B,,,H,11473,BAO_0000357,CHEMBL616518,105,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,9913.0
1633,,,,Bos taurus,,B,,,H,10639,BAO_0000357,CHEMBL616519,105,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,9913.0
1634,,,,Bos taurus,,B,,,H,10639,BAO_0000357,CHEMBL616520,105,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,9913.0
1635,,,,Bos taurus,,B,,,H,1375,BAO_0000357,CHEMBL616521,105,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,9913.0
1636,,,,Bos taurus,,B,,,H,1375,BAO_0000357,CHEMBL616522,105,,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,9913.0
1637,,,,Bos taurus,,B,,,H,16532,BAO_0000357,CHEMBL884531,105,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,9913.0
1638,,,,Bos taurus,,B,,,H,11147,BAO_0000357,CHEMBL616523,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,9913.0
1639,2435.0,,Striatum,Bos taurus,,B,,,H,13366,BAO_0000019,CHEMBL616731,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,9913.0
1640,,,,Bos taurus,,B,,,H,10444,BAO_0000019,CHEMBL616732,105,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,9913.0
1641,,,,Bos taurus,,B,,,H,16532,BAO_0000357,CHEMBL616733,105,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,9913.0
1642,,,,Bos taurus,,B,,,H,16532,BAO_0000357,CHEMBL616734,105,,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,9913.0
1643,,,,Bos taurus,,B,,,H,12827,BAO_0000249,CHEMBL616735,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,9913.0
1644,,,,Bos taurus,,B,,,H,12827,BAO_0000249,CHEMBL616736,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,9913.0
1645,,,,Bos taurus,,F,,,H,12919,BAO_0000019,CHEMBL616737,105,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,9913.0
1646,,,,Bos taurus,,B,,,H,14025,BAO_0000019,CHEMBL616738,105,,Autocuration,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,9913.0
1647,,,,Bos taurus,,F,,,H,12919,BAO_0000019,CHEMBL616739,105,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,9913.0
1648,,,,Bos taurus,,F,,,H,12919,BAO_0000019,CHEMBL616740,105,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,9913.0
1649,,,,Bos taurus,,F,,,H,12919,BAO_0000019,CHEMBL616741,105,,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,9913.0
1650,,HEK293,,Gorilla gorilla,,B,,722.0,H,14447,BAO_0000219,CHEMBL616742,105,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,9593.0
1651,,,,Cavia porcellus,,B,,,D,1375,BAO_0000019,CHEMBL616743,105570,,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,10141.0
1652,,,,Cavia porcellus,,B,,,D,1375,BAO_0000019,CHEMBL616744,105570,,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,10141.0
1653,,,,Cavia porcellus,,F,,,D,12409,BAO_0000019,CHEMBL616745,105570,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,10141.0
1654,,,,Cavia porcellus,,F,,,D,12409,BAO_0000019,CHEMBL616746,105570,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,10141.0
1655,,,,Cavia porcellus,,F,,,D,12409,BAO_0000019,CHEMBL616747,105570,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,10141.0
1656,,,,Cavia porcellus,,F,,,D,12409,BAO_0000019,CHEMBL616748,105570,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,10141.0
1657,,,,Cavia porcellus,,F,,,D,12409,BAO_0000019,CHEMBL616648,105570,,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,10141.0
1658,,,,Cavia porcellus,,B,,,D,11574,BAO_0000357,CHEMBL616649,105570,,Intermediate,Binding affinity against 5-hydroxytryptamine 1D receptor,,10141.0
1659,,,,Cavia porcellus,,B,,,D,1558,BAO_0000357,CHEMBL616650,105570,,Intermediate,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,10141.0
1660,,,,Cavia porcellus,,F,,,D,12409,BAO_0000218,CHEMBL616651,105570,,Intermediate,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,10141.0
1661,,,,Cavia porcellus,,F,,,D,12409,BAO_0000218,CHEMBL616652,105570,,Intermediate,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,10141.0
1662,,,,Cavia porcellus,,F,,,D,12409,BAO_0000218,CHEMBL616653,105570,,Intermediate,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,10141.0
1663,,,,Cavia porcellus,,F,,,D,12409,BAO_0000218,CHEMBL616654,105570,,Intermediate,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,10141.0
1664,,,,Cavia porcellus,,B,,,D,12253,BAO_0000019,CHEMBL616655,105570,,Intermediate,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,10141.0
1665,,,,Cavia porcellus,,B,,,D,12936,BAO_0000357,CHEMBL616656,105570,,Intermediate,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,10141.0
1666,,,,Cavia porcellus,,B,,,H,13181,BAO_0000019,CHEMBL616657,105,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,10141.0
1667,2435.0,,Striatum,Cavia porcellus,,B,,,D,12409,BAO_0000357,CHEMBL616658,105570,,Intermediate,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,10141.0
1668,,,,Cavia porcellus,,B,,,D,10639,BAO_0000357,CHEMBL616659,105570,,Intermediate,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,10141.0
1669,,,,,,B,,,H,5254,BAO_0000357,CHEMBL616660,51,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1670,,,,,,B,,,H,13051,BAO_0000357,CHEMBL616661,106,,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,
1671,,,,,,F,,,H,3463,BAO_0000019,CHEMBL616662,105,,Expert,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,
1672,,,,,,F,,,H,15315,BAO_0000019,CHEMBL616663,105,,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,
1673,,,,,,F,,,H,6011,BAO_0000019,CHEMBL616664,105,,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,
1674,,CHO,,Homo sapiens,,F,,449.0,D,14159,BAO_0000219,CHEMBL881820,105,,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,9606.0
1675,,CHO,,,,F,,449.0,H,14159,BAO_0000219,CHEMBL616665,105,,Autocuration,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,
1676,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616666,105,,Expert,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1677,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616667,105,,Autocuration,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,
1678,,CHO,,,,F,,449.0,H,15331,BAO_0000219,CHEMBL616668,105,,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,
1679,,CHO,,Homo sapiens,,F,,449.0,D,15332,BAO_0000219,CHEMBL616669,105,,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,9606.0
1680,,CHO,,,,F,,449.0,H,15332,BAO_0000219,CHEMBL617040,105,,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,
1681,,CHO,,,,F,,449.0,H,3294,BAO_0000219,CHEMBL617041,105,,Autocuration,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,
1682,,CHO,,,,F,,449.0,H,14158,BAO_0000219,CHEMBL617042,105,,Expert,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,
1683,,CHO,,,,F,,449.0,H,14956,BAO_0000219,CHEMBL617043,105,,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,
1684,,,,,,F,,,H,12469,BAO_0000019,CHEMBL617044,105,,Autocuration,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,
1685,,CHO,,,,F,,449.0,H,3463,BAO_0000219,CHEMBL617045,105,,Expert,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1686,,CHO,,Homo sapiens,,F,,449.0,D,15250,BAO_0000219,CHEMBL617046,105,,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,9606.0
1687,,CHO,,Homo sapiens,,F,,449.0,D,15250,BAO_0000219,CHEMBL617047,105,,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,9606.0
1688,,,,,,F,,,H,14956,BAO_0000019,CHEMBL617048,105,,Expert,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,
1689,,,,,,F,,,H,14159,BAO_0000019,CHEMBL616897,105,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,
1690,,,,Homo sapiens,,F,,,D,14159,BAO_0000019,CHEMBL616898,105,,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,9606.0
1691,,CHO,,Homo sapiens,,F,,449.0,D,14499,BAO_0000219,CHEMBL858201,105,,Expert,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,9606.0
1692,,,,,,F,,,H,15315,BAO_0000019,CHEMBL616899,105,,Autocuration,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,
1693,,,,,,B,,,H,3294,BAO_0000219,CHEMBL616900,105,,Autocuration,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,
1694,,CHO,,,,B,,449.0,H,3463,BAO_0000219,CHEMBL616901,105,,Expert,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,
1695,,,,,,B,,,H,15331,BAO_0000357,CHEMBL616902,105,,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,
1696,,CHO,,Homo sapiens,,B,,449.0,D,14159,BAO_0000219,CHEMBL616903,105,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9606.0
1697,,CHO,,,,B,,449.0,H,14158,BAO_0000219,CHEMBL616904,105,,Expert,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,
1698,,,,,,B,,,H,14159,BAO_0000357,CHEMBL616905,105,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,
1699,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616906,105,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1700,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616907,105,,Expert,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1701,,CHO,,,,B,,449.0,H,15331,BAO_0000219,CHEMBL616908,105,,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1702,,CHO,,Homo sapiens,,B,,449.0,D,15332,BAO_0000219,CHEMBL616909,105,,Expert,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9606.0
1703,,CHO,,Homo sapiens,,B,,449.0,D,14499,BAO_0000219,CHEMBL616910,105,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,9606.0
1704,,CHO,,,,B,,449.0,H,15332,BAO_0000219,CHEMBL616911,105,,Expert,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1705,,CHO,,,,B,,449.0,H,14956,BAO_0000219,CHEMBL616912,105,,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1706,,,,,,B,,,H,3805,BAO_0000357,CHEMBL616913,105,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,
1707,,CHO,,Homo sapiens,,B,,449.0,D,6011,BAO_0000219,CHEMBL616914,105,,Expert,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,9606.0
1708,,CHO,,,,B,,449.0,H,16190,BAO_0000219,CHEMBL616915,105,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,
1709,,,,,,B,,,H,14165,BAO_0000019,CHEMBL616916,105,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,
1710,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL616917,105,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,9606.0
1711,,,,,,B,,,H,15527,BAO_0000357,CHEMBL616918,105,,Autocuration,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,
1712,,,,,,B,,,H,6328,BAO_0000219,CHEMBL616919,105,,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1713,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616920,105,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,
1714,,,,,,B,,,H,14770,BAO_0000357,CHEMBL872914,105,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,
1715,,,,,,B,,,H,2598,BAO_0000357,CHEMBL616921,105,,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,
1716,,,,,,B,,,H,6897,BAO_0000357,CHEMBL616922,105,,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,
1717,,,,,,B,,,H,6013,BAO_0000357,CHEMBL616923,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor,,
1718,,,,,,B,,,H,5843,BAO_0000357,CHEMBL616924,105,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1719,,,,,,B,,,H,14454,BAO_0000357,CHEMBL875909,105,,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,
1720,,,,,,B,,,H,14454,BAO_0000357,CHEMBL616925,105,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,
1721,,,,,,B,,,H,14454,BAO_0000357,CHEMBL616926,105,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,
1722,,,,,,B,,,H,15818,BAO_0000357,CHEMBL616927,105,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,
1723,,CHO-K1,,,,F,,485.0,H,13729,BAO_0000219,CHEMBL616928,105,,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,
1724,,,,Homo sapiens,,B,,,D,6011,BAO_0000219,CHEMBL616929,105,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,9606.0
1725,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL616930,105,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,9606.0
1726,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616931,105,,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1727,,,,,,B,,,H,3025,BAO_0000357,CHEMBL616932,105,,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1728,,,,,,B,,,H,15315,BAO_0000357,CHEMBL616933,105,,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,
1729,,,,Homo sapiens,,B,,,D,14214,BAO_0000219,CHEMBL616934,105,,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,9606.0
1730,,,,Homo sapiens,,B,,,D,3804,BAO_0000357,CHEMBL616935,105,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9606.0
1731,,,,,,B,,,H,16700,BAO_0000357,CHEMBL616936,105,,Autocuration,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,
1732,,,,Homo sapiens,,B,,,D,2391,BAO_0000357,CHEMBL616937,105,,Expert,Affinity for 5-hydroxytryptamine 1D receptor subtype,,9606.0
1733,,,,Homo sapiens,,B,,,D,4175,BAO_0000357,CHEMBL616938,105,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9606.0
1734,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616939,105,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1735,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616940,105,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,
1736,,,,Homo sapiens,,B,,,D,15926,BAO_0000357,CHEMBL616941,105,,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,9606.0
1737,,CHO-K1,,,,B,,485.0,H,16312,BAO_0000219,CHEMBL616942,105,,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,
1738,,CHO-K1,,,,B,,485.0,H,16312,BAO_0000219,CHEMBL616943,105,,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,
1739,,CHO,,,,B,,449.0,H,14956,BAO_0000219,CHEMBL616944,104802,,Autocuration,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,
1740,,,,,,F,,,H,3294,BAO_0000019,CHEMBL616945,105,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,
1741,,,,,,B,,,H,12861,BAO_0000357,CHEMBL616946,105,,Autocuration,Binding activity radioligand.,,
1742,,,,,,B,,,H,12861,BAO_0000019,CHEMBL616947,105,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1743,,CHO-K1,,,,B,,485.0,H,16312,BAO_0000219,CHEMBL616948,105,,Expert,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,
1744,,,,,,B,,,H,5104,BAO_0000357,CHEMBL616851,105,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1745,,,,,,B,,,H,5105,BAO_0000357,CHEMBL616852,105,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1746,,,,,,B,,,H,14499,BAO_0000357,CHEMBL616853,105,,Autocuration,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,
1747,,,,Homo sapiens,,B,,,D,15926,BAO_0000357,CHEMBL616854,105,,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor,,9606.0
1748,,CHO,,Homo sapiens,,B,,449.0,D,4540,BAO_0000219,CHEMBL616855,105,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,9606.0
1749,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616856,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,
1750,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616857,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
1751,,,,,,B,,,H,6166,BAO_0000357,CHEMBL616858,105,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1752,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616859,105,,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,
1753,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616860,105,,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,
1754,,HEK293,,,,B,,722.0,H,17451,BAO_0000219,CHEMBL616861,105,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1755,,HEK293,,,,B,,722.0,H,17451,BAO_0000219,CHEMBL616541,105,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1756,,HEK293,,,,B,,722.0,H,17451,BAO_0000219,CHEMBL616542,105,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,
1757,,CHO,,,,B,,449.0,H,4199,BAO_0000219,CHEMBL616543,105,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,
1758,,,,Homo sapiens,,B,,,D,14875,BAO_0000357,CHEMBL616544,105,,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,9606.0
1759,,CHO,,,,B,,449.0,H,15146,BAO_0000219,CHEMBL616545,105,,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,
1760,,,,,,B,,,H,5213,BAO_0000357,CHEMBL616546,105,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,
1761,,CHO,,,,B,,449.0,H,14818,BAO_0000219,CHEMBL616547,105,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,
1762,,CHO,,,,B,,449.0,H,4829,BAO_0000219,CHEMBL616548,105,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,
1763,,,,,,F,,,H,14454,BAO_0000019,CHEMBL616549,105,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,
1764,,,,,,F,,,H,14454,BAO_0000019,CHEMBL616550,105,,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,
1765,,,,,,B,,,H,5254,BAO_0000357,CHEMBL857066,108,,Autocuration,Binding affinity against 5-HT2C receptor,,
1766,,,,,,B,,,H,5254,BAO_0000357,CHEMBL616551,108,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1767,,,,,,B,,,H,10639,BAO_0000357,CHEMBL616552,10577,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1768,,,,,,F,,,H,10639,BAO_0000019,CHEMBL832876,10577,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1769,,,,,,B,,,H,12352,BAO_0000019,CHEMBL616553,10577,,Expert,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,
1770,,,,,,B,,,H,9098,BAO_0000357,CHEMBL616554,10577,,Autocuration,Binding affinity towards 5-HT1B was determined,,
1771,,,,,,B,,,H,14430,BAO_0000019,CHEMBL616555,10577,,Expert,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,
1772,,,,,,B,,,H,13657,BAO_0000019,CHEMBL616556,10577,,Expert,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,
1773,,,,,,B,,,H,13657,BAO_0000019,CHEMBL616557,10577,,Autocuration,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,
1774,,,,,,B,,,H,15854,BAO_0000019,CHEMBL616558,10577,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1775,,,,Rattus norvegicus,,B,,,D,10639,BAO_0000019,CHEMBL616749,10577,,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,10116.0
1776,,,,,,B,,,H,10025,BAO_0000357,CHEMBL616750,10577,,Autocuration,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1777,,,,,,B,,,H,10025,BAO_0000357,CHEMBL616751,10577,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,
1778,,,,,,B,,,H,14286,BAO_0000249,CHEMBL616752,10577,,Autocuration,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1779,2435.0,,Striatum,,,B,,,H,3651,BAO_0000019,CHEMBL616753,10577,,Autocuration,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,
1780,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL616754,10577,,Expert,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,10116.0
1781,,,,,,B,,,H,10639,BAO_0000019,CHEMBL616755,10577,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,
1782,2435.0,,Striatum,,,B,,,H,13605,BAO_0000019,CHEMBL616756,10577,,Autocuration,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,
1783,2435.0,,Striatum,,,B,,,H,5834,BAO_0000019,CHEMBL616757,10577,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,
1784,2435.0,,Striatum,,,B,,,H,10922,BAO_0000357,CHEMBL616758,10577,,Autocuration,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,
1785,,,,,,B,,,H,14286,BAO_0000249,CHEMBL616759,10577,,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1786,,,,,,B,,,H,11825,BAO_0000357,CHEMBL616760,10577,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,
1787,2435.0,,Striatum,,,B,,,H,14826,BAO_0000019,CHEMBL616761,10577,,Autocuration,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,
1788,2435.0,,Striatum,,,B,,,H,9699,BAO_0000019,CHEMBL616762,10577,,Autocuration,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,
1789,,,,,,B,,,H,14423,BAO_0000019,CHEMBL616763,10577,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,
1790,,,,,,B,,,H,10062,BAO_0000357,CHEMBL872909,10577,,Expert,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,
1791,,,,,,B,,,H,10062,BAO_0000357,CHEMBL616764,10577,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1792,,,,Rattus norvegicus,,B,,,D,12280,BAO_0000357,CHEMBL616765,10577,,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,10116.0
1793,2435.0,,Striatum,,,B,,,H,15412,BAO_0000357,CHEMBL616766,10577,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,
1794,2435.0,,Striatum,,,B,,,H,15412,BAO_0000357,CHEMBL616767,10577,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,
1795,,,,,,B,,,H,10062,BAO_0000357,CHEMBL616768,10577,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1796,,,,,,B,,,H,11147,BAO_0000357,CHEMBL616769,10577,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1797,,,,,,B,,,H,9547,BAO_0000019,CHEMBL616770,10577,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,
1798,,,,,,B,,,H,10444,BAO_0000019,CHEMBL616771,10577,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,
1799,2435.0,,Striatum,,,B,,,H,12469,BAO_0000019,CHEMBL616772,10577,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,
1800,,,,,,B,,,H,9098,BAO_0000019,CHEMBL616773,10577,,Expert,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,
1801,,,,,,B,,,H,9098,BAO_0000019,CHEMBL616774,10577,,Autocuration,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,
1802,,,,,,B,,,H,9699,BAO_0000357,CHEMBL616775,10577,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,
1803,,,,,,B,,,H,10394,BAO_0000249,CHEMBL616776,10577,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1804,,,,,,B,,,H,12092,BAO_0000357,CHEMBL616777,10577,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,
1805,,,,,,B,,,H,16700,BAO_0000357,CHEMBL616778,10577,,Autocuration,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,
1806,,,,Rattus norvegicus,,B,,,D,403,BAO_0000249,CHEMBL616779,10577,,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,10116.0
1807,,,,Rattus norvegicus,,B,,,D,12771,BAO_0000357,CHEMBL616780,10577,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor,,10116.0
1808,,,,,,B,,,H,11642,BAO_0000019,CHEMBL616781,10577,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,
1809,,,,,,B,,,H,12953,BAO_0000357,CHEMBL616782,10577,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,
1810,,,,,,B,,,H,12953,BAO_0000357,CHEMBL616783,10577,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,
1811,2435.0,,Striatum,,,B,,,H,12953,BAO_0000019,CHEMBL616784,10577,,Expert,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,
1812,,,,,,B,,,H,12953,BAO_0000357,CHEMBL616785,10577,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,
1813,955.0,,Brain,,,B,,,H,9737,BAO_0000249,CHEMBL857067,10577,,Autocuration,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1814,,,,,,B,,,H,9737,BAO_0000019,CHEMBL616786,10577,,Autocuration,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,
1815,955.0,,Brain,,,B,,,H,9737,BAO_0000249,CHEMBL616787,10577,,Autocuration,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1816,,,,,,B,,,H,12827,BAO_0000357,CHEMBL616788,10577,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,
1817,,,,,,B,,,H,5033,BAO_0000357,CHEMBL616789,10577,,Autocuration,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,
1818,,,,Rattus norvegicus,,B,,,D,9786,BAO_0000019,CHEMBL616790,10577,,Expert,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,10116.0
1819,,,,,,B,,,H,13116,BAO_0000357,CHEMBL616791,10577,,Expert,Binding affinity at 5-hydroxytryptamine 1B receptor,,
1820,,,,,,B,,,H,16429,BAO_0000019,CHEMBL616792,10577,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,
1821,,,,Rattus norvegicus,,B,,,D,12409,BAO_0000249,CHEMBL616793,10577,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,10116.0
1822,,,,,,B,,,H,15194,BAO_0000357,CHEMBL616794,10577,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1823,,,,,,B,,,H,15194,BAO_0000357,CHEMBL616795,10577,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1824,,,,,,B,,,H,5486,BAO_0000019,CHEMBL616796,104686,,Autocuration,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,
1825,,,,,,B,,,H,4639,BAO_0000357,CHEMBL616797,106,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1826,,,,,,B,Brain membranes,,H,386,BAO_0000249,CHEMBL616798,106,,Autocuration,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,
1827,,,,,,B,,,H,2474,BAO_0000357,CHEMBL616799,106,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,
1828,,,,,,B,,,H,6011,BAO_0000357,CHEMBL616800,106,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,
1829,,,,,,B,,,H,5014,BAO_0000357,CHEMBL616801,106,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,
1830,,,,,,B,,,H,17515,BAO_0000357,CHEMBL616802,106,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,
1831,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616803,106,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,
1832,,,,,,B,,,H,1633,BAO_0000357,CHEMBL857068,106,,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,
1833,,,,,,B,,,H,1633,BAO_0000357,CHEMBL616804,106,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,
1834,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616805,106,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,
1835,,,,,,B,,,H,4687,BAO_0000357,CHEMBL616806,106,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,
1836,,,,,,B,,,H,11574,BAO_0000357,CHEMBL616807,106,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor,,
1837,,,,,,B,,,H,10321,BAO_0000357,CHEMBL616808,106,,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,
1838,,,,,,B,,,H,15527,BAO_0000357,CHEMBL616809,106,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1839,,,,,,B,,,H,17200,BAO_0000357,CHEMBL616810,106,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,
1840,,,,,,B,,,H,14423,BAO_0000224,CHEMBL616811,104802,,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,
1841,,,,Bos taurus,,B,,,H,5834,BAO_0000357,CHEMBL616812,108,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,9913.0
1842,,,,Sus scrofa,,B,,,H,11473,BAO_0000357,CHEMBL616813,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,9823.0
1843,,,,Sus scrofa,,B,,,H,11473,BAO_0000357,CHEMBL616814,108,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,9823.0
1844,,,,Sus scrofa,,B,,,H,10639,BAO_0000357,CHEMBL616815,108,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,9823.0
1845,,,,Sus scrofa,,B,,,H,10639,BAO_0000357,CHEMBL616816,108,,Autocuration,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,9823.0
1846,,,,Sus scrofa,,B,,,H,14331,BAO_0000357,CHEMBL616817,108,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,9823.0
1847,,,,Sus scrofa,,B,,,H,10796,BAO_0000357,CHEMBL616818,108,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,9823.0
1848,,,,Sus scrofa,,B,,,H,9098,BAO_0000357,CHEMBL616819,108,,Expert,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,9823.0
1849,,,,Sus scrofa,,B,,,H,14331,BAO_0000357,CHEMBL616820,108,,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,9823.0
1850,,,,Sus scrofa,,B,,,H,11828,BAO_0000019,CHEMBL616821,108,,Expert,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,9823.0
1851,,,,Sus scrofa,,B,,,H,11866,BAO_0000357,CHEMBL616822,108,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,9823.0
1852,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL616823,108,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,9986.0
1853,,,,Rattus norvegicus,,B,,,D,188,BAO_0000357,CHEMBL616824,12689,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,10116.0
1854,,,,Rattus norvegicus,,B,,,D,11825,BAO_0000357,CHEMBL616825,12689,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,10116.0
1855,,,,Rattus norvegicus,,B,,,D,11825,BAO_0000357,CHEMBL616826,12689,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,10116.0
1856,,,,Rattus norvegicus,,B,,,D,11624,BAO_0000019,CHEMBL616827,12689,,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,10116.0
1857,,,,Rattus norvegicus,,B,,,D,11139,BAO_0000357,CHEMBL616828,12689,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,10116.0
1858,,,,Rattus norvegicus,,B,,,D,11147,BAO_0000357,CHEMBL616829,12689,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,10116.0
1859,,,,Rattus norvegicus,,B,,,D,10444,BAO_0000019,CHEMBL616830,12689,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,10116.0
1860,,,,Rattus norvegicus,,B,,,D,11624,BAO_0000357,CHEMBL616831,12689,,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor,,10116.0
1861,,,,Rattus norvegicus,,B,,,D,11662,BAO_0000019,CHEMBL616832,12689,,Autocuration,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,10116.0
1862,,,,Rattus norvegicus,,B,,,D,11662,BAO_0000019,CHEMBL616833,12689,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,10116.0
1863,,,,Rattus norvegicus,,B,,,D,11662,BAO_0000019,CHEMBL616834,12689,,Expert,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,10116.0
1864,,,,Rattus norvegicus,,B,,,D,11662,BAO_0000019,CHEMBL829595,12689,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,10116.0
1865,,,,Rattus norvegicus,,B,,,D,9098,BAO_0000357,CHEMBL616835,12689,,Autocuration,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,10116.0
1866,,,,Rattus norvegicus,,B,,,D,10394,BAO_0000249,CHEMBL872910,12689,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,10116.0
1867,,,,,,B,,,H,11933,BAO_0000357,CHEMBL616836,12689,,Expert,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,
1868,,,,Rattus norvegicus,,B,,,D,12092,BAO_0000357,CHEMBL616837,12689,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,10116.0
1869,,,,Rattus norvegicus,,B,,,D,12253,BAO_0000019,CHEMBL616466,12689,,Autocuration,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,10116.0
1870,,HEK293,,Rattus norvegicus,,B,,722.0,D,12253,BAO_0000219,CHEMBL616467,12689,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,10116.0
1871,,,,,,B,,,H,1558,BAO_0000357,CHEMBL616468,108,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1872,,,,,,B,,,H,2474,BAO_0000357,CHEMBL616469,108,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1873,,,,,,B,,,H,2474,BAO_0000357,CHEMBL616470,108,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1874,,,,,,B,,,H,11574,BAO_0000357,CHEMBL616471,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1875,,,,,,B,,,H,1558,BAO_0000357,CHEMBL616472,12689,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1876,,,,,,B,,,H,13944,BAO_0000357,CHEMBL616473,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1877,,,,,,B,,,H,13033,BAO_0000357,CHEMBL616474,12689,,Autocuration,Binding affinity against serotonergic 5-HT1c receptor,,
1878,,,,,,B,,,H,10321,BAO_0000357,CHEMBL616475,12689,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,
1879,,,,,,B,,,H,11866,BAO_0000357,CHEMBL616476,12689,,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,
1880,,,,Oryctolagus cuniculus,,B,,,H,14454,BAO_0000019,CHEMBL616477,105,,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,9986.0
1881,,,,,,B,,,H,11574,BAO_0000224,CHEMBL616478,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,
1882,,,,,,B,,,H,11574,BAO_0000224,CHEMBL616479,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,
1883,,,,,,B,,,H,13631,BAO_0000019,CHEMBL616480,104686,,Autocuration,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,
1884,,,,Rattus norvegicus,,B,,,D,9630,BAO_0000019,CHEMBL616481,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,10116.0
1885,,,,Rattus norvegicus,,B,,,D,8822,BAO_0000249,CHEMBL616482,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,10116.0
1886,955.0,,Brain,Rattus norvegicus,,B,,,D,9064,BAO_0000221,CHEMBL884713,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,10116.0
1887,,,,,,B,,,H,8868,BAO_0000224,CHEMBL616483,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,
1888,,,,,,B,,,H,9064,BAO_0000224,CHEMBL616484,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,
1889,,,,,,B,,,H,9806,BAO_0000019,CHEMBL616485,104686,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,
1890,,,,,,B,,,H,9098,BAO_0000224,CHEMBL616486,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
1891,,,,,,B,,,H,8868,BAO_0000224,CHEMBL616487,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,
1892,,,,,,B,,,H,12765,BAO_0000224,CHEMBL616488,104686,,Autocuration,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
1893,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616489,104686,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1894,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616490,104686,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1895,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616491,104686,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,
1896,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616492,104686,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,
1897,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616493,104686,,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1898,,,,,,B,,,H,11473,BAO_0000019,CHEMBL616494,104686,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,
1899,,,,,,B,,,H,11473,BAO_0000019,CHEMBL616495,104686,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,
1900,,,,,,B,,,H,3086,BAO_0000019,CHEMBL616496,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,
1901,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616497,104686,,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1902,,,,,,B,,,H,11049,BAO_0000019,CHEMBL616498,104686,,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1903,,,,,,B,,,H,10639,BAO_0000019,CHEMBL616499,104686,,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,
1904,,,,,,B,,,H,10922,BAO_0000019,CHEMBL616500,104686,,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,
1905,955.0,,Brain,Rattus norvegicus,,B,,,D,9064,BAO_0000221,CHEMBL616501,104686,,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,10116.0
1906,955.0,,Brain,,,B,,,H,10748,BAO_0000221,CHEMBL616502,104686,,Autocuration,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,
1907,,,,,,B,Membranes,,H,11614,BAO_0000249,CHEMBL884529,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1908,,,,,,B,Membranes,,H,11615,BAO_0000249,CHEMBL616503,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1909,,,,,,B,,,H,11615,BAO_0000224,CHEMBL616964,104686,,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,
1910,,,,,,B,Membranes,,H,11614,BAO_0000249,CHEMBL616965,104686,,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1911,,,,,,B,,,H,11702,BAO_0000224,CHEMBL616966,104686,,Autocuration,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,
1912,,,,,,B,,,H,11702,BAO_0000224,CHEMBL616967,104686,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1913,,,,Rattus norvegicus,,B,,,D,11702,BAO_0000224,CHEMBL616968,104686,,Autocuration,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,10116.0
1914,,,,,,B,,,H,11702,BAO_0000224,CHEMBL616969,104686,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1915,,,,,,B,,,H,13346,BAO_0000019,CHEMBL884530,104686,,Autocuration,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,
1916,,,,,,B,,,H,10025,BAO_0000224,CHEMBL616970,104686,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1917,,,,,,B,,,H,10025,BAO_0000224,CHEMBL616971,104686,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
1918,,,,,,B,,,H,10025,BAO_0000224,CHEMBL616972,104686,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
1919,,,,,,B,,,H,9036,BAO_0000224,CHEMBL616973,104686,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,
1920,,,,,,B,,,H,9036,BAO_0000224,CHEMBL616974,104686,,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,
1921,,,,,,B,,,H,9161,BAO_0000019,CHEMBL616975,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,
1922,,,,,,B,,,H,12304,BAO_0000019,CHEMBL616976,104686,,Autocuration,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,
1923,,,,,,B,,,H,13276,BAO_0000224,CHEMBL616977,104686,,Autocuration,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,
1924,,,,,,B,,,H,11825,BAO_0000224,CHEMBL616978,104686,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1925,,,,,,B,,,H,12443,BAO_0000224,CHEMBL616979,104686,,Autocuration,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,
1926,,,,,,B,,,H,13830,BAO_0000224,CHEMBL616980,104686,,Autocuration,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1927,,,,,,B,Membranes,,H,9592,BAO_0000249,CHEMBL616981,104686,,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,
1928,,,,,,B,Membranes,,H,9592,BAO_0000249,CHEMBL616982,104686,,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,
1929,,,,,,B,,,H,10881,BAO_0000224,CHEMBL616983,104686,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,
1930,,,,,,B,,,H,13605,BAO_0000019,CHEMBL616984,104686,,Autocuration,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,
1931,,,,Rattus norvegicus,,B,,,D,11624,BAO_0000224,CHEMBL616985,104686,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,10116.0
1932,,,,,,B,,,H,4101,BAO_0000224,CHEMBL616986,104686,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1933,,,,,,B,,,H,4101,BAO_0000224,CHEMBL616987,104686,,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1934,,,,,,B,,,H,15360,BAO_0000019,CHEMBL616988,104686,,Autocuration,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,
1935,,,,,,B,,,H,11576,BAO_0000019,CHEMBL617243,104686,,Autocuration,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,
1936,,,,,,B,,,H,5834,BAO_0000019,CHEMBL617244,104686,,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,
1937,,CHO-K1,,Rattus norvegicus,,B,,485.0,D,2395,BAO_0000219,CHEMBL617245,104686,,Autocuration,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,10116.0
1938,,,,,,B,Membranes,,H,11965,BAO_0000249,CHEMBL617246,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1939,,,,,,B,,,H,3967,BAO_0000224,CHEMBL617546,104686,,Autocuration,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,
1940,,,,,,B,Brain membranes,,H,11130,BAO_0000249,CHEMBL617547,104686,,Autocuration,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,
1941,,,,,,B,,,H,13427,BAO_0000219,CHEMBL617548,104686,,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
1942,,,,,,B,,,H,9443,BAO_0000224,CHEMBL617549,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
1943,,,,,,B,,,H,9443,BAO_0000224,CHEMBL617550,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
1944,,,,,,B,,,H,11825,BAO_0000224,CHEMBL617551,104686,,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1945,,,,,,B,Membranes,,H,12120,BAO_0000249,CHEMBL617552,104686,,Autocuration,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,
1946,,,,,,B,Membranes,,H,12120,BAO_0000249,CHEMBL617553,104686,,Autocuration,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,
1947,1515.0,,Thoracic aorta,,,F,,,H,11963,BAO_0000019,CHEMBL617554,104686,,Autocuration,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,
1948,,,,,,B,,,H,9069,BAO_0000019,CHEMBL617555,104686,,Autocuration,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,
1949,,,,,,B,,,H,8868,BAO_0000224,CHEMBL617556,104686,,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
1950,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617557,10624,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1951,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617558,10624,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1952,,,,,,B,,,H,13969,BAO_0000357,CHEMBL617559,17106,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,
1953,,,,,,B,,,D,13392,BAO_0000357,CHEMBL617560,17106,,Expert,Binding affinity for 5-hydroxytryptamine 1D receptor,,
1954,,,,,,B,,,H,1742,BAO_0000249,CHEMBL617561,17106,,Autocuration,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1955,,,,,,B,,,H,1742,BAO_0000249,CHEMBL617562,17106,,Autocuration,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1956,2435.0,,Striatum,,,B,,,H,14331,BAO_0000357,CHEMBL617563,17106,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,
1957,,,,,,F,,,H,12861,BAO_0000019,CHEMBL617564,17106,,Autocuration,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,
1958,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617565,17106,,Expert,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,
1959,,,,,,B,,,H,12861,BAO_0000357,CHEMBL856076,17106,,Autocuration,Binding activity radioligand.,,
1960,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617566,17106,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
1961,,,,,,B,,,H,12861,BAO_0000019,CHEMBL875911,17106,,Expert,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1962,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617567,17106,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
1963,,,,,,B,,,H,675,BAO_0000249,CHEMBL617568,17106,,Autocuration,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1964,,,,,,B,,,H,12490,BAO_0000019,CHEMBL617569,17106,,Expert,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,
1965,,,,,,B,,,H,11828,BAO_0000249,CHEMBL617570,17106,,Expert,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,
1966,,,,,,B,,,H,11866,BAO_0000357,CHEMBL617571,17106,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,
1967,,,,Sus scrofa,,B,,,H,773,BAO_0000357,CHEMBL617572,105,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,9823.0
1968,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000357,CHEMBL617573,105,,Expert,The compound was tested for intrinsic activity against 5-HT1D receptor,,9986.0
1969,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL617574,105,,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,9986.0
1970,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000357,CHEMBL617575,105,,Expert,The compound was tested for binding affinity against 5-HT1D receptor,,9986.0
1971,,,,,,B,,,H,188,BAO_0000357,CHEMBL617576,10578,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,
1972,,,,,,F,,,H,10639,BAO_0000019,CHEMBL617577,10578,,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,
1973,,,,,,F,,,H,12438,BAO_0000019,CHEMBL617578,10578,,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,
1974,,,,,,B,,,H,12438,BAO_0000357,CHEMBL617579,10578,,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,
1975,,,,,,B,,,H,15854,BAO_0000019,CHEMBL617580,10578,,Expert,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1976,,,,,,B,,,H,10394,BAO_0000249,CHEMBL617581,10578,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1977,,,,,,B,,,H,12092,BAO_0000357,CHEMBL617582,10578,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,
1978,,,,,,B,,,H,3389,BAO_0000019,CHEMBL617583,10578,,Expert,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,
1979,,,,,,B,,,H,6011,BAO_0000357,CHEMBL617584,105,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,
1980,,,,,,B,,,H,4639,BAO_0000357,CHEMBL617585,105,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,
1981,,,,,,B,,,H,2474,BAO_0000357,CHEMBL875912,105,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,
1982,,,,,,B,,,H,5014,BAO_0000357,CHEMBL617586,105,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,
1983,,,,,,B,,,H,17515,BAO_0000357,CHEMBL617587,105,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,
1984,,,,,,B,,,H,11866,BAO_0000357,CHEMBL617588,105,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,
1985,,,,,,B,,,H,4687,BAO_0000357,CHEMBL857980,105,,Autocuration,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,
1986,,,,,,B,,,H,12146,BAO_0000357,CHEMBL617589,105,,Autocuration,Tested against 5-hydroxytryptamine 1D receptor,,
1987,,,,,,B,,,H,10321,BAO_0000357,CHEMBL617590,105,,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,
1988,,HEK293,,,,B,,722.0,H,13267,BAO_0000219,CHEMBL617591,105,,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
1989,,,,Homo sapiens,,B,,,D,1274,BAO_0000357,CHEMBL617592,105,,Expert,Binding affinity against 5-Hydroxytryptamine 1D receptor,,9606.0
1990,,,,,,B,,,H,15250,BAO_0000357,CHEMBL617593,105,,Autocuration,,,
1991,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL617594,106,,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1992,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL617595,105,,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1993,,HEK293,,,,B,,722.0,H,13706,BAO_0000219,CHEMBL617596,105,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,
1994,,HEK293,,,,B,,722.0,H,13706,BAO_0000219,CHEMBL617597,105,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
1995,,,,,,B,,,H,13047,BAO_0000019,CHEMBL617598,105,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
1996,,,,,,B,,,H,13366,BAO_0000357,CHEMBL872916,105,,Autocuration,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,
1997,,,,,,B,,,H,13366,BAO_0000357,CHEMBL617599,105,,Expert,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,
1998,,,,,,B,,,H,1558,BAO_0000357,CHEMBL617091,105,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,
1999,,CHO-K1,,,,B,,485.0,H,12902,BAO_0000219,CHEMBL617092,105,,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,
2000,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL617093,105,,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
2001,,,,,,F,,,H,13706,BAO_0000019,CHEMBL617094,105,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,
2002,,,,,,F,,,H,13706,BAO_0000019,CHEMBL617095,105,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2003,,,,,,F,,,H,14251,BAO_0000019,CHEMBL617096,105,,Autocuration,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2004,,,,,,F,,,H,14251,BAO_0000019,CHEMBL617097,105,,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2005,,,,,,F,,,H,14251,BAO_0000019,CHEMBL617098,105,,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2006,,,,,,B,,,H,13313,BAO_0000357,CHEMBL617301,105,,Autocuration,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,
2007,,,,,,B,,,H,13313,BAO_0000357,CHEMBL617302,105,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,
2008,,,,,,B,,,H,13366,BAO_0000357,CHEMBL617303,105,,Autocuration,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,
2009,,,,,,B,,,H,13051,BAO_0000357,CHEMBL617304,105,,Expert,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,
2010,,CHO,,,,B,,449.0,H,12903,BAO_0000219,CHEMBL617305,105,,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,
2011,,,,Homo sapiens,,B,,,D,12469,BAO_0000219,CHEMBL617306,105,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,9606.0
2012,,,,,,B,,,H,5619,BAO_0000357,CHEMBL617307,17106,,Autocuration,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,
2013,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL617308,105,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,9986.0
2014,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617309,105,,Autocuration,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,
2015,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617310,105,,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2016,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617311,105,,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2017,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617312,105,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,
2018,,,,,,B,,,H,3269,BAO_0000357,CHEMBL617313,105,,Autocuration,Affinity against 5-hydroxytryptamine 1D receptor alpha,,
2019,,,,,,B,,,H,12409,BAO_0000357,CHEMBL617314,105,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,
2020,,,,,,F,,,H,13706,BAO_0000019,CHEMBL617315,106,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2021,,HEK293,,,,B,,722.0,H,13706,BAO_0000219,CHEMBL617316,106,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,
2022,,HEK293,,,,B,,722.0,H,13706,BAO_0000219,CHEMBL617317,106,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
2023,,CHO,,,,B,,449.0,H,12903,BAO_0000219,CHEMBL617318,106,,Autocuration,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2024,,,,,,B,,,H,13047,BAO_0000019,CHEMBL617319,106,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
2025,,,,,,B,,,D,13366,BAO_0000357,CHEMBL617320,106,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2026,,,,,,B,,,D,13366,BAO_0000357,CHEMBL617321,106,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2027,,,,,,B,,,D,13366,BAO_0000357,CHEMBL617322,106,,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2028,,,,,,B,,,H,13366,BAO_0000357,CHEMBL616862,106,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,
2029,,,,,,B,,,H,13366,BAO_0000357,CHEMBL616863,106,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,
2030,,CHO,,,,B,,449.0,H,12469,BAO_0000219,CHEMBL616864,106,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,
2031,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL616865,106,,Autocuration,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,
2032,,CHO-K1,,,,B,,485.0,H,13706,BAO_0000219,CHEMBL616866,106,,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,
2033,,,,,,F,,,H,13706,BAO_0000019,CHEMBL616867,106,,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2034,,CHO-K1,,,,B,,485.0,H,12902,BAO_0000219,CHEMBL616868,106,,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,
2035,,,,,,B,,,H,13051,BAO_0000357,CHEMBL616869,105,,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,
2036,,CHO,,,,B,,449.0,H,12903,BAO_0000219,CHEMBL616870,106,,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2037,,CHO-K1,,,,F,,485.0,H,1558,BAO_0000219,CHEMBL616871,105,,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,
2038,,CHO-K1,,,,F,,485.0,H,1558,BAO_0000219,CHEMBL616872,105,,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,
2039,,CHO-K1,,,,F,,485.0,H,1558,BAO_0000219,CHEMBL616873,105,,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,
2040,,CHO-K1,,,,F,,485.0,H,1558,BAO_0000219,CHEMBL616838,105,,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,
2041,,,,,,B,,,H,1558,BAO_0000357,CHEMBL616839,105,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,
2042,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL616840,106,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,9986.0
2043,,,,,,B,,,H,13313,BAO_0000357,CHEMBL616841,105,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,
2044,,,,,,B,,,H,13313,BAO_0000357,CHEMBL616842,105,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,
2045,,,,,,B,,,H,12409,BAO_0000357,CHEMBL857976,105,,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,
2046,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616843,10618,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,
2047,,,,Homo sapiens,,B,,,D,1348,BAO_0000357,CHEMBL616844,10618,,Expert,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,9606.0
2048,,,,,,B,,,H,1348,BAO_0000357,CHEMBL616845,10618,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,
2049,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL616846,10618,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,9606.0
2050,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616847,10618,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,
2051,,,,,,B,,,H,10444,BAO_0000019,CHEMBL616848,10618,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,
2052,,,,,,B,,,H,3935,BAO_0000357,CHEMBL616849,10618,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,
2053,,,,,,B,,,H,15818,BAO_0000357,CHEMBL872911,10618,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,
2054,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616850,10618,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,
2055,,CHO,,Homo sapiens,,B,,449.0,D,12936,BAO_0000219,CHEMBL616699,10618,,Expert,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,9606.0
2056,,,,,,B,,,H,6166,BAO_0000357,CHEMBL616700,10618,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,
2057,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616701,10618,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2058,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616702,10618,,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,
2059,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL616703,10618,,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
2060,,,,,,B,,,H,13181,BAO_0000357,CHEMBL616704,10618,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,
2061,,CHO,,,,B,,449.0,H,4199,BAO_0000219,CHEMBL616705,10618,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,
2062,,,,,,B,,,H,14875,BAO_0000357,CHEMBL616706,10618,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,
2063,,CHO,,,,B,,449.0,H,15146,BAO_0000219,CHEMBL616707,10618,,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,
2064,,,,,,B,,,H,5213,BAO_0000357,CHEMBL616708,10618,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,
2065,,,,,,B,,,H,12146,BAO_0000357,CHEMBL616709,10618,,Autocuration,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,
2066,,CHO,,,,B,,449.0,H,13267,BAO_0000219,CHEMBL616710,10618,,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,
2067,,CHO,,,,B,,449.0,H,14818,BAO_0000219,CHEMBL616711,10618,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,
2068,,CHO,,,,B,,449.0,H,4829,BAO_0000219,CHEMBL616712,10618,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,
2069,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616713,10618,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,
2070,,,,,,B,,,H,4373,BAO_0000357,CHEMBL616714,10618,,Autocuration,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,
2071,,,,,,B,,,H,14159,BAO_0000357,CHEMBL616715,10618,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,
2072,,,,,,B,,,H,16633,BAO_0000357,CHEMBL616716,10618,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor,,
2073,,,,,,F,,,H,17085,BAO_0000019,CHEMBL616717,279,,Autocuration,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,
2074,,,,,,F,,,H,17085,BAO_0000019,CHEMBL616718,279,,Expert,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,
2075,,,,,,F,,,H,16209,BAO_0000019,CHEMBL875905,279,,Autocuration,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,
2076,,,,,,F,,,H,16209,BAO_0000019,CHEMBL616719,279,,Autocuration,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,
2077,,,,,,F,,,H,17085,BAO_0000019,CHEMBL616720,279,,Expert,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,
2078,,,,,,B,,,H,14159,BAO_0000357,CHEMBL616721,279,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,
2079,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL616722,279,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,
2080,,,,,,B,,,H,3805,BAO_0000357,CHEMBL616723,279,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,
2081,,CHO,,,,B,,449.0,H,16190,BAO_0000219,CHEMBL616724,279,,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,
2082,,,,,,B,,,H,16190,BAO_0000357,CHEMBL616725,279,,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,
2083,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616726,279,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,
2084,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616727,279,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,
2085,,,,,,B,,,H,16209,BAO_0000357,CHEMBL616728,279,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,
2086,,,,,,B,,,H,6866,BAO_0000357,CHEMBL616729,279,,Autocuration,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,
2087,,,,,,B,,,H,17085,BAO_0000019,CHEMBL616730,279,,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,
2088,,,,,,B,,,H,16312,BAO_0000357,CHEMBL617125,279,,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,
2089,,,,,,B,,,H,6166,BAO_0000357,CHEMBL857977,279,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,
2090,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL617126,279,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2091,,CHO,,,,B,,449.0,H,4199,BAO_0000219,CHEMBL617127,279,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,
2092,,,,,,B,,,H,14875,BAO_0000357,CHEMBL617128,279,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,
2093,,CHO,,,,B,,449.0,H,15146,BAO_0000219,CHEMBL617129,279,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,
2094,,,,,,B,,,H,5213,BAO_0000357,CHEMBL617130,279,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,
2095,,CHO,,,,B,,449.0,H,14818,BAO_0000219,CHEMBL617131,279,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,
2096,,CHO,,,,B,,449.0,H,4829,BAO_0000219,CHEMBL617132,279,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2097,,CHO,,,,B,,449.0,H,4829,BAO_0000219,CHEMBL617133,279,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2098,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617134,279,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,
2099,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617135,279,,Autocuration,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,
2100,,,,,,B,,,H,5014,BAO_0000357,CHEMBL617136,279,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,
2101,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617137,104686,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,
2102,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617138,104686,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2103,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617139,104686,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2104,,,,,,B,,,H,14093,BAO_0000019,CHEMBL617140,12687,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2105,,,,,,F,,,H,11200,BAO_0000218,CHEMBL617141,104686,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,
2106,,,,,,F,,,H,11200,BAO_0000019,CHEMBL858112,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2107,,,,,,B,,,H,12352,BAO_0000019,CHEMBL617142,17005,,Intermediate,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,
2108,,,,Bos taurus,,B,,,U,13657,BAO_0000019,CHEMBL617143,22226,,Autocuration,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,9913.0
2109,,,,Bos taurus,,B,,,U,14331,BAO_0000019,CHEMBL617144,22226,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,9913.0
2110,,,,Bos taurus,,B,,,U,14331,BAO_0000019,CHEMBL617145,22226,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,9913.0
2111,,,,,,B,,,U,14331,BAO_0000019,CHEMBL617146,22226,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,
2112,,,,Cavia porcellus,,B,,,H,12685,BAO_0000019,CHEMBL617147,104784,,Autocuration,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,10141.0
2113,,,,Cavia porcellus,,B,,,H,14389,BAO_0000019,CHEMBL617148,104784,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,10141.0
2114,,,,Cavia porcellus,,B,,,H,14386,BAO_0000019,CHEMBL617149,104784,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,10141.0
2115,,,,,,B,,,H,5732,BAO_0000224,CHEMBL617150,104784,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,
2116,,,,,,B,,,H,16293,BAO_0000224,CHEMBL617151,104784,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2117,,,,,,B,,,H,2078,BAO_0000224,CHEMBL617201,104784,,Autocuration,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,
2118,,,,,,B,,,H,5486,BAO_0000357,CHEMBL617202,10209,,Autocuration,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
2119,,,,,,B,,,H,11820,BAO_0000218,CHEMBL617203,104826,,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,
2120,,,,,,B,,,H,10297,BAO_0000019,CHEMBL617204,104826,,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,
2121,,,,,,B,,,H,13704,BAO_0000224,CHEMBL617205,104826,,Autocuration,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,
2122,,,,Mus musculus,,B,,,D,10297,BAO_0000019,CHEMBL617206,104826,,Autocuration,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,10090.0
2123,,,,,,B,,,H,11820,BAO_0000218,CHEMBL617207,104826,,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,
2124,,,,Mus musculus,,B,,,D,10297,BAO_0000019,CHEMBL617208,104826,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,10090.0
2125,,,,,,B,,,H,11555,BAO_0000224,CHEMBL617209,104826,,Autocuration,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,
2126,,,,,,B,,,H,11555,BAO_0000224,CHEMBL617210,104826,,Autocuration,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,
2127,,,,,,B,,,H,11555,BAO_0000224,CHEMBL617211,104826,,Autocuration,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,
2128,,,,Mus musculus,,B,,,D,10297,BAO_0000019,CHEMBL617212,104826,,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,10090.0
2129,,,,Sus scrofa,,B,,,H,16688,BAO_0000224,CHEMBL617213,104784,,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,9823.0
2130,,,,Sus scrofa,,B,,,H,16688,BAO_0000224,CHEMBL617214,104784,,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,9823.0
2131,,,,,,B,,,U,5333,BAO_0000221,CHEMBL617215,22226,,Autocuration,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2132,,,,,,B,,,U,4437,BAO_0000221,CHEMBL617216,22226,,Autocuration,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2133,,,,Sus scrofa,,B,,,H,5033,BAO_0000357,CHEMBL617217,17005,,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,9823.0
2134,,,,,,B,,,H,15267,BAO_0000019,CHEMBL617218,104686,,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2135,,,,,,B,,,H,15267,BAO_0000019,CHEMBL872913,104686,,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2136,,,,,,B,,,H,11820,BAO_0000019,CHEMBL617219,104826,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,
2137,,,,,,B,,,H,9069,BAO_0000224,CHEMBL873482,104686,,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2138,,,,Rattus norvegicus,,B,,,D,9162,BAO_0000019,CHEMBL617220,104686,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,10116.0
2139,,,,,,B,,,H,9162,BAO_0000019,CHEMBL617221,104686,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,
2140,,,,,,B,,,H,9162,BAO_0000019,CHEMBL617222,104686,,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,
2141,,,,,,F,,,H,10428,BAO_0000019,CHEMBL875906,104686,,Autocuration,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,
2142,,,,,,B,,,H,9628,BAO_0000019,CHEMBL617223,104686,,Autocuration,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,
2143,,,,,,B,,,H,12704,BAO_0000224,CHEMBL617224,104686,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,
2144,,,,Rattus norvegicus,,B,,,D,15453,BAO_0000224,CHEMBL617225,104686,,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,10116.0
2145,,,,,,B,,,H,188,BAO_0000224,CHEMBL617226,104686,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,
2146,,,,,,B,,,H,10349,BAO_0000224,CHEMBL617227,104686,,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,
2147,,,,,,B,,,H,10349,BAO_0000224,CHEMBL617228,104686,,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,
2148,,,,,,B,,,H,8868,BAO_0000224,CHEMBL617229,104686,,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
2149,,,,,,B,,,H,10025,BAO_0000224,CHEMBL617230,104686,,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
2150,,,,,,B,,,H,10025,BAO_0000224,CHEMBL617231,104686,,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
2151,,,,,,B,,,H,11702,BAO_0000224,CHEMBL617232,104686,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,
2152,,,,,,B,,,H,11702,BAO_0000224,CHEMBL617233,104686,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,
2153,,,,,,B,,,H,11702,BAO_0000224,CHEMBL617234,104686,,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,
2154,,,,,,F,,,H,11702,BAO_0000019,CHEMBL617235,104686,,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats,,
2155,,,,,,F,,,H,11702,BAO_0000019,CHEMBL617236,104686,,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,
2156,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL617237,104686,,Autocuration,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,
2157,10000000.0,,Hippocampus,,,B,,,H,10085,BAO_0000221,CHEMBL617238,104686,,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,
2158,955.0,,Brain,Rattus norvegicus,,B,,,D,9630,BAO_0000221,CHEMBL617239,104686,,Autocuration,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,10116.0
2159,,,,,,B,,,H,11070,BAO_0000019,CHEMBL617240,104686,,Autocuration,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,
2160,,,,,,B,Membranes,,H,9841,BAO_0000249,CHEMBL617241,104686,,Autocuration,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2161,,,,,,B,Membranes,,H,9841,BAO_0000249,CHEMBL875907,104686,,Autocuration,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2162,,,,,,B,,,H,13291,BAO_0000019,CHEMBL617242,104686,,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,
2163,,,,,,F,,,H,10590,BAO_0000019,CHEMBL617152,104686,,Autocuration,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,
2164,955.0,,Brain,Rattus norvegicus,,B,,,D,9064,BAO_0000221,CHEMBL617153,104686,,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,10116.0
2165,,,,Rattus norvegicus,,B,Membranes,,D,12268,BAO_0000249,CHEMBL617154,104686,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,10116.0
2166,955.0,,Brain,,,B,,,H,13508,BAO_0000221,CHEMBL617155,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,
2167,,,,,,F,,,H,11279,BAO_0000019,CHEMBL617156,104686,,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2168,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617157,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,
2169,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617158,104686,,Autocuration,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2170,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617159,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2171,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617160,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2172,,,,,,F,,,H,11200,BAO_0000019,CHEMBL858113,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2173,955.0,,Brain,,,B,,,H,9231,BAO_0000220,CHEMBL617247,104686,,Autocuration,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,
2174,,,,,,B,,,H,9737,BAO_0000019,CHEMBL617248,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2175,955.0,,Brain,,,B,,,H,9737,BAO_0000249,CHEMBL617249,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
2176,,,,,,B,,,H,9737,BAO_0000019,CHEMBL617250,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,
2177,,,,,,B,,,H,9737,BAO_0000019,CHEMBL617251,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2178,,,,Rattus norvegicus,,B,,,D,11828,BAO_0000019,CHEMBL617252,104686,,Autocuration,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,10116.0
2179,,,,,,B,,,H,12253,BAO_0000019,CHEMBL617006,104686,,Autocuration,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,
2180,,,,,,B,,,H,12253,BAO_0000019,CHEMBL617007,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,
2181,,,,,,F,,,H,11279,BAO_0000019,CHEMBL617008,104686,,Autocuration,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,
2182,,,,,,B,,,H,11866,BAO_0000019,CHEMBL617009,104686,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,
2183,,,,Rattus norvegicus,,B,,,D,14424,BAO_0000224,CHEMBL617010,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,10116.0
2184,,,,Rattus norvegicus,,B,,,D,15180,BAO_0000019,CHEMBL857978,104686,,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,10116.0
2185,,,,Rattus norvegicus,,B,,,D,15180,BAO_0000019,CHEMBL617011,104686,,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,10116.0
2186,,,,Rattus norvegicus,,B,,,D,9786,BAO_0000019,CHEMBL617012,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,10116.0
2187,,,,,,B,,,H,12132,BAO_0000224,CHEMBL617013,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,
2188,,,,,,B,,,H,5486,BAO_0000249,CHEMBL617014,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,
2189,,,,,,B,,,H,15316,BAO_0000019,CHEMBL617015,104686,,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,
2190,,,,,,B,,,H,16429,BAO_0000019,CHEMBL617016,104686,,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,
2191,,,,,,B,,,H,14617,BAO_0000224,CHEMBL617017,104686,,Autocuration,pKi value for 5-hydroxytryptamine 2 receptor binding site,,
2192,955.0,,Brain,,,B,,,H,11351,BAO_0000221,CHEMBL617018,104686,,Autocuration,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,
2193,,,,,,F,,,H,11279,BAO_0000019,CHEMBL617019,104686,,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2194,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617020,105075,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2195,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617021,105075,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2196,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617022,105075,,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2197,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617023,105075,,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2198,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617024,105075,,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2199,,,,,,B,,,H,9523,BAO_0000019,CHEMBL617025,105075,,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2200,,,,,,B,,,H,9523,BAO_0000224,CHEMBL617026,105075,,Autocuration,Hill coefficient of compound was determined,,
2201,,,,,,B,,,U,4771,BAO_0000019,CHEMBL617027,22226,,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,
2202,,,,Rattus norvegicus,,B,,,D,5033,BAO_0000019,CHEMBL617028,104686,,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,10116.0
2203,,,,,,B,,,H,10845,BAO_0000019,CHEMBL617029,12687,,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,
2204,,,,,,B,,,H,10845,BAO_0000019,CHEMBL875908,12687,,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,
2205,,,,,,B,,,H,16288,BAO_0000357,CHEMBL617030,12687,,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,
2206,,,,,,B,,,H,16288,BAO_0000019,CHEMBL617031,12687,,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,
2207,,,,,,B,,,H,16190,BAO_0000019,CHEMBL617032,12687,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,
2208,,,,Rattus norvegicus,,B,,,D,12463,BAO_0000224,CHEMBL617033,104686,,Autocuration,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,10116.0
2209,,,,,,B,,,H,9699,BAO_0000224,CHEMBL617034,104686,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,
2210,,,,,,B,,,H,9699,BAO_0000224,CHEMBL617035,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,
2211,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617036,104686,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2212,,,,,,B,,,H,1205,BAO_0000224,CHEMBL617037,104784,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,
2213,,,,,,B,,,U,11376,BAO_0000219,CHEMBL617038,22226,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,
2214,,,,,,B,,,H,11376,BAO_0000219,CHEMBL617039,104784,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,
2215,,,,,,B,,,H,4639,BAO_0000224,CHEMBL617161,104784,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,
2216,,,,,,B,,,H,2222,BAO_0000224,CHEMBL617162,104784,,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,
2217,,,,,,B,,,H,1558,BAO_0000224,CHEMBL617163,104784,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,
2218,,,,,,B,,,H,1089,BAO_0000224,CHEMBL617164,104784,,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,
2219,,,,,,B,Brain membranes,,H,386,BAO_0000249,CHEMBL617165,104784,,Autocuration,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,
2220,,,,,,B,,,H,2474,BAO_0000224,CHEMBL617166,104784,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,
2221,,,,,,B,,,H,17066,BAO_0000224,CHEMBL617167,104784,,Autocuration,Binding affinity towards 5-HT2 receptor,,
2222,,,,,,B,,,H,959,BAO_0000224,CHEMBL872912,104784,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2223,,,,,,B,,,H,6398,BAO_0000224,CHEMBL617168,104784,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,
2224,,,,,,B,,,H,11889,BAO_0000224,CHEMBL617169,104686,,Autocuration,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,
2225,,,,,,B,,,H,4221,BAO_0000224,CHEMBL617170,104784,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2226,,,,,,B,,,H,11026,BAO_0000224,CHEMBL617171,104784,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,
2227,,,,,,B,,,H,11866,BAO_0000224,CHEMBL617172,104784,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,
2228,,,,,,B,,,H,4221,BAO_0000224,CHEMBL617173,104784,,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2229,,,,,,B,,,U,13950,BAO_0000019,CHEMBL617174,22226,,Autocuration,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2230,,,,,,B,,,H,1263,BAO_0000224,CHEMBL617175,104784,,Autocuration,5-hydroxytryptamine 2 receptor binding affinity,,
2231,,,,,,B,,,H,13291,BAO_0000357,CHEMBL617176,17005,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,
2232,,,,,,B,,,H,10812,BAO_0000357,CHEMBL617177,17005,,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,
2233,,,,,,B,,,H,13020,BAO_0000224,CHEMBL617178,104784,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2234,,,,,,B,,,H,13021,BAO_0000224,CHEMBL617179,104784,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,
2235,,,,,,B,,,H,13020,BAO_0000224,CHEMBL617180,104784,,Autocuration,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2236,,,,,,B,,,H,14532,BAO_0000357,CHEMBL617181,17005,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,
2237,,,,,,B,,,H,13944,BAO_0000357,CHEMBL617182,17005,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2238,,,,,,B,,,H,14331,BAO_0000357,CHEMBL617183,17005,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2239,,,,,,B,,,H,14118,BAO_0000357,CHEMBL617184,17005,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2240,,,,,,B,,,H,13033,BAO_0000357,CHEMBL617185,17005,,Autocuration,Binding affinity against serotonergic 5-HT2 receptor,,
2241,,,,,,B,,,H,10321,BAO_0000357,CHEMBL617186,17005,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,
2242,,,,,,B,,,H,12918,BAO_0000357,CHEMBL617187,17005,,Autocuration,Compound was evaluated for the binding affinity at 5- HT2 receptor,,
2243,,,,,,B,,,H,15120,BAO_0000357,CHEMBL617188,17005,,Autocuration,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,
2244,,,,,,B,,,H,2613,BAO_0000218,CHEMBL617189,17005,,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,
2245,,,,Homo sapiens,,B,,,D,13378,BAO_0000224,CHEMBL617190,104784,,Autocuration,Inhibitory activity against cloned human 5-HT2 receptor,,9606.0
2246,,CHO,,Homo sapiens,,B,,449.0,D,2331,BAO_0000219,CHEMBL617191,104784,,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,9606.0
2247,,CHO,,Homo sapiens,,B,,449.0,D,2331,BAO_0000219,CHEMBL617192,104784,,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,9606.0
2248,,CHO,,Homo sapiens,,B,,449.0,D,2331,BAO_0000219,CHEMBL617193,104784,,Autocuration,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,9606.0
2249,,CHO,,Homo sapiens,,B,,449.0,D,2331,BAO_0000219,CHEMBL617194,104784,,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,9606.0
2250,,,,,,B,,,H,4170,BAO_0000224,CHEMBL617195,104784,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2251,,,,,,B,,,H,15453,BAO_0000224,CHEMBL881830,104784,,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,
2252,,,,,,B,,,H,1479,BAO_0000357,CHEMBL617196,17005,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2253,,,,,,B,,,H,11139,BAO_0000224,CHEMBL617197,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,
2254,,,,,,B,,,H,13969,BAO_0000357,CHEMBL617198,17005,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,
2255,,,,,,B,,,H,13392,BAO_0000357,CHEMBL873476,17005,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2256,,,,,,B,,,H,14430,BAO_0000019,CHEMBL617199,17005,,Expert,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,
2257,,,,Cavia porcellus,,B,,,H,13181,BAO_0000357,CHEMBL617200,107,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,10141.0
2258,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617484,51,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2259,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617485,107,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2260,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617486,51,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2261,,,,,,B,,,H,13463,BAO_0000357,CHEMBL858022,107,,Autocuration,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,
2262,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617049,107,,Autocuration,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2263,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617050,107,,Expert,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,9606.0
2264,,,,,,F,,,H,4176,BAO_0000219,CHEMBL617051,107,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2265,,,,,,F,,,H,4176,BAO_0000219,CHEMBL617052,107,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,
2266,,,,,,F,,,H,4176,BAO_0000219,CHEMBL617053,107,,Autocuration,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2267,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617054,107,,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,
2268,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617055,107,,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,
2269,,,,,,B,,,H,15331,BAO_0000357,CHEMBL882924,107,,Autocuration,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,
2270,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL617056,107,,Expert,Inhibition of human 5-hydroxytryptamine 2A receptor,,9606.0
2271,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL617057,107,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2272,,,,,,B,,,H,13631,BAO_0000219,CHEMBL617058,107,,Expert,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,
2273,,,,,,B,,,H,3805,BAO_0000357,CHEMBL617059,107,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,
2274,,CHO,,,,B,,449.0,H,4011,BAO_0000219,CHEMBL617060,107,,Autocuration,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,
2275,,CHO,,,,B,,449.0,H,4012,BAO_0000219,CHEMBL617061,107,,Expert,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,
2276,,L929,,,,B,,307.0,H,6366,BAO_0000219,CHEMBL617062,107,,Expert,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,
2277,,CHO,,,,B,,449.0,H,15949,BAO_0000219,CHEMBL617063,107,,Expert,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2278,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617064,107,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,
2279,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617065,107,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2280,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617066,107,,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2281,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617067,107,,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,
2282,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617068,107,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,
2283,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617069,107,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,
2284,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617070,107,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2285,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617071,107,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,
2286,,,,,,B,,,H,14442,BAO_0000357,CHEMBL872915,107,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2287,,,,,,B,,,H,14755,BAO_0000357,CHEMBL617072,107,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,
2288,,,,,,B,,,H,16441,BAO_0000357,CHEMBL617073,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,
2289,,,,,,B,,,H,14744,BAO_0000357,CHEMBL617074,107,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,
2290,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL617075,107,,Expert,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2291,,,,,,B,,,H,3307,BAO_0000357,CHEMBL617076,107,,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,
2292,,,,Homo sapiens,,B,,,D,6857,BAO_0000019,CHEMBL617077,107,,Expert,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,9606.0
2293,,,,,,B,,,H,5635,BAO_0000357,CHEMBL617078,107,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,
2294,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL617079,107,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,9606.0
2295,,,,,,B,,,H,15527,BAO_0000357,CHEMBL617080,107,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2296,,CHO,,,,B,,449.0,H,6588,BAO_0000219,CHEMBL617081,107,,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,
2297,,,,,,B,,,H,13631,BAO_0000219,CHEMBL617082,107,,Expert,Binding affinity towards human 5-HT2A receptor in BEK cells,,
2298,,,,,,B,,,H,17723,BAO_0000357,CHEMBL617083,107,,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,
2299,,,,,,B,,,H,14770,BAO_0000357,CHEMBL617084,107,,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2300,,,,Homo sapiens,,B,,,D,16293,BAO_0000357,CHEMBL617085,107,,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,,9606.0
2301,,,,,,B,,,H,16209,BAO_0000357,CHEMBL617086,107,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2302,,,,,,B,,,H,12469,BAO_0000219,CHEMBL617087,107,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,
2303,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617088,107,,Autocuration,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,
2304,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617089,107,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,
2305,,,,,,B,,,H,16441,BAO_0000019,CHEMBL617090,107,,Expert,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,
2306,,,,,,B,,,H,8,BAO_0000357,CHEMBL617513,107,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,
2307,,HEK293,,,,B,,722.0,H,4176,BAO_0000219,CHEMBL617514,107,,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,
2308,,,,,,B,,,H,17085,BAO_0000019,CHEMBL617515,107,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,
2309,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617516,107,,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2310,,,,Homo sapiens,,B,,,D,17200,BAO_0000357,CHEMBL617517,107,,Expert,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,9606.0
2311,,CHO,,Homo sapiens,,B,,449.0,D,4013,BAO_0000219,CHEMBL617518,107,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,9606.0
2312,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617519,107,,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,
2313,,,,Homo sapiens,,B,,,D,5088,BAO_0000357,CHEMBL617520,107,,Expert,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,9606.0
2314,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617521,107,,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,
2315,,,,Homo sapiens,,B,,,D,5088,BAO_0000357,CHEMBL617522,107,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,9606.0
2316,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617523,107,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,
2317,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617524,107,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2318,,,,,,B,,,H,9786,BAO_0000019,CHEMBL617525,104686,,Autocuration,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,
2319,,,,Rattus norvegicus,,B,,,D,9205,BAO_0000019,CHEMBL617526,104686,,Autocuration,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,10116.0
2320,,,,,,B,,,H,11257,BAO_0000224,CHEMBL617527,104686,,Autocuration,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,
2321,,,,,,B,,,H,9362,BAO_0000019,CHEMBL617528,104686,,Autocuration,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2322,,,,,,B,,,H,9362,BAO_0000019,CHEMBL617529,104686,,Autocuration,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2323,,,,,,B,,,H,10590,BAO_0000224,CHEMBL617530,104686,,Autocuration,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,
2324,,,,,,B,,,H,10468,BAO_0000019,CHEMBL617531,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2325,,,,,,B,,,H,13050,BAO_0000019,CHEMBL617532,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,
2326,,,,,,B,,,H,11624,BAO_0000019,CHEMBL617533,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,
2327,,,,,,B,,,H,10468,BAO_0000019,CHEMBL617534,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2328,,,,,,B,,,H,10330,BAO_0000224,CHEMBL617535,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2329,,,,,,B,,,H,10062,BAO_0000224,CHEMBL617536,104686,,Autocuration,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
2330,,,,,,B,,,H,11642,BAO_0000224,CHEMBL617537,104686,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2331,,,,,,B,,,H,10062,BAO_0000224,CHEMBL617538,104686,,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2332,,,,,,B,,,H,13427,BAO_0000219,CHEMBL617539,104686,,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
2333,,,,Rattus norvegicus,,B,,,D,12280,BAO_0000224,CHEMBL617540,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,10116.0
2334,,,,Rattus norvegicus,,B,,,D,4101,BAO_0000224,CHEMBL617541,104686,,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,10116.0
2335,,,,,,B,,,H,10062,BAO_0000224,CHEMBL617542,104686,,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,
2336,,,,,,B,,,H,11147,BAO_0000224,CHEMBL617543,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,
2337,,CHO-K1,,Rattus norvegicus,,B,,485.0,D,2395,BAO_0000219,CHEMBL617544,104686,,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,10116.0
2338,,CHO-K1,,Rattus norvegicus,,B,,485.0,D,2395,BAO_0000219,CHEMBL617545,104686,,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,10116.0
2339,,,,Rattus norvegicus,,B,,,D,9098,BAO_0000019,CHEMBL617413,104686,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,10116.0
2340,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617414,104686,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,
2341,,,,Rattus norvegicus,,B,,,D,9098,BAO_0000019,CHEMBL617415,104686,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,10116.0
2342,,,,,,B,,,H,9443,BAO_0000224,CHEMBL617416,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2343,,,,,,B,,,H,9443,BAO_0000224,CHEMBL617417,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
2344,,,,,,B,,,H,9699,BAO_0000019,CHEMBL617418,104686,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,
2345,,,,,,B,,,H,9699,BAO_0000019,CHEMBL617419,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,
2346,,,,,,B,,,H,9098,BAO_0000224,CHEMBL617420,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2347,,,,Rattus norvegicus,,B,,,D,3070,BAO_0000224,CHEMBL617421,104686,,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor,,10116.0
2348,,,,,,B,,,H,9547,BAO_0000224,CHEMBL617422,104686,,Autocuration,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,
2349,,,,,,B,,,H,10444,BAO_0000019,CHEMBL617423,104686,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,
2350,,,,,,B,,,H,14617,BAO_0000019,CHEMBL617424,104686,,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,
2351,,,,,,B,,,H,14617,BAO_0000019,CHEMBL617425,104686,,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,
2352,,,,,,B,,,H,11130,BAO_0000224,CHEMBL617426,104686,,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,
2353,,,,,,B,,,H,11130,BAO_0000218,CHEMBL617427,104686,,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,
2354,955.0,,Brain,,,B,,,H,14542,BAO_0000221,CHEMBL617428,104686,,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,
2355,,,,,,B,,,H,2797,BAO_0000224,CHEMBL617429,104686,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,
2356,,,,,,B,,,H,11332,BAO_0000019,CHEMBL617430,104686,,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2357,,,,,,B,,,H,11332,BAO_0000019,CHEMBL617431,104686,,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2358,1870.0,,Frontal cortex,,,B,,,H,10752,BAO_0000019,CHEMBL617432,104686,,Autocuration,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,
2359,,,,,,B,,,H,1185,BAO_0000224,CHEMBL617433,104686,,Autocuration,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2360,,,,,,B,,,H,1185,BAO_0000224,CHEMBL617434,104686,,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2361,,,,Rattus norvegicus,,B,,,D,11624,BAO_0000224,CHEMBL617435,104686,,Autocuration,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,10116.0
2362,,,,,,B,,,H,1344,BAO_0000019,CHEMBL617436,104686,,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,
2363,2435.0,,Striatum,Rattus norvegicus,,B,,,D,15453,BAO_0000019,CHEMBL617437,104686,,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,10116.0
2364,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617438,104686,,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2365,,,,,,B,,,H,11662,BAO_0000019,CHEMBL617439,104686,,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2366,,,,,,B,,,H,10796,BAO_0000224,CHEMBL617440,104686,,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,
2367,,,,,,B,,,H,9069,BAO_0000224,CHEMBL617441,104686,,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2368,,,,Rattus norvegicus,,B,,,D,8814,BAO_0000019,CHEMBL872918,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,10116.0
2369,,,,Rattus norvegicus,,B,,,D,8908,BAO_0000019,CHEMBL617442,104686,,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,10116.0
2370,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617443,104686,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2371,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617444,104686,,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,
2372,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617445,104686,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2373,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617446,104686,,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,
2374,,,,,,B,,,H,9098,BAO_0000249,CHEMBL617447,104686,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,
2375,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617448,104686,,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,
2376,,,,,,B,,,H,9098,BAO_0000019,CHEMBL617449,104686,,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,
2377,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617450,104686,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,
2378,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617451,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,
2379,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617452,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,
2380,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617453,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,
2381,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617660,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,
2382,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617661,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,
2383,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617662,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,
2384,,,,,,B,,,H,9161,BAO_0000019,CHEMBL872919,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,
2385,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617663,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,
2386,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617664,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,
2387,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617665,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,
2388,,,,,,B,,,H,9161,BAO_0000019,CHEMBL617666,104686,,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,
2389,,,,,,B,,,H,12094,BAO_0000019,CHEMBL617667,104686,,Autocuration,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,
2390,,,,,,B,,,H,12018,BAO_0000249,CHEMBL617668,104686,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,
2391,,,,,,B,,,H,10394,BAO_0000249,CHEMBL617669,104686,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,
2392,,,,,,B,,,H,15260,BAO_0000224,CHEMBL617670,104686,,Autocuration,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,
2393,,,,Rattus norvegicus,,B,,,D,11624,BAO_0000224,CHEMBL617671,104686,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,10116.0
2394,,,,,,B,,,H,13654,BAO_0000224,CHEMBL617672,104686,,Autocuration,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,
2395,,,,,,B,,,H,9541,BAO_0000019,CHEMBL617673,104686,,Autocuration,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,
2396,,,,,,B,,,H,11933,BAO_0000224,CHEMBL617674,104686,,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,
2397,,,,,,B,,,H,15538,BAO_0000019,CHEMBL617675,104686,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,
2398,,,,,,B,,,H,15538,BAO_0000019,CHEMBL617676,104686,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,
2399,,,,,,B,,,H,15538,BAO_0000019,CHEMBL617677,104686,,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,
2400,,,,,,B,,,D,8841,BAO_0000019,CHEMBL617678,104686,,Autocuration,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,
2401,,,,,,B,,,H,1455,BAO_0000224,CHEMBL617679,104686,,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,
2402,,,,,,B,,,H,1455,BAO_0000224,CHEMBL617680,104686,,Autocuration,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,
2403,,,,,,B,,,H,11752,BAO_0000019,CHEMBL617681,104686,,Autocuration,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,
2404,955.0,,Brain,,,B,,,H,11642,BAO_0000221,CHEMBL617682,104686,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,
2405,,,,,,B,,,H,12092,BAO_0000224,CHEMBL617683,104686,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,
2406,,,,,,B,,,H,3967,BAO_0000224,CHEMBL617684,104686,,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,
2407,,,,Rattus norvegicus,,B,,,D,12771,BAO_0000224,CHEMBL617685,104686,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,10116.0
2408,,,,,,B,,,H,11642,BAO_0000019,CHEMBL617686,104686,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,
2409,,,,,,B,,,H,11628,BAO_0000224,CHEMBL617687,104686,,Autocuration,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,
2410,,,,,,B,,,H,13654,BAO_0000224,CHEMBL617688,104686,,Autocuration,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2411,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617689,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2412,,,,,,F,,,H,11200,BAO_0000019,CHEMBL617690,104686,,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2413,,,,,,F,,,H,11200,BAO_0000218,CHEMBL617691,104686,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,
2414,,,,,,F,,,H,11200,BAO_0000218,CHEMBL617692,104686,,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,
2415,,,,,,F,,,H,11200,BAO_0000218,CHEMBL617693,104686,,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,
2416,,,,,,F,,,H,11200,BAO_0000218,CHEMBL617694,104686,,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,
2417,955.0,,Brain,,,B,,,H,15436,BAO_0000221,CHEMBL857985,12687,,Expert,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,
2418,,,,Rattus norvegicus,,B,,,D,15436,BAO_0000019,CHEMBL617695,12687,,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,10116.0
2419,,,,,,B,,,H,14025,BAO_0000019,CHEMBL617696,12687,,Autocuration,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,
2420,,,,,,B,,,H,4342,BAO_0000357,CHEMBL617697,12687,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,
2421,,,,Rattus norvegicus,,B,,,D,13735,BAO_0000019,CHEMBL617257,12687,,Expert,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,10116.0
2422,,,,Rattus norvegicus,,B,,,D,5816,BAO_0000357,CHEMBL617258,12687,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,10116.0
2423,,,,,,B,,,H,14287,BAO_0000019,CHEMBL617259,12687,,Expert,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,
2424,,,,,,B,,,H,15738,BAO_0000357,CHEMBL617260,12687,,Autocuration,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,
2425,,,,Rattus norvegicus,,B,,,D,15738,BAO_0000357,CHEMBL617261,12687,,Expert,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,10116.0
2426,,,,,,B,,,H,15026,BAO_0000019,CHEMBL617262,12687,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,
2427,,,,,,B,,,H,16647,BAO_0000019,CHEMBL617263,12687,,Expert,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2428,,,,,,B,,,H,16647,BAO_0000019,CHEMBL617264,12687,,Autocuration,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,
2429,,,,Rattus norvegicus,,B,,,D,13345,BAO_0000019,CHEMBL617265,12687,,Expert,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,10116.0
2430,,,,,,B,Membranes,,H,1543,BAO_0000249,CHEMBL617266,12687,,Autocuration,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,
2431,,,,,,B,,,H,12444,BAO_0000019,CHEMBL617267,12687,,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,
2432,,,,,,B,,,H,16404,BAO_0000019,CHEMBL617268,12687,,Expert,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,
2433,,CHO,,,,B,,449.0,H,16404,BAO_0000219,CHEMBL617269,12687,,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,
2434,,,,,,B,,,H,15577,BAO_0000357,CHEMBL617323,12687,,Expert,Kinetic inhibition constant evaluated by measuring serotonergic activity,,
2435,,,,,,B,,,H,15577,BAO_0000357,CHEMBL617324,12687,,Autocuration,Serotonergic activity of the compound.,,
2436,,,,,,B,,,H,2495,BAO_0000249,CHEMBL617325,12687,,Autocuration,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,
2437,,,,Rattus norvegicus,,B,,,D,15042,BAO_0000019,CHEMBL617326,12687,,Expert,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,10116.0
2438,,,,,,B,,,H,15026,BAO_0000249,CHEMBL617327,12687,,Expert,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,
2439,,,,Rattus norvegicus,,F,,,D,12919,BAO_0000019,CHEMBL617328,12687,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,10116.0
2440,,,,Rattus norvegicus,,F,,,D,12919,BAO_0000019,CHEMBL617329,12687,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,10116.0
2441,,,,Rattus norvegicus,,F,,,D,12919,BAO_0000019,CHEMBL617330,12687,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,10116.0
2442,,,,,,B,,,H,15194,BAO_0000357,CHEMBL617331,12687,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2443,,,,,,B,,,H,15194,BAO_0000357,CHEMBL617332,12687,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,
2444,,,,,,B,,,H,4820,BAO_0000357,CHEMBL617333,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2445,,,,,,B,,,H,6736,BAO_0000357,CHEMBL617334,107,,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,
2446,,,,,,B,,,H,5163,BAO_0000357,CHEMBL617335,107,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,
2447,,,,,,B,,,H,5163,BAO_0000357,CHEMBL617336,107,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,
2448,,,,,,B,,,H,6011,BAO_0000357,CHEMBL617337,107,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,
2449,,,,Homo sapiens,,B,,,D,14294,BAO_0000357,CHEMBL617338,107,,Expert,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,9606.0
2450,,,,,,B,,,H,5014,BAO_0000357,CHEMBL617339,107,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,
2451,,,,,,B,,,H,17066,BAO_0000357,CHEMBL617340,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2452,,,,,,B,,,H,17515,BAO_0000357,CHEMBL617341,107,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,
2453,,,,,,B,,,H,6736,BAO_0000357,CHEMBL617342,107,,Expert,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,
2454,,,,,,B,,,H,5163,BAO_0000357,CHEMBL617343,107,,Expert,Affinity for 5-hydroxytryptamine 2A receptor,,
2455,,NIH3T3,,,,B,,723.0,H,16911,BAO_0000219,CHEMBL617344,107,,Expert,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,
2456,,,,,,B,,,H,6841,BAO_0000357,CHEMBL617345,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,
2457,,,,,,B,,,H,6119,BAO_0000357,CHEMBL617346,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,
2458,,,,,,B,,,H,3962,BAO_0000357,CHEMBL617347,107,,Autocuration,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,
2459,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617348,107,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,
2460,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617349,107,,Autocuration,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,
2461,,,,,,F,,,H,3962,BAO_0000019,CHEMBL617350,107,,Autocuration,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,
2462,,,,,,B,,,H,1633,BAO_0000357,CHEMBL872339,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,
2463,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617351,107,,Autocuration,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,
2464,,,,,,B,,,H,6576,BAO_0000357,CHEMBL617352,107,,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,
2465,,,,,,B,,,H,4687,BAO_0000357,CHEMBL617353,107,,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,
2466,,,,,,B,,,H,16946,BAO_0000357,CHEMBL617354,107,,Autocuration,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,
2467,,,,,,B,,,H,14159,BAO_0000357,CHEMBL617355,107,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,
2468,,CHO,,Mus musculus,,B,,449.0,H,3032,BAO_0000219,CHEMBL617356,107,,Expert,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,10090.0
2469,,,,,,B,,,H,16655,BAO_0000357,CHEMBL617357,107,,Autocuration,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2470,,,,,,B,,,H,13964,BAO_0000357,CHEMBL617358,107,,Autocuration,Binding affinity at 5-hydroxytryptamine 2A receptor,,
2471,,,,,,B,,,H,16989,BAO_0000357,CHEMBL617359,107,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,
2472,,,,,,B,,,H,16117,BAO_0000357,CHEMBL617360,107,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,
2473,,,,,,B,,,H,16700,BAO_0000357,CHEMBL875913,107,,Autocuration,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,
2474,,,,,,B,,,H,3269,BAO_0000357,CHEMBL617361,107,,Autocuration,Affinity against 5-hydroxytryptamine 2A receptor,,
2475,,,,Homo sapiens,,B,,,D,1274,BAO_0000357,CHEMBL617362,107,,Expert,Binding affinity against 5-Hydroxytryptamine 2A receptor,,9606.0
2476,,,,,,B,,,H,1317,BAO_0000357,CHEMBL617363,107,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2477,,,,,,B,,,H,12146,BAO_0000357,CHEMBL617364,107,,Autocuration,Tested against 5-hydroxytryptamine 2A receptor,,
2478,,,,,,B,,,H,12652,BAO_0000224,CHEMBL617365,105075,,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2479,,,,,,B,,,H,12652,BAO_0000224,CHEMBL617366,105075,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,
2480,,,,,,B,,,H,12652,BAO_0000224,CHEMBL617367,105075,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,
2481,,,,,,B,,,H,12652,BAO_0000224,CHEMBL617368,105075,,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2482,,,,,,B,,,H,16647,BAO_0000357,CHEMBL617369,107,,Autocuration,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,
2483,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617370,227,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,9606.0
2484,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617371,227,,Expert,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,9606.0
2485,,,,,,B,,,H,3805,BAO_0000357,CHEMBL617372,227,,Autocuration,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,
2486,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL617373,227,,Expert,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,9606.0
2487,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617374,227,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,
2488,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617375,227,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,
2489,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617376,227,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,
2490,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617377,227,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,
2491,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617378,227,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,
2492,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617379,227,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2493,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617380,227,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,
2494,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617381,227,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,
2495,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617382,227,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2496,,,,,,B,,,H,12369,BAO_0000357,CHEMBL617383,107,,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,
2497,,,,,,B,,,H,12369,BAO_0000357,CHEMBL617384,107,,Expert,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,
2498,,,,,,B,,,H,12369,BAO_0000357,CHEMBL617385,107,,Expert,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,
2499,,,,,,B,,,H,14447,BAO_0000019,CHEMBL617386,107,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,
2500,,,,,,B,,,H,14447,BAO_0000019,CHEMBL617387,107,,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,
2501,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL617388,107,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2502,,CHO,,,,F,,449.0,H,6857,BAO_0000219,CHEMBL617389,107,,Autocuration,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2503,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617390,107,,Expert,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9606.0
2504,,,,,,B,,,H,5635,BAO_0000224,CHEMBL617391,104817,,Autocuration,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,
2505,,,,,,B,,,H,12861,BAO_0000357,CHEMBL617392,107,,Autocuration,Binding activity radioligand.,,
2506,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617393,107,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2507,,L929,,,,B,,307.0,H,5105,BAO_0000219,CHEMBL617394,107,,Autocuration,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2508,,L929,,,,B,,307.0,H,5104,BAO_0000219,CHEMBL617395,107,,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2509,,L929,,,,B,,307.0,H,5105,BAO_0000219,CHEMBL617396,107,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,
2510,,L929,,,,B,,307.0,H,5105,BAO_0000219,CHEMBL617397,107,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,
2511,,,,,,B,,,H,5254,BAO_0000357,CHEMBL617398,107,,Autocuration,Binding affinity against 5-HT2A receptor,,
2512,,,,,,B,,,H,5254,BAO_0000357,CHEMBL617399,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2513,,HEK293,,,,B,,722.0,H,13267,BAO_0000219,CHEMBL617400,107,,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
2514,,HEK293,,,,B,,722.0,H,13267,BAO_0000219,CHEMBL617401,107,,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2515,,HEK293,,Homo sapiens,,B,,722.0,D,14157,BAO_0000219,CHEMBL617402,107,,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,9606.0
2516,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL617403,107,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9606.0
2517,,,,,,B,,,H,14068,BAO_0000357,CHEMBL617404,107,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,
2518,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL857981,107,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9606.0
2519,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL617405,107,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9606.0
2520,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL617253,107,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,9606.0
2521,,,,,,B,,,H,6166,BAO_0000357,CHEMBL617254,107,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,
2522,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL617255,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2523,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL617256,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2524,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL616874,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,
2525,,HEK293,,Homo sapiens,,B,,722.0,D,15779,BAO_0000219,CHEMBL616875,107,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,9606.0
2526,,HEK293,,,,B,,722.0,H,14391,BAO_0000219,CHEMBL616876,107,,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,
2527,,HEK293,,,,B,,722.0,H,15851,BAO_0000219,CHEMBL616877,107,,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,
2528,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL616878,107,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,9606.0
2529,,HEK293,,,,B,,722.0,H,3832,BAO_0000219,CHEMBL616879,107,,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,
2530,,HEK293,,,,B,,722.0,H,3833,BAO_0000219,CHEMBL616880,107,,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,
2531,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL616881,107,,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,9606.0
2532,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL616882,107,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2533,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL616883,107,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2534,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL616884,107,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2535,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL616885,107,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,
2536,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL616886,107,,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,
2537,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL616887,107,,Expert,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,
2538,,,,Homo sapiens,,B,,,D,14875,BAO_0000357,CHEMBL616888,107,,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,,9606.0
2539,,HEK293,,,,B,,722.0,H,15146,BAO_0000219,CHEMBL616889,107,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,
2540,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL616890,107,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2541,,CHO,,Homo sapiens,,B,,449.0,D,16404,BAO_0000219,CHEMBL616891,107,,Expert,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,9606.0
2542,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL616892,107,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,
2543,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL616893,107,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,
2544,,NIH3T3,,,,F,,723.0,H,12652,BAO_0000219,CHEMBL616894,10620,,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,
2545,,NIH3T3,,,,B,,723.0,H,4682,BAO_0000219,CHEMBL616895,107,,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,
2546,,,,,,F,,,H,12652,BAO_0000019,CHEMBL616896,10620,,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,
2547,,,,,,B,,,H,4921,BAO_0000357,CHEMBL617099,10621,,Autocuration,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,
2548,,,,,,B,,,H,4921,BAO_0000357,CHEMBL617100,10621,,Autocuration,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,
2549,,,,Oryctolagus cuniculus,,B,,,H,16312,BAO_0000357,CHEMBL884532,107,,Autocuration,Binding affinity against rabbit aorta 5-HT2A receptor,,9986.0
2550,,,,Oryctolagus cuniculus,,B,,,H,14998,BAO_0000357,CHEMBL617101,107,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,9986.0
2551,,,,Oryctolagus cuniculus,,B,,,H,14025,BAO_0000357,CHEMBL617102,107,,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,9986.0
2552,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL617103,107,,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,9986.0
2553,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000357,CHEMBL617104,107,,Expert,The compound was tested for binding affinity against 5-HT2A receptor,,9986.0
2554,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL857979,10576,,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,
2555,,,,,,B,,,H,13463,BAO_0000019,CHEMBL857502,12687,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,
2556,,,,,,B,,,H,13463,BAO_0000019,CHEMBL617105,12687,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2557,945.0,,Stomach,,,B,,,H,13463,BAO_0000019,CHEMBL858021,12687,,Autocuration,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,
2558,945.0,,Stomach,Rattus norvegicus,,B,,,D,13463,BAO_0000019,CHEMBL875910,12687,,Expert,Binding affinity for 5-HT 2A in rat stomach fundus,,10116.0
2559,,,,,,B,,,H,13463,BAO_0000019,CHEMBL617106,12687,,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2560,,NIH3T3,,,,B,,723.0,H,16326,BAO_0000219,CHEMBL617107,12687,,Expert,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,
2561,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617108,12687,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,
2562,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617109,12687,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,
2563,,,,,,B,,,H,15740,BAO_0000357,CHEMBL617110,12687,,Autocuration,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2564,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617111,12687,,Autocuration,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,
2565,,,,Rattus norvegicus,,F,,,D,17200,BAO_0000019,CHEMBL617112,12687,,Expert,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,10116.0
2566,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617113,12687,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2567,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617114,12687,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2568,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617115,12687,,Autocuration,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2569,,,,,,F,,,H,17200,BAO_0000219,CHEMBL617116,12687,,Autocuration,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2570,,,,,,F,,,H,15363,BAO_0000019,CHEMBL617117,12687,,Autocuration,Efficacy at 5-hydroxytryptamine 2A receptor,,
2571,,,,,,B,,,H,17200,BAO_0000357,CHEMBL617118,12687,,Autocuration,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,
2572,,,,Rattus norvegicus,,B,,,D,17200,BAO_0000357,CHEMBL617119,12687,,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,10116.0
2573,,,,Rattus norvegicus,,B,,,D,17200,BAO_0000357,CHEMBL617120,12687,,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,10116.0
2574,,,,Rattus norvegicus,,F,,,D,17200,BAO_0000219,CHEMBL617121,12687,,Expert,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,10116.0
2575,,,,,,F,,,H,17200,BAO_0000219,CHEMBL617122,12687,,Autocuration,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2576,,,,,,B,,,H,17211,BAO_0000019,CHEMBL617123,12687,,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,
2577,,,,,,B,,,H,17331,BAO_0000019,CHEMBL617124,12687,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,
2578,,,,,,B,,,H,13565,BAO_0000249,CHEMBL617600,12687,,Expert,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,
2579,,,,,,B,,,H,13730,BAO_0000357,CHEMBL617601,12687,,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,
2580,,,,,,B,,,H,12416,BAO_0000019,CHEMBL882923,12687,,Expert,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,
2581,,,,,,B,,,H,15295,BAO_0000357,CHEMBL617602,12687,,Autocuration,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,
2582,,,,,,B,,,H,1742,BAO_0000019,CHEMBL617603,12687,,Autocuration,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,
2583,,,,,,B,,,H,15295,BAO_0000357,CHEMBL617604,12687,,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2584,,,,,,B,,,H,14970,BAO_0000019,CHEMBL617605,12687,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,
2585,,,,,,B,,,H,16693,BAO_0000019,CHEMBL617606,12687,,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,
2586,,,,Rattus norvegicus,,B,,,D,14776,BAO_0000019,CHEMBL617607,12687,,Expert,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,10116.0
2587,,,,,,B,,,H,14286,BAO_0000249,CHEMBL617455,12687,,Autocuration,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2588,,,,Rattus norvegicus,,B,,,D,17200,BAO_0000019,CHEMBL617456,12687,,Expert,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,10116.0
2589,,,,,,B,,,H,15306,BAO_0000357,CHEMBL617457,12687,,Expert,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,
2590,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL617458,12687,,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,10116.0
2591,,,,Rattus norvegicus,,B,,,D,14229,BAO_0000019,CHEMBL617459,12687,,Expert,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,10116.0
2592,,,,,,B,,,H,12884,BAO_0000357,CHEMBL617460,12687,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,
2593,,,,,,B,,,H,13149,BAO_0000357,CHEMBL617461,12687,,Expert,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,
2594,,,,Rattus norvegicus,,B,,,D,15295,BAO_0000019,CHEMBL617462,12687,,Expert,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,10116.0
2595,,,,,,B,,,H,15740,BAO_0000357,CHEMBL617463,12687,,Autocuration,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,
2596,,,,,,B,,,H,15185,BAO_0000019,CHEMBL617464,12687,,Autocuration,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,
2597,,,,,,B,,,H,15185,BAO_0000019,CHEMBL617465,12687,,Autocuration,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,
2598,,,,,,B,,,H,17529,BAO_0000019,CHEMBL617466,12687,,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,
2599,,,,,,B,,,H,14826,BAO_0000019,CHEMBL617467,12687,,Autocuration,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2600,,,,,,B,,,H,17211,BAO_0000019,CHEMBL617468,12687,,Expert,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,
2601,,,,,,B,,,H,14826,BAO_0000019,CHEMBL617469,12687,,Autocuration,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2602,,,,,,B,,,H,14093,BAO_0000019,CHEMBL617470,12687,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2603,,,,,,B,,,H,14093,BAO_0000019,CHEMBL617471,12687,,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,
2604,,NIH3T3,,,,B,,723.0,H,13246,BAO_0000219,CHEMBL617472,12687,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,
2605,,,,,,B,,,H,13246,BAO_0000357,CHEMBL617473,12687,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,
2606,,,,Rattus norvegicus,,B,,,D,15436,BAO_0000019,CHEMBL617474,12687,,Expert,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,10116.0
2607,,,,Rattus norvegicus,,B,,,D,15436,BAO_0000019,CHEMBL617475,12687,,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,10116.0
2608,955.0,,Brain,,,B,,,H,14442,BAO_0000221,CHEMBL617476,12687,,Autocuration,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,
2609,,,,,,B,,,H,12457,BAO_0000357,CHEMBL617477,12687,,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,
2610,,NIH3T3,,,,B,,723.0,H,12457,BAO_0000219,CHEMBL617478,12687,,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,
2611,,,,,,F,,,H,14755,BAO_0000221,CHEMBL617479,12687,,Autocuration,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,
2612,,,,,,B,,,H,4707,BAO_0000357,CHEMBL617480,12687,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,
2613,,,,,,B,,,H,13297,BAO_0000357,CHEMBL617481,12687,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2614,,,,,,B,,,H,17331,BAO_0000019,CHEMBL617482,12687,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,
2615,,,,,,B,,,H,4664,BAO_0000019,CHEMBL617483,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,
2616,,,,,,B,,,H,16633,BAO_0000357,CHEMBL621528,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2617,,NIH3T3,,Rattus norvegicus,,B,,723.0,D,4664,BAO_0000219,CHEMBL621529,12687,,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,10116.0
2618,,,,,,B,,,H,16133,BAO_0000357,CHEMBL621530,12687,,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2619,,,,,,B,,,H,16133,BAO_0000357,CHEMBL621531,12687,,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2620,,,,Rattus norvegicus,,B,,,D,14060,BAO_0000019,CHEMBL621532,12687,,Expert,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,10116.0
2621,,,,,,B,,,H,16326,BAO_0000357,CHEMBL621533,12687,,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2622,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL621534,12687,,Expert,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2623,,,,,,B,,,H,14776,BAO_0000019,CHEMBL621535,12687,,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,
2624,,,,,,B,,,H,13481,BAO_0000357,CHEMBL621536,12687,,Autocuration,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2625,,,,,,B,,,H,17386,BAO_0000357,CHEMBL621537,12687,,Autocuration,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,
2626,,,,Rattus norvegicus,,B,,,D,6611,BAO_0000357,CHEMBL621538,12687,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor,,10116.0
2627,,,,,,B,,,H,14423,BAO_0000019,CHEMBL621539,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,
2628,,,,,,B,,,H,15412,BAO_0000019,CHEMBL621540,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,
2629,,,,,,B,,,H,15412,BAO_0000019,CHEMBL621541,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,
2630,,,,,,B,,,H,6238,BAO_0000019,CHEMBL621542,12687,,Autocuration,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,
2631,,,,,,B,,,H,6648,BAO_0000357,CHEMBL621543,12687,,Expert,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,
2632,,,,,,B,,,H,5667,BAO_0000357,CHEMBL621544,12687,,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,
2633,,,,Rattus norvegicus,,B,,,D,6611,BAO_0000357,CHEMBL621545,12687,,Expert,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,10116.0
2634,,,,,,B,,,H,13481,BAO_0000357,CHEMBL621546,12687,,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2635,,,,,,B,,,H,13481,BAO_0000357,CHEMBL621547,12687,,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,
2636,,NIH3T3,,,,B,,723.0,H,15558,BAO_0000219,CHEMBL618692,12687,,Expert,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,
2637,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618693,12687,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2638,,,,,,B,,,H,16633,BAO_0000357,CHEMBL872922,12687,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2639,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618694,12687,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,
2640,,,,Rattus norvegicus,,B,,,D,6013,BAO_0000357,CHEMBL618695,12687,,Expert,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,10116.0
2641,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618696,12687,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,
2642,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618697,12687,,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,
2643,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618892,12687,,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,
2644,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618893,12687,,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,
2645,,,,,,B,,,H,16293,BAO_0000357,CHEMBL618894,12687,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2646,,NIH3T3,,,,B,,723.0,H,17175,BAO_0000219,CHEMBL618895,12687,,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,
2647,,,,Rattus norvegicus,,B,,,D,13278,BAO_0000357,CHEMBL618896,12687,,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,10116.0
2648,5383.0,,Caudate-putamen,,,B,,,H,3682,BAO_0000019,CHEMBL618897,12687,,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,
2649,,,,,,B,,,H,2014,BAO_0000357,CHEMBL618898,12687,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,
2650,,,,,,B,,,H,2014,BAO_0000357,CHEMBL618899,12687,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,
2651,,,,,,B,,,H,4932,BAO_0000357,CHEMBL618900,12687,,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,
2652,,,,,,B,,,H,4932,BAO_0000019,CHEMBL618901,12687,,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,
2653,,,,,,B,,,H,3935,BAO_0000357,CHEMBL618902,12687,,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,
2654,10000000.0,,Hippocampus,Rattus norvegicus,,B,,,D,5432,BAO_0000221,CHEMBL618903,12687,,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,10116.0
2655,,,,,,B,,,H,15818,BAO_0000357,CHEMBL618904,12687,,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2656,,,,,,B,,,H,13672,BAO_0000357,CHEMBL618905,12687,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,
2657,,,,,,B,,,H,13672,BAO_0000357,CHEMBL618906,12687,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,
2658,,NIH3T3,,,,B,,723.0,H,14749,BAO_0000219,CHEMBL618907,12687,,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,
2659,,,,,,B,,,H,13462,BAO_0000019,CHEMBL618908,12687,,Autocuration,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,
2660,,,,,,B,,,H,15740,BAO_0000357,CHEMBL617909,12687,,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2661,,,,,,B,,,H,16647,BAO_0000019,CHEMBL617910,12687,,Expert,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2662,955.0,,Brain,,,B,,,H,13345,BAO_0000221,CHEMBL617911,12687,,Autocuration,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,
2663,,,,,,B,,,H,16740,BAO_0000249,CHEMBL872923,12687,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2664,,,,,,B,,,H,16740,BAO_0000249,CHEMBL617912,12687,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2665,,,,Rattus norvegicus,,B,,,D,15535,BAO_0000019,CHEMBL617913,12687,,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,10116.0
2666,,,,,,B,,,H,16740,BAO_0000249,CHEMBL617914,12687,,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2667,,,,,,B,,,H,16740,BAO_0000249,CHEMBL617915,12687,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2668,,,,,,B,,,H,16740,BAO_0000249,CHEMBL617916,12687,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2669,,,,Rattus norvegicus,,B,,,D,4795,BAO_0000019,CHEMBL617917,12687,,Expert,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,10116.0
2670,,,,,,B,,,H,8,BAO_0000019,CHEMBL617918,12687,,Expert,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,
2671,,,,,,B,,,H,8,BAO_0000019,CHEMBL617919,12687,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,
2672,,,,Rattus norvegicus,,B,,,D,17200,BAO_0000019,CHEMBL617920,12687,,Expert,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,10116.0
2673,,,,Rattus norvegicus,,B,,,D,2148,BAO_0000019,CHEMBL617921,12687,,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,10116.0
2674,,,,Rattus norvegicus,,B,,,D,13345,BAO_0000224,CHEMBL617922,105102,,Expert,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,10116.0
2675,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617923,12687,,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2676,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617924,12687,,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2677,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617925,12687,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,
2678,,,,Rattus norvegicus,,B,,,D,17133,BAO_0000357,CHEMBL617926,12687,,Expert,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,10116.0
2679,,,,,,B,,,H,16532,BAO_0000357,CHEMBL617927,12687,,Autocuration,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,
2680,,,,,,B,,,H,15086,BAO_0000357,CHEMBL617928,12687,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,
2681,,,,Rattus norvegicus,,B,,,D,2309,BAO_0000019,CHEMBL617929,12687,,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,10116.0
2682,,,,,,B,,,H,12953,BAO_0000019,CHEMBL617930,12687,,Expert,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,
2683,,,,,,B,,,H,12953,BAO_0000019,CHEMBL617931,12687,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,
2684,,,,,,B,,,H,12953,BAO_0000019,CHEMBL617932,12687,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,
2685,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL617933,12687,,Autocuration,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,
2686,,,,,,B,,,H,16740,BAO_0000019,CHEMBL617934,12687,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2687,,,,,,B,,,H,16740,BAO_0000019,CHEMBL617935,12687,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2688,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617936,12687,,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,
2689,,,,,,B,,,H,17211,BAO_0000019,CHEMBL617937,12687,,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,
2690,,,,,,B,,,H,17331,BAO_0000019,CHEMBL617938,12687,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,
2691,,,,,,B,,,H,16633,BAO_0000218,CHEMBL617939,12687,,Autocuration,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,
2692,,,,,,B,,,H,16633,BAO_0000218,CHEMBL617940,12687,,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,
2693,,,,,,B,,,H,16633,BAO_0000218,CHEMBL617941,12687,,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,
2694,,,,,,B,,,H,15026,BAO_0000357,CHEMBL617942,12687,,Expert,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,
2695,,,,,,B,,,H,15026,BAO_0000357,CHEMBL617943,12687,,Expert,Ratio of pKi of 5-HT2A to that of D2 receptor,,
2696,,,,,,B,,,H,16404,BAO_0000224,CHEMBL617944,105093,,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2697,,,,,,B,,,H,16404,BAO_0000224,CHEMBL617945,105093,,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2698,,,,,,B,,,H,16404,BAO_0000224,CHEMBL617946,105075,,Expert,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,
2699,,,,,,B,,,H,16404,BAO_0000357,CHEMBL617947,12687,,Autocuration,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,
2700,,,,,,B,,,H,16326,BAO_0000357,CHEMBL617948,12687,,Expert,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,
2701,,,,,,F,,,H,15847,BAO_0000019,CHEMBL858116,12687,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,
2702,,,,,,F,,,H,15847,BAO_0000019,CHEMBL617949,12687,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,
2703,,,,,,F,,,H,15329,BAO_0000019,CHEMBL617950,12687,,Autocuration,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,
2704,1515.0,,Thoracic aorta,,,F,,,H,16404,BAO_0000019,CHEMBL617951,12687,,Expert,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,
2705,1515.0,,Thoracic aorta,,,F,,,H,16404,BAO_0000019,CHEMBL617952,12687,,Expert,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,
2706,1515.0,,Thoracic aorta,,,F,,,H,16404,BAO_0000019,CHEMBL617953,12687,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,
2707,,,,,,B,,,H,12861,BAO_0000357,CHEMBL617954,12687,,Autocuration,Binding activity radioligand.,,
2708,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617955,12687,,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2709,,,,,,B,,,H,12861,BAO_0000019,CHEMBL857071,12687,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2710,,,,,,B,,,H,12490,BAO_0000019,CHEMBL617270,12687,,Expert,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,
2711,,N1E-115,,,,B,,339.0,H,12827,BAO_0000219,CHEMBL617271,12687,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,
2712,,N1E-115,,,,B,,339.0,H,12827,BAO_0000219,CHEMBL617272,12687,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,
2713,,,,,,B,,,H,12918,BAO_0000019,CHEMBL617273,12687,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,
2714,,,,Rattus norvegicus,,F,,,D,12919,BAO_0000019,CHEMBL617274,12687,,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,10116.0
2715,,,,,,B,,,H,17723,BAO_0000357,CHEMBL617275,108,,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,
2716,,,,,,B,,,H,6013,BAO_0000357,CHEMBL617276,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2717,,,,,,B,,,H,16293,BAO_0000357,CHEMBL617277,108,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,
2718,,,,,,B,,,H,3857,BAO_0000019,CHEMBL617278,108,,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2719,,,,,,B,,,H,3857,BAO_0000019,CHEMBL617279,108,,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,
2720,,,,,,B,,,H,3857,BAO_0000019,CHEMBL617280,108,,Expert,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2721,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617281,108,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2722,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617282,108,,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2723,,,,,,B,,,H,16441,BAO_0000019,CHEMBL617283,108,,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,
2724,,,,,,B,,,H,16441,BAO_0000019,CHEMBL617284,108,,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,
2725,,HEK293,,,,B,,722.0,H,4176,BAO_0000219,CHEMBL617285,108,,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,
2726,,,,,,B,,,H,17085,BAO_0000019,CHEMBL617286,108,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,
2727,,,,Homo sapiens,,B,,,D,17200,BAO_0000357,CHEMBL617287,108,,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,9606.0
2728,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617288,108,,Expert,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,
2729,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617289,108,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,
2730,,,,,,B,,,H,5088,BAO_0000357,CHEMBL872917,108,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2731,,,,,,B,,,H,5088,BAO_0000357,CHEMBL617290,108,,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2732,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL617291,108,,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2733,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL617292,108,,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,
2734,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL617293,108,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2735,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617294,108,,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9606.0
2736,,,,,,B,,,H,3857,BAO_0000019,CHEMBL617295,108,,Expert,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2737,,,,,,B,,,H,12861,BAO_0000357,CHEMBL617296,108,,Autocuration,Binding activity radioligand.,,
2738,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617297,108,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2739,,CHO,,,,B,,449.0,H,5104,BAO_0000219,CHEMBL617298,108,,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,
2740,,CHO,,,,B,,449.0,H,5105,BAO_0000219,CHEMBL617299,108,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,
2741,,CHO,,,,B,,449.0,H,5105,BAO_0000219,CHEMBL617300,108,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,
2742,,,,,,B,,,H,5254,BAO_0000357,CHEMBL617454,108,,Autocuration,Binding affinity against 5-HT2C receptor,,
2743,,HEK293,,,,B,,722.0,H,13267,BAO_0000219,CHEMBL617505,108,,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2744,,HEK293,,Homo sapiens,,B,,722.0,D,14157,BAO_0000219,CHEMBL617506,108,,Expert,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,9606.0
2745,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL617507,108,,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,9606.0
2746,,,,,,B,,,H,14068,BAO_0000357,CHEMBL617508,108,,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,
2747,,HEK293,,Homo sapiens,,B,,722.0,D,12936,BAO_0000219,CHEMBL857982,108,,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,9606.0
2748,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL617509,108,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,9606.0
2749,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL617510,108,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,9606.0
2750,,,,,,B,,,H,6166,BAO_0000357,CHEMBL617511,108,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,
2751,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL617512,108,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,
2752,,HEK293,,,,B,,722.0,H,17296,BAO_0000219,CHEMBL617749,108,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,
2753,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617750,108,,Autocuration,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2754,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617751,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2755,,HEK293,,,,B,,722.0,H,14391,BAO_0000219,CHEMBL617752,108,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,
2756,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617753,108,,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,
2757,,HEK293,,,,B,,722.0,H,15851,BAO_0000219,CHEMBL617754,108,,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,
2758,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617755,108,,Expert,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,9606.0
2759,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617756,108,,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,
2760,,HEK293,,,,B,,722.0,H,3832,BAO_0000219,CHEMBL617757,108,,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,
2761,,HEK293,,,,B,,722.0,H,3833,BAO_0000219,CHEMBL617758,108,,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,
2762,,NIH3T3,,,,B,,723.0,H,17451,BAO_0000219,CHEMBL617759,108,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2763,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL617760,108,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,
2764,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL617761,108,,Expert,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,
2765,,,,Homo sapiens,,B,,,D,4321,BAO_0000357,CHEMBL617762,108,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,9606.0
2766,,,,,,B,,,H,14875,BAO_0000357,CHEMBL617763,108,,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,
2767,,HEK293,,,,B,,722.0,H,15146,BAO_0000219,CHEMBL857983,108,,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,
2768,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL617764,108,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,
2769,,HeLa,,,,B,,308.0,H,16404,BAO_0000219,CHEMBL617765,108,,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,
2770,,,,,,F,,,H,13267,BAO_0000019,CHEMBL617766,108,,Autocuration,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,
2771,10000000.0,,Hippocampus,,,F,,,H,13267,BAO_0000221,CHEMBL617767,108,,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,
2772,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL617768,108,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,
2773,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL617769,108,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,
2774,,,,,,B,,,H,13463,BAO_0000357,CHEMBL858023,11864,,Autocuration,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,
2775,945.0,,Stomach,,,B,,,H,13463,BAO_0000019,CHEMBL617770,11864,,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,
2776,945.0,,Stomach,,,B,,,H,13463,BAO_0000019,CHEMBL617771,11864,,Autocuration,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,
2777,,A9,,,,F,,625.0,H,12652,BAO_0000219,CHEMBL617772,11864,,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,
2778,,NIH3T3,,,,B,,723.0,H,4682,BAO_0000219,CHEMBL617773,11864,,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2779,,NIH3T3,,,,B,,723.0,H,4682,BAO_0000219,CHEMBL617850,11864,,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,
2780,,NIH3T3,,,,B,,723.0,H,4682,BAO_0000219,CHEMBL617851,11864,,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2781,,,,,,F,,,H,12652,BAO_0000019,CHEMBL617852,11864,,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,
2782,945.0,,Stomach,Mus musculus,,B,,,H,13463,BAO_0000019,CHEMBL858024,12689,,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,10090.0
2783,945.0,,Stomach,Rattus norvegicus,,B,,,D,13463,BAO_0000019,CHEMBL617853,12689,,Expert,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,10116.0
2784,,,,,,B,,,H,13969,BAO_0000357,CHEMBL617854,108,,Expert,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,
2785,,,,Sus scrofa,,B,,,H,13392,BAO_0000357,CHEMBL873477,108,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,9823.0
2786,,,,,,B,,,H,13392,BAO_0000357,CHEMBL617855,108,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2787,,,,,,B,,,H,14430,BAO_0000019,CHEMBL617856,108,,Expert,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,
2788,,,,,,B,,,H,1742,BAO_0000019,CHEMBL617857,108,,Autocuration,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,
2789,,,,,,B,,,H,14286,BAO_0000249,CHEMBL617858,108,,Autocuration,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,
2790,,,,,,B,,,H,5619,BAO_0000357,CHEMBL617859,108,,Autocuration,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,
2791,,,,,,B,,,H,15086,BAO_0000357,CHEMBL617860,108,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2792,,,,,,B,,,H,12861,BAO_0000357,CHEMBL617861,108,,Autocuration,Binding activity radioligand.,,
2793,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617862,108,,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2794,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617863,108,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2795,,,,,,B,,,H,12827,BAO_0000249,CHEMBL617864,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,
2796,,,,,,B,,,H,12827,BAO_0000249,CHEMBL617649,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,
2797,,,,Sus scrofa,,F,,,H,12919,BAO_0000019,CHEMBL617650,108,,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,9823.0
2798,,,,Sus scrofa,,F,,,H,12919,BAO_0000019,CHEMBL617651,108,,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,9823.0
2799,,,,Sus scrofa,,B,,,H,16429,BAO_0000357,CHEMBL617652,108,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,9823.0
2800,,,,Sus scrofa,,B,,,H,773,BAO_0000019,CHEMBL857072,108,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,9823.0
2801,,,,Sus scrofa,,B,,,H,5033,BAO_0000357,CHEMBL617653,108,,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,9823.0
2802,,,,,,B,,,H,12861,BAO_0000019,CHEMBL617654,12687,,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2803,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617655,12689,,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,
2804,,,,,,B,,,H,14970,BAO_0000357,CHEMBL617656,12689,,Expert,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,
2805,,,,,,B,,,H,14970,BAO_0000357,CHEMBL617657,12689,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,
2806,,,,,,B,,,H,14970,BAO_0000357,CHEMBL617658,12689,,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,
2807,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL617659,12689,,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,10116.0
2808,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL617838,12689,,Expert,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,10116.0
2809,,,,Rattus norvegicus,,B,Brain membranes,,D,14229,BAO_0000249,CHEMBL617839,12689,,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,10116.0
2810,,,,,,B,,,H,16532,BAO_0000357,CHEMBL617840,12689,,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,
2811,,,,,,B,,,H,14826,BAO_0000019,CHEMBL617841,12689,,Autocuration,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,
2812,,,,,,B,,,H,17211,BAO_0000019,CHEMBL875915,12689,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,
2813,,,,,,B,,,H,17211,BAO_0000219,CHEMBL617842,12689,,Expert,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,
2814,,NIH3T3,,,,B,,723.0,H,13246,BAO_0000219,CHEMBL617843,12689,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,
2815,,,,,,B,,,H,13246,BAO_0000357,CHEMBL617844,12689,,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,
2816,,,,,,B,,,H,12457,BAO_0000357,CHEMBL617845,12689,,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,
2817,,NIH3T3,,,,B,,723.0,H,12457,BAO_0000219,CHEMBL617846,12689,,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,
2818,,,,,,B,,,H,4707,BAO_0000357,CHEMBL617847,12689,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,
2819,,,,,,B,,,H,13297,BAO_0000357,CHEMBL617848,12689,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,
2820,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617849,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2821,,,,,,B,,,H,16133,BAO_0000357,CHEMBL621507,12689,,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2822,,,,,,B,,,H,16326,BAO_0000357,CHEMBL621508,12689,,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,
2823,,,,,,B,,,H,14423,BAO_0000019,CHEMBL621509,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,
2824,,,,,,B,,,H,15412,BAO_0000019,CHEMBL621510,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,
2825,,,,,,B,,,H,15412,BAO_0000019,CHEMBL621511,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,
2826,,A9,,,,B,,625.0,H,15558,BAO_0000219,CHEMBL621512,12689,,Expert,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,
2827,,,,,,B,,,H,16633,BAO_0000357,CHEMBL621513,12689,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2828,,,,,,B,,,H,6013,BAO_0000357,CHEMBL621514,12689,,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,
2829,,,,,,B,,,H,17175,BAO_0000219,CHEMBL621515,12689,,Expert,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,
2830,,,,,,B,,,H,12469,BAO_0000219,CHEMBL621516,12689,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,
2831,5383.0,,Caudate-putamen,,,B,,,H,3682,BAO_0000019,CHEMBL621517,12689,,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,
2832,,,,,,B,,,H,4932,BAO_0000357,CHEMBL621518,12689,,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,
2833,,,,,,B,,,H,4932,BAO_0000019,CHEMBL621519,12689,,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,
2834,,,,,,B,,,H,3935,BAO_0000357,CHEMBL621520,12689,,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,
2835,,,,,,B,,,H,15818,BAO_0000357,CHEMBL621521,12689,,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,
2836,,,,,,B,,,H,15818,BAO_0000357,CHEMBL621522,12689,,Autocuration,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,
2837,,,,,,B,,,H,14749,BAO_0000219,CHEMBL621523,12689,,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,
2838,,,,,,B,,,H,15740,BAO_0000357,CHEMBL621524,12689,,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,
2839,,,,Rattus norvegicus,,B,,,D,17133,BAO_0000357,CHEMBL621525,12689,,Expert,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,10116.0
2840,,,,,,B,,,H,16532,BAO_0000357,CHEMBL872921,12689,,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,
2841,,,,,,B,,,H,12369,BAO_0000357,CHEMBL621526,12689,,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,
2842,,,,,,B,,,H,12369,BAO_0000219,CHEMBL621527,12689,,Expert,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,
2843,,,,Rattus norvegicus,,B,,,D,2309,BAO_0000019,CHEMBL617865,12689,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,10116.0
2844,,,,,,B,,,H,12953,BAO_0000357,CHEMBL617866,12689,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,
2845,,,,,,B,,,H,12953,BAO_0000019,CHEMBL617867,12689,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,
2846,,,,,,B,,,H,12953,BAO_0000357,CHEMBL617487,12689,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,
2847,,,,,,B,,,H,12953,BAO_0000357,CHEMBL617488,12689,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,
2848,,,,,,B,,,H,17133,BAO_0000357,CHEMBL617489,12689,,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,
2849,,,,,,B,,,H,17211,BAO_0000019,CHEMBL617490,12689,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,
2850,,,,,,B,,,H,17211,BAO_0000019,CHEMBL617491,12689,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,
2851,,,,,,B,,,H,14025,BAO_0000019,CHEMBL617492,12689,,Autocuration,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,
2852,,,,,,B,,,H,14998,BAO_0000019,CHEMBL617493,12689,,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,
2853,,,,,,B,,,H,4342,BAO_0000357,CHEMBL617494,12689,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,
2854,,,,Rattus norvegicus,,B,,,D,13735,BAO_0000019,CHEMBL617495,12689,,Expert,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,10116.0
2855,,,,,,B,,,H,13181,BAO_0000357,CHEMBL617496,12689,,Autocuration,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2856,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL617497,12689,,Autocuration,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,
2857,,,,,,B,,,H,15194,BAO_0000357,CHEMBL617498,12689,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2858,,,,,,B,,,H,15194,BAO_0000357,CHEMBL617499,12689,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,
2859,,,,,,F,,,H,14579,BAO_0000019,CHEMBL617500,12689,,Autocuration,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,
2860,,,,,,B,,,H,4639,BAO_0000357,CHEMBL617501,108,,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2861,,,,,,B,,,H,4820,BAO_0000357,CHEMBL617502,108,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2862,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617503,227,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,
2863,,,,,,B,,,H,14755,BAO_0000357,CHEMBL617504,227,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,
2864,,,,,,B,,,H,14744,BAO_0000357,CHEMBL617406,227,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,
2865,,,,Homo sapiens,,B,,,D,6857,BAO_0000019,CHEMBL617407,227,,Expert,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,9606.0
2866,,,,,,B,,,H,16209,BAO_0000357,CHEMBL617408,227,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,
2867,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617409,227,,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2868,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617410,227,,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2869,,,,,,B,,,H,15363,BAO_0000357,CHEMBL617411,227,,Autocuration,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,
2870,,,,,,B,,,H,17085,BAO_0000019,CHEMBL617412,227,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,
2871,,,,Homo sapiens,,B,,,D,17200,BAO_0000357,CHEMBL617774,227,,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,9606.0
2872,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617775,227,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,9606.0
2873,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617776,227,,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,9606.0
2874,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617777,227,,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9606.0
2875,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617778,227,,Expert,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,9606.0
2876,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617779,227,,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2877,,HEK293,,,,B,,722.0,H,15851,BAO_0000219,CHEMBL617780,227,,Expert,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,
2878,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617781,227,,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,
2879,,HEK293,,Homo sapiens,,B,,722.0,D,14157,BAO_0000219,CHEMBL617782,227,,Expert,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,9606.0
2880,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL617783,227,,Expert,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,9606.0
2881,,,,,,B,,,H,6166,BAO_0000357,CHEMBL617784,227,,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,
2882,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL617785,227,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,
2883,,HEK293,,,,B,,722.0,H,14391,BAO_0000219,CHEMBL857984,227,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,
2884,,HEK293,,,,B,,722.0,H,3832,BAO_0000219,CHEMBL617786,227,,Expert,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,
2885,,HEK293,,,,B,,722.0,H,3833,BAO_0000219,CHEMBL617787,227,,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,
2886,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617788,227,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,9606.0
2887,,HEK293,,Homo sapiens,,B,,722.0,D,15851,BAO_0000219,CHEMBL617789,227,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,9606.0
2888,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL617790,227,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,
2889,,CHO-K1,,,,B,,485.0,H,1883,BAO_0000219,CHEMBL617791,227,,Expert,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,
2890,,,,,,B,,,H,4321,BAO_0000357,CHEMBL617608,227,,Expert,Binding affinity against 5-hydroxytryptamine 2B receptor,,
2891,,HEK293,,,,B,,722.0,H,15146,BAO_0000219,CHEMBL617609,227,,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,
2892,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL617610,227,,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2893,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL617611,227,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,
2894,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL617612,227,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2895,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL617613,227,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2896,,,,Oryctolagus cuniculus,,B,,,H,14025,BAO_0000019,CHEMBL617614,227,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,9986.0
2897,945.0,,Stomach,,,B,,,H,13463,BAO_0000019,CHEMBL617615,12688,,Expert,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,
2898,945.0,,Stomach,,,B,,,H,7259,BAO_0000357,CHEMBL858114,12688,,Expert,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,
2899,945.0,,Stomach,,,B,,,H,7259,BAO_0000357,CHEMBL617616,12688,,Autocuration,Affinity against serotonergic receptor in the isolated rat stomach fundus,,
2900,945.0,,Stomach,Rattus norvegicus,,F,,,D,7185,BAO_0000019,CHEMBL617617,12688,,Expert,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,10116.0
2901,,,,Rattus norvegicus,,F,,,D,7185,BAO_0000019,CHEMBL875914,12688,,Expert,Antagonistic against 5-hydroxytryptamine 2B receptor,,10116.0
2902,945.0,,Stomach,,,F,,,H,13267,BAO_0000019,CHEMBL617618,12688,,Autocuration,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,
2903,945.0,,Stomach,Rattus norvegicus,,B,,,D,13735,BAO_0000357,CHEMBL617619,12688,,Expert,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,10116.0
2904,,,,,,F,,,H,15738,BAO_0000019,CHEMBL617620,12688,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,
2905,,,,,,F,,,H,15738,BAO_0000019,CHEMBL617621,12688,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,
2906,,,,,,F,,,H,15738,BAO_0000019,CHEMBL617622,12688,,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,
2907,945.0,,Stomach,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL617623,12688,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,10116.0
2908,945.0,,Stomach,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL617624,12688,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,10116.0
2909,945.0,,Stomach,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL617625,12688,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,10116.0
2910,945.0,,Stomach,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL617626,12688,,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,10116.0
2911,945.0,,Stomach,,,F,,,H,16404,BAO_0000019,CHEMBL617627,12688,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2912,945.0,,Stomach,,,F,,,H,16404,BAO_0000019,CHEMBL617628,12688,,Expert,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2913,945.0,,Stomach,,,F,,,H,16404,BAO_0000019,CHEMBL617629,12688,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,
2914,945.0,,Stomach,,,F,,,H,16404,BAO_0000019,CHEMBL858115,12688,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,
2915,945.0,,Stomach,Rattus norvegicus,,F,,,D,16404,BAO_0000019,CHEMBL617630,12688,,Expert,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,10116.0
2916,1515.0,,Thoracic aorta,,,F,,,H,16404,BAO_0000019,CHEMBL617631,12688,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,
2917,,,,,,B,,,H,7483,BAO_0000357,CHEMBL617632,12688,,Autocuration,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2918,,,,,,B,,,H,7483,BAO_0000357,CHEMBL617633,12688,,Expert,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,
2919,,,,,,B,,,H,7483,BAO_0000357,CHEMBL617634,12688,,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2920,,,,,,B,,,H,7483,BAO_0000357,CHEMBL617635,12688,,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,
2922,945.0,,Stomach,Rattus norvegicus,,F,,,D,16404,BAO_0000019,CHEMBL617637,12688,,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,10116.0
2923,,,,,,B,,,H,6347,BAO_0000357,CHEMBL617638,227,,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,
2924,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617639,227,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,
2925,,,,,,B,,,H,4373,BAO_0000357,CHEMBL617640,227,,Autocuration,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,
2926,,,,,,B,,,H,4687,BAO_0000357,CHEMBL617641,227,,Autocuration,Evaluated for the binding affinity to 5-HT 2B receptor,,
2927,,,,,,B,,,H,16946,BAO_0000357,CHEMBL617642,227,,Autocuration,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,
2928,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617643,227,,Autocuration,Binding affinities against 5-hydroxytryptamine 2B receptor,,
2929,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617644,227,,Autocuration,Binding affinities towards 5-hydroxytryptamine 2B receptor,,
2930,,,,,,B,,,H,16633,BAO_0000357,CHEMBL617645,227,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,
2931,,,,,,B,,,H,15026,BAO_0000357,CHEMBL617646,108,,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,
2932,,,,Bos taurus,,B,,,H,15738,BAO_0000357,CHEMBL617647,108,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,9913.0
2933,,,,Bos taurus,,B,,,H,15738,BAO_0000357,CHEMBL617648,108,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,9913.0
2934,,,,Bos taurus,,B,,,H,15738,BAO_0000357,CHEMBL617875,108,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,9913.0
2935,,,,Bos taurus,,B,,,H,15738,BAO_0000357,CHEMBL617876,108,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,9913.0
2936,,,,Bos taurus,,B,,,H,16404,BAO_0000357,CHEMBL617877,108,,Expert,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,9913.0
2937,,,,Bos taurus,,B,,,H,15026,BAO_0000357,CHEMBL617878,108,,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,9913.0
2938,,,,Bos taurus,,B,,,H,15738,BAO_0000357,CHEMBL617879,108,,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,9913.0
2939,,,,Cavia porcellus,,B,,,H,16312,BAO_0000019,CHEMBL617880,108,,Autocuration,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,10141.0
2940,2435.0,,Striatum,Cavia porcellus,,B,,,D,5486,BAO_0000357,CHEMBL617881,20033,,Intermediate,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,10141.0
2941,,,,,,B,,,H,5254,BAO_0000357,CHEMBL857073,51,,Autocuration,Binding affinity against 5-HT1A receptor,,
2942,,CHO,,,,F,,449.0,H,3857,BAO_0000219,CHEMBL617882,108,,Expert,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,
2943,,CHO,,Homo sapiens,,F,,449.0,D,6857,BAO_0000219,CHEMBL617883,108,,Expert,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,9606.0
2944,,,,,,F,,,H,4176,BAO_0000219,CHEMBL617884,108,,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,
2945,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617885,108,,Autocuration,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,
2946,,CHO,,,,B,,449.0,H,6347,BAO_0000219,CHEMBL617886,108,,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,
2947,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL617887,108,,Expert,Inhibition of human 5-hydroxytryptamine 2C receptor,,9606.0
2948,,,,,,B,,,H,3805,BAO_0000357,CHEMBL617888,108,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,
2949,,,,,,B,,,H,3857,BAO_0000019,CHEMBL617889,108,,Autocuration,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2950,,,,,,B,,,H,5635,BAO_0000357,CHEMBL617890,108,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,
2951,,,,,,B,,,H,5635,BAO_0000357,CHEMBL617891,108,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2952,,,,,,B,,,H,5635,BAO_0000357,CHEMBL617892,108,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2953,,CHO,,,,B,,449.0,H,4012,BAO_0000219,CHEMBL617893,108,,Expert,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,
2954,,CHO,,,,B,,449.0,H,6366,BAO_0000219,CHEMBL617894,108,,Expert,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,
2955,,CHO,,,,B,,449.0,H,15949,BAO_0000219,CHEMBL617895,108,,Expert,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2956,,CHO,,,,B,,449.0,H,17211,BAO_0000219,CHEMBL617896,108,,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,
2957,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL617897,108,,Expert,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,9606.0
2958,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617898,108,,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,
2959,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617899,108,,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2960,,CHO,,Rattus norvegicus,,B,,449.0,H,6347,BAO_0000219,CHEMBL617900,108,,Expert,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,10116.0
2961,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617901,108,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,
2962,,,,,,F,,,H,14093,BAO_0000019,CHEMBL617902,108,,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,
2963,,,,,,F,,,H,13481,BAO_0000019,CHEMBL617903,108,,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2964,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617904,108,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,
2965,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617905,108,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,
2966,,,,,,B,,,H,14442,BAO_0000357,CHEMBL617906,108,,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,
2967,,,,,,B,,,H,14755,BAO_0000357,CHEMBL617907,108,,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,
2968,,,,,,B,,,H,14744,BAO_0000357,CHEMBL617908,108,,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,
2969,,CHO,,,,B,,449.0,H,16659,BAO_0000219,CHEMBL620617,108,,Expert,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2970,,,,Homo sapiens,,B,,,D,6857,BAO_0000019,CHEMBL620618,108,,Expert,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,9606.0
2971,,,,,,B,,,H,5635,BAO_0000357,CHEMBL620619,108,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,
2972,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL620620,108,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,9606.0
2973,,,,,,B,,,H,16209,BAO_0000357,CHEMBL620621,108,,Autocuration,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,
2974,,,,Rattus norvegicus,,B,Membranes,,D,5778,BAO_0000249,CHEMBL872920,104698,,Autocuration,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,10116.0
2975,,,,,,B,,,H,5094,BAO_0000223,CHEMBL620622,104698,,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,
2976,,,,Rattus norvegicus,,B,,,D,809,BAO_0000019,CHEMBL620623,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,10116.0
2977,,,,,,B,,,H,1578,BAO_0000019,CHEMBL620624,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,
2978,,,,,,B,,,H,809,BAO_0000019,CHEMBL620625,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,
2979,,,,,,B,,,H,12469,BAO_0000219,CHEMBL620626,104698,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,
2980,,,,,,B,,,H,14290,BAO_0000019,CHEMBL621307,104698,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,
2981,,,,,,B,,,H,14290,BAO_0000019,CHEMBL621308,104698,,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,
2982,,,,,,B,,,H,10609,BAO_0000223,CHEMBL621309,104698,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,
2983,,,,,,B,,,H,10609,BAO_0000223,CHEMBL621310,104698,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,
2984,,,,,,B,,,H,10609,BAO_0000223,CHEMBL621311,104698,,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,
2985,,,,,,B,,,H,15253,BAO_0000249,CHEMBL621502,104698,,Autocuration,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2986,,,,,,B,,,H,15253,BAO_0000249,CHEMBL621503,104698,,Autocuration,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2987,,,,,,B,Membranes,,H,11683,BAO_0000249,CHEMBL621504,104698,,Autocuration,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,
2988,,,,,,B,,,H,12092,BAO_0000223,CHEMBL621505,104698,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,
2989,,,,,,B,,,H,1946,BAO_0000019,CHEMBL621506,104698,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
2990,,,,,,B,,,H,11623,BAO_0000223,CHEMBL619781,104698,,Autocuration,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,
2991,,,,,,B,,,H,11623,BAO_0000223,CHEMBL619782,104698,,Autocuration,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,
2992,,,,,,B,,,H,14788,BAO_0000019,CHEMBL619783,104698,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,
2993,,,,Rattus norvegicus,,B,,,D,5432,BAO_0000019,CHEMBL619784,104698,,Autocuration,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,10116.0
2994,,,,,,B,,,H,14826,BAO_0000249,CHEMBL619785,104698,,Autocuration,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
2995,,,,,,B,,,H,2222,BAO_0000223,CHEMBL619786,104698,,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
2996,,,,,,B,,,H,11963,BAO_0000019,CHEMBL619787,104698,,Autocuration,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,
2997,,,,,,B,,,H,14145,BAO_0000019,CHEMBL872925,104698,,Autocuration,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,
2998,,,,,,B,,,H,17819,BAO_0000019,CHEMBL619788,104698,,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,
2999,,,,,,B,,,H,10394,BAO_0000249,CHEMBL619789,104698,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3000,,,,,,B,,,H,10394,BAO_0000249,CHEMBL619790,104698,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3001,,,,,,B,,,H,15034,BAO_0000019,CHEMBL619791,104698,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3002,,,,,,B,,,H,691,BAO_0000019,CHEMBL619792,104698,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
3003,,,,,,B,Membranes,,H,12092,BAO_0000249,CHEMBL619793,104698,,Autocuration,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,
3004,,,,Rattus norvegicus,,B,,,D,11752,BAO_0000223,CHEMBL619794,104698,,Autocuration,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,10116.0
3005,955.0,,Brain,,,B,,,H,11752,BAO_0000221,CHEMBL619795,104698,,Autocuration,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,
3006,,,,,,B,,,H,301,BAO_0000019,CHEMBL619796,104698,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,
3007,,,,,,B,,,H,16532,BAO_0000223,CHEMBL620448,104698,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,
3008,,,,,,B,,,H,16532,BAO_0000223,CHEMBL620449,104698,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3009,,,,,,B,,,H,12092,BAO_0000223,CHEMBL620450,104698,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,
3010,,,,,,B,,,H,11684,BAO_0000223,CHEMBL620451,104698,,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,
3011,,,,,,B,,,H,11684,BAO_0000223,CHEMBL620631,104698,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,
3012,,,,,,B,,,H,12953,BAO_0000019,CHEMBL620632,104698,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,
3013,,,,,,B,,,H,12953,BAO_0000019,CHEMBL620633,104698,,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,
3014,,,,,,B,,,H,12953,BAO_0000223,CHEMBL620634,104698,,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,
3015,,,,,,B,,,H,12861,BAO_0000019,CHEMBL620635,104698,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
3016,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620636,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3017,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620637,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3018,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620638,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3019,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620639,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3020,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620640,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3021,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620641,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3022,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620642,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,
3023,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620643,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3024,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620644,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3025,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620645,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3026,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620646,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3027,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620647,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3028,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620648,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3029,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620649,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3030,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620650,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3031,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620651,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3032,,,,,,F,,,H,11454,BAO_0000218,CHEMBL872875,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3033,,,,,,F,,,H,11454,BAO_0000218,CHEMBL620652,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3034,,,,,,F,,,H,10609,BAO_0000019,CHEMBL620653,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,
3035,,,,,,B,,,H,12861,BAO_0000019,CHEMBL857076,104698,,Autocuration,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,
3036,,,,Rattus norvegicus,,B,,,D,12861,BAO_0000019,CHEMBL620654,104698,,Autocuration,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,10116.0
3037,,,,,,B,,,H,12861,BAO_0000223,CHEMBL620655,104698,,Autocuration,Binding activity radioligand.,,
3038,,,,,,B,Brain membranes,,H,10728,BAO_0000249,CHEMBL620656,104698,,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,
3039,,,,,,B,Brain membranes,,H,10728,BAO_0000249,CHEMBL620657,104698,,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,
3040,,,,,,B,,,H,5163,BAO_0000357,CHEMBL620658,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,
3041,,,,,,B,,,H,5163,BAO_0000357,CHEMBL620659,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,
3042,,,,,,B,,,H,6011,BAO_0000357,CHEMBL620660,108,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,
3043,,,,,,B,,,H,5014,BAO_0000357,CHEMBL620661,108,,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,
3044,,,,,,B,,,H,5635,BAO_0000357,CHEMBL620662,108,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,
3045,,,,,,B,,,H,5163,BAO_0000357,CHEMBL620663,108,,Expert,Affinity for 5-hydroxytryptamine 2C receptor,,
3046,,,,,,B,,,H,6841,BAO_0000357,CHEMBL620664,108,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
3047,,,,,,B,,,H,6119,BAO_0000357,CHEMBL620665,108,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,
3048,,,,,,B,,,H,4373,BAO_0000357,CHEMBL620666,108,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,
3049,,,,,,B,,,H,1633,BAO_0000357,CHEMBL620667,108,,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,
3050,,,,,,B,,,H,1633,BAO_0000357,CHEMBL620668,108,,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,
3051,,,,,,B,,,H,4373,BAO_0000357,CHEMBL620669,108,,Autocuration,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,
3052,,,,,,B,,,H,6576,BAO_0000357,CHEMBL620670,108,,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,
3053,,,,,,B,,,H,4687,BAO_0000357,CHEMBL620671,108,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,
3054,,,,,,B,,,H,12146,BAO_0000357,CHEMBL620672,108,,Autocuration,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,
3055,,,,,,B,,,H,12146,BAO_0000357,CHEMBL620673,108,,Autocuration,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,
3056,,,,,,B,,,H,16946,BAO_0000357,CHEMBL620674,108,,Autocuration,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,
3057,,,,,,B,,,H,14159,BAO_0000357,CHEMBL620675,108,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,
3058,,,,,,B,,,H,16700,BAO_0000357,CHEMBL620676,108,,Autocuration,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,
3059,,,,,,B,,,H,3269,BAO_0000357,CHEMBL621382,108,,Autocuration,Affinity against 5-hydroxytryptamine 2C receptor,,
3060,,,,Homo sapiens,,B,,,D,1274,BAO_0000357,CHEMBL621383,108,,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,9606.0
3061,,,,,,B,,,H,1317,BAO_0000357,CHEMBL621384,108,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,
3062,,,,Bos taurus,,B,,,H,5834,BAO_0000357,CHEMBL621385,144,,Autocuration,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,9913.0
3063,,,,Bos taurus,,B,,,H,11147,BAO_0000357,CHEMBL617989,144,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,9913.0
3064,,,,Cavia porcellus,,F,,,H,14145,BAO_0000019,CHEMBL617990,104714,,Expert,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,10141.0
3065,2116.0,,Ileum,Cavia porcellus,,B,,,H,10561,BAO_0000221,CHEMBL875085,104714,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10141.0
3066,,,,Cavia porcellus,,F,,,H,15847,BAO_0000019,CHEMBL617991,104714,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,10141.0
3067,,,,Cavia porcellus,,F,,,H,15847,BAO_0000019,CHEMBL617992,104714,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,10141.0
3068,2116.0,,Ileum,Cavia porcellus,,B,,,H,10561,BAO_0000221,CHEMBL617993,104714,,Autocuration,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10141.0
3069,2116.0,,Ileum,Cavia porcellus,,B,,,H,11454,BAO_0000221,CHEMBL617994,104714,,Autocuration,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,10141.0
3070,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL617995,104714,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,10141.0
3071,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL617996,104714,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,10141.0
3072,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL617997,104714,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,10141.0
3073,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL617998,104714,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,10141.0
3074,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL617999,104714,,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,10141.0
3075,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618000,104714,,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,10141.0
3076,2116.0,,Ileum,Cavia porcellus,,F,,,H,15253,BAO_0000221,CHEMBL617815,104714,,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,10141.0
3077,2116.0,,Ileum,Cavia porcellus,,F,,,H,15253,BAO_0000221,CHEMBL617816,104714,,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,10141.0
3078,2116.0,,Ileum,Cavia porcellus,,F,,,H,11963,BAO_0000221,CHEMBL617817,104714,,Autocuration,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,10141.0
3079,2116.0,,Ileum,Cavia porcellus,,B,,,H,1946,BAO_0000221,CHEMBL617818,104714,,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,10141.0
3080,2116.0,,Ileum,Cavia porcellus,,B,,,H,1946,BAO_0000221,CHEMBL617819,104714,,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,10141.0
3081,,,,Cavia porcellus,,B,,,H,12045,BAO_0000223,CHEMBL617820,104714,,Autocuration,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,10141.0
3082,2116.0,,Ileum,Cavia porcellus,,B,,,H,1559,BAO_0000221,CHEMBL617821,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,10141.0
3083,2116.0,,Ileum,Cavia porcellus,,F,,,H,273,BAO_0000221,CHEMBL617822,104714,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,10141.0
3084,2116.0,,Ileum,Cavia porcellus,,F,,,H,273,BAO_0000221,CHEMBL617823,104714,,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,10141.0
3085,2116.0,,Ileum,Cavia porcellus,,F,,,H,188,BAO_0000221,CHEMBL617824,104714,,Autocuration,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,10141.0
3086,2116.0,,Ileum,Cavia porcellus,,F,,,H,12919,BAO_0000221,CHEMBL617825,104714,,Autocuration,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,10141.0
3087,2116.0,,Ileum,Cavia porcellus,,F,,,H,12918,BAO_0000221,CHEMBL617826,104714,,Autocuration,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,10141.0
3088,2116.0,,Ileum,Cavia porcellus,,B,,,H,1559,BAO_0000221,CHEMBL617827,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,10141.0
3089,2116.0,,Ileum,Cavia porcellus,,F,,,H,273,BAO_0000221,CHEMBL617828,104714,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,10141.0
3090,2116.0,,Ileum,Cavia porcellus,,B,,,H,1559,BAO_0000221,CHEMBL617829,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,10141.0
3091,2116.0,,Ileum,Cavia porcellus,,B,,,H,1559,BAO_0000221,CHEMBL617830,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,10141.0
3092,2116.0,,Ileum,Cavia porcellus,,B,,,H,1559,BAO_0000221,CHEMBL617831,104714,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,10141.0
3093,2116.0,,Ileum,Cavia porcellus,,B,,,H,14424,BAO_0000221,CHEMBL617832,104714,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,10141.0
3094,,,,Cavia porcellus,,B,,,U,13181,BAO_0000019,CHEMBL617833,22226,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,10141.0
3095,,,,,,B,,,H,5486,BAO_0000357,CHEMBL617834,51,,Autocuration,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,
3096,,,,Homo sapiens,,B,,,D,6491,BAO_0000223,CHEMBL617835,104714,,Expert,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,9606.0
3097,,,,,,B,,,H,6013,BAO_0000223,CHEMBL617836,104714,,Autocuration,Binding affinity towards 5-HT3 receptor,,
3098,,,,,,B,,,H,12861,BAO_0000223,CHEMBL617837,104714,,Autocuration,Binding activity radioligand.,,
3099,,,,,,B,,,H,12861,BAO_0000019,CHEMBL620392,104714,,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,
3100,,,,,,B,,,H,5104,BAO_0000223,CHEMBL620393,104714,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3101,,,,,,B,,,H,5105,BAO_0000223,CHEMBL620394,104714,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3102,,,,,,B,,,H,5104,BAO_0000223,CHEMBL620395,104714,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,
3103,,,,,,B,,,U,3935,BAO_0000019,CHEMBL620396,22226,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,
3104,,NG108-15,,,,B,,433.0,H,13657,BAO_0000219,CHEMBL620582,105030,,Expert,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,
3105,,,,,,B,,,H,10369,BAO_0000218,CHEMBL620583,105030,,Autocuration,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,
3106,,,,,,B,,,H,10369,BAO_0000019,CHEMBL620584,105030,,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3107,,,,,,B,,,H,12918,BAO_0000224,CHEMBL620585,105030,,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,
3108,,,,,,B,,,H,12918,BAO_0000224,CHEMBL620586,105030,,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor,,
3109,,,,,,B,,,H,10369,BAO_0000019,CHEMBL620587,105030,,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3110,,,,,,B,,,H,773,BAO_0000019,CHEMBL620588,105030,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3111,,,,,,F,,,H,12918,BAO_0000218,CHEMBL620589,105030,,Autocuration,5-hydroxytryptamine 3 receptor agonism in mouse,,
3112,,,,,,B,,,H,10561,BAO_0000219,CHEMBL620590,105030,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,
3113,,,,,,B,,,H,12827,BAO_0000019,CHEMBL617956,105030,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3114,,,,,,B,,,H,12827,BAO_0000019,CHEMBL617957,105030,,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3115,,,,,,B,,,H,12918,BAO_0000224,CHEMBL617958,105030,,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,
3116,,,,,,B,,,H,273,BAO_0000219,CHEMBL617959,105030,,Autocuration,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3117,,,,,,B,,,H,273,BAO_0000219,CHEMBL617960,105030,,Autocuration,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3118,,,,,,B,,,H,10561,BAO_0000224,CHEMBL617961,105030,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,
3119,,,,,,B,,,H,5033,BAO_0000219,CHEMBL617962,105030,,Autocuration,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,
3120,,N1E-115,,,,B,,339.0,H,16429,BAO_0000219,CHEMBL617963,105030,,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,
3121,,,,,,B,,,H,10322,BAO_0000019,CHEMBL617964,11765,,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3122,,,,,,B,,,H,14331,BAO_0000219,CHEMBL617965,11765,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,
3123,,,,Mus musculus,,B,,,D,13462,BAO_0000357,CHEMBL617966,10630,,Autocuration,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,10090.0
3124,,,,,,B,,,H,12861,BAO_0000019,CHEMBL857074,17106,,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
3125,,,,Sus scrofa,,B,,,H,15086,BAO_0000357,CHEMBL617967,144,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,9823.0
3126,,,,Sus scrofa,,B,,,H,12861,BAO_0000357,CHEMBL617968,144,,Autocuration,Binding activity radioligand.,,9823.0
3127,,,,Oryctolagus cuniculus,,B,,,H,10561,BAO_0000223,CHEMBL617969,104714,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,9986.0
3128,,,,Oryctolagus cuniculus,,B,,,H,10561,BAO_0000223,CHEMBL617970,104714,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,9986.0
3129,,,,Oryctolagus cuniculus,,B,,,H,10561,BAO_0000223,CHEMBL617971,104714,,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,9986.0
3130,,,,Oryctolagus cuniculus,,B,,,H,10561,BAO_0000019,CHEMBL617972,104714,,Autocuration,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,9986.0
3131,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617973,104714,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,9986.0
3132,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617974,104714,,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,9986.0
3133,2116.0,,Ileum,Oryctolagus cuniculus,,F,,,H,273,BAO_0000221,CHEMBL617975,104714,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,9986.0
3134,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617976,104714,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,9986.0
3135,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617977,104714,,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,9986.0
3136,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617978,104714,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,9986.0
3137,,,,Oryctolagus cuniculus,,F,,,H,273,BAO_0000019,CHEMBL617979,104714,,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,9986.0
3138,,CHO,,Oryctolagus cuniculus,,B,,449.0,H,13047,BAO_0000219,CHEMBL617980,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,9986.0
3139,,,,Rattus norvegicus,,B,,,D,1650,BAO_0000019,CHEMBL617981,104698,,Autocuration,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,10116.0
3140,,,,,,B,,,H,16288,BAO_0000019,CHEMBL617982,12020,,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,
3141,,,,,,B,,,H,16288,BAO_0000357,CHEMBL617983,12020,,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,
3142,,,,Rattus norvegicus,,B,,,D,10254,BAO_0000019,CHEMBL617984,104698,,Autocuration,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,10116.0
3143,,,,,,B,,,H,14532,BAO_0000019,CHEMBL617985,104698,,Autocuration,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,
3144,948.0,,Heart,,,F,,,H,13392,BAO_0000218,CHEMBL617986,104698,,Autocuration,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,
3145,948.0,,Heart,,,F,,,H,13392,BAO_0000019,CHEMBL617987,104698,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3146,948.0,,Heart,,,F,,,H,13392,BAO_0000019,CHEMBL617988,104698,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3147,948.0,,Heart,,,F,,,H,13392,BAO_0000019,CHEMBL617792,104698,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,
3148,948.0,,Heart,,,F,,,H,13392,BAO_0000019,CHEMBL617793,104698,,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3149,,,,,,F,,,H,13392,BAO_0000019,CHEMBL617794,104698,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,
3150,,,,,,F,,,H,13392,BAO_0000019,CHEMBL617795,104698,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3151,,,,,,F,,,H,13392,BAO_0000019,CHEMBL617796,104698,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3152,,,,,,F,,,H,13392,BAO_0000019,CHEMBL617797,104698,,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,
3153,,,,Rattus norvegicus,,F,,,D,1089,BAO_0000218,CHEMBL617798,104698,,Autocuration,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,10116.0
3154,,,,,,F,,,H,1089,BAO_0000218,CHEMBL617799,104698,,Autocuration,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,
3155,,,,Rattus norvegicus,,F,,,D,11454,BAO_0000218,CHEMBL617800,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,10116.0
3156,,,,Rattus norvegicus,,F,,,D,11454,BAO_0000019,CHEMBL617801,104698,,Autocuration,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,10116.0
3157,,,,Rattus norvegicus,,F,,,D,12205,BAO_0000218,CHEMBL617802,104698,,Autocuration,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,10116.0
3158,,,,Rattus norvegicus,,F,,,D,1089,BAO_0000019,CHEMBL617803,104698,,Autocuration,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,10116.0
3159,,,,,,B,,,H,5094,BAO_0000019,CHEMBL617804,104698,,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3160,,,,Rattus norvegicus,,B,,,D,2622,BAO_0000019,CHEMBL617805,104698,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,10116.0
3161,,,,,,B,,,H,245,BAO_0000223,CHEMBL617806,104698,,Autocuration,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,
3162,,,,,,B,,,H,14788,BAO_0000019,CHEMBL617807,104698,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,
3163,,,,,,B,,,H,14788,BAO_0000019,CHEMBL617808,104698,,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,
3164,,,,,,B,,,H,3020,BAO_0000249,CHEMBL617809,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,
3165,,,,,,B,,,H,1742,BAO_0000019,CHEMBL617810,104698,,Autocuration,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,
3166,955.0,,Brain,,,B,,,H,17394,BAO_0000249,CHEMBL617811,104698,,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,
3167,955.0,,Brain,,,B,,,H,17394,BAO_0000221,CHEMBL617812,104698,,Autocuration,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,
3168,,,,,,B,,,H,17394,BAO_0000249,CHEMBL617813,104698,,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3169,,,,,,B,,,H,14286,BAO_0000249,CHEMBL617814,104698,,Autocuration,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3170,,,,,,B,,,H,14178,BAO_0000019,CHEMBL617698,104698,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,
3171,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000019,CHEMBL617699,104698,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,10116.0
3172,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000019,CHEMBL617700,104698,,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,10116.0
3173,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000223,CHEMBL617701,104698,,Autocuration,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,10116.0
3174,,,,,,B,,,H,15034,BAO_0000019,CHEMBL617702,104698,,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3175,,,,,,B,Membranes,,H,1089,BAO_0000249,CHEMBL617703,104698,,Autocuration,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,
3176,,,,Rattus norvegicus,,B,,,D,1089,BAO_0000019,CHEMBL617704,104698,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,10116.0
3177,,,,,,B,,,H,16532,BAO_0000223,CHEMBL617705,104698,,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3178,,,,Rattus norvegicus,,B,,,D,12801,BAO_0000223,CHEMBL617706,104698,,Autocuration,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,10116.0
3179,,NG108-15,,,,B,,433.0,H,15194,BAO_0000219,CHEMBL617707,104698,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,
3180,,NG108-15,,,,B,,433.0,H,15194,BAO_0000219,CHEMBL617708,104698,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,
3181,,,,,,B,,,H,15194,BAO_0000019,CHEMBL617709,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,
3182,,,,,,B,,,H,15194,BAO_0000019,CHEMBL617710,104698,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,
3183,,,,,,B,,,H,15194,BAO_0000019,CHEMBL882925,104698,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,
3184,,,,,,B,,,H,15194,BAO_0000019,CHEMBL617711,104698,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,
3185,,,,,,F,,,H,10610,BAO_0000019,CHEMBL617712,104698,,Autocuration,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,
3186,,,,Rattus norvegicus,,F,,,D,10355,BAO_0000019,CHEMBL617713,104698,,Autocuration,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,10116.0
3187,,,,,,F,,,H,691,BAO_0000019,CHEMBL617714,104698,,Autocuration,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,
3188,,,,,,F,,,H,10611,BAO_0000218,CHEMBL617715,104698,,Autocuration,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,
3189,,,,,,F,,,H,12801,BAO_0000218,CHEMBL617716,104698,,Autocuration,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,
3190,,,,,,F,,,H,10609,BAO_0000218,CHEMBL617717,104698,,Autocuration,Inhibition of 5-HT evoked reflex bradycardia in rat.,,
3191,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617718,104698,,Autocuration,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3192,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617719,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,
3193,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617720,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,
3194,,,,Rattus norvegicus,,F,,,D,11454,BAO_0000218,CHEMBL617721,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,10116.0
3195,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617722,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3196,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617723,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,
3197,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617724,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,
3198,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617725,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3199,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617726,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,
3200,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617727,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3201,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617728,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3202,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617729,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,
3203,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617730,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,
3204,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617731,104698,,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3205,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617732,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,
3206,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617733,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,
3207,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617734,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3208,,,,,,F,,,H,11454,BAO_0000218,CHEMBL872874,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,
3209,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617735,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,
3210,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617736,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,
3211,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617737,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,
3212,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617738,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,
3213,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617739,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3214,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617740,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,
3215,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617741,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3216,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617742,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3217,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617743,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,
3218,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617744,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3219,,,,,,F,,,H,11454,BAO_0000218,CHEMBL617745,104698,,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,
3220,,,,,,F,,,H,670,BAO_0000218,CHEMBL617746,104698,,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,
3221,,,,,,F,,,H,670,BAO_0000218,CHEMBL617747,104698,,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,
3222,,,,,,F,,,H,10321,BAO_0000218,CHEMBL617748,104698,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,
3223,,,,,,F,,,H,10321,BAO_0000218,CHEMBL618909,104698,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,
3224,,,,,,F,,,H,10321,BAO_0000218,CHEMBL618910,104698,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,
3225,,,,,,F,,,H,10321,BAO_0000218,CHEMBL618911,104698,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,
3226,,,,,,F,,,H,10321,BAO_0000218,CHEMBL618912,104698,,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,
3227,,,,,,F,,,H,10322,BAO_0000218,CHEMBL618913,104698,,Autocuration,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,
3228,,,,,,F,,,H,15412,BAO_0000019,CHEMBL618914,104698,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3229,,,,,,F,,,H,15412,BAO_0000019,CHEMBL618915,104698,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3230,,,,Rattus norvegicus,,B,,,D,15412,BAO_0000223,CHEMBL618916,104698,,Autocuration,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,10116.0
3231,,,,,,F,,,H,15412,BAO_0000019,CHEMBL618917,104698,,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,
3232,10000000.0,,Hippocampus,,,B,,,D,15412,BAO_0000221,CHEMBL618918,104698,,Intermediate,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,
3233,,,,Rattus norvegicus,,B,,,D,15412,BAO_0000019,CHEMBL618919,104698,,Autocuration,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,10116.0
3234,,,,Rattus norvegicus,,B,,,D,17394,BAO_0000019,CHEMBL618920,104698,,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,10116.0
3235,,,,,,B,,,H,12457,BAO_0000223,CHEMBL618921,104698,,Autocuration,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,
3236,,,,,,B,,,H,12457,BAO_0000019,CHEMBL618922,104698,,Autocuration,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,
3237,,,,,,B,,,H,12205,BAO_0000019,CHEMBL618923,104698,,Autocuration,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,
3238,,,,,,B,,,H,14532,BAO_0000019,CHEMBL618924,104698,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,
3239,,,,,,B,,,H,1122,BAO_0000019,CHEMBL618925,104698,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,
3240,,,,,,B,,,H,5094,BAO_0000019,CHEMBL618926,104698,,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3241,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL618927,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,10141.0
3242,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL618928,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,10141.0
3243,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL618929,20033,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,10141.0
3244,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL618930,20033,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,10141.0
3245,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL618931,20033,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,10141.0
3246,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619594,20033,,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,10141.0
3247,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619595,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,10141.0
3248,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL619596,20033,,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,10141.0
3249,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL619755,20033,,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,10141.0
3250,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL619756,20033,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,10141.0
3251,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL619757,20033,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,10141.0
3252,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL619758,20033,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,10141.0
3253,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619759,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,10141.0
3254,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619760,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,10141.0
3255,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619761,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,10141.0
3256,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619762,20033,,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,10141.0
3257,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL619763,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,10141.0
3258,2116.0,,Ileum,Cavia porcellus,,F,,,D,14290,BAO_0000221,CHEMBL617868,20033,,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,10141.0
3259,,,,Cavia porcellus,,B,,,D,15034,BAO_0000357,CHEMBL617869,20033,,Intermediate,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,10141.0
3260,2435.0,,Striatum,Cavia porcellus,,B,,,D,5094,BAO_0000249,CHEMBL882926,20033,,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,10141.0
3261,2435.0,,Striatum,Cavia porcellus,,B,,,D,5094,BAO_0000249,CHEMBL617870,20033,,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,10141.0
3262,2435.0,,Striatum,Cavia porcellus,,B,,,D,5399,BAO_0000357,CHEMBL617871,20033,,Intermediate,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,10141.0
3263,2435.0,,Striatum,Cavia porcellus,,B,,,D,17394,BAO_0000357,CHEMBL617872,20033,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,10141.0
3264,2435.0,,Striatum,Cavia porcellus,,B,,,D,17394,BAO_0000357,CHEMBL617873,20033,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,10141.0
3265,2435.0,,Striatum,Cavia porcellus,,B,,,D,17394,BAO_0000357,CHEMBL617874,20033,,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,10141.0
3266,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL619067,20033,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,10141.0
3267,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL619068,20033,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,10141.0
3268,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL619069,20033,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,10141.0
3269,,,,Cavia porcellus,,B,,,D,16946,BAO_0000357,CHEMBL619070,20033,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,10141.0
3270,,,,Cavia porcellus,,B,,,D,16946,BAO_0000357,CHEMBL619071,20033,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,10141.0
3271,,,,Cavia porcellus,,F,,,D,15034,BAO_0000019,CHEMBL619072,20033,,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor,,10141.0
3272,,,,Cavia porcellus,,F,,,D,15034,BAO_0000019,CHEMBL619073,20033,,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,10141.0
3273,,,,Cavia porcellus,,F,,,D,12918,BAO_0000019,CHEMBL619074,20033,,Intermediate,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,10141.0
3274,,,,Cavia porcellus,,B,,,D,16946,BAO_0000357,CHEMBL619075,20033,,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,10141.0
3275,2435.0,,Striatum,Cavia porcellus,,B,,,D,17394,BAO_0000357,CHEMBL619076,20033,,Intermediate,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,10141.0
3276,2435.0,,Striatum,Cavia porcellus,,B,,,D,15034,BAO_0000357,CHEMBL619077,20033,,Intermediate,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,10141.0
3277,2435.0,,Striatum,Cavia porcellus,,B,,,D,5094,BAO_0000249,CHEMBL619078,20033,,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,10141.0
3278,2435.0,,Striatum,Cavia porcellus,,B,,,D,5094,BAO_0000249,CHEMBL619079,20033,,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,10141.0
3279,2116.0,,Ileum,Cavia porcellus,,B,,,D,17358,BAO_0000221,CHEMBL619080,20033,,Intermediate,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,10141.0
3280,,,,Cavia porcellus,,B,,,D,12953,BAO_0000357,CHEMBL619081,20033,,Expert,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,10141.0
3281,,,,Cavia porcellus,,B,,,D,12953,BAO_0000357,CHEMBL619082,20033,,Intermediate,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,10141.0
3282,,,,Cavia porcellus,,B,,,D,12953,BAO_0000357,CHEMBL619083,20033,,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,10141.0
3283,,,,Cavia porcellus,,B,,,D,12953,BAO_0000357,CHEMBL619084,20033,,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,10141.0
3284,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL859397,20033,,Intermediate,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,10141.0
3285,2116.0,,Ileum,Cavia porcellus,,F,,,D,12918,BAO_0000221,CHEMBL619085,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,10141.0
3286,2116.0,,Ileum,Cavia porcellus,,F,,,D,12919,BAO_0000221,CHEMBL619086,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,10141.0
3287,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL619087,20033,,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,10141.0
3288,2116.0,,Ileum,Cavia porcellus,,F,,,D,273,BAO_0000221,CHEMBL619088,20033,,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,10141.0
3289,,,,Cavia porcellus,,B,,,D,13181,BAO_0000357,CHEMBL619089,20033,,Intermediate,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,10141.0
3290,,,,Cavia porcellus,,B,,,H,13181,BAO_0000357,CHEMBL619090,168,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,10141.0
3291,,,,Cavia porcellus,,F,,,D,15034,BAO_0000019,CHEMBL619091,20033,,Intermediate,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,10141.0
3292,,,,Cavia porcellus,,B,,,D,5033,BAO_0000357,CHEMBL619092,20033,,Intermediate,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,10141.0
3293,,,,Cavia porcellus,,B,,,D,1980,BAO_0000019,CHEMBL619093,20033,,Intermediate,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,10141.0
3294,,HEK293,,Cavia porcellus,,B,,722.0,H,13181,BAO_0000219,CHEMBL619094,168,,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,10141.0
3295,,,,Cavia porcellus,,B,,,D,14287,BAO_0000019,CHEMBL619095,20033,,Intermediate,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,10141.0
3296,,,,Cavia porcellus,,B,,,D,1317,BAO_0000357,CHEMBL857988,20033,,Intermediate,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,10141.0
3297,,,,Cavia porcellus,,B,,,D,15316,BAO_0000357,CHEMBL619096,20033,,Intermediate,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,10141.0
3298,2435.0,,Striatum,Cavia porcellus,,B,,,D,16429,BAO_0000357,CHEMBL619097,20033,,Intermediate,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,10141.0
3299,10000000.0,,Hippocampus,Cavia porcellus,,B,,,D,14818,BAO_0000221,CHEMBL619098,20033,,Intermediate,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,10141.0
3300,,,,Cavia porcellus,,B,,,D,15194,BAO_0000357,CHEMBL619751,20033,,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,10141.0
3301,,,,Cavia porcellus,,B,,,D,15194,BAO_0000357,CHEMBL619752,20033,,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,10141.0
3302,2116.0,,Ileum,Cavia porcellus,,F,,,D,13961,BAO_0000221,CHEMBL875096,20033,,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,10141.0
3303,,,,,,B,,,H,5486,BAO_0000357,CHEMBL619004,108,,Autocuration,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,
3304,,,,,,B,,,H,16209,BAO_0000357,CHEMBL619005,168,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,
3305,,,,,,B,,,H,17085,BAO_0000019,CHEMBL619006,168,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,
3306,,HeLa,,,,B,,308.0,H,4199,BAO_0000219,CHEMBL619007,168,,Autocuration,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,
3307,,,,,,B,,,H,15146,BAO_0000357,CHEMBL619008,168,,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,
3308,,,,,,B,,,H,5213,BAO_0000357,CHEMBL619009,168,,Autocuration,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,
3309,,HeLa,,,,B,,308.0,H,4829,BAO_0000219,CHEMBL619010,168,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,
3310,,,,,,B,,,H,17358,BAO_0000357,CHEMBL619011,10622,,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,
3311,,,,,,B,,,H,17358,BAO_0000357,CHEMBL619012,10622,,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,
3312,,,,,,B,,,H,16946,BAO_0000219,CHEMBL619013,10622,,Autocuration,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,
3313,,,,,,B,,,H,17358,BAO_0000357,CHEMBL619014,10622,,Autocuration,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,
3314,2081.0,,Cardiac atrium,,,F,,,H,268,BAO_0000019,CHEMBL857503,11249,,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,
3315,2081.0,,Cardiac atrium,,,F,,,H,268,BAO_0000019,CHEMBL619015,11249,,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,
3316,,,,,,B,,,H,15086,BAO_0000357,CHEMBL619016,11249,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,
3317,10000000.0,,Hippocampus,,,B,,,H,14875,BAO_0000221,CHEMBL619017,11249,,Autocuration,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,
3318,10000000.0,,Hippocampus,Sus scrofa,,B,,,H,13267,BAO_0000221,CHEMBL619018,168,,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,9823.0
3319,,,,Oryctolagus cuniculus,,B,,,H,13047,BAO_0000019,CHEMBL619019,168,,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,9986.0
3320,,,,Rattus norvegicus,,B,,,D,1650,BAO_0000357,CHEMBL619020,10623,,Expert,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,10116.0
3321,,,,,,F,,,H,567,BAO_0000019,CHEMBL619021,10623,,Autocuration,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3322,,,,,,B,,,H,17358,BAO_0000357,CHEMBL619022,10623,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,
3323,,,,,,B,,,H,188,BAO_0000357,CHEMBL619023,10623,,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,
3324,,,,,,F,,,H,670,BAO_0000019,CHEMBL619024,10623,,Autocuration,lntrinsic activity relative to 5-HT receptor,,
3325,,,,,,F,,,H,204,BAO_0000019,CHEMBL619025,10623,,Autocuration,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,
3326,,,,,,F,,,H,1946,BAO_0000019,CHEMBL619026,10623,,Expert,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,
3327,,,,,,F,,,H,6398,BAO_0000019,CHEMBL619027,10623,,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,
3328,,,,,,F,,,H,6398,BAO_0000019,CHEMBL619028,10623,,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,
3329,,,,,,F,,,H,17358,BAO_0000019,CHEMBL619029,10623,,Autocuration,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,
3330,,,,,,F,,,H,6398,BAO_0000019,CHEMBL619030,10623,,Autocuration,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,
3331,,,,,,B,,,H,11752,BAO_0000357,CHEMBL619031,10623,,Expert,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,
3332,,,,,,F,,,H,809,BAO_0000019,CHEMBL619032,10623,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,
3333,,,,Rattus norvegicus,,B,,,D,14178,BAO_0000357,CHEMBL619033,10623,,Expert,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,10116.0
3334,,,,,,B,,,H,567,BAO_0000357,CHEMBL619034,10623,,Autocuration,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3335,,,,,,B,,,H,1946,BAO_0000357,CHEMBL619035,10623,,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,
3336,,,,,,B,,,H,1946,BAO_0000357,CHEMBL619036,10623,,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,
3337,,,,Rattus norvegicus,,B,,,D,13961,BAO_0000019,CHEMBL619037,10623,,Expert,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,10116.0
3338,2435.0,,Striatum,,,B,,,H,6238,BAO_0000249,CHEMBL619038,10623,,Autocuration,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,
3339,,,,,,B,,,H,14290,BAO_0000249,CHEMBL619039,10623,,Autocuration,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,
3340,,,,,,B,,,H,14290,BAO_0000249,CHEMBL619040,10623,,Expert,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,
3341,2435.0,,Striatum,Rattus norvegicus,,B,,,D,809,BAO_0000019,CHEMBL619041,10623,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10116.0
3342,2435.0,,Striatum,,,B,,,H,1578,BAO_0000019,CHEMBL619042,10623,,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,
3343,2435.0,,Striatum,,,B,,,H,16709,BAO_0000249,CHEMBL619043,10623,,Expert,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,
3344,2435.0,,Striatum,,,B,,,H,1946,BAO_0000019,CHEMBL619044,10623,,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,
3345,2435.0,,Striatum,,,B,,,H,15253,BAO_0000249,CHEMBL619045,10623,,Expert,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,
3346,2435.0,,Striatum,,,B,,,H,4535,BAO_0000249,CHEMBL619046,10623,,Expert,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3347,,,,,,B,,,H,13961,BAO_0000249,CHEMBL619047,10623,,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,
3348,955.0,,Brain,,,F,,,H,17358,BAO_0000221,CHEMBL619048,10623,,Autocuration,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,
3349,,,,,,F,,,H,15847,BAO_0000019,CHEMBL859398,10623,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,
3350,,,,,,F,,,H,15847,BAO_0000019,CHEMBL619049,10623,,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,
3351,,,,,,F,,,H,670,BAO_0000019,CHEMBL857886,10623,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,
3352,,,,,,F,,,H,670,BAO_0000019,CHEMBL619050,10623,,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,
3353,,,,,,F,,,H,1317,BAO_0000019,CHEMBL620591,10623,,Autocuration,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,
3354,,,,Rattus norvegicus,,B,,,D,12936,BAO_0000357,CHEMBL620592,10623,,Expert,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,10116.0
3355,2435.0,,Striatum,,,B,,,H,4535,BAO_0000249,CHEMBL620593,10623,,Expert,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3356,,,,Rattus norvegicus,,F,,,D,14424,BAO_0000019,CHEMBL620594,10623,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,10116.0
3357,,,,,,F,,,H,14424,BAO_0000019,CHEMBL875079,10623,,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,
3358,,,,,,F,,,H,14424,BAO_0000019,CHEMBL620595,10623,,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3359,,,,Rattus norvegicus,,F,,,D,14424,BAO_0000019,CHEMBL620596,10623,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,10116.0
3360,,,,,,F,,,H,14424,BAO_0000019,CHEMBL620597,10623,,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,
3361,,,,,,F,,,H,14424,BAO_0000019,CHEMBL620598,10623,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,
3362,,,,,,F,,,H,14424,BAO_0000218,CHEMBL620599,10623,,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,
3363,,,,,,F,,,H,14424,BAO_0000019,CHEMBL620600,10623,,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3364,,,,Rattus norvegicus,,F,,,H,1980,BAO_0000019,CHEMBL620601,168,,Autocuration,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,10116.0
3365,,,,,,F,,,H,4639,BAO_0000019,CHEMBL620602,168,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,
3366,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620603,168,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,
3367,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620604,168,,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,
3368,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620605,168,,Autocuration,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,
3369,,,,,,B,,,H,1558,BAO_0000357,CHEMBL620606,168,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,
3370,,,,,,F,,,H,17358,BAO_0000019,CHEMBL620607,168,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3371,,,,,,B,,,H,16117,BAO_0000357,CHEMBL620608,168,,Autocuration,In vitro binding affinity towards 5-HT4 receptor was determined,,
3372,,,,,,F,,,H,17358,BAO_0000019,CHEMBL620609,168,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3373,,,,,,F,,,H,17358,BAO_0000019,CHEMBL620610,168,,Autocuration,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,
3374,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620611,168,,Autocuration,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,
3375,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620612,168,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,
3376,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620613,168,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,
3377,,,,,,B,,,H,17358,BAO_0000357,CHEMBL620614,168,,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,
3378,,,,,,B,,,H,1274,BAO_0000357,CHEMBL620615,168,,Expert,Binding affinity against 5-Hydroxytryptamine 4 receptor,,
3379,,,,,,B,Brain membranes,,H,10728,BAO_0000249,CHEMBL857075,104698,,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,
3380,,,,,,B,Brain membranes,,H,11695,BAO_0000249,CHEMBL620616,104698,,Autocuration,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,
3381,,,,,,B,Brain membranes,,H,11695,BAO_0000249,CHEMBL619411,104698,,Autocuration,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,
3382,,,,,,B,,,H,12490,BAO_0000019,CHEMBL619412,104698,,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,
3383,,,,Rattus norvegicus,,B,,,D,11828,BAO_0000019,CHEMBL619413,104698,,Autocuration,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,10116.0
3384,10000000.0,,Hippocampus,,,B,,,H,12253,BAO_0000221,CHEMBL619414,104698,,Autocuration,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,
3385,,,,,,B,,,H,10561,BAO_0000019,CHEMBL619415,104698,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,
3386,,,,,,B,,,H,10561,BAO_0000019,CHEMBL619416,104698,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,
3387,,,,,,F,,,H,14432,BAO_0000019,CHEMBL619417,104698,,Autocuration,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,
3388,,,,Rattus norvegicus,,B,,,D,12936,BAO_0000223,CHEMBL619418,104698,,Autocuration,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,10116.0
3389,,,,Rattus norvegicus,,B,,,D,1274,BAO_0000223,CHEMBL619419,104698,,Autocuration,Binding affinity against 5-Hydroxytryptamine 3 receptor,,10116.0
3390,,,,,,B,,,H,1980,BAO_0000019,CHEMBL619420,104698,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,
3391,,,,,,B,,,H,670,BAO_0000249,CHEMBL619421,104698,,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,
3392,,,,Rattus norvegicus,,B,,,D,968,BAO_0000019,CHEMBL619422,104698,,Autocuration,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,10116.0
3393,,,,,,B,,,H,14287,BAO_0000019,CHEMBL619423,104698,,Autocuration,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,
3394,,,,,,B,,,H,567,BAO_0000019,CHEMBL875080,104698,,Autocuration,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,
3395,,,,,,B,,,H,13267,BAO_0000019,CHEMBL619424,104698,,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,
3396,,,,,,B,,,H,14826,BAO_0000249,CHEMBL619425,104698,,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,
3397,,,,,,B,,,H,15194,BAO_0000223,CHEMBL619426,104698,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,
3398,,,,,,B,,,H,15194,BAO_0000223,CHEMBL619427,104698,,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,
3399,,,,Rattus norvegicus,,B,,,D,10394,BAO_0000223,CHEMBL619645,104698,,Autocuration,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,10116.0
3400,,,,,,B,,,D,13657,BAO_0000249,CHEMBL619646,10576,,Expert,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,
3401,955.0,,Brain,,,F,,,H,1879,BAO_0000221,CHEMBL619647,12020,,Autocuration,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,
3402,,,,,,F,,,H,1879,BAO_0000019,CHEMBL619648,12020,,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,
3403,,,,,,F,,,H,1879,BAO_0000019,CHEMBL619165,12020,,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,
3404,,,,,,F,,,H,204,BAO_0000218,CHEMBL620719,12020,,Autocuration,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,
3405,,,,,,B,,,H,1879,BAO_0000019,CHEMBL872924,12020,,Autocuration,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3406,,,,,,B,,,H,1879,BAO_0000357,CHEMBL620720,12020,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3407,,,,,,B,,,H,1879,BAO_0000019,CHEMBL620721,12020,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3408,,,,,,B,,,H,1879,BAO_0000019,CHEMBL620722,12020,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,
3409,,,,,,B,,,H,10641,BAO_0000019,CHEMBL620723,104698,,Autocuration,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,
3410,,,,,,B,,,H,773,BAO_0000019,CHEMBL620724,12020,,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3411,,,,,,B,,,H,11952,BAO_0000249,CHEMBL620725,104698,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,
3412,,,,Rattus norvegicus,,F,,,D,14145,BAO_0000019,CHEMBL620726,12020,,Autocuration,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,10116.0
3413,,,,,,B,,,H,17066,BAO_0000357,CHEMBL620727,144,,Expert,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3414,,,,,,B,,,H,6398,BAO_0000223,CHEMBL620728,104714,,Autocuration,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,
3415,,,,,,B,,,U,10321,BAO_0000019,CHEMBL620729,22226,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3416,,,,,,F,,,H,511,BAO_0000019,CHEMBL858288,104714,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,
3417,,,,,,B,,,H,4639,BAO_0000223,CHEMBL620730,104714,,Autocuration,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,
3418,,,,,,B,,,H,4639,BAO_0000223,CHEMBL620731,104714,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3419,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL620732,104714,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,10141.0
3420,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618042,104714,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,10141.0
3421,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618043,104714,,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,10141.0
3422,,,,,,B,,,H,1558,BAO_0000223,CHEMBL618044,104714,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3423,,,,,,F,,,H,268,BAO_0000019,CHEMBL618045,104714,,Autocuration,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,
3424,,,,,,B,,,H,2474,BAO_0000223,CHEMBL618046,104714,,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,
3425,,,,,,F,,,H,5067,BAO_0000019,CHEMBL618047,104714,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,
3426,,,,,,F,,,H,5067,BAO_0000019,CHEMBL875084,104714,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,
3427,,,,,,F,,,H,5067,BAO_0000019,CHEMBL618048,104714,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,
3428,,,,,,B,,,H,5067,BAO_0000223,CHEMBL618049,104714,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,
3429,,,,,,F,,,H,5067,BAO_0000019,CHEMBL619764,104714,,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,
3430,,,,,,F,,,H,5067,BAO_0000019,CHEMBL619765,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,
3431,,,,,,F,,,H,5067,BAO_0000019,CHEMBL619766,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,
3432,,,,,,B,,,H,5067,BAO_0000223,CHEMBL619767,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,
3433,,,,,,B,,,H,5067,BAO_0000223,CHEMBL619768,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,
3434,,,,,,F,,,H,5067,BAO_0000019,CHEMBL619769,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,
3435,,,,,,B,,,H,5067,BAO_0000223,CHEMBL619770,104714,,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,
3436,,,,,,B,,,H,5067,BAO_0000223,CHEMBL619771,104714,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3437,,,,,,B,,,H,14331,BAO_0000219,CHEMBL619772,104714,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,
3438,,,,,,B,,,H,5067,BAO_0000223,CHEMBL619773,104714,,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,
3439,,NG108-15,,,,B,,433.0,H,6179,BAO_0000219,CHEMBL619774,104714,,Autocuration,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,
3440,,,,,,B,,,H,4265,BAO_0000019,CHEMBL875083,104714,,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,
3441,,NG108-15,,,,B,,433.0,H,4265,BAO_0000219,CHEMBL620718,104714,,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,
3442,,,,,,B,,,H,17358,BAO_0000223,CHEMBL618127,104714,,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3443,,,,,,B,,,H,17358,BAO_0000223,CHEMBL618128,104714,,Autocuration,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,
3444,,,,,,B,,,H,13628,BAO_0000219,CHEMBL618129,104714,,Autocuration,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,
3445,,,,,,B,,,H,4612,BAO_0000223,CHEMBL618130,104714,,Autocuration,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3446,,,,,,F,,,H,17358,BAO_0000019,CHEMBL618131,104714,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,
3447,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618132,104714,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,10141.0
3448,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618133,104714,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,10141.0
3449,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618134,104714,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,10141.0
3450,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618135,104714,,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,10141.0
3451,,,,,,B,,,H,511,BAO_0000223,CHEMBL618136,104714,,Autocuration,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,
3452,,,,,,B,,,H,1479,BAO_0000223,CHEMBL618137,104714,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3453,,,,,,B,,,H,1317,BAO_0000223,CHEMBL618138,104714,,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,
3454,,,,,,B,,,H,12146,BAO_0000223,CHEMBL618139,104714,,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,
3455,,,,,,B,,,H,12146,BAO_0000223,CHEMBL618140,104714,,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,
3456,,,,,,B,,,H,13969,BAO_0000223,CHEMBL618141,104714,,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,
3457,,,,,,B,,,H,13392,BAO_0000357,CHEMBL873478,108,,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,
3458,,,,,,B,,,H,13392,BAO_0000223,CHEMBL618142,104698,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3459,,,,,,B,,,H,14159,BAO_0000357,CHEMBL618143,144,,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,
3460,,,,,,B,,,H,1558,BAO_0000357,CHEMBL618144,144,,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3461,,,,,,B,,,H,16655,BAO_0000357,CHEMBL618145,144,,Autocuration,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,
3462,,,,,,B,,,H,13020,BAO_0000223,CHEMBL618146,104714,,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3463,,,,,,B,,,H,13021,BAO_0000223,CHEMBL618147,104714,,Autocuration,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,
3464,,,,,,B,,,H,13020,BAO_0000223,CHEMBL618148,104714,,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3465,,,,,,B,,,H,10321,BAO_0000019,CHEMBL618149,144,,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3466,,,,,,B,,,H,15818,BAO_0000357,CHEMBL872927,144,,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3467,,,,,,B,,,H,15818,BAO_0000357,CHEMBL618150,144,,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3468,,,,,,B,,,H,17358,BAO_0000357,CHEMBL618151,144,,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3469,,,,,,B,,,H,2222,BAO_0000357,CHEMBL875094,144,,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
3470,,,,,,B,,,H,10322,BAO_0000019,CHEMBL618152,144,,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3471,,,,,,B,,,H,16117,BAO_0000357,CHEMBL618153,144,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3472,,,,,,B,,,H,17200,BAO_0000357,CHEMBL618888,144,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,
3473,,,,,,F,,,H,17358,BAO_0000019,CHEMBL618889,144,,Autocuration,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,
3474,,,,,,B,,,H,16700,BAO_0000357,CHEMBL618890,144,,Autocuration,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,
3475,,,,,,B,,,H,1980,BAO_0000019,CHEMBL618891,144,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,
3476,,,,,,B,,,H,1980,BAO_0000019,CHEMBL619054,144,,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,
3477,,,,,,B,,,H,12409,BAO_0000223,CHEMBL619055,104714,,Autocuration,Binding affinity against the 5-hydroxytryptamine 3 receptor,,
3478,,,,,,B,,,H,4365,BAO_0000357,CHEMBL619056,144,,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3479,,,,,,F,,,H,4365,BAO_0000019,CHEMBL619057,144,,Autocuration,Percent efficacy against 5-hydroxytryptamine 3A receptor,,
3480,,,,,,B,,,H,4365,BAO_0000357,CHEMBL619058,144,,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3481,,Oocytes,,Rattus norvegicus,,F,,,D,6769,BAO_0000219,CHEMBL619059,12020,,Expert,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,10116.0
3482,,Oocytes,,Rattus norvegicus,,F,,,D,6769,BAO_0000219,CHEMBL619060,12020,,Expert,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,10116.0
3483,,Oocytes,,Rattus norvegicus,,F,,,D,6769,BAO_0000219,CHEMBL875095,12020,,Expert,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,10116.0
3484,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL619061,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,10141.0
3485,2116.0,,Ileum,Cavia porcellus,,F,,,D,809,BAO_0000221,CHEMBL619062,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,10141.0
3486,,,,Cavia porcellus,,F,,,D,14290,BAO_0000019,CHEMBL619063,20033,,Intermediate,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,10141.0
3487,2116.0,,Ileum,Cavia porcellus,,B,,,D,17358,BAO_0000221,CHEMBL619064,20033,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,10141.0
3488,,,,Cavia porcellus,,B,,,D,17358,BAO_0000357,CHEMBL619065,20033,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,10141.0
3489,2116.0,,Ileum,Cavia porcellus,,B,,,D,17358,BAO_0000221,CHEMBL619066,20033,,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,10141.0
3490,2116.0,,Ileum,,,B,,,H,17386,BAO_0000221,CHEMBL619775,10209,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3491,,,,,,B,,,H,3269,BAO_0000357,CHEMBL619776,10209,,Autocuration,Affinity against 5-hydroxytryptamine 7 receptor,,
3492,,,,Cavia porcellus,,B,,,H,7721,BAO_0000224,CHEMBL619777,104841,,Autocuration,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,10141.0
3493,,,,Cavia porcellus,,B,,,H,7721,BAO_0000224,CHEMBL619778,104841,,Autocuration,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,10141.0
3494,2116.0,,Ileum,Cavia porcellus,,B,,,H,9117,BAO_0000221,CHEMBL619779,104841,,Autocuration,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,10141.0
3495,,,,Cavia porcellus,,B,,,H,7721,BAO_0000224,CHEMBL619780,104841,,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,10141.0
3496,,,,Cavia porcellus,,B,,,H,7721,BAO_0000224,CHEMBL619166,104841,,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,10141.0
3497,,,,Cavia porcellus,,F,,,H,15796,BAO_0000019,CHEMBL619167,104841,,Autocuration,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,10141.0
3498,,,,Cavia porcellus,,F,,,H,15796,BAO_0000019,CHEMBL619168,104841,,Autocuration,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,10141.0
3499,2081.0,,Cardiac atrium,Homo sapiens,,B,,,D,15650,BAO_0000219,CHEMBL619169,168,,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,9606.0
3500,2081.0,,Cardiac atrium,Homo sapiens,,B,,,D,15650,BAO_0000219,CHEMBL619170,168,,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,9606.0
3501,,,,Homo sapiens,,F,,,D,6866,BAO_0000019,CHEMBL619171,104841,,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,9606.0
3502,2081.0,,Cardiac atrium,Homo sapiens,,F,,,D,15650,BAO_0000219,CHEMBL619172,168,,Expert,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,9606.0
3503,,,,Mus musculus,,B,,,U,10063,BAO_0000019,CHEMBL619173,22226,,Autocuration,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,10090.0
3504,,,,Mus musculus,,B,,,U,12665,BAO_0000019,CHEMBL619174,22226,,Autocuration,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,10090.0
3505,,,,,,B,,,H,7504,BAO_0000019,CHEMBL619175,104705,,Autocuration,5-hydroxytryptamine receptor binding affinity was determined in rats,,
3506,,,,,,B,,,H,7504,BAO_0000224,CHEMBL619176,104705,,Autocuration,Binding affinity at rat 5-hydroxytryptamine receptor.,,
3507,,,,,,B,,,H,7038,BAO_0000019,CHEMBL619177,104705,,Autocuration,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,
3508,,,,,,B,,,H,7626,BAO_0000224,CHEMBL619178,104705,,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,
3509,,,,,,B,,,H,7626,BAO_0000224,CHEMBL619179,104705,,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,
3510,945.0,,Stomach,,,F,,,H,7185,BAO_0000019,CHEMBL619180,104705,,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,
3511,945.0,,Stomach,,,F,,,H,7185,BAO_0000019,CHEMBL619181,104705,,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,
3512,,,,,,F,,,H,7185,BAO_0000019,CHEMBL619182,104705,,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
3513,,,,,,B,,,H,6960,BAO_0000224,CHEMBL619183,104705,,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,
3514,,,,,,B,,,H,6960,BAO_0000224,CHEMBL619184,104705,,Autocuration,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,
3515,10000000.0,,Hippocampus,,,B,,,H,12416,BAO_0000221,CHEMBL619185,10576,,Autocuration,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
3516,,,,,,B,,,H,15753,BAO_0000357,CHEMBL619186,12198,,Expert,Binding affinity for rat 5-hydroxytryptamine transporter.,,
3517,,,,,,B,,,H,8062,BAO_0000019,CHEMBL619187,104705,,Autocuration,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,
3518,,,,Rattus norvegicus,,B,,,D,9036,BAO_0000019,CHEMBL619188,104705,,Autocuration,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,10116.0
3519,,,,Rattus norvegicus,,B,,,D,15067,BAO_0000224,CHEMBL619189,104705,,Autocuration,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,10116.0
3520,955.0,,Brain,Rattus norvegicus,,F,,,D,15753,BAO_0000019,CHEMBL619190,12198,,Expert,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,10116.0
3521,2037.0,,Cerebellum,Rattus norvegicus,,F,,,D,15753,BAO_0000221,CHEMBL619191,12198,,Expert,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,10116.0
3522,,,,Rattus norvegicus,,B,,,D,15295,BAO_0000019,CHEMBL619192,104705,,Autocuration,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,10116.0
3523,,,,Rattus norvegicus,,B,,,D,6347,BAO_0000224,CHEMBL619193,104705,,Autocuration,Percent binding affinity against 5-hydroxytryptamine receptor,,10116.0
3524,,,,,,B,,,U,6763,BAO_0000019,CHEMBL619194,22226,,Autocuration,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,
3525,,,,Rattus norvegicus,,B,,,D,12092,BAO_0000224,CHEMBL619195,104705,,Autocuration,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,10116.0
3526,,,,Rattus norvegicus,,B,,,D,1579,BAO_0000224,CHEMBL619196,104705,,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined,,10116.0
3527,945.0,,Stomach,Rattus norvegicus,,B,,,D,1579,BAO_0000019,CHEMBL619197,104705,,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,10116.0
3528,,,,Homo sapiens,,B,,,D,5963,BAO_0000219,CHEMBL619198,121,,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,9606.0
3529,,,,Homo sapiens,,B,,,D,5963,BAO_0000219,CHEMBL875081,121,,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,9606.0
3530,,,,,,B,,,H,5030,BAO_0000357,CHEMBL884712,18065,,Autocuration,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,
3531,,,,,,B,,,H,15796,BAO_0000357,CHEMBL884710,121,,Expert,Inhibition of 5-hydroxytryptamine reuptake,,
3532,,,,,,F,,,H,15413,BAO_0000019,CHEMBL619199,18065,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,
3533,,,,,,F,,,H,15413,BAO_0000019,CHEMBL619200,18065,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,
3534,,,,,,F,,,H,15413,BAO_0000019,CHEMBL619201,18065,,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,
3535,,,,,,F,,,H,12409,BAO_0000019,CHEMBL619202,18065,,Autocuration,Tested for 5-hydroxytryptamine receptor uptake,,
3536,,CHO,,Homo sapiens,,B,,449.0,D,16909,BAO_0000219,CHEMBL619203,51,,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,9606.0
3537,,,,Homo sapiens,,F,,,D,16909,BAO_0000019,CHEMBL619204,51,,Expert,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,9606.0
3538,,,,Homo sapiens,,B,,,H,15629,BAO_0000249,CHEMBL619205,10576,,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,9606.0
3539,,,,,,B,,,H,15629,BAO_0000357,CHEMBL619206,10576,,Autocuration,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,
3540,,,,,,B,,,H,15629,BAO_0000249,CHEMBL619207,10576,,Expert,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,
3541,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL619208,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,
3542,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL619209,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,
3543,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL619210,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,
3544,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL619211,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3545,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL619212,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,
3546,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620681,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,
3547,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620682,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,
3548,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620683,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,
3549,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620684,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,
3550,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620685,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3551,2435.0,,Striatum,,,F,,,H,10034,BAO_0000019,CHEMBL620686,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,
3552,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620687,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,
3553,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620688,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3554,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620689,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,
3555,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620690,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,
3556,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620691,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,
3557,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620692,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,
3558,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL620693,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,
3559,,,,,,B,,,H,1274,BAO_0000357,CHEMBL620694,168,,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,,
3560,,,,,,F,,,H,17358,BAO_0000019,CHEMBL857986,168,,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3561,,,,,,B,,,H,14532,BAO_0000357,CHEMBL620695,168,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,
3562,,,,,,B,,,H,16989,BAO_0000357,CHEMBL620696,168,,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,
3563,,,,,,B,,,H,17200,BAO_0000357,CHEMBL620697,168,,Autocuration,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,
3564,,,,,,B,,,H,15779,BAO_0000357,CHEMBL620698,168,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor,,
3565,,,,,,B,,,H,15779,BAO_0000357,CHEMBL620699,168,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3566,,,,,,B,,,H,15779,BAO_0000357,CHEMBL620700,168,,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3567,,COS-7,,,,B,,643.0,H,15650,BAO_0000219,CHEMBL620701,168,,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,
3568,,COS-7,,,,B,,643.0,H,15650,BAO_0000219,CHEMBL875082,168,,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,
3569,,COS-7,,,,B,,643.0,H,15650,BAO_0000219,CHEMBL620702,168,,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,
3570,,COS-7,,,,B,,643.0,H,15650,BAO_0000219,CHEMBL620703,168,,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,
3571,,C6,,,,B,,673.0,H,17046,BAO_0000219,CHEMBL620704,168,,Autocuration,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3572,,C6,,,,B,,673.0,H,17046,BAO_0000219,CHEMBL620705,168,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3573,,C6,,,,B,,673.0,H,15650,BAO_0000219,CHEMBL620706,168,,Expert,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,
3574,,C6,,,,B,,673.0,H,17046,BAO_0000219,CHEMBL620707,168,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,
3575,,,,,,B,,,H,17066,BAO_0000357,CHEMBL620708,10624,,Expert,Binding affinity towards 5-hydroxytryptamine 5 receptor,,
3576,,,,,,B,,,H,17200,BAO_0000357,CHEMBL620709,105,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,
3577,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL620710,10624,,Expert,Binding affinity against 5-hydroxytryptamine 5A receptor,,9606.0
3578,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL620711,10624,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,
3579,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL620712,10624,,Expert,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,9606.0
3580,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL620713,10624,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,9606.0
3581,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL620714,10624,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,9606.0
3582,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL620715,10624,,Expert,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,9606.0
3583,,,,,,B,,,H,6013,BAO_0000357,CHEMBL620716,10624,,Autocuration,Binding affinity towards 5-HT5A receptor,,
3584,,,,,,B,,,H,17175,BAO_0000357,CHEMBL620717,10624,,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3585,,,,,,B,,,H,15818,BAO_0000357,CHEMBL618072,10624,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,
3586,,,,,,B,,,H,6166,BAO_0000357,CHEMBL857987,10624,,Autocuration,Binding affinity towards cloned human 5-HT5A receptor was determined,,
3587,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL618073,10624,,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3588,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL618074,10624,,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3589,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL618075,10624,,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,
3590,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL618076,10625,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,10090.0
3591,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL618077,10625,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,10090.0
3592,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL618078,10625,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,10090.0
3593,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL881821,10625,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,10090.0
3594,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL618079,10625,,Expert,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,10090.0
3595,,,,,,B,,,H,17175,BAO_0000357,CHEMBL618080,10625,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3596,,HEK293,,,,B,,722.0,H,16190,BAO_0000219,CHEMBL618081,10576,,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3597,,HEK293,,,,B,,722.0,H,16190,BAO_0000219,CHEMBL618082,10626,,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3598,,,,,,B,,,H,4820,BAO_0000357,CHEMBL618083,10624,,Expert,Binding affinity towards 5-HT5a receptor,,
3599,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL618084,10624,,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor,,9606.0
3600,,,,,,B,,,H,17066,BAO_0000357,CHEMBL618085,10624,,Expert,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,
3601,,,,,,B,,,H,17175,BAO_0000357,CHEMBL618086,10624,,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,
3602,,,,,,B,,,H,16633,BAO_0000357,CHEMBL875092,10624,,Autocuration,Binding affinities against 5-hydroxytryptamine 5A receptor,,
3603,,,,,,B,,,H,16633,BAO_0000357,CHEMBL618087,10624,,Autocuration,Binding affinities towards 5-hydroxytryptamine 5A receptor,,
3604,,,,,,B,,,H,16700,BAO_0000357,CHEMBL872926,10624,,Autocuration,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,
3605,,,,Cavia porcellus,,F,,,H,4639,BAO_0000019,CHEMBL618088,104714,,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,10141.0
3606,,,,,,B,,,H,5486,BAO_0000223,CHEMBL618089,104714,,Autocuration,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,
3607,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL618090,10627,,Expert,Inhibition of human 5-hydroxytryptamine 6 receptor,,9606.0
3608,,,,Homo sapiens,,B,,,D,17273,BAO_0000357,CHEMBL618091,10627,,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,9606.0
3609,,,,,,B,,,H,17687,BAO_0000357,CHEMBL618092,10627,,Autocuration,Inhibition against human 5-hydroxytryptamine 6 receptor,,
3610,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL618093,10627,,Expert,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,9606.0
3611,,HeLa,,,,B,,308.0,H,16190,BAO_0000219,CHEMBL618094,10627,,Expert,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,
3612,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL618095,10627,,Expert,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,9606.0
3613,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL875093,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,9606.0
3614,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL618096,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,9606.0
3615,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL618118,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,9606.0
3616,,,,Homo sapiens,,B,,,D,3555,BAO_0000357,CHEMBL618119,10627,,Expert,Binding affinity against 5-hydroxytryptamine 6 receptor,,9606.0
3617,,,,,,B,,,H,5808,BAO_0000357,CHEMBL618120,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3618,,,,,,B,,,H,6013,BAO_0000357,CHEMBL618121,10627,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3619,,HEK293,,,,B,,722.0,H,15818,BAO_0000219,CHEMBL618122,10627,,Expert,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,
3620,,,,,,B,,,H,16209,BAO_0000357,CHEMBL618123,10627,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,
3621,,HEK293,,,,B,,722.0,H,3935,BAO_0000219,CHEMBL618124,10627,,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,
3622,,,,,,B,,,H,15818,BAO_0000357,CHEMBL618125,10627,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3623,,HEK293,,Homo sapiens,,B,,722.0,D,3805,BAO_0000219,CHEMBL618126,10627,,Expert,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,9606.0
3624,,,,,,B,,,H,16441,BAO_0000019,CHEMBL618236,10627,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,
3625,,,,,,B,,,H,16441,BAO_0000019,CHEMBL618237,10627,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3626,,COS-7,,,,B,,643.0,H,6786,BAO_0000219,CHEMBL618238,10627,,Expert,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,
3627,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL618239,10627,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,9606.0
3628,,,,,,B,,,H,17085,BAO_0000019,CHEMBL618240,10627,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,
3629,,,,,,B,,,H,17200,BAO_0000357,CHEMBL618241,10627,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,
3630,,HEK293,,,,B,,722.0,H,17451,BAO_0000219,CHEMBL859399,10627,,Autocuration,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,
3631,,,,,,F,,,H,3935,BAO_0000019,CHEMBL618242,10627,,Autocuration,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,
3632,,,,,,B,,,H,5033,BAO_0000357,CHEMBL857991,10627,,Autocuration,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,
3633,,,,,,B,,,H,4540,BAO_0000357,CHEMBL619951,10627,,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3634,,HeLa,,Homo sapiens,,B,,308.0,D,4540,BAO_0000219,CHEMBL619952,10627,,Expert,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,9606.0
3635,,HeLa,,Homo sapiens,,B,,308.0,D,4540,BAO_0000219,CHEMBL619953,10627,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,9606.0
3636,,HeLa,,,,B,,308.0,H,17296,BAO_0000219,CHEMBL619954,10627,,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,
3637,,HeLa,,,,B,,308.0,H,17296,BAO_0000219,CHEMBL619955,10627,,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3638,,HeLa,,,,B,,308.0,H,17296,BAO_0000219,CHEMBL619956,10627,,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3639,,CHO,,,,B,,449.0,H,15779,BAO_0000219,CHEMBL619957,10627,,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
3640,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL619958,10627,,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3641,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL620627,10627,,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,
3642,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL620628,10627,,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3643,,HeLa,,,,B,,308.0,H,15779,BAO_0000219,CHEMBL620629,10627,,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,
3644,,,,,,B,,,H,6166,BAO_0000357,CHEMBL620630,10627,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3645,,HeLa,,,,B,,308.0,H,17451,BAO_0000219,CHEMBL620782,10627,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,
3646,,,,,,B,,,H,15316,BAO_0000357,CHEMBL620783,10627,,Autocuration,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,
3647,,,,,,B,,,H,4199,BAO_0000357,CHEMBL620784,10627,,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3648,,HeLa,,,,B,,308.0,H,15146,BAO_0000219,CHEMBL620785,10627,,Expert,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,
3649,,,,,,B,,,H,5213,BAO_0000357,CHEMBL857992,10627,,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,
3650,,,,,,B,,,H,16429,BAO_0000219,CHEMBL620786,10627,,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,
3651,,HeLa,,,,B,,308.0,H,14818,BAO_0000219,CHEMBL620787,10627,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,
3652,,HeLa,,,,B,,308.0,H,4829,BAO_0000219,CHEMBL620788,10627,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,
3653,,HeLa,,,,B,,308.0,H,4829,BAO_0000219,CHEMBL620789,10627,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,
3654,,HeLa,,,,B,,308.0,H,4829,BAO_0000219,CHEMBL620790,10627,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,
3655,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL620791,10628,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,
3656,,,,,,B,,,H,14423,BAO_0000019,CHEMBL620792,10628,,Autocuration,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,
3657,,,,,,B,,,H,15086,BAO_0000357,CHEMBL620793,10628,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,
3658,,,,,,B,,,H,4342,BAO_0000357,CHEMBL620794,10628,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,
3659,,HeLa,,Homo sapiens,,B,,308.0,D,16190,BAO_0000219,CHEMBL620795,10627,,Autocuration,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,9606.0
3660,,,,,,B,,,H,4820,BAO_0000357,CHEMBL620796,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3661,,,,,,B,,,H,4639,BAO_0000357,CHEMBL620797,10627,,Autocuration,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,
3662,,,,Homo sapiens,,F,,,D,17066,BAO_0000019,CHEMBL620798,10627,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,9606.0
3663,,,,,,B,,,H,6011,BAO_0000357,CHEMBL620799,10627,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,
3664,,,,,,B,,,H,17066,BAO_0000357,CHEMBL620800,10627,,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3665,,,,,,B,,,H,17515,BAO_0000357,CHEMBL620801,10627,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,
3666,,,,,,B,,,H,5014,BAO_0000357,CHEMBL875100,10627,,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,
3667,,,,,,B,,,H,4373,BAO_0000357,CHEMBL620802,10627,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,
3668,,,,,,F,,,H,17066,BAO_0000019,CHEMBL620803,10627,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,
3669,,,,,,F,,,H,17066,BAO_0000019,CHEMBL620804,10627,,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,
3670,,,,,,B,,,H,4373,BAO_0000357,CHEMBL620805,10627,,Autocuration,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,
3671,,,,,,B,,,H,4687,BAO_0000357,CHEMBL620806,10627,,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,
3672,,,,,,B,,,H,16946,BAO_0000357,CHEMBL620807,10627,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,
3673,,,,,,B,,,H,16946,BAO_0000357,CHEMBL620808,10627,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,
3674,,,,,,B,,,H,16633,BAO_0000357,CHEMBL620809,10627,,Autocuration,Binding affinities against 5-hydroxytryptamine 6 receptor,,
3675,,,,,,B,,,H,16633,BAO_0000357,CHEMBL620810,10627,,Autocuration,Binding affinities towards 5-hydroxytryptamine 6 receptor,,
3676,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL620811,10627,,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor,,9606.0
3677,,,,,,B,,,H,16700,BAO_0000357,CHEMBL620812,10627,,Autocuration,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,
3678,,,,,,B,,,H,3269,BAO_0000357,CHEMBL620813,10627,,Autocuration,Affinity against 5-hydroxytryptamine 6 receptor,,
3679,,,,,,B,,,H,5486,BAO_0000357,CHEMBL620814,10627,,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,
3680,,,,Homo sapiens,,B,,,D,16146,BAO_0000357,CHEMBL620815,10209,,Expert,Inhibition of human 5-hydroxytryptamine 7 receptor,,9606.0
3681,,HEK293,,,,B,,722.0,H,5014,BAO_0000219,CHEMBL620816,10209,,Autocuration,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,
3682,,,,,,B,,,H,15463,BAO_0000357,CHEMBL620817,10209,,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,
3683,,,,,,B,,,H,3805,BAO_0000357,CHEMBL620818,10209,,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,
3684,,HEK293,,,,B,,722.0,H,5014,BAO_0000219,CHEMBL620819,10209,,Expert,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,
3685,,,,Homo sapiens,,B,,,D,6491,BAO_0000357,CHEMBL620820,10209,,Expert,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,9606.0
3686,,CHO,,,,B,,449.0,H,16190,BAO_0000219,CHEMBL620821,10209,,Autocuration,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,
3687,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL620822,10209,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,9606.0
3688,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL620823,10209,,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,9606.0
3689,,,,Homo sapiens,,B,,,D,3555,BAO_0000357,CHEMBL620824,10209,,Expert,Binding affinity against 5-hydroxytryptamine 7 receptor,,9606.0
3690,,CHO,,,,B,,449.0,H,6588,BAO_0000219,CHEMBL620825,10209,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,
3691,,,,,,B,,,H,15463,BAO_0000357,CHEMBL872930,10209,,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,
3692,,,,,,B,,,H,6013,BAO_0000357,CHEMBL620826,10209,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3693,,,,,,B,,,H,16209,BAO_0000357,CHEMBL620827,10209,,Autocuration,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3694,,,,,,B,,,H,3935,BAO_0000357,CHEMBL620828,10209,,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,
3695,,,,,,B,,,H,15818,BAO_0000357,CHEMBL620829,10209,,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3696,,HEK293,,,,B,,722.0,H,5014,BAO_0000219,CHEMBL620830,10209,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,
3697,,,,,,B,,,H,16441,BAO_0000019,CHEMBL620831,10209,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,
3698,,,,,,B,,,H,16441,BAO_0000019,CHEMBL620832,10209,,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3699,,,,Homo sapiens,,B,,,D,4234,BAO_0000357,CHEMBL621548,10209,,Expert,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,9606.0
3700,,,,,,B,,,H,17085,BAO_0000019,CHEMBL621549,10209,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,
3701,,,,,,B,,,H,17200,BAO_0000357,CHEMBL621550,10209,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,
3702,,CHO,,,,B,,449.0,H,17451,BAO_0000219,CHEMBL621551,10209,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,
3703,,,,,,B,,,H,17085,BAO_0000019,CHEMBL621552,10209,,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,
3704,,,,,,B,,,H,5104,BAO_0000357,CHEMBL857077,10209,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,
3705,,,,,,B,,,H,5104,BAO_0000357,CHEMBL618158,10209,,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,
3706,,COS-7,,Homo sapiens,,B,,643.0,D,5033,BAO_0000219,CHEMBL618159,10209,,Expert,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,9606.0
3707,,COS-7,,,,B,,643.0,H,5486,BAO_0000219,CHEMBL875101,10209,,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,
3708,,HEK293,,Homo sapiens,,B,,722.0,D,4540,BAO_0000219,CHEMBL618160,10209,,Expert,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,9606.0
3709,,,,,,B,,,H,6166,BAO_0000357,CHEMBL618161,10209,,Expert,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,
3710,,HEK293,,,,B,,722.0,H,17342,BAO_0000219,CHEMBL618162,10209,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,
3711,,,,,,B,,,H,17342,BAO_0000357,CHEMBL618163,10209,,Expert,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,
3712,,,,,,B,,,H,17296,BAO_0000357,CHEMBL618164,10209,,Autocuration,Binding affinity against 5-hydroxytryptamine 7 human receptors,,
3713,,,,,,B,,,H,16429,BAO_0000219,CHEMBL618165,10209,,Expert,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,
3714,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL618166,10209,,Autocuration,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,
3715,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL857989,10209,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3716,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL619888,10209,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3717,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL619889,10209,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3718,,HEK293,,,,B,,722.0,H,15779,BAO_0000219,CHEMBL619890,10209,,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,
3719,,CHO,,,,B,,449.0,H,17451,BAO_0000219,CHEMBL619891,10209,,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,
3720,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL619892,10209,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,
3721,,HEK293,,,,B,,722.0,D,4199,BAO_0000219,CHEMBL619893,10209,,Expert,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,
3722,,HEK293,,,,B,,722.0,H,4199,BAO_0000219,CHEMBL619894,10209,,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,
3723,,HEK293,,,,B,,722.0,D,3680,BAO_0000219,CHEMBL619895,10209,,Intermediate,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,
3724,,,,,,B,,,D,3680,BAO_0000357,CHEMBL619896,10209,,Intermediate,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,
3725,,COS-7,,,,B,,643.0,H,15316,BAO_0000219,CHEMBL619897,10209,,Autocuration,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,
3726,,HEK293,,,,B,,722.0,H,15146,BAO_0000219,CHEMBL619898,10209,,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,
3727,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL619899,10209,,Expert,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,
3728,,HEK293,,,,B,,722.0,H,5213,BAO_0000219,CHEMBL619900,10209,,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,
3729,,HEK293,,Homo sapiens,,B,,722.0,D,14818,BAO_0000219,CHEMBL619901,10209,,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,9606.0
3730,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL620580,10209,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,
3731,,HEK293,,,,B,,722.0,H,14818,BAO_0000219,CHEMBL620581,10209,,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,
3732,,HEK293,,,,B,,722.0,H,4829,BAO_0000219,CHEMBL620733,10209,,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,
3733,,,,Homo sapiens,,B,,,D,17200,BAO_0000357,CHEMBL620734,10209,,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,9606.0
3734,,,,Mus musculus,,B,,,D,17066,BAO_0000357,CHEMBL620735,10022,,Expert,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,10090.0
3735,,,,Oryctolagus cuniculus,,B,,,H,14025,BAO_0000019,CHEMBL620736,10209,,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,9986.0
3736,,CHO,,,,B,,449.0,H,15250,BAO_0000219,CHEMBL620737,11923,,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,
3737,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620738,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,
3738,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620739,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,
3739,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620740,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,
3740,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620741,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,
3741,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620742,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,
3742,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620743,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,
3743,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620744,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,
3744,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620745,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,
3745,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620746,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,
3746,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620747,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,
3747,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620748,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,
3748,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620749,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,
3749,,,,,,B,,,H,17066,BAO_0000357,CHEMBL620750,11923,,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,
3750,,,,Rattus norvegicus,,B,,,D,17066,BAO_0000357,CHEMBL620751,11923,,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,10116.0
3751,,,,,,B,,,H,17386,BAO_0000357,CHEMBL620752,11923,,Expert,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,
3752,,,,,,B,,,H,14423,BAO_0000019,CHEMBL872929,11923,,Autocuration,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,
3753,,,,Rattus norvegicus,,B,,,D,15874,BAO_0000357,CHEMBL620753,11923,,Expert,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,10116.0
3754,,,,Rattus norvegicus,,B,,,D,15874,BAO_0000357,CHEMBL620754,11923,,Expert,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,10116.0
3755,,CHO,,Rattus norvegicus,,B,,449.0,D,16372,BAO_0000219,CHEMBL620755,11923,,Expert,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,10116.0
3756,,,,,,B,,,H,4622,BAO_0000357,CHEMBL620756,11923,,Autocuration,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3757,,,,,,B,,,H,15086,BAO_0000357,CHEMBL620757,11923,,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,
3758,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620758,11923,,Autocuration,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,
3759,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620759,11923,,Autocuration,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,
3760,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620760,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,
3761,,CHO,,,,B,,449.0,H,16372,BAO_0000219,CHEMBL620761,11923,,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,
3762,2116.0,,Ileum,,,F,,,H,17386,BAO_0000221,CHEMBL620762,11923,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3763,2116.0,,Ileum,,,F,,,H,17386,BAO_0000221,CHEMBL620763,11923,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3764,2116.0,,Ileum,,,F,,,H,17386,BAO_0000221,CHEMBL620764,11923,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,
3765,,,,Rattus norvegicus,,B,Membranes,,D,5831,BAO_0000249,CHEMBL857990,11923,,Expert,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,10116.0
3766,,,,,,B,,,H,4342,BAO_0000357,CHEMBL620765,11923,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,
3767,,,,,,B,,,H,17319,BAO_0000357,CHEMBL620766,11923,,Expert,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,
3768,1898.0,,Hypothalamus,,,B,,,H,17342,BAO_0000019,CHEMBL620767,11923,,Expert,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,
3769,,,,,,B,,,H,17342,BAO_0000357,CHEMBL620768,11923,,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,
3770,1898.0,,Hypothalamus,,,B,,,H,3680,BAO_0000249,CHEMBL619051,11923,,Expert,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,
3771,,,,,,B,,,H,3680,BAO_0000357,CHEMBL619052,11923,,Expert,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3772,,HEK293,,Rattus norvegicus,,F,,722.0,D,17319,BAO_0000219,CHEMBL619053,11923,,Expert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,10116.0
3773,,HEK293,,Rattus norvegicus,,F,,722.0,D,17319,BAO_0000219,CHEMBL619703,11923,,Expert,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,10116.0
3774,,HEK293,,Rattus norvegicus,,F,,722.0,D,17319,BAO_0000219,CHEMBL619704,11923,,Autocuration,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,10116.0
3775,,,,,,B,,,H,4820,BAO_0000357,CHEMBL619851,10209,,Expert,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3776,,,,,,B,,,H,4639,BAO_0000357,CHEMBL619852,10209,,Autocuration,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,
3777,,,,,,B,,,H,6011,BAO_0000357,CHEMBL619853,10209,,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,
3778,,,,Homo sapiens,,B,,,D,17066,BAO_0000357,CHEMBL619854,10209,,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,9606.0
3779,,,,,,B,,,H,17066,BAO_0000357,CHEMBL619855,10209,,Expert,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,
3780,,,,,,B,,,H,17515,BAO_0000357,CHEMBL619856,10209,,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,
3781,,,,,,B,,,H,4373,BAO_0000357,CHEMBL619857,10209,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3782,,,,,,F,,,H,17066,BAO_0000019,CHEMBL619858,10209,,Expert,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,
3783,,,,,,B,,,H,4373,BAO_0000357,CHEMBL619859,10209,,Autocuration,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,
3784,,,,,,B,,,H,4373,BAO_0000357,CHEMBL619860,10209,,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3785,,,,,,B,,,H,4687,BAO_0000357,CHEMBL619861,10209,,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,
3786,,,,,,B,,,H,17342,BAO_0000357,CHEMBL619862,10209,,Expert,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,
3787,,,,,,B,,,H,16946,BAO_0000357,CHEMBL619863,10209,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,
3788,,,,,,B,,,H,16946,BAO_0000357,CHEMBL619864,10209,,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,
3789,,,,,,B,,,H,16633,BAO_0000357,CHEMBL872928,10209,,Autocuration,Binding affinities against 5-hydroxytryptamine 7 receptor,,
3790,,,,,,B,,,H,16633,BAO_0000357,CHEMBL619865,10209,,Autocuration,Binding affinities towards 5-hydroxytryptamine 7 receptor,,
3791,,,,,,B,,,H,17066,BAO_0000357,CHEMBL619866,10209,,Expert,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,
3792,,,,,,B,,,H,16700,BAO_0000357,CHEMBL619867,10209,,Autocuration,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,
3793,2116.0,,Ileum,,,B,,,H,17386,BAO_0000221,CHEMBL619868,10209,,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3794,,,,,,F,,,H,14080,BAO_0000019,CHEMBL619869,55,,Autocuration,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,
3795,,,,Homo sapiens,,F,,,D,14080,BAO_0000019,CHEMBL619870,55,,Expert,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,9606.0
3796,,,,,,B,,,H,409,BAO_0000357,CHEMBL619871,55,,Autocuration,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,
3797,,,,,,B,,,H,409,BAO_0000357,CHEMBL619872,55,,Autocuration,In vitro inhibition of human recombinant lipoxygenase enzyme,,
3798,,,,,,B,,,H,409,BAO_0000357,CHEMBL619873,55,,Autocuration,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,
3799,178.0,,Blood,,,B,,,H,11090,BAO_0000357,CHEMBL619874,55,,Expert,Inhibition of 5-lipoxygenase in human whole blood.,,
3800,178.0,,Blood,,,B,,,H,11090,BAO_0000357,CHEMBL619875,55,,Expert,Inhibition of 5-lipoxygenase in human whole blood.,,
3801,,,,,,B,,,H,948,BAO_0000357,CHEMBL619876,55,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,
3802,,,,,,B,,,H,948,BAO_0000357,CHEMBL619877,55,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,
3803,,,,,,F,,,H,13622,BAO_0000219,CHEMBL619878,55,,Expert,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,
3804,178.0,,Blood,,,F,,,H,13622,BAO_0000019,CHEMBL619879,55,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,
3805,,,,,,B,,,H,9637,BAO_0000357,CHEMBL619880,55,,Autocuration,In vitro inhibition of 5-lipoxygenase from human polymorphs,,
3806,,,,,,B,,,H,11320,BAO_0000357,CHEMBL619881,55,,Autocuration,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,
3807,,,,,,B,,,H,11320,BAO_0000357,CHEMBL619882,55,,Expert,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,
3808,,,,,,B,,,H,6838,BAO_0000357,CHEMBL619883,55,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,
3809,178.0,,Blood,Homo sapiens,,B,,,D,17667,BAO_0000357,CHEMBL619884,55,,Expert,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,9606.0
3810,,,,,,B,,,H,12703,BAO_0000357,CHEMBL619885,55,,Autocuration,In vitro potency against human 5-Lipoxygenase,,
3811,,,,Homo sapiens,,F,,,D,14312,BAO_0000019,CHEMBL619886,55,,Expert,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,9606.0
3812,178.0,,Blood,,,F,,,H,14312,BAO_0000019,CHEMBL619887,55,,Autocuration,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,
3813,,,,,,F,,,H,5364,BAO_0000019,CHEMBL875097,55,,Autocuration,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3814,,,,,,B,,,H,951,BAO_0000219,CHEMBL618001,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,
3815,,,,,,B,,,H,951,BAO_0000219,CHEMBL618002,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,
3816,,,,,,B,,,H,951,BAO_0000219,CHEMBL618003,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,
3817,,,,,,B,,,H,951,BAO_0000219,CHEMBL618004,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,
3818,,,,,,B,,,H,12365,BAO_0000219,CHEMBL618005,55,,Autocuration,Inhibition of human 5-lipoxygenase in human cells,,
3819,,,,,,B,,,H,10603,BAO_0000357,CHEMBL618006,55,,Expert,Inhibition of human neutrophil 5-lipoxygenase,,
3820,,,,,,B,,,H,10501,BAO_0000019,CHEMBL875086,55,,Autocuration,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,
3821,178.0,,Blood,,,B,,,H,12281,BAO_0000357,CHEMBL618007,55,,Expert,Inhibition of 5-lipoxygenase from human whole blood,,
3822,,,,,,B,,,H,2567,BAO_0000357,CHEMBL618008,55,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3823,,,,,,B,,,H,2567,BAO_0000219,CHEMBL618009,55,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,
3824,,,,,,B,,,H,10193,BAO_0000357,CHEMBL618010,55,,Expert,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,
3825,,,,,,B,,,H,10193,BAO_0000357,CHEMBL618011,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3826,,,,,,B,,,H,13623,BAO_0000357,CHEMBL618012,55,,Expert,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,
3827,,,,,,B,,,H,12780,BAO_0000357,CHEMBL882927,55,,Autocuration,Tested against 5-lipoxygenase,,
3828,,,,,,B,,,H,12780,BAO_0000357,CHEMBL618013,55,,Autocuration,Tested for activity against 5-Lipoxygenase (5-LO),,
3829,,,,,,B,,,H,12780,BAO_0000357,CHEMBL618014,55,,Autocuration,Tested for activity against 5-lipoxygenase,,
3830,,,,,,B,,,H,11966,BAO_0000357,CHEMBL618015,55,,Autocuration,Tested for inhibition of 5-HPETE production by human 5-LO,,
3831,,,,,,F,,,H,5364,BAO_0000019,CHEMBL618016,55,,Autocuration,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3832,,,,,,B,,,H,13165,BAO_0000357,CHEMBL618017,55,,Expert,Inhibition of Human 5-lipoxygenase,,
3833,,,,,,B,,,H,5364,BAO_0000019,CHEMBL618018,55,,Autocuration,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,
3834,,,,,,B,,,H,11311,BAO_0000219,CHEMBL875087,55,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
3835,,,,,,B,,,H,11311,BAO_0000219,CHEMBL618019,55,,Autocuration,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,
3836,,,,,,B,,,H,14863,BAO_0000019,CHEMBL618020,55,,Autocuration,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,
3837,,,,,,B,,,H,14863,BAO_0000019,CHEMBL618021,55,,Autocuration,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,
3838,178.0,,Blood,,,B,,,H,11087,BAO_0000357,CHEMBL618022,55,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,
3839,,,,,,B,,,H,455,BAO_0000357,CHEMBL618023,55,,Autocuration,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,
3840,,,,,,B,,,H,13183,BAO_0000357,CHEMBL618024,55,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
3841,,,,,,B,,,H,10319,BAO_0000019,CHEMBL873950,55,,Expert,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,
3842,,,,,,B,,,H,10193,BAO_0000357,CHEMBL618025,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3843,,,,,,B,,,H,951,BAO_0000219,CHEMBL618026,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,
3844,,,,,,B,,,H,951,BAO_0000219,CHEMBL618027,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,
3845,,,,,,B,,,H,951,BAO_0000219,CHEMBL618028,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,
3846,,,,,,B,,,H,951,BAO_0000219,CHEMBL618029,55,,Autocuration,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,
3847,,,,,,B,,,H,9859,BAO_0000357,CHEMBL618030,55,,Expert,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,
3848,,,,,,B,,,H,9859,BAO_0000357,CHEMBL618031,55,,Expert,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,
3849,,,,,,B,,,H,9859,BAO_0000357,CHEMBL618032,55,,Autocuration,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,
3850,,,,,,B,,,H,2567,BAO_0000357,CHEMBL618033,55,,Autocuration,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3851,,,,,,B,,,H,10193,BAO_0000357,CHEMBL618034,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,
3852,,,,,,B,,,H,10193,BAO_0000357,CHEMBL875088,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3853,,,,,,B,,,H,949,BAO_0000019,CHEMBL618035,55,,Autocuration,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,
3854,,,,,,B,,,H,949,BAO_0000019,CHEMBL618036,55,,Autocuration,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,
3855,,,,,,B,,,H,10603,BAO_0000357,CHEMBL618037,55,,Expert,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,
3856,,,,,,B,,,H,10603,BAO_0000357,CHEMBL618038,55,,Expert,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3857,,,,,,F,,,H,10603,BAO_0000019,CHEMBL618761,55,,Autocuration,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3858,,,,,,B,,,H,10603,BAO_0000357,CHEMBL618762,55,,Expert,Inhibition of lipoxygenase at the concentration of 0.1 uM,,
3859,,,,,,B,,,H,10603,BAO_0000357,CHEMBL618763,55,,Expert,Inhibition of lipoxygenase at the concentration of 1 uM,,
3860,,,,,,B,,,H,10193,BAO_0000357,CHEMBL618764,55,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,
3861,,,,Homo sapiens,,B,,,D,14580,BAO_0000357,CHEMBL618765,55,,Expert,Inhibition of 5-Lipoxygenase (5-LOX),,9606.0
3862,,,,,,B,,,H,11090,BAO_0000357,CHEMBL618766,17087,,Expert,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3863,,,,,,B,,,H,11090,BAO_0000357,CHEMBL618767,17087,,Expert,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3864,,,,,,B,,,H,6339,BAO_0000357,CHEMBL619380,17087,,Autocuration,Inhibitory activity against lipoxygenase-2 in mice,,
3865,,,,,,B,,,H,6339,BAO_0000357,CHEMBL619381,17087,,Expert,Inhibitory activity against murine lipoxygenase-2.,,
3866,,,,Mus musculus,,B,,,D,12281,BAO_0000357,CHEMBL619382,17087,,Expert,Inhibition of 5-lipoxygenase from mouse macrophage,,10090.0
3867,,,,,,B,,,H,11311,BAO_0000357,CHEMBL619383,17087,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,
3868,,,,Sus scrofa,,B,,,H,11089,BAO_0000019,CHEMBL619384,55,,Autocuration,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,9823.0
3869,,,,Sus scrofa,,B,,,H,10091,BAO_0000019,CHEMBL619385,55,,Autocuration,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,9823.0
3870,,,,Oryctolagus cuniculus,,B,,,H,14352,BAO_0000019,CHEMBL882928,55,,Autocuration,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,9986.0
3871,,,,Rattus norvegicus,,B,,,D,13329,BAO_0000019,CHEMBL619386,12166,,Expert,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,10116.0
3872,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619387,12166,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,
3873,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619388,12166,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3874,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619389,12166,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,
3875,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619390,12166,,Expert,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,
3876,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619391,12166,,Expert,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,
3877,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619392,12166,,Autocuration,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,
3878,,,,,,B,,,H,11311,BAO_0000019,CHEMBL619393,12166,,Autocuration,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,
3879,,,,,,B,,,H,11311,BAO_0000019,CHEMBL619394,12166,,Autocuration,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,
3880,,RBL-1,,,,B,,702.0,H,105,BAO_0000219,CHEMBL619395,12166,,Autocuration,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3881,,RBL-1,,,,B,,702.0,H,105,BAO_0000219,CHEMBL619396,12166,,Autocuration,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3882,,,,,,B,,,H,9138,BAO_0000357,CHEMBL619397,12166,,Autocuration,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,
3883,,,,,,B,,,H,9138,BAO_0000357,CHEMBL619398,12166,,Autocuration,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,
3884,,,,,,B,,,H,9138,BAO_0000357,CHEMBL619399,12166,,Autocuration,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,
3885,,,,,,B,,,H,14427,BAO_0000357,CHEMBL619400,12166,,Autocuration,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3886,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619401,12166,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3887,,,,,,B,,,H,13329,BAO_0000019,CHEMBL619402,12166,,Autocuration,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,
3888,,RBL-2H3,,Rattus norvegicus,,B,,663.0,D,14427,BAO_0000219,CHEMBL619403,12166,,Expert,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,10116.0
3889,,,,,,B,,,H,14427,BAO_0000357,CHEMBL619404,12166,,Autocuration,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3890,,,,,,B,,,H,14427,BAO_0000357,CHEMBL619405,12166,,Autocuration,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,
3891,,RBL-1,,,,B,,702.0,H,10293,BAO_0000219,CHEMBL619406,12166,,Expert,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,
3892,,RBL-1,,Rattus norvegicus,,B,,702.0,D,338,BAO_0000219,CHEMBL619407,12166,,Expert,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,10116.0
3893,,,,,,B,,,H,303,BAO_0000357,CHEMBL619408,12166,,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,
3894,,RBL-1,,,,B,,702.0,H,303,BAO_0000219,CHEMBL619409,12166,,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,
3895,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL619410,12166,,Expert,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,
3896,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL619753,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
3897,,RBL-1,,,,B,,702.0,H,137,BAO_0000219,CHEMBL619754,12166,,Autocuration,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,
3898,,,,,,B,,,H,11481,BAO_0000357,CHEMBL619903,12166,,Expert,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,
3899,,,,,,B,,,H,11481,BAO_0000357,CHEMBL619904,12166,,Expert,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,
3900,,,,,,B,,,H,9029,BAO_0000357,CHEMBL619905,12166,,Expert,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,
3901,,,,,,B,,,H,1701,BAO_0000019,CHEMBL619906,12166,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,
3902,,,,,,B,,,H,1701,BAO_0000019,CHEMBL619907,12166,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,
3903,,,,,,B,,,H,1701,BAO_0000019,CHEMBL619908,12166,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,
3904,,,,,,B,,,H,1701,BAO_0000019,CHEMBL619909,12166,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,
3905,,RBL-1,,,,F,,702.0,H,13358,BAO_0000219,CHEMBL619910,12166,,Expert,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,
3906,,RBL-1,,,,B,,702.0,H,1175,BAO_0000219,CHEMBL882929,12166,,Expert,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,
3907,,RBL-1,,,,B,,702.0,H,8797,BAO_0000219,CHEMBL619911,12166,,Expert,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,
3908,,,,,,B,,,H,8797,BAO_0000019,CHEMBL619912,12166,,Autocuration,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,
3909,,,,Rattus norvegicus,,B,,,D,577,BAO_0000357,CHEMBL619913,12166,,Expert,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,10116.0
3910,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL619914,12166,,Expert,In vitro inhibitory activity against RBL-1 5-LO,,
3911,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL619915,12166,,Autocuration,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,
3912,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL619916,12166,,Autocuration,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,
3913,,,,,,B,,,H,9295,BAO_0000218,CHEMBL619917,12166,,Autocuration,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,
3914,,,,,,B,,,H,9295,BAO_0000357,CHEMBL619918,12166,,Autocuration,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,
3915,,,,,,B,,,H,216,BAO_0000218,CHEMBL619919,12166,,Autocuration,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,
3916,,RBL-1,,,,B,,702.0,H,11090,BAO_0000219,CHEMBL883710,12166,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,
3917,178.0,,Blood,,,B,,,H,11090,BAO_0000019,CHEMBL619920,12166,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,
3918,,,,,,B,,,H,10091,BAO_0000357,CHEMBL619921,12166,,Expert,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,
3919,,,,,,F,,,H,10274,BAO_0000019,CHEMBL619922,12166,,Autocuration,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,
3920,,,,,,F,,,H,13622,BAO_0000219,CHEMBL619923,12166,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,
3921,,RBL-1,,,,B,,702.0,H,12118,BAO_0000219,CHEMBL619924,12166,,Expert,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,
3922,,,,,,B,,,H,12576,BAO_0000357,CHEMBL619925,12166,,Expert,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,
3923,,RBL-1,,,,B,,702.0,H,9546,BAO_0000219,CHEMBL619926,12166,,Expert,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,
3924,,RBL-1,,,,B,,702.0,H,9521,BAO_0000219,CHEMBL619927,12166,,Autocuration,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,
3925,,RBL-1,,,,B,,702.0,H,10626,BAO_0000219,CHEMBL619928,12166,,Expert,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,
3926,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619929,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase,,
3927,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL875089,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,
3928,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619930,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,
3929,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619931,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,
3930,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619932,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,
3931,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619933,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,
3932,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619934,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,
3933,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619935,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,
3934,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619936,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,
3935,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619937,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,
3936,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619938,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,
3937,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619939,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,
3938,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619940,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,
3939,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL875090,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,
3940,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619941,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,
3941,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619942,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,
3942,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL883711,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,
3943,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619943,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,
3944,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619944,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,
3945,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619945,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,
3946,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619946,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,
3947,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619947,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,
3948,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619948,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,
3949,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL619949,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,
3950,,,,,,B,,,H,9401,BAO_0000019,CHEMBL619950,12166,,Expert,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,
3951,,,,,,B,,,H,10325,BAO_0000019,CHEMBL618050,12166,,Autocuration,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,
3952,,RBL-2H3,,,,F,,663.0,H,1556,BAO_0000219,CHEMBL875091,12166,,Expert,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,
3953,,RBL-2H3,,,,F,,663.0,H,1556,BAO_0000219,CHEMBL618051,12166,,Expert,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,
3954,,RBL-1,,Rattus norvegicus,,B,,702.0,D,961,BAO_0000219,CHEMBL618052,12166,,Expert,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,10116.0
3955,,,,,,B,,,H,6838,BAO_0000019,CHEMBL618053,12166,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,
3956,,,,,,B,,,H,10325,BAO_0000019,CHEMBL618054,12166,,Expert,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,
3957,,RBL-1,,Rattus norvegicus,,B,,702.0,D,9209,BAO_0000219,CHEMBL618055,12166,,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,10116.0
3958,,RBL-1,,,,B,,702.0,H,11520,BAO_0000219,CHEMBL618056,12166,,Expert,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,
3959,,,,,,B,,,H,137,BAO_0000357,CHEMBL618057,12166,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined,,
3960,,RBL-1,,,,B,,702.0,H,4717,BAO_0000219,CHEMBL618058,12166,,Autocuration,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,
3961,,RBL-1,,,,B,,702.0,H,10636,BAO_0000219,CHEMBL618059,12166,,Expert,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,
3962,,,,Rattus norvegicus,,F,,,D,14312,BAO_0000019,CHEMBL618060,12166,,Expert,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,10116.0
3963,,RBL-1,,,,B,,702.0,H,1203,BAO_0000219,CHEMBL618061,12166,,Autocuration,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,
3964,,,,,,B,,,H,1203,BAO_0000019,CHEMBL618062,12166,,Autocuration,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,
3965,,RBL-1,,,,B,,702.0,H,13622,BAO_0000219,CHEMBL618063,12166,,Expert,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,
3966,,,,,,B,,,H,9793,BAO_0000357,CHEMBL618064,12166,,Autocuration,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,
3967,,RBL-1,,Rattus norvegicus,,B,,702.0,D,1143,BAO_0000219,CHEMBL618065,12166,,Expert,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,10116.0
3968,,RBL-1,,Rattus norvegicus,,B,,702.0,D,11854,BAO_0000219,CHEMBL618066,12166,,Expert,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,10116.0
3969,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL618067,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
3970,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL618068,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
3971,,RBL-1,,Rattus norvegicus,,B,,702.0,D,10501,BAO_0000219,CHEMBL618069,12166,,Expert,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,10116.0
3972,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL618070,12166,,Expert,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
3973,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL618071,10825,,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,
3974,349.0,,Limbic system,,,F,,,H,10034,BAO_0000019,CHEMBL619247,10825,,Autocuration,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3975,,,,,,F,,,H,10034,BAO_0000019,CHEMBL619248,10825,,Autocuration,Approximate dose levels for a half maximal reduction of 5-HTP levels,,
3976,10000000.0,,Hippocampus,,,B,,,H,10046,BAO_0000221,CHEMBL619249,10576,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3977,10000000.0,,Hippocampus,,,B,,,H,10046,BAO_0000221,CHEMBL619250,10576,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3978,,,,,,B,,,H,10046,BAO_0000019,CHEMBL619251,10577,,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
3979,178.0,,Blood,Canis lupus familiaris,,F,,,H,12079,BAO_0000019,CHEMBL619252,55,,Autocuration,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,9615.0
3980,178.0,,Blood,,,F,,,H,12079,BAO_0000019,CHEMBL619253,55,,Autocuration,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,
3981,,,,,,B,,,H,11311,BAO_0000219,CHEMBL619254,12166,,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
3982,,,,,,B,,,H,12338,BAO_0000219,CHEMBL619255,17140,,Expert,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,
3983,,,,,,B,,,H,12143,BAO_0000219,CHEMBL619256,17140,,Expert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,
3984,,,,,,B,,,H,12143,BAO_0000219,CHEMBL875418,17140,,Autocuration,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,
3985,,,,,,B,,,H,12143,BAO_0000219,CHEMBL619257,17140,,Expert,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3986,,,,,,B,,,H,12143,BAO_0000219,CHEMBL619258,17140,,Autocuration,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3987,,,,,,B,,,H,12365,BAO_0000357,CHEMBL619259,17140,,Expert,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,
3988,,,,,,B,,,H,13500,BAO_0000357,CHEMBL619260,17140,,Expert,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,
3989,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619261,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3990,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619263,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3991,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619264,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3992,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619265,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3993,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619266,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3994,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619902,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3995,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620058,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3996,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620059,55,,Autocuration,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3997,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620060,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3998,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620061,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
3999,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620062,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4000,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620063,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4001,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620064,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4002,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620065,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4003,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620066,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4004,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620067,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4005,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620068,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4006,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620069,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4007,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620070,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4008,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620071,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4009,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620072,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4010,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620036,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4011,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL857702,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4012,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620037,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4013,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620038,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4014,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620039,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4015,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620040,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4016,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620041,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4017,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620042,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4018,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620043,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4019,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620044,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4020,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620045,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4021,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620046,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4022,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620047,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4023,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620048,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,9615.0
4024,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL857703,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4025,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620049,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,9615.0
4026,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620050,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4027,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL620051,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4028,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619213,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4029,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619214,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4030,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619804,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4031,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619805,55,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,9615.0
4032,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619806,55,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4033,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619807,55,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4034,178.0,,Blood,Canis lupus familiaris,,F,,,H,12832,BAO_0000218,CHEMBL619808,55,,Autocuration,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,9615.0
4035,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL619809,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,9615.0
4036,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL619810,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,9615.0
4037,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL619811,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,9615.0
4038,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL620769,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,9615.0
4039,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL620770,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,9615.0
4040,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL620771,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,9615.0
4041,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL620772,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,9615.0
4042,,,,Canis lupus familiaris,,B,,,H,3595,BAO_0000218,CHEMBL620773,55,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,9615.0
4043,,,,Cavia porcellus,,B,,,H,9203,BAO_0000357,CHEMBL620774,55,,Autocuration,Ability to inhibit 5-lipoxygenase in guinea pig,,10141.0
4044,,,,Cavia porcellus,,B,,,H,82,BAO_0000357,CHEMBL620775,55,,Expert,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,10141.0
4045,,,,Cavia porcellus,,B,,,H,11090,BAO_0000357,CHEMBL620776,55,,Autocuration,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,10141.0
4046,178.0,,Blood,Cavia porcellus,,B,,,H,12832,BAO_0000218,CHEMBL620777,55,,Autocuration,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,10141.0
4047,,,,Cavia porcellus,,B,,,H,1065,BAO_0000357,CHEMBL620778,55,,Autocuration,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,10141.0
4048,,,,Cavia porcellus,,B,,,H,1065,BAO_0000357,CHEMBL620779,55,,Autocuration,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,10141.0
4049,,,,Cavia porcellus,,B,,,H,12832,BAO_0000019,CHEMBL621500,55,,Expert,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,10141.0
4050,,,,Cavia porcellus,,B,,,H,12832,BAO_0000019,CHEMBL621501,55,,Expert,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,10141.0
4051,,,,Cavia porcellus,,B,,,H,12832,BAO_0000019,CHEMBL618098,55,,Autocuration,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,10141.0
4052,,,,Cavia porcellus,,B,,,H,10504,BAO_0000019,CHEMBL618099,55,,Autocuration,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10141.0
4053,,,,Cavia porcellus,,B,,,H,7788,BAO_0000357,CHEMBL618100,55,,Autocuration,Inhibitory activity against 5-lipoxygenase,,10141.0
4054,,,,Cavia porcellus,,B,,,H,10001,BAO_0000357,CHEMBL618101,55,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,10141.0
4055,,,,Cavia porcellus,,B,,,H,10193,BAO_0000357,CHEMBL618102,55,,Autocuration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,10141.0
4056,,,,Cavia porcellus,,B,,,H,13243,BAO_0000357,CHEMBL618103,55,,Autocuration,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,10141.0
4057,,,,Cavia porcellus,,B,,,H,13243,BAO_0000357,CHEMBL618104,55,,Autocuration,Inhibitory activity uM,,10141.0
4058,,,,Cavia porcellus,,B,,,H,969,BAO_0000219,CHEMBL883712,55,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,10141.0
4059,,,,Cavia porcellus,,B,,,H,10001,BAO_0000357,CHEMBL618105,55,,Autocuration,Inhibitory activity against 5-lipoxygenase at 10 uM,,10141.0
4060,,,,Cavia porcellus,,B,,,H,7788,BAO_0000357,CHEMBL618106,55,,Autocuration,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,10141.0
4061,,,,Cavia porcellus,,B,,,H,10001,BAO_0000357,CHEMBL618107,55,,Autocuration,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,10141.0
4062,,,,Cavia porcellus,,B,,,H,10193,BAO_0000357,CHEMBL618108,55,,Autocuration,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10141.0
4063,,,,Cavia porcellus,,B,,,H,13243,BAO_0000357,CHEMBL618109,55,,Autocuration,Inhibitory activity uM,,10141.0
4064,,,,Cavia porcellus,,B,,,H,13243,BAO_0000357,CHEMBL618110,55,,Autocuration,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,10141.0
4065,,,,Cavia porcellus,,B,,,H,13243,BAO_0000357,CHEMBL618111,55,,Expert,Inhibitory activity uM,,10141.0
4066,,,,Cavia porcellus,,F,,,H,13243,BAO_0000019,CHEMBL618112,55,,Autocuration,Inhibitory activity uM,,10141.0
4067,,,,Cavia porcellus,,B,,,H,10504,BAO_0000019,CHEMBL618113,55,,Autocuration,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10141.0
4068,,,,Cavia porcellus,,B,,,H,7788,BAO_0000357,CHEMBL618114,55,,Autocuration,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,10141.0
4069,2116.0,,Ileum,Cavia porcellus,,F,,,H,10546,BAO_0000221,CHEMBL620871,55,,Expert,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,10141.0
4070,,,,,,B,,,H,13183,BAO_0000357,CHEMBL620872,55,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4071,,,,,,B,,,H,13183,BAO_0000357,CHEMBL620873,55,,Autocuration,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4072,,,,,,B,,,H,2578,BAO_0000357,CHEMBL620874,55,,Autocuration,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,
4073,,,,,,B,,,H,12780,BAO_0000357,CHEMBL620875,55,,Expert,In vitro inhibition of human 5-Lipoxygenase.,,
4074,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620876,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,10116.0
4075,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620877,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,10116.0
4076,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL857854,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,10116.0
4077,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620878,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,10116.0
4078,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620879,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,10116.0
4079,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620880,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,10116.0
4080,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620881,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,10116.0
4081,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620882,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,10116.0
4082,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620883,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,10116.0
4083,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620884,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,10116.0
4084,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620885,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,10116.0
4085,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620886,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,10116.0
4086,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620887,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,10116.0
4087,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618039,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,10116.0
4088,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618040,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,10116.0
4089,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618041,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,10116.0
4090,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618216,22226,,Autocuration,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,10116.0
4091,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618217,22226,,Autocuration,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,10116.0
4092,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618218,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,10116.0
4093,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618219,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,10116.0
4094,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618220,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,10116.0
4095,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618221,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,10116.0
4096,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618222,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,10116.0
4097,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618223,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,10116.0
4098,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618224,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,10116.0
4099,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618225,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,10116.0
4100,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618226,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,10116.0
4101,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618227,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,10116.0
4102,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618228,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,10116.0
4103,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618229,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,10116.0
4104,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618230,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,10116.0
4105,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618231,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,10116.0
4106,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618232,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,10116.0
4107,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618233,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,10116.0
4108,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618234,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,10116.0
4109,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618235,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,10116.0
4110,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618115,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,10116.0
4111,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618116,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,10116.0
4112,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL618117,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,10116.0
4113,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619968,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,10116.0
4114,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619969,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,10116.0
4115,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619970,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,10116.0
4116,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619971,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,10116.0
4117,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619972,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,10116.0
4118,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619973,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,10116.0
4119,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619974,22226,,Autocuration,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,10116.0
4120,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619975,22226,,Autocuration,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,10116.0
4121,,,,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619976,22226,,Autocuration,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,10116.0
4122,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619977,22226,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,10116.0
4123,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619978,22226,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,10116.0
4124,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619979,22226,,Autocuration,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,10116.0
4125,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619980,22226,,Autocuration,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,10116.0
4126,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619981,22226,,Autocuration,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,10116.0
4127,,RPMI-8226,,Homo sapiens,,F,,741.0,N,10797,BAO_0000219,CHEMBL619982,80433,,Intermediate,In vitro inhibition of 7226/S myeloma cancer cell line,,9606.0
4128,,BEL-7404 tumor cell line,,Homo sapiens,,F,,993.0,N,6881,BAO_0000219,CHEMBL619983,80698,,Intermediate,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,9606.0
4129,,786-0,,Homo sapiens,,F,,391.0,N,3838,BAO_0000219,CHEMBL620031,80640,,Intermediate,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,9606.0
4130,,786-0,,Homo sapiens,,F,,391.0,N,3838,BAO_0000219,CHEMBL620032,80640,,Intermediate,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,9606.0
4131,,V79,,Cricetulus griseus,,F,,505.0,N,12981,BAO_0000219,CHEMBL620033,81264,,Expert,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,10029.0
4132,,V79,,Cricetulus griseus,,F,,505.0,N,12981,BAO_0000219,CHEMBL620034,81264,,Expert,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,10029.0
4133,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL620035,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,10116.0
4134,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL618318,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,10116.0
4135,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL618319,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,10116.0
4136,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL618320,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,10116.0
4137,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL618321,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,10116.0
4138,,7800C1 cell line,,Rattus norvegicus,,F,,1119.0,N,7653,BAO_0000219,CHEMBL883118,80635,,Intermediate,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,10116.0
4139,,786-0,,Homo sapiens,,F,,391.0,N,17229,BAO_0000219,CHEMBL883795,80640,,Intermediate,In vitro antitumor activity against renal 786-0 tumor cell lines,,9606.0
4140,,786-0,,Homo sapiens,,F,,391.0,N,12858,BAO_0000219,CHEMBL618322,80640,,Intermediate,Cytotoxic activity against 786-0 Renal cancer cell line,,9606.0
4141,,786-0,,Homo sapiens,,F,,391.0,N,16325,BAO_0000219,CHEMBL618323,80640,,Intermediate,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,9606.0
4142,,786-0,,Homo sapiens,,F,,391.0,N,16325,BAO_0000219,CHEMBL618324,80640,,Intermediate,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,9606.0
4143,,786-0,,Homo sapiens,,F,,391.0,N,5858,BAO_0000219,CHEMBL618325,80640,,Intermediate,In vitro antitumor activity against human renal 786-0 cell line,,9606.0
4144,,786-0,,Homo sapiens,,F,,391.0,N,16325,BAO_0000219,CHEMBL875416,80640,,Intermediate,Inhibition of Renal cancer in 786-0 cancer cell lines,,9606.0
4145,,786-0,,Homo sapiens,,F,,391.0,N,14696,BAO_0000219,CHEMBL618326,80640,,Intermediate,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,9606.0
4146,,786-0,,Homo sapiens,,F,,391.0,N,3786,BAO_0000219,CHEMBL618327,80640,,Intermediate,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,9606.0
4147,,786-0,,Homo sapiens,,F,,391.0,N,14696,BAO_0000219,CHEMBL619215,80640,,Intermediate,inhibition of the growth of renal cancer(786-0) cell line,,9606.0
4148,,786-0,,Homo sapiens,,F,,391.0,N,14769,BAO_0000219,CHEMBL619216,80640,,Intermediate,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,9606.0
4149,,786-0,,Homo sapiens,,F,,391.0,N,15354,BAO_0000219,CHEMBL619217,80640,,Intermediate,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,9606.0
4150,,786-0,,Homo sapiens,,F,,391.0,N,14255,BAO_0000219,CHEMBL619218,80640,,Intermediate,The IC50 value was measured on 786-0 cell line in ovarian tumor,,9606.0
4151,,786-0,,Homo sapiens,,F,,391.0,N,14255,BAO_0000219,CHEMBL619219,80640,,Intermediate,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,9606.0
4152,,786-0,,Homo sapiens,,F,,391.0,N,14255,BAO_0000219,CHEMBL619220,80640,,Intermediate,The IC50 value was measured on 786-0 cell line in renal tumor type.,,9606.0
4153,,786-0,,Homo sapiens,,F,,391.0,N,14696,BAO_0000219,CHEMBL619221,80640,,Intermediate,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,9606.0
4154,,786-0,,Homo sapiens,,F,,391.0,N,12016,BAO_0000219,CHEMBL619222,80640,,Intermediate,Tested for cytotoxic activity against renal cancer 786-0 cell line,,9606.0
4155,,786-0,,Homo sapiens,,F,,391.0,N,2597,BAO_0000219,CHEMBL857454,80640,,Intermediate,Compound was tested for growth inhibitory activity against 786-0 cell line,,9606.0
4156,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL619223,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,
4157,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL619224,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,
4158,,,,,,B,,,H,14799,BAO_0000019,CHEMBL619225,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,
4159,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL619226,12166,,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
4160,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL619227,12166,,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
4161,,,,,,B,,,H,12767,BAO_0000357,CHEMBL619228,12166,,Autocuration,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,
4162,,,,,,B,,,H,10997,BAO_0000219,CHEMBL619229,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,
4163,,RBL-1,,,,B,,702.0,H,11388,BAO_0000219,CHEMBL619230,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,
4164,,,,,,B,,,H,167,BAO_0000357,CHEMBL619231,12166,,Autocuration,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,
4165,,,,,,B,,,H,167,BAO_0000357,CHEMBL619232,12166,,Autocuration,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,
4166,,,,,,B,,,H,13744,BAO_0000357,CHEMBL619233,12166,,Expert,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,
4167,,,,,,B,,,H,1630,BAO_0000357,CHEMBL619234,12166,,Autocuration,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,
4168,,,,,,B,,,H,1630,BAO_0000357,CHEMBL619235,12166,,Autocuration,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,
4169,,,,Rattus norvegicus,,B,,,D,969,BAO_0000019,CHEMBL619236,12166,,Expert,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,10116.0
4170,,RBL-1,,,,B,,702.0,H,13621,BAO_0000219,CHEMBL619237,12166,,Autocuration,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,
4171,,,,,,B,,,H,10089,BAO_0000357,CHEMBL619238,12166,,Autocuration,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,
4172,,,,,,B,,,H,10193,BAO_0000357,CHEMBL619239,12166,,Expert,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,
4173,,,,,,B,,,H,11966,BAO_0000357,CHEMBL619240,12166,,Autocuration,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,
4174,,,,,,B,,,H,12251,BAO_0000019,CHEMBL875417,12166,,Autocuration,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4175,,RBL-1,,,,B,,702.0,H,211,BAO_0000219,CHEMBL619241,12166,,Autocuration,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,
4176,,,,,,F,,,H,12251,BAO_0000019,CHEMBL619242,12166,,Expert,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4177,,RBL-1,,,,B,,702.0,H,12495,BAO_0000219,CHEMBL883796,12166,,Autocuration,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,
4178,,,,,,B,,,H,414,BAO_0000357,CHEMBL619243,12166,,Autocuration,Tested for its inhibitory activity against 5-lipoxygenase,,
4179,,,,,,B,,,H,414,BAO_0000357,CHEMBL619244,12166,,Autocuration,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,
4180,,,,,,B,,,H,10325,BAO_0000019,CHEMBL619245,12166,,Expert,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,
4181,,,,,,B,,,H,11966,BAO_0000019,CHEMBL619246,12166,,Expert,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4182,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL619984,12166,,Expert,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4183,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL619985,12166,,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,
4184,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL619986,12166,,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4185,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL619987,12166,,Expert,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4186,,,,,,B,,,H,11311,BAO_0000218,CHEMBL619988,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,
4187,,RBL-1,,,,B,,702.0,H,11311,BAO_0000219,CHEMBL619989,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,
4188,,RBL-1,,,,B,,702.0,H,11311,BAO_0000219,CHEMBL619990,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,
4189,,,,,,B,,,H,11311,BAO_0000219,CHEMBL619991,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
4190,,,,,,B,,,H,11311,BAO_0000219,CHEMBL619992,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,
4191,,,,,,B,,,H,11311,BAO_0000218,CHEMBL619993,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,
4192,,RBL-2H3,,,,F,,663.0,H,11311,BAO_0000219,CHEMBL619994,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,
4193,,RBL-2H3,,,,F,,663.0,H,11311,BAO_0000219,CHEMBL619995,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,
4194,,,,,,B,,,H,11311,BAO_0000019,CHEMBL619996,12166,,Autocuration,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,
4195,,,,,,B,,,H,11732,BAO_0000019,CHEMBL619997,12166,,Autocuration,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,
4196,,,,,,B,,,H,11732,BAO_0000019,CHEMBL619998,12166,,Expert,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,
4197,,,,,,B,,,H,11087,BAO_0000019,CHEMBL619999,12166,,Expert,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,
4198,,,,,,B,,,H,11087,BAO_0000019,CHEMBL620000,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,
4199,,RBL-1,,,,B,,702.0,H,11087,BAO_0000219,CHEMBL620001,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,
4200,,,,Rattus norvegicus,,B,,,D,11087,BAO_0000357,CHEMBL620002,12166,,Expert,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,10116.0
4201,,RBL-1,,,,B,,702.0,H,496,BAO_0000219,CHEMBL620003,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,
4202,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620004,12166,,Expert,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,
4203,,,,,,B,,,H,11520,BAO_0000357,CHEMBL874063,12166,,Autocuration,Compound was evaluated for the inhibition of 5-lipoxygenase,,
4204,,RBL-1,,,,B,,702.0,H,10293,BAO_0000219,CHEMBL620005,12166,,Autocuration,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,
4205,,RBL-1,,,,B,,702.0,H,303,BAO_0000219,CHEMBL620006,12166,,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,
4206,,RBL-1,,,,B,,702.0,H,303,BAO_0000219,CHEMBL620007,12166,,Autocuration,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,
4207,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620008,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,
4208,,RBL-1,,Rattus norvegicus,,B,,702.0,D,9247,BAO_0000219,CHEMBL620009,12166,,Expert,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,10116.0
4209,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620010,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
4210,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620011,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,
4211,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620677,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,
4212,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620678,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,
4213,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620679,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,
4214,,RBL-1,,,,B,,702.0,H,9247,BAO_0000219,CHEMBL620680,12166,,Autocuration,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,
4215,,,,Rattus norvegicus,,B,,,D,11481,BAO_0000357,CHEMBL620838,12166,,Expert,Inhibitory activity against 5-lipoxygenase at 10 uM,,10116.0
4216,,,,,,B,,,H,105,BAO_0000357,CHEMBL620839,12166,,Autocuration,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,
4217,,,,,,B,,,H,9029,BAO_0000357,CHEMBL620840,12166,,Expert,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,
4218,,RBL-1,,,,B,,702.0,H,1175,BAO_0000219,CHEMBL620841,12166,,Expert,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,
4219,,RBL-1,,,,B,,702.0,H,12118,BAO_0000219,CHEMBL620842,12166,,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,
4220,,RBL-1,,,,B,,702.0,H,12118,BAO_0000219,CHEMBL620843,12166,,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,
4221,,RBL-1,,,,B,,702.0,H,12118,BAO_0000219,CHEMBL620844,12166,,Autocuration,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,
4222,,RBL-1,,,,B,,702.0,H,9225,BAO_0000219,CHEMBL620845,12166,,Autocuration,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,
4223,,,,,,B,,,H,9401,BAO_0000019,CHEMBL620846,12166,,Autocuration,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,
4224,,,,,,B,,,H,137,BAO_0000357,CHEMBL873951,12166,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4225,,,,,,B,,,H,137,BAO_0000357,CHEMBL620847,12166,,Autocuration,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4226,,RBL-1,,,,B,,702.0,H,4717,BAO_0000219,CHEMBL620848,12166,,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4227,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL620849,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4228,,RBL-1,,,,B,,702.0,H,10501,BAO_0000219,CHEMBL620850,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,
4229,,RBL-1,,,,B,,702.0,H,10501,BAO_0000219,CHEMBL620851,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,
4230,,RBL-1,,,,B,,702.0,H,10501,BAO_0000219,CHEMBL620852,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,
4231,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL875098,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4232,,RBL-1,,Rattus norvegicus,,B,,702.0,D,14799,BAO_0000219,CHEMBL620853,12166,,Expert,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,10116.0
4233,,,,,,B,,,H,14799,BAO_0000019,CHEMBL620854,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,
4234,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL620855,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4235,,RBL-1,,,,B,,702.0,H,3595,BAO_0000219,CHEMBL839884,12166,,Expert,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
4236,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL620856,12166,,Autocuration,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4237,,RBL-1,,,,B,,702.0,H,12526,BAO_0000219,CHEMBL620857,12166,,Autocuration,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4238,,,,,,B,,,H,10193,BAO_0000019,CHEMBL620858,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4239,,,,,,B,,,H,10193,BAO_0000019,CHEMBL620859,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4240,,,,,,B,,,H,10193,BAO_0000019,CHEMBL620860,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4241,,,,,,B,,,H,10193,BAO_0000019,CHEMBL620861,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,
4242,,,,,,B,,,H,9138,BAO_0000357,CHEMBL620862,12166,,Expert,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,
4243,,,,,,B,,,H,9138,BAO_0000357,CHEMBL620863,12166,,Autocuration,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,
4244,,,,,,B,,,H,11966,BAO_0000019,CHEMBL620864,12166,,Autocuration,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4245,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL620865,12166,,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,
4246,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL620866,12166,,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,
4247,,RBL-2H3,,,,B,,663.0,H,11311,BAO_0000219,CHEMBL620867,12166,,Autocuration,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,
4248,,RBL-2H3,,,,B,,663.0,H,11311,BAO_0000219,CHEMBL620868,12166,,Autocuration,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4249,,RBL-2H3,,,,F,,663.0,H,11311,BAO_0000219,CHEMBL620869,12166,,Autocuration,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4250,,,,,,F,,,H,11311,BAO_0000019,CHEMBL873952,12166,,Autocuration,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,
4251,,,,,,B,,,H,11311,BAO_0000357,CHEMBL875099,12166,,Autocuration,The compound was tested for inhibition of isolated 5-lipoxygenase,,
4252,,RBL-2H3,,,,F,,663.0,H,11311,BAO_0000219,CHEMBL620870,12166,,Autocuration,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,
4253,,,,,,B,,,H,11087,BAO_0000019,CHEMBL618261,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,
4254,,,,,,B,,,H,11087,BAO_0000019,CHEMBL618262,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,
4255,,,,,,B,,,H,11087,BAO_0000019,CHEMBL619428,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,
4256,,,,,,B,,,H,11087,BAO_0000019,CHEMBL619429,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4257,,,,,,B,,,H,11087,BAO_0000019,CHEMBL619430,12166,,Autocuration,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4258,,RBL-1,,,,B,,702.0,H,496,BAO_0000219,CHEMBL620017,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,
4259,,RBL-1,,,,B,,702.0,H,496,BAO_0000219,CHEMBL620018,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,
4260,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620019,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,
4261,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620020,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,
4262,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620021,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,
4263,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620022,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,
4264,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620023,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,
4265,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620024,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,
4266,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620025,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,
4267,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620026,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,
4268,,RBL-1,,,,F,,702.0,H,13986,BAO_0000219,CHEMBL620027,12166,,Autocuration,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,
4269,,,,Rattus norvegicus,,F,,,D,13986,BAO_0000019,CHEMBL620028,12166,,Expert,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,10116.0
4270,,,,,,B,,,H,10193,BAO_0000357,CHEMBL620029,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,
4271,,,,,,B,,,H,9295,BAO_0000357,CHEMBL620030,12166,,Autocuration,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,
4272,,RBL-1,,,,B,,702.0,H,4717,BAO_0000219,CHEMBL875415,12166,,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,
4273,,RBL-1,,,,B,,702.0,H,4717,BAO_0000219,CHEMBL618256,12166,,Autocuration,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4274,,RBL-1,,,,B,,702.0,H,11854,BAO_0000219,CHEMBL618257,12166,,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,
4275,,RBL-1,,,,B,,702.0,H,11854,BAO_0000219,CHEMBL618258,12166,,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,
4276,,RBL-1,,,,B,,702.0,H,11854,BAO_0000219,CHEMBL618259,12166,,Autocuration,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,
4277,,,,,,B,,,H,10193,BAO_0000019,CHEMBL618260,12166,,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4278,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL618215,12166,,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,
4279,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL618390,12166,,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,
4280,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL618391,12166,,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,
4281,,RBL-1,,,,B,,702.0,H,9295,BAO_0000219,CHEMBL618392,12166,,Autocuration,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,
4282,,RBL-1,,,,B,,702.0,H,165,BAO_0000219,CHEMBL618393,12166,,Autocuration,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,
4283,,,,,,B,,,H,11311,BAO_0000219,CHEMBL618394,12166,,Autocuration,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,
4284,,RBL-1,,Homo sapiens,,B,,702.0,H,10489,BAO_0000219,CHEMBL618395,12166,,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,9606.0
4285,,RBL-1,,Rattus norvegicus,,B,,702.0,D,10489,BAO_0000219,CHEMBL618396,12166,,Expert,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,10116.0
4286,,RBL-1,,Rattus norvegicus,,B,,702.0,D,10489,BAO_0000219,CHEMBL858253,12166,,Expert,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,10116.0
4287,,,,Rattus norvegicus,,B,,,D,14799,BAO_0000019,CHEMBL618397,12166,,Autocuration,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,10116.0
4288,,,,Glycine max,,B,,,H,9295,BAO_0000357,CHEMBL618398,12054,,Autocuration,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,3847.0
4289,,,,,,B,,,U,16811,BAO_0000019,CHEMBL618399,22226,,Autocuration,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,
4290,,,,,,B,,,H,168,BAO_0000357,CHEMBL618400,55,,Expert,In vitro inhibition of 5-Lipoxygenase; Inactive.,,
4291,,,,,,B,,,H,6309,BAO_0000357,CHEMBL618401,55,,Autocuration,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,
4292,,,,,,B,,,H,6309,BAO_0000357,CHEMBL618402,55,,Autocuration,Inhibitory concentration against 5-lipoxygenase; No inhibition,,
4293,,RBL-1,,,,B,,702.0,H,3092,BAO_0000219,CHEMBL876400,55,,Autocuration,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,
4294,,,,,,B,,,H,168,BAO_0000357,CHEMBL618403,55,,Expert,Inhibitory activity against 5-lipoxygenase.,,
4295,,,,,,B,,,H,168,BAO_0000357,CHEMBL618404,55,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,
4296,,,,,,B,,,H,168,BAO_0000357,CHEMBL618405,55,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,
4297,,,,,,B,,,H,168,BAO_0000357,CHEMBL618406,55,,Autocuration,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,
4298,,,,,,F,,,H,12338,BAO_0000019,CHEMBL618407,55,,Expert,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,
4299,,,,,,B,,,H,4501,BAO_0000357,CHEMBL618408,55,,Autocuration,Tested for the inhibitory activity against 5-lipoxygenase,,
4300,,,,,,B,,,H,1132,BAO_0000357,CHEMBL618409,55,,Autocuration,Compound was tested for its inhibitory activity against 5-lipoxygenase,,
4301,,,,,,B,,,H,2117,BAO_0000357,CHEMBL618410,55,,Autocuration,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,
4302,,,,,,B,,,H,168,BAO_0000357,CHEMBL618411,55,,Autocuration,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,
4303,,,,,,B,,,H,168,BAO_0000357,CHEMBL618412,55,,Autocuration,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,
4304,,RBL-1,,,,B,,702.0,H,13575,BAO_0000219,CHEMBL618413,12166,,Autocuration,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,
4305,,,,,,B,,,H,11089,BAO_0000357,CHEMBL618414,12166,,Autocuration,,,
4306,,,,,,B,,,H,216,BAO_0000357,CHEMBL618415,10102,,Autocuration,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,
4307,,,,,,B,,,H,13165,BAO_0000019,CHEMBL618416,10102,,Autocuration,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,
4308,,,,,,B,,,H,3278,BAO_0000357,CHEMBL876401,10102,,Autocuration,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,
4309,,,,,,B,,,H,3278,BAO_0000357,CHEMBL618417,10102,,Expert,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,
4310,,,,,,B,,,H,11966,BAO_0000357,CHEMBL618418,10102,,Autocuration,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,
4311,,,,,,B,,,H,175,BAO_0000357,CHEMBL618419,10102,,Autocuration,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,
4312,,,,,,B,,,H,175,BAO_0000357,CHEMBL618420,10102,,Autocuration,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,
4313,,,,,,B,,,H,13449,BAO_0000357,CHEMBL618421,10102,,Autocuration,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,
4314,,,,,,B,,,H,12014,BAO_0000019,CHEMBL618422,11238,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,
4315,,,,,,B,,,H,12014,BAO_0000019,CHEMBL618423,11238,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,
4316,,,,,,B,,,H,12014,BAO_0000019,CHEMBL618424,11238,,Autocuration,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,
4317,,,,,,B,,,S,99,BAO_0000220,CHEMBL618425,100284,,Intermediate,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,
4318,,,,Homo sapiens,,F,,,U,4349,BAO_0000019,CHEMBL618426,22226,,Autocuration,The dark toxicity against 543 human galactophore carcinoma cells,,9606.0
4319,,Panel (56 tumour cell lines),,Homo sapiens,,F,,390.0,N,4071,BAO_0000219,CHEMBL618427,80623,,Expert,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,9606.0
4320,,5637,,Homo sapiens,,F,,345.0,N,17589,BAO_0000219,CHEMBL618428,80008,,Expert,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,9606.0
4321,,5637,,Homo sapiens,,F,,345.0,N,15002,BAO_0000219,CHEMBL618429,80008,,Intermediate,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,9606.0
4322,,5637,,Homo sapiens,,F,,345.0,N,13958,BAO_0000219,CHEMBL618430,80008,,Intermediate,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,9606.0
4323,,5637,,Homo sapiens,,F,,345.0,N,17589,BAO_0000219,CHEMBL618431,80008,,Expert,Growth inhibition against human 5637 cell lines,,9606.0
4324,,5637,,Homo sapiens,,F,,345.0,N,16748,BAO_0000219,CHEMBL883799,80008,,Expert,Antitumor activity against human bladder carcinoma 5637 cells.,,9606.0
4325,,5637,,Homo sapiens,,F,,345.0,N,16747,BAO_0000219,CHEMBL618432,80008,,Intermediate,Antitumor activity against human bladder carcinoma 5637 cells,,9606.0
4326,,5637,,Homo sapiens,,F,,345.0,N,16747,BAO_0000219,CHEMBL618433,80008,,Intermediate,Antitumor activity against human bladder carcinoma 5637 cells,,9606.0
4327,,,,Bos taurus,,B,,,D,15285,BAO_0000357,CHEMBL618434,10443,,Expert,In vitro inhibition of bovine trypsin(Trp).,,9913.0
4328,,CV-1,,Cercopithecidae,,B,,407.0,H,3726,BAO_0000219,CHEMBL618435,240,,Expert,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,9527.0
4329,,,,,,B,,,H,5033,BAO_0000357,CHEMBL876402,10577,,Autocuration,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,
4330,,,,,,F,,,H,11756,BAO_0000019,CHEMBL618436,104698,,Autocuration,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,
4331,,,,,,F,,,U,11953,BAO_0000218,CHEMBL618437,22226,,Autocuration,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,
4332,,,,Cavia porcellus,,B,,,D,5033,BAO_0000357,CHEMBL618438,20033,,Intermediate,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,10141.0
4333,,,,Rattus norvegicus,,A,Microsomes,,H,11347,BAO_0000251,CHEMBL883800,17045,,Expert,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,10116.0
4334,,,,Rattus norvegicus,,A,Microsomes,,H,11347,BAO_0000251,CHEMBL618439,17045,,Expert,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,10116.0
4335,,,,,,F,,,U,1229,BAO_0000019,CHEMBL618440,22226,,Intermediate,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4336,,,,,,F,,,U,1229,BAO_0000019,CHEMBL618441,22226,,Intermediate,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4337,,,,Trypanosoma brucei,,B,,,H,17588,BAO_0000019,CHEMBL618442,11938,,Expert,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,5691.0
4338,,,,Trypanosoma brucei,,B,,,H,17588,BAO_0000019,CHEMBL618443,11938,,Autocuration,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,5691.0
4339,,,,Ovis aries,,B,,,H,17588,BAO_0000019,CHEMBL619158,11938,,Expert,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,9940.0
4340,,,,Ovis aries,,B,,,H,17588,BAO_0000019,CHEMBL620974,11938,,Autocuration,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,9940.0
4341,,,,,,B,,,H,16485,BAO_0000357,CHEMBL620975,11938,,Autocuration,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,
4342,,,,Homo sapiens,,F,,,U,4337,BAO_0000019,CHEMBL620976,22226,,Intermediate,Average inhibitory concentration against 60 human cell lines was reported,,9606.0
4343,,,,Homo sapiens,,F,,,U,4112,BAO_0000019,CHEMBL620977,22226,,Expert,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,9606.0
4344,,Panel NCI-60 (60 carcinoma cell lines),,Homo sapiens,,F,,542.0,N,16160,BAO_0000219,CHEMBL620978,80315,,Intermediate,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,9606.0
4345,,Panel NCI-60 (60 carcinoma cell lines),,Homo sapiens,,F,,542.0,N,16160,BAO_0000219,CHEMBL620979,80315,,Intermediate,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,9606.0
4346,,Panel NCI-60 (60 carcinoma cell lines),,,,F,,542.0,N,17376,BAO_0000219,CHEMBL620980,80315,,Expert,In vitro mean growth inhibitory activity against 60-cell panel,,
4347,,Panel NCI-60 (60 carcinoma cell lines),,,,F,,542.0,N,17376,BAO_0000219,CHEMBL620981,80315,,Expert,In vitro mean growth lethal concentration against 60-cell panel,,
4348,,Panel NCI-60 (60 carcinoma cell lines),,,,F,,542.0,N,17376,BAO_0000219,CHEMBL620982,80315,,Expert,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,
4349,,Panel NCI-60 (60 carcinoma cell lines),,,,F,,542.0,N,17376,BAO_0000219,CHEMBL620983,80315,,Expert,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,
4350,,,,,,F,,,H,3241,BAO_0000019,CHEMBL620984,104775,,Autocuration,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4351,,,,,,F,,,H,3241,BAO_0000019,CHEMBL620985,104775,,Autocuration,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4352,,,,,,B,,,H,3725,BAO_0000357,CHEMBL620986,275,,Expert,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,
4353,,,,Plasmodium falciparum,,F,,,N,10805,BAO_0000218,CHEMBL620987,50425,,Expert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,5833.0
4354,,,,Plasmodium falciparum,,F,,,N,10805,BAO_0000218,CHEMBL620988,50425,,Expert,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,5833.0
4355,,,,Plasmodium falciparum,,F,,,N,10805,BAO_0000218,CHEMBL620989,50425,,Expert,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,5833.0
4356,,,,Plasmodium falciparum,,F,,,N,10805,BAO_0000218,CHEMBL620990,50425,,Expert,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,5833.0
4357,,,,Plasmodium falciparum,,F,,,N,10805,BAO_0000218,CHEMBL620991,50425,,Intermediate,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,5833.0
4358,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL620992,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10090.0
4359,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL620993,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10090.0
4360,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL620994,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,10090.0
4361,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL620995,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10090.0
4362,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL620996,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10090.0
4363,,6C3HED,,Mus musculus,,F,,850.0,N,10144,BAO_0000218,CHEMBL875581,80628,,Intermediate,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,10090.0
4364,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL620997,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,10090.0
4365,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL620998,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,10090.0
4366,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL620999,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,10090.0
4367,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621000,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,10090.0
4368,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621001,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,10090.0
4369,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621002,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,10090.0
4370,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621003,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,10090.0
4371,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621004,22224,,Autocuration,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,10090.0
4372,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621005,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,10090.0
4373,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621006,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,10090.0
4374,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL621007,22224,,Autocuration,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,10090.0
4375,,,,Mus musculus,,F,,,U,10144,BAO_0000218,CHEMBL621008,22224,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10090.0
4376,,,,Mus musculus,,F,,,U,10144,BAO_0000218,CHEMBL621009,22224,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10090.0
4377,,,,Mus musculus,,F,,,U,10144,BAO_0000218,CHEMBL857705,22224,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10090.0
4378,,,,Mus musculus,,F,,,U,10144,BAO_0000218,CHEMBL619828,22224,,Autocuration,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10090.0
4379,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL619829,22224,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,10090.0
4380,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL619830,22224,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,10090.0
4381,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL619831,22224,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,10090.0
4382,,,,Mus musculus,,F,,,U,10685,BAO_0000218,CHEMBL619832,22224,,Autocuration,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,10090.0
4383,,,,Mus musculus,,A,,,U,10685,BAO_0000218,CHEMBL619833,22224,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,10090.0
4384,,,,Mus musculus,,A,,,U,10685,BAO_0000218,CHEMBL619834,22224,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,10090.0
4385,,,,Mus musculus,,A,,,U,10685,BAO_0000218,CHEMBL619835,22224,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,10090.0
4386,,,,Mus musculus,,A,,,U,10685,BAO_0000218,CHEMBL619836,22224,,Autocuration,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,10090.0
4387,,6C3HED,,Mus musculus,,F,,850.0,N,8831,BAO_0000218,CHEMBL619837,80628,,Intermediate,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,10090.0
4388,,,,,,F,,,U,11704,BAO_0000218,CHEMBL619838,22224,,Autocuration,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,
4389,,,,Mus musculus,,A,,,N,11704,BAO_0000218,CHEMBL619839,50594,,Intermediate,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,10090.0
4390,,6C3HED,,Mus musculus,,F,,850.0,N,10685,BAO_0000218,CHEMBL619840,80628,,Intermediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,10090.0
4391,,6C3HED,,Mus musculus,,F,,850.0,N,10685,BAO_0000218,CHEMBL619841,80628,,Intermediate,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,10090.0
4392,,6C3HED,,Mus musculus,,F,,850.0,N,11368,BAO_0000218,CHEMBL857704,80628,,Expert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,10090.0
4393,,6C3HED,,Mus musculus,,F,,850.0,N,11368,BAO_0000218,CHEMBL619842,80628,,Intermediate,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,10090.0
4394,,6C3HED,,Mus musculus,,F,,850.0,N,11368,BAO_0000218,CHEMBL619843,80628,,Expert,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,10090.0
4395,,,,Staphylococcus aureus,,B,,,U,17763,BAO_0000019,CHEMBL619844,22226,,Autocuration,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,1280.0
4396,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL857855,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,10116.0
4397,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619845,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,10116.0
4398,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619846,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,10116.0
4399,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619847,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,10116.0
4400,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL619848,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,10116.0
4401,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620893,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,10116.0
4402,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620894,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,10116.0
4403,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620895,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,10116.0
4404,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620896,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,10116.0
4405,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620897,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,10116.0
4406,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620898,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,10116.0
4407,2107.0,,Liver,Rattus norvegicus,,B,Microsomes,,U,7411,BAO_0000251,CHEMBL620899,22226,,Autocuration,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,10116.0
4408,1969.0,,Plasma,Cercopithecidae,,A,,,U,347,BAO_0000218,CHEMBL620900,22224,,Autocuration,The apparent total plasma clearance in monkey,In vivo,9527.0
4409,,,,Cercopithecidae,,A,,,U,3341,BAO_0000218,CHEMBL620901,22224,,Autocuration,Compound was evaluated for Hepatic clearance in monkey,In vivo,9527.0
4410,,,,Cercopithecidae,,A,,,U,17853,BAO_0000218,CHEMBL620902,22224,,Autocuration,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,9527.0
4411,,,,Cercopithecidae,,A,,,U,4514,BAO_0000218,CHEMBL620903,22224,,Autocuration,Plasma clearance in rhesus monkey,In vivo,9527.0
4412,,,,Cercopithecidae,,A,,,U,6062,BAO_0000218,CHEMBL620904,22224,,Autocuration,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,9527.0
4413,,,,Cercopithecidae,,A,,,U,6821,BAO_0000218,CHEMBL620905,22224,,Autocuration,Plasma clearance of compound was determined in monkey,In vivo,9527.0
4414,,,,Cercopithecidae,,A,,,U,6057,BAO_0000218,CHEMBL620906,22224,,Autocuration,Plasma clearance was calculated in rhesus monkey,In vivo,9527.0
4415,,,,Cercopithecidae,,A,,,U,5145,BAO_0000218,CHEMBL875420,22224,,Autocuration,Plasma clearance in rhesus monkey,In vivo,9527.0
4416,,,,Cercopithecidae,,A,,,U,6641,BAO_0000218,CHEMBL620907,22224,,Autocuration,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9527.0
4417,,,,Cercopithecidae,,A,,,U,5472,BAO_0000218,CHEMBL620908,22224,,Autocuration,Plasma clearance was evaluated in rhesus,In vivo,9527.0
4418,,,,Cercopithecidae,,A,,,U,4257,BAO_0000218,CHEMBL620909,22224,,Autocuration,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,9527.0
4419,,,,Cercopithecidae,,A,,,U,5546,BAO_0000218,CHEMBL620910,22224,,Autocuration,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,9527.0
4420,,,,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL620911,22224,,Autocuration,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,9527.0
4421,,,,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL620912,22224,,Autocuration,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,9527.0
4422,,,,Cercopithecidae,,A,,,U,17509,BAO_0000218,CHEMBL620913,22224,,Autocuration,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,9527.0
4423,,,,Cercopithecidae,,A,,,U,6535,BAO_0000218,CHEMBL620914,22224,,Autocuration,Cmax in monkey after administration of 1 mg/kg iv,In vivo,9527.0
4424,,,,Cercopithecidae,,A,,,U,5668,BAO_0000218,CHEMBL620915,22224,,Autocuration,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,9527.0
4425,,,,Cercopithecidae,,A,,,U,5922,BAO_0000218,CHEMBL620916,22224,,Autocuration,Cmax in cynomolgus monkey by iv administration,In vivo,9527.0
4426,,,,Cercopithecidae,,A,,,U,5922,BAO_0000218,CHEMBL620917,22224,,Autocuration,Cmax in cynomolgus monkey by po administration,In vivo,9527.0
4427,,,,Cercopithecidae,,A,,,U,6078,BAO_0000218,CHEMBL620918,22224,,Autocuration,Cmax value evaluated in monkey,In vivo,9527.0
4428,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL620919,22224,,Autocuration,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,9527.0
4429,1969.0,,Plasma,Cercopithecidae,,A,,,U,3249,BAO_0000218,CHEMBL620920,22224,,Autocuration,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,9527.0
4430,1969.0,,Plasma,Cercopithecidae,,A,,,U,3249,BAO_0000218,CHEMBL620921,22224,,Autocuration,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,9527.0
4431,1969.0,,Plasma,Cercopithecidae,,A,,,U,5553,BAO_0000218,CHEMBL620922,22224,,Autocuration,Maximal plasma concentration in squirrel monkeys,In vivo,9527.0
4432,,,,Cercopithecidae,,A,,,U,1916,BAO_0000218,CHEMBL620923,22224,,Autocuration,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,9527.0
4433,1969.0,,Plasma,Cercopithecidae,,A,,,U,6227,BAO_0000218,CHEMBL620924,22224,,Autocuration,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,9527.0
4434,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL620925,22224,,Autocuration,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,9527.0
4435,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620926,22224,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,9527.0
4436,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620927,22224,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,9527.0
4437,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620928,22224,,Autocuration,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,9527.0
4438,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620929,22224,,Autocuration,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,9527.0
4439,1969.0,,Plasma,Cercopithecidae,,A,,,U,6221,BAO_0000218,CHEMBL620930,22224,,Autocuration,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,9527.0
4440,,,,Cercopithecidae,,A,,,U,167,BAO_0000218,CHEMBL620931,22224,,Autocuration,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,9527.0
4441,,,,Cercopithecidae,,A,,,U,167,BAO_0000218,CHEMBL620932,22224,,Autocuration,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,9527.0
4442,,,,monkey,,A,,,U,4257,BAO_0000218,CHEMBL620933,22224,,Autocuration,Absolute bioavailability was evaluated in monkey,In vivo,9443.0
4443,,,,monkey,,A,,,U,6221,BAO_0000218,CHEMBL620934,22224,,Autocuration,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,9443.0
4444,,,,monkey,,A,,,U,17667,BAO_0000218,CHEMBL620935,22224,,Autocuration,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,9443.0
4445,,,,Macaca mulatta,,A,,,U,17267,BAO_0000218,CHEMBL620936,22224,,Autocuration,Bioavailability of compound was determined in rhesus monkey,In vivo,9544.0
4446,,,,marmosets,,A,,,U,4256,BAO_0000218,CHEMBL620937,22224,,Autocuration,Bioavailability determined after oral administration in marmoset,In vivo,38020.0
4447,,,,Macaca fascicularis,,A,,,U,4256,BAO_0000218,CHEMBL620938,22224,,Autocuration,Oral bioavailability in cynomolgus monkey,In vivo,9541.0
4448,,,,monkey,,A,,,U,17853,BAO_0000218,CHEMBL620939,22224,,Autocuration,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,9443.0
4449,,,,monkey,,A,,,U,16365,BAO_0000218,CHEMBL620940,22224,,Autocuration,Bioavailability was evaluated after oral administration in monkey,In vivo,9443.0
4450,,,,Macaca fascicularis,,A,,,U,1916,BAO_0000218,CHEMBL620941,22224,,Autocuration,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,9541.0
4451,,,,Macaca mulatta,,A,,,U,5334,BAO_0000218,CHEMBL620942,22224,,Autocuration,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,9544.0
4452,,,,Macaca mulatta,,A,,,U,5334,BAO_0000218,CHEMBL620943,22224,,Autocuration,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,9544.0
4453,,,,monkey,,A,,,U,17592,BAO_0000218,CHEMBL620944,22224,,Autocuration,Bioavailability of the compound was determined in monkey,In vivo,9443.0
4454,,,,Saimiri sciureus,,A,,,U,1399,BAO_0000218,CHEMBL620945,22224,,Autocuration,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,9521.0
4455,,,,monkey,,A,,,U,4809,BAO_0000218,CHEMBL620946,22224,,Autocuration,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,9443.0
4456,,,,monkey,,A,,,U,3341,BAO_0000218,CHEMBL620947,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4457,,,,Saimiri sciureus,,A,,,U,64,BAO_0000218,CHEMBL620948,22224,,Autocuration,Compound was tested for bioavailability in squirrel monkey,In vivo,9521.0
4458,,,,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL620949,22224,,Autocuration,Oral bioavailability in Rhesus monkey,In vivo,9544.0
4459,,,,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL620950,22224,,Autocuration,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,9544.0
4460,,,,Macaca fascicularis,,A,,,U,5237,BAO_0000218,CHEMBL620951,22224,,Autocuration,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,9541.0
4461,,,,Macaca fascicularis,,A,,,U,5237,BAO_0000218,CHEMBL620952,22224,,Autocuration,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,9541.0
4462,,,,monkey,,A,,,U,5302,BAO_0000218,CHEMBL875421,22224,,Autocuration,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,9443.0
4463,,,,monkey,,A,,,U,17667,BAO_0000218,CHEMBL620953,22224,,Autocuration,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,9443.0
4464,,,,Canis lupus familiaris,,A,,,N,6161,BAO_0000218,CHEMBL873491,50588,,Intermediate,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,9615.0
4465,,,,Canis lupus familiaris,,A,,,N,6161,BAO_0000218,CHEMBL620954,50588,,Intermediate,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,9615.0
4466,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3854,BAO_0000218,CHEMBL620955,50588,,Intermediate,Plasma half life determined,,9615.0
4467,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,993,BAO_0000218,CHEMBL618097,50588,,Intermediate,Plasma half life in dog,,9615.0
4468,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4514,BAO_0000218,CHEMBL618268,50588,,Intermediate,Plasma half-life in Beagle dogs,,9615.0
4469,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL618269,50588,,Intermediate,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,9615.0
4470,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL618270,50588,,Intermediate,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,9615.0
4471,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL618271,50588,,Intermediate,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,9615.0
4472,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL873493,50588,,Intermediate,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,9615.0
4473,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL621031,50588,,Intermediate,Tested for the half life period in dog,,9615.0
4474,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL621032,50588,,Intermediate,Tested for the half life period in dog at dosage of 10 mpk,In vivo,9615.0
4475,,,,Canis lupus familiaris,,A,,,N,3880,BAO_0000218,CHEMBL621033,50588,,Intermediate,The compound was tested for half life in dog,,9615.0
4476,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL621034,50588,,Intermediate,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,9615.0
4477,,,,Canis lupus familiaris,,A,,,N,3880,BAO_0000218,CHEMBL621035,50588,,Intermediate,The half life was determined,,9615.0
4478,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3918,BAO_0000218,CHEMBL621036,50588,,Intermediate,The plasma half-life in dogs,,9615.0
4479,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL621037,50588,,Intermediate,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,9615.0
4480,,,,Canis lupus familiaris,,A,,,N,17796,BAO_0000218,CHEMBL619812,50588,,Intermediate,Half life in dog,,9615.0
4481,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL619813,50588,,Intermediate,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,9615.0
4482,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL873335,50588,,Intermediate,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,9615.0
4483,,,,Canis lupus familiaris,,A,,,N,16456,BAO_0000218,CHEMBL619814,50588,,Intermediate,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,9615.0
4484,,,,Mustela putorius furo,,A,,,N,6113,BAO_0000218,CHEMBL619815,50506,,Expert,Cmax in ferrets after 30 mg/kg oral dose,In vivo,9669.0
4485,,,,Mustela putorius furo,,F,,,N,6113,BAO_0000218,CHEMBL619816,50506,,Expert,Emesis in ferrets at 30 mg/kg oral dose,In vivo,9669.0
4486,,,,Macaca fascicularis,,A,,,U,17796,BAO_0000218,CHEMBL619817,22224,,Autocuration,Bioavailability in cynomolgus monkey,In vivo,9541.0
4487,,,,Macaca fascicularis,,A,,,N,17796,BAO_0000218,CHEMBL619818,100710,,Intermediate,Volume of distribution in cynomolgus,In vivo,9541.0
4488,1969.0,,Plasma,Cavia porcellus,,A,,,U,5308,BAO_0000218,CHEMBL619819,22224,,Autocuration,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,10141.0
4489,,,,Cavia porcellus,,A,,,U,4877,BAO_0000218,CHEMBL619820,22224,,Autocuration,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,10141.0
4490,,,,Cavia porcellus,,A,,,U,4876,BAO_0000218,CHEMBL875419,22224,,Autocuration,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,10141.0
4491,1969.0,,Plasma,Cavia porcellus,,A,,,U,4878,BAO_0000218,CHEMBL619821,22224,,Autocuration,AUC in guinea pig after 3mg/kg oral dose,In vivo,10141.0
4492,,,,Cavia porcellus,,A,,,U,5308,BAO_0000218,CHEMBL619822,22224,,Autocuration,Bioavailability in guinea pig was tested,In vivo,10141.0
4493,,,,Cavia porcellus,,A,,,U,4877,BAO_0000218,CHEMBL619823,22224,,Autocuration,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,10141.0
4494,,,,Cavia porcellus,,A,,,U,4876,BAO_0000218,CHEMBL619824,22224,,Autocuration,Tested for the oral bioavailability of the compound,In vivo,10141.0
4495,,,,Cavia porcellus,,A,,,U,4876,BAO_0000218,CHEMBL619825,22224,,Autocuration,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,10141.0
4496,,,,Cavia porcellus,,A,,,U,5308,BAO_0000218,CHEMBL619826,22224,,Autocuration,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,10141.0
4497,2048.0,,Lung,Cavia porcellus,,A,,,U,4877,BAO_0000218,CHEMBL619827,22224,,Autocuration,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,10141.0
4498,,,,Cavia porcellus,,A,,,U,4878,BAO_0000218,CHEMBL618167,22224,,Autocuration,Cmax in guinea pig after 3mg/kg oral dose,In vivo,10141.0
4499,178.0,,Blood,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618168,22224,,Autocuration,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4500,955.0,,Brain,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618169,22224,,Autocuration,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4501,,,,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618170,22224,,Autocuration,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4502,160.0,,Intestine,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618171,22224,,Autocuration,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4503,2113.0,,Kidney,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618172,22224,,Autocuration,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4504,2107.0,,Liver,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618173,22224,,Autocuration,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4505,,,,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618174,22224,,Autocuration,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4506,2106.0,,Spleen,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL875408,22224,,Autocuration,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,10141.0
4507,,,,Cavia porcellus,,A,,,U,14465,BAO_0000218,CHEMBL839827,22224,,Autocuration,Elimination T1/2 in Guinea pig (PO dose),In vivo,10141.0
4508,,,,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL618175,22224,,Autocuration,Partition coefficient was measured as -log (counts per min ),,10141.0
4509,,,,Cavia porcellus,,A,,,U,611,BAO_0000218,CHEMBL618176,22224,,Autocuration,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,10141.0
4510,,,,Cavia porcellus,,A,,,U,611,BAO_0000218,CHEMBL618177,22224,,Autocuration,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,10141.0
4511,,,,Cavia porcellus,,A,,,U,14465,BAO_0000218,CHEMBL618178,22224,,Autocuration,Elimination T1/2 in Guinea pig (PO dose),In vivo,10141.0
4512,,,,Cavia porcellus,,A,,,U,4876,BAO_0000218,CHEMBL618179,22224,,Autocuration,"Tested for the half life period of the compound, intravenously",In vivo,10141.0
4513,,,,Cavia porcellus,,A,,,U,5689,BAO_0000019,CHEMBL873489,22224,,Autocuration,Half-life was measured,,10141.0
4514,,,,Cavia porcellus,,A,,,U,7515,BAO_0000019,CHEMBL618180,22224,,Autocuration,The time required for onset of inotropy after addition of a single dose of delta F75,,10141.0
4515,,,,Cavia porcellus,,A,,,U,17667,BAO_0000218,CHEMBL618181,22224,,Autocuration,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,10141.0
4516,,,,Cavia porcellus,,A,,,U,17667,BAO_0000218,CHEMBL618182,22224,,Autocuration,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,10141.0
4517,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL618183,22224,,Autocuration,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,10029.0
4518,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618184,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
4519,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618185,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
4520,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618186,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
4521,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618187,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
4522,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618188,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,10090.0
4523,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL875409,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
4524,,,,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618189,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
4525,178.0,,Blood,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618190,50594,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,10090.0
4526,178.0,,Blood,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618191,50594,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,10090.0
4527,178.0,,Blood,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618192,50594,,Intermediate,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,10090.0
4528,10000001.0,,Bone,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618193,50594,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,10090.0
4529,10000001.0,,Bone,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618194,50594,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,10090.0
4530,10000001.0,,Bone,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618195,50594,,Intermediate,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,10090.0
4531,955.0,,Brain,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618196,50594,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,10090.0
4532,955.0,,Brain,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618197,50594,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,10090.0
4533,955.0,,Brain,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618198,50594,,Intermediate,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,10090.0
4534,948.0,,Heart,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618199,50594,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,10090.0
4535,948.0,,Heart,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618200,50594,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,10090.0
4536,948.0,,Heart,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618201,50594,,Intermediate,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,10090.0
4537,160.0,,Intestine,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618202,50594,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,10090.0
4538,160.0,,Intestine,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618203,50594,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,10090.0
4539,160.0,,Intestine,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618204,50594,,Intermediate,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,10090.0
4540,2113.0,,Kidney,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618205,50594,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,10090.0
4541,2113.0,,Kidney,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618206,50594,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,10090.0
4542,2113.0,,Kidney,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618207,50594,,Intermediate,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,10090.0
4543,2107.0,,Liver,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618208,50594,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,10090.0
4544,2107.0,,Liver,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618932,50594,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,10090.0
4545,2107.0,,Liver,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618933,50594,,Intermediate,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,10090.0
4546,2048.0,,Lung,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618934,50594,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,10090.0
4547,2048.0,,Lung,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618935,50594,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,10090.0
4548,2048.0,,Lung,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618936,50594,,Intermediate,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,10090.0
4549,2385.0,,Muscle tissue,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618937,50594,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,10090.0
4550,2385.0,,Muscle tissue,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL618938,50594,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,10090.0
4551,2385.0,,Muscle tissue,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619104,50594,,Intermediate,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,10090.0
4552,2106.0,,Spleen,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619105,50594,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,10090.0
4553,2106.0,,Spleen,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619106,50594,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,10090.0
4554,2106.0,,Spleen,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619107,50594,,Intermediate,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,10090.0
4555,945.0,,Stomach,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL875410,50594,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,10090.0
4556,945.0,,Stomach,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619108,50594,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,10090.0
4557,945.0,,Stomach,Mus musculus,,A,,,N,3655,BAO_0000218,CHEMBL619109,50594,,Intermediate,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,10090.0
4558,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619110,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,10090.0
4559,,,,Mus musculus,,F,,,N,16597,BAO_0000218,CHEMBL619111,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,10090.0
4560,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619112,50594,,Intermediate,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
4561,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619113,50594,,Intermediate,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,10090.0
4562,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL619114,50594,,Intermediate,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,10090.0
4563,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL619115,50594,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,10090.0
4564,,A2780,,Homo sapiens,,F,,478.0,N,3830,BAO_0000219,CHEMBL619116,81034,,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,9606.0
4565,,A2780,,Homo sapiens,,F,,478.0,N,3829,BAO_0000219,CHEMBL619117,81034,,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,9606.0
4566,,A2780,,Homo sapiens,,F,,478.0,N,2040,BAO_0000219,CHEMBL619118,81034,,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell lines.,,9606.0
4567,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619119,81034,,Intermediate,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,9606.0
4568,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619120,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,9606.0
4569,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619121,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,9606.0
4570,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619122,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,9606.0
4571,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619123,81034,,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,9606.0
4572,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619124,81034,,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,9606.0
4573,,A2780,,Homo sapiens,,F,,478.0,N,2859,BAO_0000219,CHEMBL619125,81034,,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell line,,9606.0
4574,,A2780,,Homo sapiens,,F,,478.0,N,5618,BAO_0000219,CHEMBL875411,81034,,Intermediate,In vitro inhibitory activity against human tumor cell line A2780,,9606.0
4575,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619126,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,9606.0
4576,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619127,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,9606.0
4577,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619128,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,9606.0
4578,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619129,81034,,Intermediate,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,9606.0
4579,,A2780,,Homo sapiens,,F,,478.0,N,2113,BAO_0000219,CHEMBL619130,81034,,Intermediate,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,9606.0
4580,,A2780,,Homo sapiens,,F,,478.0,N,2113,BAO_0000219,CHEMBL619131,81034,,Intermediate,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,9606.0
4581,,A2780,,Homo sapiens,,F,,478.0,N,16745,BAO_0000219,CHEMBL619132,81034,,Intermediate,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,9606.0
4582,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000218,CHEMBL619133,81034,,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,9606.0
4583,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619134,81034,,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,9606.0
4584,,A2780,,Homo sapiens,,F,,478.0,N,15684,BAO_0000219,CHEMBL619135,81034,,Intermediate,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,9606.0
4585,,A2780,,Homo sapiens,,F,,478.0,N,2040,BAO_0000219,CHEMBL619136,81034,,Intermediate,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,9606.0
4586,,A2780,,Homo sapiens,,F,,478.0,N,2040,BAO_0000219,CHEMBL619137,81034,,Intermediate,Relative resistance factor in A2780 cisplatin-resistant line,,9606.0
4587,,A2780,,Homo sapiens,,F,,478.0,N,16165,BAO_0000219,CHEMBL883713,81034,,Intermediate,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,9606.0
4588,,A2780,,Homo sapiens,,F,,478.0,N,16165,BAO_0000219,CHEMBL875412,81034,,Intermediate,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,9606.0
4589,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000218,CHEMBL619138,81034,,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,9606.0
4590,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000218,CHEMBL619262,81034,,Expert,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,9606.0
4591,,A2780,,Homo sapiens,,F,,478.0,N,3992,BAO_0000219,CHEMBL619139,81034,,Intermediate,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,9606.0
4592,,A2780,,Homo sapiens,,F,,478.0,N,10553,BAO_0000219,CHEMBL619140,81034,,Intermediate,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,9606.0
4593,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619141,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,9606.0
4594,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619142,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,9606.0
4595,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619143,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,9606.0
4596,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619144,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,9606.0
4597,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619145,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,9606.0
4598,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL619146,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,9606.0
4599,,A2780,,Homo sapiens,,F,,478.0,N,15569,BAO_0000219,CHEMBL619147,81034,,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,9606.0
4600,,A2780,,Homo sapiens,,F,,478.0,N,17420,BAO_0000219,CHEMBL619148,81034,,Intermediate,Antiproliferative effect of compound on A2780/DX cell line,,9606.0
4601,,A2780,,Homo sapiens,,F,,478.0,N,17420,BAO_0000219,CHEMBL619149,81034,,Intermediate,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,9606.0
4602,,A2780,,Homo sapiens,,F,,478.0,N,15099,BAO_0000219,CHEMBL619150,81034,,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,9606.0
4603,,A2780,,Homo sapiens,,F,,478.0,N,15099,BAO_0000219,CHEMBL619151,81034,,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,9606.0
4604,,A2780,,Homo sapiens,,F,,478.0,N,17672,BAO_0000219,CHEMBL883794,81034,,Intermediate,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,9606.0
4605,,A2780,,Homo sapiens,,F,,478.0,N,17672,BAO_0000219,CHEMBL619152,81034,,Intermediate,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,9606.0
4606,,A2780,,Homo sapiens,,F,,478.0,N,17270,BAO_0000219,CHEMBL619153,81034,,Intermediate,In vitro cytotoxicity against A2780ADR cell line,,9606.0
4607,,A2780,,Homo sapiens,,F,,478.0,N,17270,BAO_0000219,CHEMBL619154,81034,,Intermediate,In vitro cytotoxicity against A2780CIS cell line,,9606.0
4608,,A2780,,Homo sapiens,,F,,478.0,N,5574,BAO_0000219,CHEMBL619155,81034,,Intermediate,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,9606.0
4609,,A2780,,Homo sapiens,,F,,478.0,N,2113,BAO_0000219,CHEMBL619156,81034,,Intermediate,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,9606.0
4610,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL619157,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,9606.0
4611,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL619797,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,9606.0
4612,,,,Macaca mulatta,,A,,,U,17839,BAO_0000218,CHEMBL619798,22224,,Autocuration,Oral bioavailability of compound in rhesus macaques,In vivo,9544.0
4613,,,,monkey,,A,,,U,6821,BAO_0000218,CHEMBL619799,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4614,,,,monkey,,A,,,U,6078,BAO_0000218,CHEMBL619800,22224,,Autocuration,Oral bioavailability evaluated in monkey,In vivo,9443.0
4615,,,,monkey,,A,,,U,6535,BAO_0000218,CHEMBL619801,22224,,Autocuration,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,9443.0
4616,,,,Macaca mulatta,,A,,,U,4449,BAO_0000218,CHEMBL619802,22224,,Autocuration,Oral bioavailability in Rhesus monkey,In vivo,9544.0
4617,,,,Macaca mulatta,,A,,,U,6057,BAO_0000218,CHEMBL619803,22224,,Autocuration,Oral bioavailability was calculated in rhesus monkey,In vivo,9544.0
4618,,,,Macaca fascicularis,,A,,,U,5922,BAO_0000218,CHEMBL619965,22224,,Autocuration,Oral bioavailability in cynomolgus monkey,In vivo,9541.0
4619,,,,monkey,,A,,,U,5940,BAO_0000218,CHEMBL619966,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4620,,,,monkey,,A,,,U,6265,BAO_0000218,CHEMBL619967,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4621,,,,monkey,,A,,,U,6265,BAO_0000218,CHEMBL620073,22224,,Autocuration,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,9443.0
4622,,,,monkey,,A,,,U,6265,BAO_0000218,CHEMBL620074,22224,,Autocuration,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,9443.0
4623,,,,monkey,,A,,,U,5940,BAO_0000218,CHEMBL620075,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4624,,,,monkey,,A,,,U,5940,BAO_0000218,CHEMBL620076,22224,,Autocuration,Oral bioavailability in monkey,In vivo,9443.0
4625,,,,Macaca mulatta,,A,,,U,4514,BAO_0000218,CHEMBL620077,22224,,Autocuration,Oral bioavailability in rhesus monkey,In vivo,9544.0
4626,,,,Macaca mulatta,,A,,,U,5546,BAO_0000218,CHEMBL620078,22224,,Autocuration,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,9544.0
4627,,,,Saimiri sciureus,,A,,,U,5553,BAO_0000218,CHEMBL620079,22224,,Autocuration,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,9521.0
4628,,,,monkey,,A,,,U,6641,BAO_0000218,CHEMBL620080,22224,,Autocuration,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9443.0
4629,,,,Macaca mulatta,,A,,,U,5472,BAO_0000218,CHEMBL620081,22224,,Autocuration,Oral bioavailability in Rhesus monkey,In vivo,9544.0
4630,,,,Macaca mulatta,,A,,,U,5668,BAO_0000218,CHEMBL620082,22224,,Autocuration,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,9544.0
4631,,,,monkey,,A,,,U,5711,BAO_0000218,CHEMBL620083,22224,,Autocuration,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,9443.0
4632,,,,Macaca mulatta,,A,,,U,5145,BAO_0000218,CHEMBL620084,22224,,Autocuration,Bioavailability in Rhesus monkey,In vivo,9544.0
4633,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620085,22224,,Autocuration,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4634,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL874595,22224,,Autocuration,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4635,,,,Cercopithecidae,,A,,,U,3249,BAO_0000218,CHEMBL873352,22224,,Autocuration,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,9527.0
4636,,,,Cercopithecidae,,A,,,U,3249,BAO_0000218,CHEMBL620086,22224,,Autocuration,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,9527.0
4637,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620087,22224,,Autocuration,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,9527.0
4638,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620088,22224,,Autocuration,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,9527.0
4639,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL620089,22224,,Autocuration,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,9527.0
4640,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL620090,22224,,Autocuration,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,9527.0
4641,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL620091,22224,,Autocuration,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,9527.0
4642,,,,Cercopithecidae,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620092,22224,,Autocuration,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,9527.0
4643,,,,Cercopithecidae,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620093,22224,,Autocuration,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,9527.0
4644,,,,Cercopithecidae,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620094,22224,,Autocuration,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,9527.0
4645,,,,Cercopithecidae,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620095,22224,,Autocuration,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,9527.0
4646,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620096,22224,,Autocuration,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,9527.0
4647,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620097,22224,,Autocuration,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,9527.0
4648,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL620098,22224,,Autocuration,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,9527.0
4649,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620099,22224,,Autocuration,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4650,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620100,22224,,Autocuration,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4651,,,,Cercopithecidae,,A,,,U,6821,BAO_0000019,CHEMBL620101,22224,,Autocuration,Elimination Half-life of compound was determined in monkey,,9527.0
4652,,,,Cercopithecidae,,A,,,U,17267,BAO_0000019,CHEMBL620102,22224,,Autocuration,Half life of compound was determined in rhesus monkey,,9527.0
4653,1969.0,,Plasma,Cercopithecidae,,A,,,U,5819,BAO_0000366,CHEMBL620103,22224,,Autocuration,Half life in monkey plasma,,9527.0
4654,1969.0,,Plasma,Cercopithecidae,,A,,,U,5819,BAO_0000366,CHEMBL620104,22224,,Autocuration,Half life in monkey plasma; Not detected,,9527.0
4655,,,,Cercopithecidae,,A,,,U,1916,BAO_0000218,CHEMBL874596,22224,,Autocuration,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,9527.0
4656,,,,Cercopithecidae,,A,,,U,17509,BAO_0000218,CHEMBL873490,22224,,Autocuration,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,9527.0
4657,,,,Cercopithecidae,,A,,,U,1399,BAO_0000019,CHEMBL620105,22224,,Autocuration,Terminal half life of the compound.,,9527.0
4658,,,,Cercopithecidae,,A,,,U,1916,BAO_0000218,CHEMBL620780,22224,,Autocuration,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,9527.0
4659,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL620781,22224,,Autocuration,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,9527.0
4660,,,,Cercopithecidae,,A,,,U,5546,BAO_0000218,CHEMBL620956,22224,,Autocuration,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,9527.0
4661,1088.0,,Urine,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620957,22224,,Autocuration,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4662,1088.0,,Urine,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL620958,22224,,Autocuration,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
4663,,,,Cercopithecidae,,A,,,U,4257,BAO_0000218,CHEMBL620959,22224,,Autocuration,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,9527.0
4664,,,,Cercopithecidae,,A,,,U,6221,BAO_0000218,CHEMBL620960,22224,,Autocuration,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,9527.0
4665,,,,Cercopithecidae,,A,,,U,5472,BAO_0000218,CHEMBL620961,22224,,Autocuration,Volume of distribution was evaluated in rhesus,In vivo,9527.0
4666,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL620962,22224,,Autocuration,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,10029.0
4667,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL620963,22224,,Autocuration,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,10029.0
4668,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL620964,22224,,Autocuration,Bioavailability in hamster was determined,In vivo,10029.0
4669,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL620965,22224,,Autocuration,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,10029.0
4670,,,,Cricetulus griseus,,A,,,U,4727,BAO_0000218,CHEMBL620966,22224,,Autocuration,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,10029.0
4671,178.0,,Blood,Cricetulus griseus,,A,,,U,4727,BAO_0000221,CHEMBL620967,22224,,Autocuration,Half life of compound was determined in hamster blood,,10029.0
4672,,,,Sus scrofa,,A,,,U,1452,BAO_0000019,CHEMBL620968,22224,,Autocuration,Michaelis-Menten constant of the compound.,,9823.0
4673,,,,Sus scrofa,,A,,,U,1452,BAO_0000019,CHEMBL874597,22224,,Autocuration,Vmax value was measured at 0 uM concentration of silyl ether.,,9823.0
4674,,,,Sus scrofa,,A,,,U,1452,BAO_0000019,CHEMBL620969,22224,,Autocuration,Vmax value was measured at 10 uM concentration of silyl ether.,,9823.0
4675,,,,Sus scrofa,,A,,,U,1452,BAO_0000019,CHEMBL620970,22224,,Autocuration,Vmax value was measured at 5 uM concentration of silyl ether.,,9823.0
4676,,,,Homo sapiens,,B,,,D,11706,BAO_0000357,CHEMBL620971,235,,Expert,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,9606.0
4677,,,,Homo sapiens,,A,,,U,1916,BAO_0000218,CHEMBL620972,22224,,Autocuration,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,9606.0
4678,,,,Homo sapiens,,A,,,U,17791,BAO_0000019,CHEMBL620973,22224,,Autocuration,Compound was evaluated for area under the curve expressed as (h*ug/ml),,9606.0
4679,,,,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618243,22224,,Autocuration,Active metabolite of ifosfamide determined in humans; A-Active,,9606.0
4680,,,,Homo sapiens,,A,,,U,6567,BAO_0000019,CHEMBL618244,22224,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,9606.0
4681,,,,Homo sapiens,,A,,,U,6567,BAO_0000019,CHEMBL618245,22224,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,9606.0
4682,,,,Homo sapiens,,A,,,U,6567,BAO_0000019,CHEMBL618246,22224,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,9606.0
4683,,,,Homo sapiens,,A,,,U,6567,BAO_0000019,CHEMBL618247,22224,,Autocuration,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,9606.0
4684,,,,Homo sapiens,,A,,,U,17791,BAO_0000218,CHEMBL618248,22224,,Autocuration,Compound was evaluated for oral bioavailability in human,,9606.0
4685,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618249,22224,,Autocuration,Metabolite of ifosfamide determined in urine; NF-Not found,,9606.0
4686,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618250,22224,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,9606.0
4687,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL874598,22224,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,9606.0
4688,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618251,22224,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,9606.0
4689,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618252,22224,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,9606.0
4690,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618253,22224,,Autocuration,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,9606.0
4691,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618254,22224,,Autocuration,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,9606.0
4692,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL618255,22224,,Autocuration,Percent of compound in healthy individuals (Group D),,9606.0
4693,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,4397,BAO_0000251,CHEMBL618983,22224,,Autocuration,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,9606.0
4694,,,,Homo sapiens,,A,,,U,17409,BAO_0000019,CHEMBL618984,22224,,Autocuration,Binding towards human plasma protein at 10 uM,,9606.0
4695,,,,Homo sapiens,,A,,,U,17409,BAO_0000019,CHEMBL618985,22224,,Autocuration,Binding towards human plasma protein at 100 uM,,9606.0
4696,,,,Homo sapiens,,A,,,U,17176,BAO_0000019,CHEMBL618986,22224,,Autocuration,Human plasma protein binding activity was determined,,9606.0
4697,,,,Homo sapiens,,A,,,U,15444,BAO_0000019,CHEMBL618987,22224,,Autocuration,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,9606.0
4698,,,,Homo sapiens,,A,,,U,17267,BAO_0000019,CHEMBL618988,22224,,Autocuration,Percent binding of compound towards human plasma protein was determined,,9606.0
4699,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5944,BAO_0000251,CHEMBL618989,22224,,Autocuration,Plasma clearance in human liver microsomes,In vitro,9606.0
4700,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5668,BAO_0000251,CHEMBL618990,22224,,Autocuration,In vitro intrinsic clearance in human liver microsome,In vitro,9606.0
4701,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5669,BAO_0000251,CHEMBL618991,22224,,Autocuration,In vitro intrinsic clearance in human liver microsome,In vitro,9606.0
4702,,,,Homo sapiens,,A,Microsomes,,U,5041,BAO_0000251,CHEMBL876725,22224,,Autocuration,In vitro microsome metabolism clearance in human was determined,In vitro,9606.0
4703,,,,Homo sapiens,,A,Microsomes,,U,5041,BAO_0000251,CHEMBL618992,22224,,Autocuration,In vitro microsome metabolism clearance in human was determined; High,In vitro,9606.0
4704,,,,Homo sapiens,,A,Microsomes,,U,5041,BAO_0000251,CHEMBL618993,22224,,Autocuration,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,9606.0
4705,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5676,BAO_0000251,CHEMBL618994,22224,,Autocuration,Pharmacokinetic property (clearance) in human liver microsome,In vitro,9606.0
4706,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5944,BAO_0000251,CHEMBL618995,22224,,Autocuration,Plasma clearance in human liver microsomes,In vitro,9606.0
4707,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,17538,BAO_0000251,CHEMBL618996,22224,,Autocuration,In vitro clearance in human liver microsomes,In vitro,9606.0
4708,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6331,BAO_0000251,CHEMBL618997,22224,,Autocuration,Intrinsic clearance in human liver microsomes was determined,In vitro,9606.0
4709,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5948,BAO_0000251,CHEMBL618998,22224,,Autocuration,Intrinsic clearance in human liver microsomes was determined,In vitro,9606.0
4710,,,,Homo sapiens,,A,,,U,5965,BAO_0000218,CHEMBL618999,22224,,Autocuration,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,9606.0
4711,,,,Homo sapiens,,A,,,U,1916,BAO_0000218,CHEMBL620223,22224,,Autocuration,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,9606.0
4712,,,,Homo sapiens,,A,,,U,5965,BAO_0000218,CHEMBL620224,22224,,Autocuration,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,9606.0
4713,,,,Homo sapiens,,A,,,U,1299,BAO_0000019,CHEMBL620225,22224,,Autocuration,Stability in human plasma 2 hr after incubation expressed as percent concentration,,9606.0
4714,,,,Homo sapiens,,A,,,U,1299,BAO_0000019,CHEMBL620226,22224,,Autocuration,Stability in human plasma 4 hr after incubation expressed as percent concentration,,9606.0
4715,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL620227,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4716,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL876726,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4717,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL620228,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4718,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL620229,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4719,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620230,50594,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,10090.0
4720,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620231,50594,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,10090.0
4721,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620232,50594,,Intermediate,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,10090.0
4722,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620233,50594,,Intermediate,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,10090.0
4723,,,,Mus musculus,,A,,,N,14294,BAO_0000218,CHEMBL620234,50594,,Intermediate,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,10090.0
4724,,,,Mus musculus,,A,,,N,14294,BAO_0000218,CHEMBL620235,50594,,Intermediate,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,10090.0
4725,,,,Mus musculus,,A,,,N,14294,BAO_0000218,CHEMBL620236,50594,,Intermediate,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,10090.0
4726,2107.0,,Liver,Mus musculus,,A,,,N,6251,BAO_0000218,CHEMBL620237,50594,,Intermediate,In vitro metabolic potential in mouse liver microsomes,,10090.0
4727,,,,Mus musculus,,A,,,N,17582,BAO_0000218,CHEMBL620238,50594,,Intermediate,Ability of compound to bind to plasma protein was evaluated in HSA cells,,10090.0
4728,2369.0,,Adrenal gland,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL620239,50594,,Intermediate,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,10090.0
4729,955.0,,Brain,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL620240,50594,,Intermediate,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,10090.0
4730,955.0,,Brain,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL620241,50594,,Intermediate,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,10090.0
4731,,,,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL876727,50594,,Intermediate,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,10090.0
4732,2113.0,,Kidney,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL620242,50594,,Intermediate,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,10090.0
4733,,,,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL620243,50594,,Intermediate,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,10090.0
4734,,,,Mus musculus,,A,,,N,5288,BAO_0000218,CHEMBL620244,50594,,Intermediate,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,10090.0
4735,1977.0,,Serum,Mus musculus,,A,,,N,2717,BAO_0000218,CHEMBL620245,50594,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,10090.0
4736,1977.0,,Serum,Mus musculus,,A,,,N,2717,BAO_0000218,CHEMBL620246,50594,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,10090.0
4737,1977.0,,Serum,Mus musculus,,A,,,N,2717,BAO_0000218,CHEMBL620247,50594,,Intermediate,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,10090.0
4738,1969.0,,Plasma,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL620248,50594,,Intermediate,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,10090.0
4739,1969.0,,Plasma,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL873497,50594,,Intermediate,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,10090.0
4740,1969.0,,Plasma,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL620249,50594,,Intermediate,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,10090.0
4741,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620250,50594,,Intermediate,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,10090.0
4742,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620251,50594,,Intermediate,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,10090.0
4743,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620252,50594,,Intermediate,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,10090.0
4744,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620253,50594,,Intermediate,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,10090.0
4745,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL620254,50594,,Intermediate,Half life after intravenous administration in mice at 23 uM/kg,In vivo,10090.0
4746,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL620255,50594,,Intermediate,Half life after intravenous administration in mice at 24 uM/kg,In vivo,10090.0
4747,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL620256,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,10090.0
4748,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL876728,50594,,Intermediate,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,10090.0
4749,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL620257,50594,,Intermediate,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,10090.0
4750,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL620258,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,10090.0
4751,,,,Mus musculus,,A,,,N,4890,BAO_0000218,CHEMBL620259,50594,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,10090.0
4752,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL620260,50594,,Intermediate,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,10090.0
4753,178.0,,Blood,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL620261,50594,,Intermediate,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,10090.0
4754,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL620262,50594,,Intermediate,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
4755,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL620263,50594,,Intermediate,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,10090.0
4756,,,,Mus musculus,,A,,,N,6619,BAO_0000218,CHEMBL620264,50594,,Intermediate,Half life in ob/ob mice,,10090.0
4757,,,,Mus musculus,,A,,,N,4066,BAO_0000218,CHEMBL620265,50594,,Intermediate,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,10090.0
4758,,,,Mus musculus,,A,,,N,4239,BAO_0000218,CHEMBL620266,50594,,Intermediate,Half-life was measured in mouse,,10090.0
4759,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL620267,50594,,Intermediate,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,10090.0
4760,,,,Mus musculus,,A,,,N,8999,BAO_0000218,CHEMBL619364,50594,,Intermediate,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,10090.0
4761,,,,Mus musculus,,A,,,N,8999,BAO_0000218,CHEMBL619365,50594,,Intermediate,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,10090.0
4762,955.0,,Brain,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL619366,50594,,Intermediate,T2 in brain of mice at the oral dose of 50 mg/kg,,10090.0
4763,2113.0,,Kidney,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL619367,50594,,Intermediate,T2 in kidney of mice at the oral dose of 50 mg/kg,,10090.0
4764,2107.0,,Liver,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL619368,50594,,Intermediate,T2 in liver of mice at the oral dose of 50 mg/kg,,10090.0
4765,2048.0,,Lung,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL619369,50594,,Intermediate,T2 in lungs of mice at the oral dose of 50 mg/kg,,10090.0
4766,2106.0,,Spleen,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL876729,50594,,Intermediate,T2 in spleen of mice at the oral dose of 50 mg/kg,,10090.0
4767,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619370,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,10090.0
4768,,,,Mus musculus,,A,,,N,4890,BAO_0000218,CHEMBL619371,50594,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,10090.0
4769,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL619372,50594,,Intermediate,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,10090.0
4770,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL620012,50594,,Intermediate,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,10090.0
4771,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL620013,50594,,Intermediate,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,10090.0
4772,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL620014,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,9606.0
4773,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL620015,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,9606.0
4774,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL621010,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,9606.0
4775,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL621011,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,9606.0
4776,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL621012,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,9606.0
4777,,A2780,,Homo sapiens,,F,,478.0,N,16913,BAO_0000219,CHEMBL621013,81034,,Intermediate,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,9606.0
4778,,A2780,,Homo sapiens,,F,,478.0,N,17270,BAO_0000219,CHEMBL621014,81034,,Intermediate,In vitro cytotoxicity against A2780TAX cell line,,9606.0
4779,,A2780cisR,,Homo sapiens,,F,,481.0,N,5618,BAO_0000219,CHEMBL618154,80017,,Intermediate,In vitro inhibitory activity against human tumor cell line A2780cis,,9606.0
4780,,A2780,,Homo sapiens,,F,,478.0,N,17777,BAO_0000219,CHEMBL618155,81034,,Expert,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,9606.0
4781,,A2780cisR,,Homo sapiens,,F,,481.0,N,16112,BAO_0000219,CHEMBL618156,80017,,Intermediate,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,9606.0
4782,,A2780cisR,,Homo sapiens,,F,,481.0,N,15748,BAO_0000219,CHEMBL618157,80017,,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,9606.0
4783,,A2780,,Homo sapiens,,F,,478.0,N,6633,BAO_0000219,CHEMBL618328,81034,,Intermediate,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,9606.0
4784,,A2780,,Homo sapiens,,F,,478.0,N,16930,BAO_0000219,CHEMBL618329,81034,,Intermediate,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,9606.0
4785,,A2780,,Homo sapiens,,F,,478.0,N,17496,BAO_0000219,CHEMBL618330,81034,,Intermediate,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,9606.0
4786,,A2780,,Homo sapiens,,F,,478.0,N,12989,BAO_0000219,CHEMBL618331,81034,,Expert,In vitro antitumor activity against A2780cisR cell line.,,9606.0
4787,,A2780,,Homo sapiens,,F,,478.0,N,4840,BAO_0000219,CHEMBL618332,81034,,Intermediate,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,9606.0
4788,,A2780,,Homo sapiens,,F,,478.0,N,12989,BAO_0000219,CHEMBL618333,81034,,Expert,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,9606.0
4789,,A2780cisR,,Homo sapiens,,F,,481.0,N,16745,BAO_0000219,CHEMBL618334,80017,,Intermediate,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,9606.0
4790,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000219,CHEMBL618335,81034,,Expert,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,9606.0
4791,,,,Rattus norvegicus,,B,,,D,16547,BAO_0000019,CHEMBL618336,11736,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,10116.0
4792,,,,,,F,,,H,16547,BAO_0000019,CHEMBL618337,11736,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,
4793,,,,Rattus norvegicus,,F,,,D,16547,BAO_0000019,CHEMBL618338,11736,,Expert,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,10116.0
4794,,HEK293,,Homo sapiens,,F,,722.0,D,15856,BAO_0000219,CHEMBL618339,278,,Expert,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,9606.0
4795,,HEK293,,Homo sapiens,,F,,722.0,D,15856,BAO_0000219,CHEMBL618340,278,,Expert,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,9606.0
4796,,,,Mus musculus,,B,,,D,16547,BAO_0000019,CHEMBL618341,11831,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,10090.0
4797,,,,,,F,,,H,16547,BAO_0000019,CHEMBL618342,11831,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,
4798,,,,Mus musculus,,F,,,D,16547,BAO_0000019,CHEMBL618343,11831,,Expert,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,10090.0
4799,,,,,,B,,,H,17402,BAO_0000357,CHEMBL621038,280,,Expert,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,
4800,,T-cells,,Homo sapiens,,F,,574.0,U,11746,BAO_0000219,CHEMBL621039,22226,,Autocuration,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,9606.0
4801,,T-cells,,Homo sapiens,,F,,574.0,U,11746,BAO_0000219,CHEMBL621040,22226,,Autocuration,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,9606.0
4802,,A-375,,Homo sapiens,,F,,455.0,N,5455,BAO_0000219,CHEMBL621041,80018,,Intermediate,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,9606.0
4803,,A-375,,Homo sapiens,,F,,455.0,N,2068,BAO_0000219,CHEMBL621042,80018,,Intermediate,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,9606.0
4804,,A-375,,Homo sapiens,,F,,455.0,N,2683,BAO_0000219,CHEMBL621043,80018,,Intermediate,In vitro antitumor activity against A375cell line extracted form melanoma,,9606.0
4805,,A-375,,Homo sapiens,,F,,455.0,N,15313,BAO_0000219,CHEMBL621044,80018,,Expert,Inhibition of cell growth in (A375) melan cell line,,9606.0
4806,,A-375,,Homo sapiens,,F,,455.0,N,13739,BAO_0000219,CHEMBL621045,80018,,Intermediate,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,9606.0
4807,,A-375,,Homo sapiens,,F,,455.0,N,13739,BAO_0000219,CHEMBL621046,80018,,Intermediate,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,9606.0
4808,,A-375,,Homo sapiens,,F,,455.0,N,14750,BAO_0000219,CHEMBL621047,80018,,Intermediate,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,9606.0
4809,,A-427,,Homo sapiens,,F,,797.0,N,14777,BAO_0000219,CHEMBL621048,80019,,Intermediate,Antiproliferative activity measured against A427 human lung carcinoma,,9606.0
4810,,A-427,,Homo sapiens,,F,,797.0,N,14777,BAO_0000219,CHEMBL883798,80019,,Intermediate,Antiproliferative activity measured against A427 human lung carcinoma,,9606.0
4811,,A-427,,Homo sapiens,,F,,797.0,N,17672,BAO_0000219,CHEMBL621049,80019,,Intermediate,Cytotoxicity against lung carcinoma A427 tumor cell lines,,9606.0
4812,,A-427,,Homo sapiens,,F,,797.0,N,14368,BAO_0000219,CHEMBL621050,80019,,Intermediate,Inhibition of large cell lung carcinoma (A427),,9606.0
4813,,A-427,,Homo sapiens,,F,,797.0,N,14368,BAO_0000219,CHEMBL621051,80019,,Intermediate,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,9606.0
4814,,A-427,,Homo sapiens,,F,,797.0,N,13866,BAO_0000219,CHEMBL621052,80019,,Intermediate,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,9606.0
4815,,A-427,,Homo sapiens,,F,,797.0,N,2545,BAO_0000219,CHEMBL621053,80019,,Intermediate,Inhibitory concentration in human lung carcinoma A427 cell line,,9606.0
4816,,A-427,,Homo sapiens,,F,,797.0,N,2545,BAO_0000219,CHEMBL621054,80019,,Intermediate,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,9606.0
4817,,,,Cercopithecidae,,A,,,U,6062,BAO_0000218,CHEMBL621055,22224,,Autocuration,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,9527.0
4818,,,,Cercopithecidae,,A,,,U,4578,BAO_0000218,CHEMBL876398,22224,,Autocuration,Tested for volume of distribution upon iv administration to african green monkey,In vivo,9527.0
4819,,,,Cercopithecidae,,A,,,U,17592,BAO_0000218,CHEMBL621056,22224,,Autocuration,Volume of distribution in monkey,In vivo,9527.0
4820,,,,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL621057,22224,,Autocuration,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,9544.0
4821,,,,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL621058,22224,,Autocuration,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,9544.0
4822,,,,Cercopithecidae,,A,,,U,5922,BAO_0000218,CHEMBL621059,22224,,Autocuration,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,9527.0
4823,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL621060,22224,,Autocuration,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,9527.0
4824,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL621061,22224,,Autocuration,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,9527.0
4825,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL621062,22224,,Autocuration,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,9527.0
4826,,,,Cercopithecidae,,A,,,U,6057,BAO_0000218,CHEMBL621063,22224,,Autocuration,Volume displacement was calculated in rhesus monkey,In vivo,9527.0
4827,,,,Cercopithecidae,,A,,,U,5145,BAO_0000218,CHEMBL621064,22224,,Autocuration,Volume of distribution in steady state was determined in rhesus monkey,In vivo,9527.0
4828,,,,Cercopithecidae,,A,,,U,6821,BAO_0000218,CHEMBL621065,22224,,Autocuration,Volume of distribution of compound was determined in monkey,In vivo,9527.0
4829,,,,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL621066,22224,,Autocuration,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,9527.0
4830,,,,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL621067,22224,,Autocuration,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,9527.0
4831,,,,Cercopithecidae,,A,,,U,6641,BAO_0000218,CHEMBL621068,22224,,Autocuration,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9527.0
4832,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL876399,22224,,Autocuration,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,9527.0
4833,,,,Cercopithecidae,,A,,,U,6535,BAO_0000218,CHEMBL621069,22224,,Autocuration,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,9527.0
4834,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL621070,22224,,Autocuration,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,9527.0
4835,,,,Cercopithecidae,,A,,,U,6062,BAO_0000218,CHEMBL621071,22224,,Autocuration,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,9527.0
4836,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL621072,22224,,Autocuration,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,9527.0
4837,,,,Cercopithecidae,,A,,,U,4578,BAO_0000218,CHEMBL618209,22224,,Autocuration,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,9527.0
4838,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL618210,22224,,Autocuration,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,9527.0
4839,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL618211,22224,,Autocuration,Baboon plasma free fraction. ,,9527.0
4840,,,,Cercopithecidae,,A,,,U,6057,BAO_0000218,CHEMBL618212,22224,,Autocuration,Area under the curve was calculated in rhesus monkey after iv administration,,9527.0
4841,,,,Cercopithecidae,,A,,,U,6057,BAO_0000019,CHEMBL618213,22224,,Autocuration,Area under the curve was calculated in rhesus monkey after peroral administration,,9527.0
4842,,,,Cercopithecidae,,A,,,U,17853,BAO_0000019,CHEMBL618214,22224,,Autocuration,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,9527.0
4843,,,,Cercopithecidae,,A,,,U,5302,BAO_0000218,CHEMBL873492,22224,,Autocuration,Half life period in monkey after 5 mg/kg dose,In vivo,9527.0
4844,,,,Cercopithecidae,,A,,,U,4257,BAO_0000218,CHEMBL618272,22224,,Autocuration,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,9527.0
4845,,,,Cercopithecidae,,A,,,U,4257,BAO_0000218,CHEMBL618273,22224,,Autocuration,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,9527.0
4846,1969.0,,Plasma,Cercopithecidae,,A,,,U,13501,BAO_0000218,CHEMBL618274,22224,,Autocuration,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,9527.0
4847,,,,Cercopithecidae,,A,,,U,5394,BAO_0000218,CHEMBL618275,22224,,Autocuration,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,9527.0
4848,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL618276,22224,,Autocuration,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,9527.0
4849,,,,Cercopithecidae,,A,,,U,3341,BAO_0000019,CHEMBL618277,22224,,Autocuration,Compound was evaluated for terminal half life in monkey,,9527.0
4850,,,,Cercopithecidae,,A,,,U,3045,BAO_0000218,CHEMBL618278,22224,,Autocuration,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,9527.0
4851,1969.0,,Plasma,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL618279,22224,,Autocuration,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,9544.0
4852,,,,Cercopithecidae,,A,,,U,4847,BAO_0000019,CHEMBL618280,22224,,Autocuration,Half life of compound was determined in squirrel monkey,,9527.0
4853,,,,Macaca fascicularis,,A,,,U,4256,BAO_0000218,CHEMBL618281,22224,,Autocuration,Half life after iv administration in cynomolgus monkey,In vivo,9541.0
4854,1969.0,,Plasma,Cercopithecidae,,A,,,U,6535,BAO_0000218,CHEMBL618282,22224,,Autocuration,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,9527.0
4855,,,,Cercopithecidae,,A,,,U,6057,BAO_0000019,CHEMBL618283,22224,,Autocuration,Half life was calculated in rhesus monkey,,9527.0
4856,,,,Cercopithecidae,,A,,,U,17592,BAO_0000019,CHEMBL618284,22224,,Autocuration,Half life in monkey,,9527.0
4857,,,,Cercopithecidae,,A,,,U,6641,BAO_0000218,CHEMBL618285,22224,,Autocuration,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9527.0
4858,,,,Cercopithecidae,,A,,,U,5472,BAO_0000019,CHEMBL618286,22224,,Autocuration,Half life was evaluated in rhesus,,9527.0
4859,,,,Cercopithecidae,,A,,,U,6221,BAO_0000218,CHEMBL618287,22224,,Autocuration,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,9527.0
4860,,,,Cercopithecidae,,A,,,U,5668,BAO_0000218,CHEMBL618288,22224,,Autocuration,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,9527.0
4861,,,,Cercopithecidae,,A,,,U,4809,BAO_0000218,CHEMBL876393,22224,,Autocuration,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,9527.0
4862,,,,Cercopithecidae,,A,,,U,5546,BAO_0000218,CHEMBL618289,22224,,Autocuration,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,9527.0
4863,,,,Cercopithecidae,,A,,,U,5553,BAO_0000218,CHEMBL618290,22224,,Autocuration,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,9527.0
4864,,,,Cercopithecidae,,A,,,U,6078,BAO_0000019,CHEMBL618291,22224,,Autocuration,Half-life was calculated in monkey,,9527.0
4865,,,,Cercopithecidae,,A,,,U,5147,BAO_0000019,CHEMBL618292,22224,,Autocuration,Half-life in Squirrel monkey,,9527.0
4866,,,,Cercopithecidae,,A,,,U,5145,BAO_0000019,CHEMBL618293,22224,,Autocuration,Half-life in rhesus monkey,,9527.0
4867,,,,Cercopithecidae,,A,,,U,6062,BAO_0000218,CHEMBL618294,22224,,Autocuration,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,9527.0
4868,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL618295,22224,,Autocuration,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,9527.0
4869,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL618296,22224,,Autocuration,Half-life period after oral administration in cynomolgus monkeys,In vivo,9527.0
4870,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL618297,22224,,Autocuration,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,9527.0
4871,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618298,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4872,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618299,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4873,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618300,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4874,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618301,22224,,Autocuration,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,9606.0
4875,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618302,22224,,Autocuration,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,9606.0
4876,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL876394,22224,,Autocuration,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,9606.0
4877,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618303,22224,,Autocuration,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,9606.0
4878,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618304,22224,,Autocuration,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,9606.0
4879,,,,Homo sapiens,,A,,,U,1916,BAO_0000218,CHEMBL618305,22224,,Autocuration,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,9606.0
4880,,,,Homo sapiens,,A,,,U,16643,BAO_0000218,CHEMBL618306,22224,,Autocuration,Oral bioavailability in human,In vivo,9606.0
4881,,,,Homo sapiens,,A,,,U,17248,BAO_0000019,CHEMBL618307,22224,,Autocuration,Compound was tested for human plasma protein binding,,9606.0
4882,,,,Homo sapiens,,A,,,U,17248,BAO_0000019,CHEMBL618308,22224,,Autocuration,Compound was tested for human plasma protein binding; Not determined,,9606.0
4883,,,,Homo sapiens,,A,,,U,6241,BAO_0000019,CHEMBL618309,22224,,Autocuration,Protein binding activity of compound in human plasma; % Free,,9606.0
4884,,,,Homo sapiens,,A,,,U,17716,BAO_0000019,CHEMBL618310,22224,,Autocuration,Unbound fraction (plasma),,9606.0
4885,1969.0,,Plasma,Homo sapiens,,A,,,U,17605,BAO_0000366,CHEMBL873353,22224,,Autocuration,Half life for the hydrolysis of compound in human blood serum,,9606.0
4886,1969.0,,Plasma,Homo sapiens,,A,,,U,17625,BAO_0000366,CHEMBL618311,22224,,Autocuration,Half life period in human plasma using phosphate buffer (0.08 M),,9606.0
4887,1969.0,,Plasma,Homo sapiens,,A,,,U,17625,BAO_0000366,CHEMBL618312,22224,,Autocuration,Half life period in human plasma using phosphate buffer (0.1 M),,9606.0
4888,1969.0,,Plasma,Homo sapiens,,A,,,U,17747,BAO_0000366,CHEMBL618313,22224,,Autocuration,Half-life in human plasma was determined,,9606.0
4889,,,,Homo sapiens,,A,,,U,15613,BAO_0000019,CHEMBL618314,22224,,Autocuration,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,9606.0
4890,,,,Homo sapiens,,A,,,U,354,BAO_0000019,CHEMBL618315,22224,,Autocuration,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,9606.0
4891,,,,Homo sapiens,,A,,,U,3741,BAO_0000019,CHEMBL618316,22224,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,9606.0
4892,,,,Homo sapiens,,A,,,U,3741,BAO_0000019,CHEMBL618317,22224,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,9606.0
4893,,,,Homo sapiens,,A,,,U,3741,BAO_0000019,CHEMBL620138,22224,,Autocuration,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,9606.0
4894,,,,Homo sapiens,,A,,,U,17599,BAO_0000019,CHEMBL858280,22224,,Autocuration,Partition coefficient (logP),,9606.0
4895,,,,Homo sapiens,,A,,,U,5486,BAO_0000019,CHEMBL620139,22224,,Autocuration,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,9606.0
4896,,,,Homo sapiens,,A,Microsomes,,U,5600,BAO_0000251,CHEMBL620140,22224,,Autocuration,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,9606.0
4897,,,,Homo sapiens,,A,,,U,14294,BAO_0000019,CHEMBL620141,22224,,Autocuration,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,9606.0
4898,,,,Homo sapiens,,A,,,U,14294,BAO_0000019,CHEMBL620142,22224,,Autocuration,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,9606.0
4899,,,,Homo sapiens,,A,,,U,14294,BAO_0000019,CHEMBL620143,22224,,Autocuration,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,9606.0
4900,,,,Homo sapiens,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620144,22224,,Autocuration,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,9606.0
4901,,,,Homo sapiens,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620145,22224,,Autocuration,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,9606.0
4902,,,,Homo sapiens,,A,Microsomes,,U,14294,BAO_0000251,CHEMBL620146,22224,,Autocuration,Metabolism of compound in human microsomes; Trace,,9606.0
4903,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6260,BAO_0000251,CHEMBL620147,22224,,Autocuration,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,9606.0
4904,,,,Homo sapiens,,A,Microsomes,,U,6187,BAO_0000251,CHEMBL620148,22224,,Autocuration,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,9606.0
4905,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6251,BAO_0000251,CHEMBL620149,22224,,Autocuration,In vitro metabolic potential in human liver microsomes,,9606.0
4906,,,,Homo sapiens,,A,,,U,3246,BAO_0000019,CHEMBL876412,22224,,Autocuration,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,9606.0
4907,,,,Homo sapiens,,A,,,U,17313,BAO_0000019,CHEMBL619352,22224,,Autocuration,Tested for human plasma protein binding of the compound; Not tested,,9606.0
4908,,,,Homo sapiens,,A,,,U,6227,BAO_0000019,CHEMBL619353,22224,,Autocuration,Compound was tested for percent protein binding (PB) in human,,9606.0
4909,1969.0,,Plasma,Homo sapiens,,A,,,U,5530,BAO_0000019,CHEMBL619354,22224,,Autocuration,Protein binding in human plasma,,9606.0
4910,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL619355,22224,,Autocuration,Permeability coefficient (B to A) in Caco-2 cell,,9606.0
4911,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL619356,22224,,Autocuration,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,9606.0
4912,,,,Homo sapiens,,A,,,U,2774,BAO_0000019,CHEMBL619357,22224,,Autocuration,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,9606.0
4913,,,,Homo sapiens,,A,,,U,16643,BAO_0000019,CHEMBL619358,22224,,Autocuration,In vitro rate of absorption observed as Caco-2 permeability in humans,,9606.0
4914,,Caco-2,,Homo sapiens,,A,,495.0,U,17582,BAO_0000219,CHEMBL619359,22224,,Autocuration,Cellular permeability of compound was determined in Caco-2 cells; High,,9606.0
4915,,Caco-2,,Homo sapiens,,A,,495.0,U,6838,BAO_0000219,CHEMBL619360,22224,,Autocuration,Permeability in Caco-2 cells of compound,,9606.0
4916,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL619361,22224,,Autocuration,Permeability coefficient (A to B) in Caco-2 cell,,9606.0
4917,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL619362,22224,,Autocuration,Permeability coefficient (B to A) in Caco-2 cell,,9606.0
4918,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL619363,22224,,Autocuration,Permeability coefficient (Papp) (Caco-2 cell monolayer),,9606.0
4919,,,,Homo sapiens,,A,,,U,2146,BAO_0000019,CHEMBL618942,22224,,Autocuration,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,9606.0
4920,,,,Homo sapiens,,A,,,U,4514,BAO_0000019,CHEMBL618943,22224,,Autocuration,Compound was tested for protein binding in human plasma,,9606.0
4921,,,,Homo sapiens,,A,,,U,6108,BAO_0000019,CHEMBL618944,22224,,Autocuration,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,9606.0
4922,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL618945,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,9606.0
4923,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL618946,50594,,Intermediate,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,10090.0
4924,,,,Mus musculus,,A,,,N,3277,BAO_0000218,CHEMBL876413,50594,,Intermediate,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,10090.0
4925,,,,Mus musculus,,A,,,N,3802,BAO_0000218,CHEMBL618947,50594,,Intermediate,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,10090.0
4926,1969.0,,Plasma,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL618948,50594,,Intermediate,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,10090.0
4927,1969.0,,Plasma,Mus musculus,,A,,,N,6348,BAO_0000218,CHEMBL618949,50594,,Intermediate,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,10090.0
4928,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL618950,50594,,Intermediate,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,10090.0
4929,,,,Mus musculus,,A,,,N,5781,BAO_0000218,CHEMBL618951,50594,,Intermediate,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,10090.0
4930,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL618952,50594,,Intermediate,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,10090.0
4931,,,,Mus musculus,,A,,,N,4066,BAO_0000218,CHEMBL618953,50594,,Intermediate,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,10090.0
4932,955.0,,Brain,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL618954,50594,,Intermediate,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,10090.0
4933,2113.0,,Kidney,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL618955,50594,,Intermediate,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,10090.0
4934,2107.0,,Liver,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL618956,50594,,Intermediate,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,10090.0
4935,2048.0,,Lung,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL618957,50594,,Intermediate,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,10090.0
4936,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL618958,50594,,Intermediate,Tmax in mice at 18 uM/kg i.p. administration,In vivo,10090.0
4937,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL618959,50594,,Intermediate,Tmax in mice at 23 uM/kg i.v. administration,In vivo,10090.0
4938,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL618960,50594,,Intermediate,Tmax in mice at 25 uM/kg i.p. administration,In vivo,10090.0
4939,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL876723,50594,,Intermediate,Tmax in mice at 26 uM/kg i.p. administration,In vivo,10090.0
4940,2106.0,,Spleen,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL618961,50594,,Intermediate,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,10090.0
4941,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL618962,50594,,Intermediate,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
4942,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL618963,50594,,Intermediate,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,10090.0
4943,,,,Mus musculus,,A,,,N,5951,BAO_0000218,CHEMBL618964,50594,,Intermediate,Tmax value in IRC mice,,10090.0
4944,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL618965,50594,,Intermediate,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,10090.0
4945,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL618966,50594,,Intermediate,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,10090.0
4946,1088.0,,Urine,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL618967,50594,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,10090.0
4947,1088.0,,Urine,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL618968,50594,,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,10090.0
4948,1088.0,,Urine,Mus musculus,,A,,,N,4066,BAO_0000218,CHEMBL618969,50594,,Intermediate,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,10090.0
4949,,,,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL618970,50594,,Intermediate,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,10090.0
4950,,,,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL618971,50594,,Intermediate,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,10090.0
4951,,,,Mus musculus,,A,,,N,6062,BAO_0000218,CHEMBL618972,50594,,Intermediate,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,10090.0
4952,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL618973,50594,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,10090.0
4953,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL618974,50594,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,10090.0
4954,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL618975,50594,,Intermediate,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,10090.0
4955,,,,Mus musculus,,A,,,N,5980,BAO_0000218,CHEMBL618976,50594,,Intermediate,Vd in mice,In vivo,10090.0
4956,,,,Mus musculus,,A,,,N,17592,BAO_0000218,CHEMBL618977,50594,,Intermediate,Volume of distribution in mouse,In vivo,10090.0
4957,,,,Mus musculus,,A,,,N,6348,BAO_0000218,CHEMBL876724,50594,,Intermediate,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,10090.0
4958,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL618978,50594,,Intermediate,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,10090.0
4959,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL618979,50594,,Intermediate,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,10090.0
4960,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL618980,50594,,Intermediate,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,10090.0
4961,,,,Mus musculus,,A,,,N,4239,BAO_0000218,CHEMBL618981,50594,,Intermediate,Pharmacokinetic property (vdss) was measured in mouse,In vivo,10090.0
4962,,,,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL618982,50594,,Intermediate,Value distribution upon iv administration in mouse,In vivo,10090.0
4963,,,,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL620150,50594,,Intermediate,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,10090.0
4964,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL620151,50594,,Intermediate,Volume of distribution was evaluated in mice after intravenous administration,In vivo,10090.0
4965,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL620152,50594,,Intermediate,Volume of distribution was evaluated in mice after oral administration,In vivo,10090.0
4966,,,,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL620153,50594,,Intermediate,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,10090.0
4967,,,,Mus musculus,,A,,,N,5727,BAO_0000218,CHEMBL876395,50594,,Intermediate,Steady state volume of distribution was determined in mice,In vivo,10090.0
4968,,,,Mus musculus,,A,,,N,17852,BAO_0000218,CHEMBL620154,50594,,Intermediate,Volume distribution (steady state) of compound was determined in mouse,In vivo,10090.0
4969,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL620155,50594,,Intermediate,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,10090.0
4970,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL620156,50594,,Intermediate,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
4971,,,,Mus musculus,,A,,,N,6062,BAO_0000218,CHEMBL620157,50594,,Intermediate,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,10090.0
4972,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL620158,50594,,Intermediate,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,10090.0
4973,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL620159,50594,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,10090.0
4974,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL620160,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,10090.0
4975,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL620161,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
4976,,A-427,,Homo sapiens,,F,,797.0,N,10708,BAO_0000219,CHEMBL620162,80019,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,9606.0
4977,,A-431,,Homo sapiens,,F,,500.0,N,16597,BAO_0000219,CHEMBL620163,80852,,Expert,Inhibition of A431 human squamous cell carcinoma cell proliferation,,9606.0
4978,,A-431,,Homo sapiens,,F,,500.0,N,16062,BAO_0000219,CHEMBL620833,80852,,Expert,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,9606.0
4979,,A-431,,Homo sapiens,,F,,500.0,N,16062,BAO_0000219,CHEMBL876396,80852,,Expert,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,9606.0
4980,,A-431,,Homo sapiens,,F,,500.0,N,16958,BAO_0000219,CHEMBL620834,80852,,Expert,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,9606.0
4981,,A-431,,Homo sapiens,,F,,500.0,N,6700,BAO_0000219,CHEMBL620835,80852,,Expert,Inhibition of A431 human carcinoma cell proliferation,,9606.0
4982,,A-431,,Homo sapiens,,F,,500.0,N,17226,BAO_0000219,CHEMBL620836,80852,,Expert,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,9606.0
4983,,A-431,,Homo sapiens,,F,,500.0,N,6828,BAO_0000219,CHEMBL620837,80852,,Intermediate,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,9606.0
4984,,A-431,,Homo sapiens,,F,,500.0,N,12314,BAO_0000219,CHEMBL621017,80852,,Intermediate,In vitro cytotoxicity against epidermoid carcinoma cell line,,9606.0
4985,,A-431,,Homo sapiens,,F,,500.0,D,13412,BAO_0000218,CHEMBL621018,9,,Expert,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,9606.0
4986,,A-431,,Homo sapiens,,F,,500.0,N,13299,BAO_0000219,CHEMBL621019,80852,,Intermediate,Antiproliferative activity of compound was measured on human tumor cell line A431.,,9606.0
4987,,A-431,,Homo sapiens,,F,,500.0,N,17420,BAO_0000219,CHEMBL621020,80852,,Intermediate,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,9606.0
4988,,A-431,,Homo sapiens,,F,,500.0,N,13678,BAO_0000219,CHEMBL621021,80852,,Intermediate,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,9606.0
4989,,A-431,,,,F,,500.0,H,14171,BAO_0000219,CHEMBL621022,9,,Expert,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,
4990,,A-431,,Homo sapiens,,F,,500.0,N,6333,BAO_0000219,CHEMBL621023,80852,,Expert,Tested for antiproliferative activity against human A431 cells,,9606.0
4991,,A-431,,Homo sapiens,,F,,500.0,D,2356,BAO_0000219,CHEMBL621024,9,,Expert,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,9606.0
4992,,A-431,,Homo sapiens,,F,,500.0,N,15578,BAO_0000219,CHEMBL621025,80852,,Expert,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,9606.0
4993,,A-431,,Homo sapiens,,F,,500.0,N,5126,BAO_0000219,CHEMBL621026,80852,,Expert,Inhibition of A431 cell proliferation,,9606.0
4994,,A-431,,Homo sapiens,,F,,500.0,N,6844,BAO_0000219,CHEMBL621027,80852,,Expert,Cytotoxic effect on A431 human epidermoid carcinoma cells,,9606.0
4995,,A-431,,Homo sapiens,,F,,500.0,N,6844,BAO_0000219,CHEMBL876397,80852,,Expert,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,9606.0
4996,,A-431,,Homo sapiens,,F,,500.0,N,4925,BAO_0000219,CHEMBL883797,80852,,Intermediate,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,9606.0
4997,,A-431,,Homo sapiens,,F,,500.0,N,4925,BAO_0000219,CHEMBL621028,80852,,Intermediate,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,9606.0
4998,,A-431,,Homo sapiens,,F,,500.0,N,13978,BAO_0000219,CHEMBL621029,80852,,Intermediate,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,9606.0
4999,,A-431,,Homo sapiens,,F,,500.0,N,16786,BAO_0000219,CHEMBL621030,80852,,Intermediate,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,9606.0
5000,,A-431,,,,F,,500.0,H,13412,BAO_0000219,CHEMBL621147,9,,Expert,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,
5001,,A-431,,Homo sapiens,,F,,500.0,N,17824,BAO_0000218,CHEMBL621148,80852,,Intermediate,In vivo antiproliferative activity against A431 cell line,,9606.0
5002,,A-431,,Homo sapiens,,F,,500.0,D,12751,BAO_0000219,CHEMBL621149,9,,Expert,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,9606.0
5003,,A-431,,Homo sapiens,,F,,500.0,N,12380,BAO_0000219,CHEMBL621150,80852,,Expert,Inhibition of A431 human epidermoid carcinoma cell proliferation,,9606.0
5004,,A-431,,Homo sapiens,,F,,500.0,D,4959,BAO_0000219,CHEMBL621151,9,,Expert,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,9606.0
5005,,A-431,,Homo sapiens,,F,,500.0,N,6333,BAO_0000219,CHEMBL621152,80852,,Intermediate,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,9606.0
5006,,A-431,,Homo sapiens,,F,,500.0,N,6333,BAO_0000219,CHEMBL621153,80852,,Intermediate,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,9606.0
5007,,A-431,,Homo sapiens,,F,,500.0,N,6333,BAO_0000219,CHEMBL884000,80852,,Intermediate,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,9606.0
5008,,,,Homo sapiens,,F,,,D,5296,BAO_0000019,CHEMBL621154,9,,Expert,Inhibition of EGFR overexpressing A431 cell proliferation,,9606.0
5009,,A-431,,Homo sapiens,,F,,500.0,N,12624,BAO_0000219,CHEMBL621155,80852,,Expert,Inhibition of A431 cell proliferation,,9606.0
5010,,A-431,,Homo sapiens,,F,,500.0,D,14926,BAO_0000219,CHEMBL621156,9,,Expert,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,9606.0
5011,,A-431,,Homo sapiens,,F,,500.0,D,14926,BAO_0000219,CHEMBL621157,9,,Expert,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,9606.0
5012,,A-431,,,,F,,500.0,H,14926,BAO_0000219,CHEMBL621158,9,,Expert,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,
5013,,A-431,,Homo sapiens,,F,,500.0,N,15144,BAO_0000219,CHEMBL621159,80852,,Intermediate,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,9606.0
5014,,A-431,,Homo sapiens,,F,,500.0,N,15144,BAO_0000219,CHEMBL621160,80852,,Intermediate,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,9606.0
5015,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621161,80852,,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,9606.0
5016,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621162,80852,,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,9606.0
5017,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621163,80852,,Intermediate,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,9606.0
5018,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621164,80852,,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,9606.0
5019,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621165,80852,,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,9606.0
5020,,,,Cercopithecidae,,A,,,U,5922,BAO_0000019,CHEMBL619159,22224,,Autocuration,Half-life period in cynomolgus monkey,,9527.0
5021,1969.0,,Plasma,Cercopithecidae,,A,,,U,1116,BAO_0000366,CHEMBL619160,22224,,Autocuration,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,9527.0
5022,,,,Cercopithecidae,,A,,,U,17853,BAO_0000218,CHEMBL619161,22224,,Autocuration,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,9527.0
5023,1969.0,,Plasma,Cercopithecidae,,A,,,U,993,BAO_0000366,CHEMBL619162,22224,,Autocuration,Plasma half life in monkey,,9527.0
5024,1969.0,,Plasma,Cercopithecidae,,A,,,U,4514,BAO_0000366,CHEMBL619163,22224,,Autocuration,Plasma half-life in rhesus monkey,,9527.0
5025,1969.0,,Plasma,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL619164,22224,,Autocuration,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,9527.0
5026,1969.0,,Plasma,Cercopithecidae,,A,,,U,5334,BAO_0000218,CHEMBL619320,22224,,Autocuration,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,9527.0
5027,,,,Cercopithecidae,,A,,,U,4578,BAO_0000218,CHEMBL619321,22224,,Autocuration,Tested for half life upon iv administration to african green monkey,In vivo,9527.0
5028,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL873336,22224,,Autocuration,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,9527.0
5029,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL619322,22224,,Autocuration,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,9527.0
5030,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL619323,22224,,Autocuration,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,9527.0
5031,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL619324,22224,,Autocuration,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,9527.0
5032,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619325,22224,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,9527.0
5033,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL876411,22224,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,9527.0
5034,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619326,22224,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,9527.0
5035,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619327,22224,,Autocuration,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,9527.0
5036,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619328,22224,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,9527.0
5037,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619329,22224,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,9527.0
5038,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619330,22224,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,9527.0
5039,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619331,22224,,Autocuration,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,9527.0
5040,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619332,22224,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,9527.0
5041,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619333,22224,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,9527.0
5042,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619334,22224,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,9527.0
5043,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619335,22224,,Autocuration,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,9527.0
5044,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619336,22224,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,9527.0
5045,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619337,22224,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,9527.0
5046,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619338,22224,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,9527.0
5047,,,,Cercopithecidae,,A,,,U,11271,BAO_0000019,CHEMBL619339,22224,,Autocuration,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,9527.0
5048,,,,Rattus norvegicus,,A,,,N,5809,BAO_0000218,CHEMBL619340,50597,,Intermediate,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,10116.0
5049,1969.0,,Plasma,Rattus norvegicus,,A,,,N,17720,BAO_0000218,CHEMBL873496,50597,,Intermediate,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,10116.0
5050,1969.0,,Plasma,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619341,50597,,Intermediate,AUC value in rat after IV administration at a dose of 10 mg/kg,,10116.0
5051,1969.0,,Plasma,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619342,50597,,Intermediate,AUC value in rat after oral administration at a dose of 10 mg/kg,,10116.0
5052,,,,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619343,50597,,Intermediate,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,10116.0
5053,,,,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619344,50597,,Intermediate,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,10116.0
5054,,,,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619345,50597,,Intermediate,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,10116.0
5055,,,,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619346,50597,,Intermediate,Vc value in rat after IV administration at a dose of 10 mg/kg,,10116.0
5056,,,,Rattus norvegicus,,A,,,N,3546,BAO_0000218,CHEMBL619347,50597,,Intermediate,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,10116.0
5057,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL619348,22224,,Autocuration,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,9557.0
5058,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL619349,22224,,Autocuration,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,9557.0
5059,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL619350,22224,,Autocuration,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,9557.0
5060,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL619351,22224,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,9557.0
5061,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL875953,22224,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,9557.0
5062,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL621716,22224,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,9557.0
5063,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL621717,22224,,Autocuration,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,9557.0
5064,,,,Papio hamadryas,,A,,,U,10625,BAO_0000019,CHEMBL621718,22224,,Autocuration,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,9557.0
5065,,,,beagle,,A,,,U,3510,BAO_0000019,CHEMBL621719,22224,,Autocuration,Area under curve after 1 mpk peroral administration to beagles,,9615.0
5066,,,,beagle,,A,,,U,3510,BAO_0000019,CHEMBL621720,22224,,Autocuration,Area under curve after 2 mpk peroral administration to beagles,,9615.0
5067,,,,beagle,,A,,,U,3510,BAO_0000218,CHEMBL621721,22224,,Autocuration,Cmax value after 1 mpk peroral administration to beagles,In vivo,9615.0
5068,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL621722,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,9606.0
5069,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL621723,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,9606.0
5070,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL621724,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,9606.0
5071,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL623443,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,9606.0
5072,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL623444,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,9606.0
5073,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL623445,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,9606.0
5074,1088.0,,Urine,Homo sapiens,,A,,,U,7766,BAO_0000019,CHEMBL623446,22224,,Autocuration,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,9606.0
5075,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,16643,BAO_0000251,CHEMBL623447,22224,,Autocuration,Metabolic stability observed at 30 min after administration in human liver microsomes,,9606.0
5076,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL623448,22224,,Autocuration,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,9606.0
5077,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL623449,22224,,Autocuration,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,9606.0
5078,,,,Homo sapiens,,A,,,U,6852,BAO_0000019,CHEMBL623450,22224,,Autocuration,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,9606.0
5079,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6567,BAO_0000251,CHEMBL623451,22224,,Autocuration,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,9606.0
5080,,,,Homo sapiens,,A,,,U,6570,BAO_0000019,CHEMBL623452,22224,,Autocuration,Metabolic stability (% remaining at 30 mins) in human S9.,,9606.0
5081,,,,Homo sapiens,,A,,,U,6570,BAO_0000019,CHEMBL623453,22224,,Autocuration,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,9606.0
5082,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5237,BAO_0000251,CHEMBL623454,22224,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes,,9606.0
5083,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5237,BAO_0000251,CHEMBL623455,22224,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,9606.0
5084,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5237,BAO_0000251,CHEMBL624371,22224,,Autocuration,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,9606.0
5085,,,,Homo sapiens,,A,,,U,5202,BAO_0000218,CHEMBL624372,22224,,Autocuration,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,9606.0
5086,,,,Homo sapiens,,A,,,U,5481,BAO_0000019,CHEMBL624373,22224,,Autocuration,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,9606.0
5087,,,,Homo sapiens,,A,,,U,5481,BAO_0000019,CHEMBL624374,22224,,Autocuration,Percent remaining in human plasma after incubation for 60 min at 37 C.,,9606.0
5088,,,,Homo sapiens,,A,,,U,3956,BAO_0000019,CHEMBL624556,22224,,Autocuration,The percent remaining in human plasma after 30 min was determined,,9606.0
5089,1969.0,,Plasma,Homo sapiens,,A,,,U,5074,BAO_0000366,CHEMBL624557,22224,,Autocuration,Conversion rate of the prodrug in human plasma,,9606.0
5090,1969.0,,Plasma,Homo sapiens,,A,,,U,5074,BAO_0000366,CHEMBL624558,22224,,Autocuration,Conversion rate of the prodrug in human plasma; ND means no data,,9606.0
5091,178.0,,Blood,Homo sapiens,,A,,,U,4727,BAO_0000221,CHEMBL624559,22224,,Autocuration,Half life of compound was determined in human blood,,9606.0
5092,,,,Homo sapiens,,A,,,U,5965,BAO_0000019,CHEMBL624560,22224,,Autocuration,Half life of compound was determined in man with once daily dosing,,9606.0
5093,,,,Homo sapiens,,A,Microsomes,,U,5732,BAO_0000251,CHEMBL624561,22224,,Autocuration,Half life in human microsomes,In vitro,9606.0
5094,1969.0,,Plasma,Homo sapiens,,A,,,U,5819,BAO_0000366,CHEMBL624562,22224,,Autocuration,Half life in human plasma,,9606.0
5095,1969.0,,Plasma,Homo sapiens,,A,,,U,5819,BAO_0000366,CHEMBL624563,22224,,Autocuration,Half life in human plasma; Not detected,,9606.0
5096,,,,Homo sapiens,,A,,,U,1916,BAO_0000218,CHEMBL624564,22224,,Autocuration,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,9606.0
5097,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6597,BAO_0000251,CHEMBL624565,22224,,Autocuration,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,9606.0
5098,1969.0,,Plasma,Homo sapiens,,A,,,U,5229,BAO_0000366,CHEMBL875152,22224,,Autocuration,Half-life in human plasma,,9606.0
5099,1969.0,,Plasma,Homo sapiens,,A,,,U,5229,BAO_0000366,CHEMBL624566,22224,,Autocuration,Half-life of the parent prodrug in plasma,,9606.0
5100,1969.0,,Plasma,Homo sapiens,,A,,,U,2192,BAO_0000366,CHEMBL873805,22224,,Autocuration,In vitro half life in human plasma was determined,In vitro,9606.0
5101,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,3032,BAO_0000251,CHEMBL624567,22224,,Autocuration,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,9606.0
5102,,,,Homo sapiens,,A,,,U,1916,BAO_0000218,CHEMBL624568,22224,,Autocuration,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,9606.0
5103,,,,Homo sapiens,,A,,,U,17716,BAO_0000218,CHEMBL624569,22224,,Autocuration,Observed volume of distribution,In vivo,9606.0
5104,,,,Homo sapiens,,A,,,U,15778,BAO_0000218,CHEMBL624570,22224,,Autocuration,Oral bioavailability in human,In vivo,9606.0
5105,,,,Homo sapiens,,A,,,U,17313,BAO_0000019,CHEMBL624571,22224,,Autocuration,Tested for human plasma protein binding of the compound,,9606.0
5106,,,,Homo sapiens,,A,,,U,4231,BAO_0000019,CHEMBL624572,22224,,Autocuration,"First order rate constant, k was determined in human plasma",,9606.0
5107,,,,Homo sapiens,,A,,,U,4755,BAO_0000019,CHEMBL624573,22224,,Autocuration,Observed rate constant in 80% human plasma at 37 degree Centigrade,,9606.0
5108,,,,Homo sapiens,,A,,,U,4755,BAO_0000019,CHEMBL875153,22224,,Autocuration,Observed rate constant in 80% human plasma at 37 degree Centigrade,,9606.0
5109,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,16907,BAO_0000251,CHEMBL624574,22224,,Autocuration,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,9606.0
5110,,,,Homo sapiens,,A,,,U,10839,BAO_0000019,CHEMBL624575,22224,,Autocuration,The compound was tested for the plasma binding in human,,9606.0
5111,,,,Homo sapiens,,A,,,U,10839,BAO_0000019,CHEMBL624576,22224,,Autocuration,Plasma protein binding (human),,9606.0
5112,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,3199,BAO_0000251,CHEMBL624577,22224,,Autocuration,Compound was evaluated for half-life in human liver microsomes,In vitro,9606.0
5113,178.0,,Blood,Homo sapiens,,A,,,U,1345,BAO_0000221,CHEMBL624578,22224,,Autocuration,Half life measured in vitro for its stability in human blood,In vitro,9606.0
5114,1977.0,,Serum,Homo sapiens,,A,,,U,4297,BAO_0000019,CHEMBL622796,22224,,Autocuration,Half life in human serum,,9606.0
5115,1977.0,,Serum,Homo sapiens,,A,,,U,4297,BAO_0000019,CHEMBL622797,22224,,Autocuration,Half life in human serum; ND=not determined,,9606.0
5116,,,,Homo sapiens,,A,,,U,4297,BAO_0000019,CHEMBL622798,22224,,Autocuration,Half life were determined in CEM-SS cell extract in decomposition step 1,,9606.0
5117,,,,Homo sapiens,,A,,,U,4297,BAO_0000019,CHEMBL622799,22224,,Autocuration,Half life were determined in CEM-SS cell extract in decomposition step 2,,9606.0
5118,1969.0,,Plasma,Homo sapiens,,A,,,U,4231,BAO_0000366,CHEMBL622800,22224,,Autocuration,Half life of the in human plasma,,9606.0
5119,,,,Homo sapiens,,A,S9,,U,5633,BAO_0000220,CHEMBL622801,22224,,Autocuration,Half life period in human hepatic S9 fraction was determined,In vitro,9606.0
5120,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,5633,BAO_0000251,CHEMBL622802,22224,,Autocuration,Half life period in human liver microsome was determined,In vitro,9606.0
5121,,,,Homo sapiens,,A,,,U,17791,BAO_0000019,CHEMBL622803,22224,,Autocuration,Half life period was determined; 6-7,,9606.0
5122,,,,Homo sapiens,,A,,,U,17791,BAO_0000019,CHEMBL875154,22224,,Autocuration,Half life period was evaluated in human,,9606.0
5123,1969.0,,Plasma,Homo sapiens,,A,,,U,3160,BAO_0000366,CHEMBL622804,22224,,Autocuration,Half life time in human plasma,,9606.0
5124,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622805,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5125,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622611,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5126,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622612,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5127,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL875160,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5128,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622613,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,10090.0
5129,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622614,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5130,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622615,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5131,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622616,50594,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,10090.0
5132,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622617,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5133,2106.0,,Spleen,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622618,50594,,Intermediate,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,10090.0
5134,2106.0,,Spleen,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622619,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,10090.0
5135,2106.0,,Spleen,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622620,50594,,Intermediate,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5136,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622621,50594,,Intermediate,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5137,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622622,50594,,Intermediate,Biodistribution of compound (oxidized form) in blood tissue,In vivo,10090.0
5138,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622623,50594,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5139,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622624,50594,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,10090.0
5140,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622625,50594,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5141,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622626,50594,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5142,178.0,,Blood,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622627,50594,,Intermediate,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,10090.0
5143,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622628,50594,,Intermediate,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,10090.0
5144,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622629,50594,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5145,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622630,50594,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5146,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622631,50594,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5147,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622632,50594,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,10090.0
5148,955.0,,Brain,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622633,50594,,Intermediate,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,10090.0
5149,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622634,50594,,Intermediate,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,10090.0
5150,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622635,50594,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5151,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL875161,50594,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5152,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL622636,50594,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5153,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623335,50594,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5154,948.0,,Heart,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623336,50594,,Intermediate,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,10090.0
5155,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623337,50594,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5156,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623338,50594,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,10090.0
5157,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623339,50594,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5158,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623524,50594,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,10090.0
5159,2113.0,,Kidney,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623525,50594,,Intermediate,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,10090.0
5160,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623526,50594,,Intermediate,Biodistribution of compound (oxidized form) in liver tissue,In vivo,10090.0
5161,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623527,50594,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,10090.0
5162,2107.0,,Liver,Mus musculus,,A,,,N,16438,BAO_0000218,CHEMBL623528,50594,,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,10090.0
5163,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL624615,80852,,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,9606.0
5164,,A-431,,Homo sapiens,,F,,500.0,N,5245,BAO_0000219,CHEMBL621672,80852,,Intermediate,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,9606.0
5165,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL621673,80852,,Expert,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,
5166,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL621674,80852,,Expert,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,
5167,,A-431,,Homo sapiens,,F,,500.0,D,16093,BAO_0000219,CHEMBL884002,9,,Expert,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9606.0
5168,,A-431,,Homo sapiens,,F,,500.0,N,16825,BAO_0000219,CHEMBL621850,80852,,Intermediate,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,9606.0
5169,,A-431,,Homo sapiens,,F,,500.0,N,4848,BAO_0000219,CHEMBL621851,80852,,Intermediate,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,9606.0
5170,,A-431,,Homo sapiens,,F,,500.0,D,14827,BAO_0000219,CHEMBL621852,9,,Expert,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,9606.0
5171,,A-431,,Homo sapiens,,F,,500.0,D,14827,BAO_0000219,CHEMBL621853,9,,Expert,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,9606.0
5172,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL621854,80852,,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,
5173,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL621855,80852,,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5174,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623724,80852,,Expert,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5175,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623725,80852,,Expert,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,
5176,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623726,80852,,Expert,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,
5177,,A-431,,Homo sapiens,,F,,500.0,D,16289,BAO_0000219,CHEMBL623727,9,,Expert,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,9606.0
5178,,A-431,,,,F,,500.0,H,16289,BAO_0000219,CHEMBL623728,9,,Expert,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,
5179,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623729,80852,,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,
5180,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623730,80852,,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5181,,A-431,,,,F,,500.0,N,16289,BAO_0000218,CHEMBL623731,80852,,Expert,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5182,,A-431,,Mus musculus,,F,,500.0,N,14555,BAO_0000218,CHEMBL623732,80852,,Expert,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,10090.0
5183,,A-431,,Mus musculus,,F,,500.0,N,14555,BAO_0000218,CHEMBL623733,80852,,Expert,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,10090.0
5184,,A-431,,Mus musculus,,F,,500.0,N,14555,BAO_0000218,CHEMBL623734,80852,,Expert,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,10090.0
5185,,A-431,,Mus musculus,,F,,500.0,N,14555,BAO_0000218,CHEMBL623735,80852,,Expert,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,10090.0
5186,,A-431,,Homo sapiens,,F,,500.0,N,1937,BAO_0000219,CHEMBL623736,80852,,Expert,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,9606.0
5187,,A-431,,Homo sapiens,,F,,500.0,N,13739,BAO_0000219,CHEMBL623737,80852,,Intermediate,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,9606.0
5188,,A-431,,Homo sapiens,,F,,500.0,N,3558,BAO_0000219,CHEMBL623738,80852,,Intermediate,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,9606.0
5189,,A-431,,Homo sapiens,,F,,500.0,N,3558,BAO_0000219,CHEMBL875168,80852,,Intermediate,Dose giving a 50% decrease in the living cell number (A437 cells),,9606.0
5190,,A549,,Homo sapiens,,F,,646.0,N,17686,BAO_0000219,CHEMBL623739,80682,,Expert,In vitro inhibitory concentration against proliferation of A459 cell line.,,9606.0
5191,,A549,,Homo sapiens,,F,,646.0,N,5305,BAO_0000219,CHEMBL623740,80682,,Intermediate,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,9606.0
5192,,A549,,Homo sapiens,,F,,646.0,N,3614,BAO_0000219,CHEMBL624424,80682,,Intermediate,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,9606.0
5193,,A498,,Homo sapiens,,F,,624.0,N,17229,BAO_0000219,CHEMBL624425,80021,,Intermediate,In vitro antitumor activity against renal A498 tumor cell lines,,9606.0
5194,,A498,,Homo sapiens,,F,,624.0,N,15935,BAO_0000219,CHEMBL624426,80021,,Intermediate,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,9606.0
5195,,A498,,Homo sapiens,,F,,624.0,N,15935,BAO_0000219,CHEMBL624427,80021,,Intermediate,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,9606.0
5196,,A498,,Homo sapiens,,F,,624.0,N,15560,BAO_0000219,CHEMBL624428,80021,,Intermediate,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,9606.0
5197,,A498,,Homo sapiens,,F,,624.0,N,13891,BAO_0000219,CHEMBL624429,80021,,Intermediate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,9606.0
5198,,A498,,Homo sapiens,,F,,624.0,N,13891,BAO_0000219,CHEMBL624620,80021,,Intermediate,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,9606.0
5199,,A498,,Homo sapiens,,F,,624.0,N,13788,BAO_0000219,CHEMBL624621,80021,,Intermediate,Cytotoxicity on kidney carcinoma (A-498) cell line,,9606.0
5200,,A498,,Homo sapiens,,F,,624.0,N,15403,BAO_0000219,CHEMBL624622,80021,,Intermediate,Compound was evaluated against Human cell line renal A498,,9606.0
5201,,A498,,Homo sapiens,,F,,624.0,N,1009,BAO_0000219,CHEMBL624623,80021,,Intermediate,Compound was tested for inhibition of A498 human renal cancer cell line,,9606.0
5202,,A498,,Homo sapiens,,F,,624.0,N,1043,BAO_0000219,CHEMBL874365,80021,,Intermediate,Growth inhibitory activity against A498 human cancer cell line,,9606.0
5203,,A498,,Homo sapiens,,F,,624.0,N,5858,BAO_0000219,CHEMBL624624,80021,,Intermediate,In vitro antitumor activity against human renal A498 cell line,,9606.0
5204,,A498,,Homo sapiens,,F,,624.0,N,5958,BAO_0000219,CHEMBL624625,80021,,Intermediate,In vitro cytotoxic activity against renal (A498) cell line,,9606.0
5205,,A498,,Homo sapiens,,F,,624.0,N,5506,BAO_0000219,CHEMBL624626,80021,,Intermediate,In vitro cytotoxic activity against human renal cancer (A498) cell line,,9606.0
5206,,A498,,Homo sapiens,,F,,624.0,N,12781,BAO_0000219,CHEMBL624627,80021,,Intermediate,Tested for cytostatic activity against renal A498 cell line,,9606.0
5207,,A498,,Homo sapiens,,F,,624.0,N,14399,BAO_0000219,CHEMBL883157,80021,,Intermediate,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,9606.0
5208,,A498,,Homo sapiens,,F,,624.0,N,5958,BAO_0000219,CHEMBL624628,80021,,Expert,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,9606.0
5209,,,,beagle,,A,,,U,3510,BAO_0000218,CHEMBL624629,22224,,Autocuration,Cmax value after 2 mpk peroral administration to beagles,In vivo,9615.0
5210,,,,Canis lupus familiaris,,A,,,U,3510,BAO_0000218,CHEMBL623551,22224,,Autocuration,Bioavailability,In vivo,9615.0
5211,,,,Canis lupus familiaris,,A,,,U,3510,BAO_0000218,CHEMBL623552,22224,,Autocuration,Bioavailability after 1 mpk peroral administration to beagles,In vivo,9615.0
5212,,,,Canis lupus familiaris,,A,,,U,3510,BAO_0000218,CHEMBL623553,22224,,Autocuration,Bioavailability after 2 mpk peroral administration to beagles,In vivo,9615.0
5213,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL623554,22224,,Autocuration,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,9913.0
5214,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL623555,22224,,Autocuration,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,9913.0
5215,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL623556,22224,,Autocuration,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,9913.0
5216,,,,Bos taurus,,A,,,U,9372,BAO_0000019,CHEMBL623557,22224,,Autocuration,Solubility against bovine alpha-chymotrypsin,,9913.0
5217,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL623558,22224,,Autocuration,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,9913.0
5218,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL623559,22224,,Autocuration,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,9913.0
5219,2106.0,,Spleen,Bos taurus,,A,,,U,1469,BAO_0000221,CHEMBL623560,22224,,Autocuration,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,9913.0
5220,,,,Bos taurus,,A,,,U,4297,BAO_0000019,CHEMBL623561,22224,,Autocuration,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,9913.0
5221,,,,Bos taurus,,A,,,U,4297,BAO_0000019,CHEMBL623562,22224,,Autocuration,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,9913.0
5222,,,,Bos taurus,,A,,,U,17585,BAO_0000019,CHEMBL623563,22224,,Autocuration,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,9913.0
5223,2106.0,,Spleen,Bos taurus,,A,,,U,1336,BAO_0000221,CHEMBL623564,22224,,Autocuration,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,9913.0
5224,,,,Bos taurus,,A,,,U,3085,BAO_0000019,CHEMBL873806,22224,,Autocuration,Half life in presence of 2 mg/mL BSA at pH 8.8,,9913.0
5225,,,,Bos taurus,,A,,,U,2857,BAO_0000019,CHEMBL623565,22224,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,9913.0
5226,,,,Bos taurus,,A,,,U,2857,BAO_0000019,CHEMBL623566,22224,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,9913.0
5227,,,,Bos taurus,,A,,,U,2857,BAO_0000019,CHEMBL623567,22224,,Autocuration,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,9913.0
5228,,,,Bos taurus,,A,,,U,1540,BAO_0000019,CHEMBL623568,22224,,Autocuration,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,9913.0
5229,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6316,BAO_0000218,CHEMBL623569,50588,,Intermediate,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,9615.0
5230,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL623570,50588,,Intermediate,AUC after administration at 100 mg/kg/day in dogs,,9615.0
5231,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4953,BAO_0000218,CHEMBL624254,50588,,Intermediate,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,9615.0
5232,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL624255,50588,,Intermediate,AUC value after 15 mg/kg iv dose in Dogs,,9615.0
5233,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL624256,50588,,Intermediate,AUC value after 30 mg/kg po dose in Dogs,,9615.0
5234,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL624257,50588,,Intermediate,AUC value after administration of 4 mg/Kg oral dose in dog,,9615.0
5235,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL624258,50588,,Intermediate,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,9615.0
5236,,,,Canis lupus familiaris,,A,,,N,5356,BAO_0000218,CHEMBL875277,50588,,Intermediate,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,9615.0
5237,,,,Canis lupus familiaris,,A,,,N,16807,BAO_0000218,CHEMBL622667,50588,,Intermediate,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,9615.0
5238,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL622668,50588,,Intermediate,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,9615.0
5239,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL622669,50588,,Intermediate,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,9615.0
5240,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL622670,50588,,Intermediate,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,9615.0
5241,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL622671,50588,,Intermediate,Area under curve determined in dogs after oral administration of 10 mg/kg,,9615.0
5242,,,,Canis lupus familiaris,,A,,,N,5802,BAO_0000218,CHEMBL622672,50588,,Intermediate,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,9615.0
5243,,,,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL622673,50588,,Expert,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,9615.0
5244,,,,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL622674,50588,,Expert,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,9615.0
5245,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL622675,50588,,Intermediate,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,9615.0
5246,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL622676,50588,,Intermediate,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,9615.0
5247,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL622677,50588,,Intermediate,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,9615.0
5248,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL622678,50588,,Intermediate,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,9615.0
5249,,,,Canis lupus familiaris,,A,,,N,4186,BAO_0000218,CHEMBL622679,50588,,Intermediate,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,9615.0
5250,,,,Canis lupus familiaris,,A,,,N,5007,BAO_0000218,CHEMBL622680,50588,,Intermediate,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,9615.0
5251,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL622681,50588,,Intermediate,Area under curve was determine after peroral administration at 10 mpk in dog,,9615.0
5252,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL875278,50588,,Intermediate,Area under curve was determine after peroral administration at 5 mpk in dog,,9615.0
5253,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL622682,50588,,Intermediate,Area under curve was determined,,9615.0
5254,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL622683,50588,,Intermediate,Area under curve in dogs,,9615.0
5255,,,,Canis lupus familiaris,,A,,,N,3771,BAO_0000218,CHEMBL622684,50588,,Intermediate,Area under curve in dogs at 10 mg/kg dose fo oral administration,,9615.0
5256,,,,Canis lupus familiaris,,A,,,N,3771,BAO_0000218,CHEMBL622685,50588,,Intermediate,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,9615.0
5257,,,,Canis lupus familiaris,,A,,,N,3771,BAO_0000218,CHEMBL622686,50588,,Intermediate,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,9615.0
5258,,,,Canis lupus familiaris,,A,,,N,1916,BAO_0000218,CHEMBL618344,50588,,Intermediate,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,9615.0
5259,,,,Canis lupus familiaris,,A,,,N,5302,BAO_0000218,CHEMBL875582,50588,,Intermediate,Area under curve value in dog at a dose of 5 mg/kg,,9615.0
5260,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL618345,50588,,Intermediate,Area under curve was determined after 0.1 mg/kg iv administration in dog,,9615.0
5261,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL618346,50588,,Intermediate,Area under curve was determined after 0.3 mg/kg po administration in dog,,9615.0
5262,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL618347,50588,,Intermediate,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,9615.0
5263,,,,Canis lupus familiaris,,A,,,N,4368,BAO_0000218,CHEMBL618348,50588,,Intermediate,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,9615.0
5264,,,,Homo sapiens,,A,,,U,5318,BAO_0000019,CHEMBL618349,22224,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,9606.0
5265,,,,Homo sapiens,,A,,,U,5318,BAO_0000019,CHEMBL618350,22224,,Autocuration,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,9606.0
5266,,,,Homo sapiens,,A,,,U,5318,BAO_0000019,CHEMBL618351,22224,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,9606.0
5267,,,,Homo sapiens,,A,,,U,5318,BAO_0000019,CHEMBL618352,22224,,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,9606.0
5268,178.0,,Blood,Homo sapiens,,A,,,U,14518,BAO_0000221,CHEMBL873494,22224,,Autocuration,Time taken to reduce 50% of the concentration of compound in blood plasma,,9606.0
5269,1969.0,,Plasma,Homo sapiens,,A,,,U,2209,BAO_0000366,CHEMBL618353,22224,,Autocuration,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,9606.0
5270,1969.0,,Plasma,Homo sapiens,,A,,,U,6787,BAO_0000366,CHEMBL618354,22224,,Autocuration,Half life in human plasma,,9606.0
5271,1969.0,,Plasma,Homo sapiens,,A,,,U,4898,BAO_0000366,CHEMBL875583,22224,,Autocuration,Half life in human plasma was reported,,9606.0
5272,1977.0,,Serum,Homo sapiens,,A,,,U,6072,BAO_0000019,CHEMBL618355,22224,,Autocuration,Half life in human serum,,9606.0
5273,1969.0,,Plasma,Homo sapiens,,A,,,U,16907,BAO_0000366,CHEMBL618356,22224,,Autocuration,Half life upon exposure to human plasma,,9606.0
5274,,,,Homo sapiens,,A,Microsomes,,U,5656,BAO_0000251,CHEMBL618357,22224,,Autocuration,t1/2 in human microsomes,In vitro,9606.0
5275,1969.0,,Plasma,Homo sapiens,,A,,,U,4755,BAO_0000366,CHEMBL618358,22224,,Autocuration,Half life period in 80% human plasma at 37 degree Centigrade,,9606.0
5276,14.0,,Zone of skin,Homo sapiens,,A,,,U,17503,BAO_0000221,CHEMBL618359,22224,,Autocuration,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,9606.0
5277,1969.0,,Plasma,Homo sapiens,,A,,,U,12357,BAO_0000366,CHEMBL618360,22224,,Autocuration,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,9606.0
5278,,,,Homo sapiens,,A,,,U,3076,BAO_0000019,CHEMBL618361,22224,,Autocuration,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,9606.0
5279,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,6410,BAO_0000251,CHEMBL618362,22224,,Autocuration,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,9606.0
5280,1969.0,,Plasma,Homo sapiens,,A,,,U,3741,BAO_0000366,CHEMBL618363,22224,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,9606.0
5281,1969.0,,Plasma,Homo sapiens,,A,,,U,3741,BAO_0000366,CHEMBL618364,22224,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,9606.0
5282,1969.0,,Plasma,Homo sapiens,,A,,,U,3741,BAO_0000366,CHEMBL875584,22224,,Autocuration,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,9606.0
5283,,,,Homo sapiens,,A,,,U,1540,BAO_0000019,CHEMBL618365,22224,,Autocuration,Half-life in the CEM cell extracts,,9606.0
5284,1969.0,,Plasma,Homo sapiens,,A,,,U,2905,BAO_0000366,CHEMBL873495,22224,,Autocuration,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,9606.0
5285,1969.0,,Plasma,Homo sapiens,,A,,,U,2905,BAO_0000366,CHEMBL618366,22224,,Autocuration,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,9606.0
5286,,,,Homo sapiens,,A,,,U,5523,BAO_0000019,CHEMBL618367,22224,,Autocuration,Half-life was determined,,9606.0
5287,178.0,,Blood,Homo sapiens,,A,,,U,1499,BAO_0000221,CHEMBL618368,22224,,Autocuration,Half-life (human blood stability),,9606.0
5288,178.0,,Blood,Homo sapiens,,A,,,U,1499,BAO_0000221,CHEMBL618369,22224,,Autocuration,Half-life (human blood stability); no data,,9606.0
5289,1969.0,,Plasma,Homo sapiens,,A,,,U,17065,BAO_0000366,CHEMBL618370,22224,,Autocuration,Half-life in human plasma,,9606.0
5290,,,,Homo sapiens,,A,,,U,6861,BAO_0000019,CHEMBL618371,22224,,Autocuration,CYP3A4 metabolism half-life (t1/2),,9606.0
5291,178.0,,Blood,Homo sapiens,,A,,,U,1499,BAO_0000221,CHEMBL618372,22224,,Autocuration,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,9606.0
5292,1969.0,,Plasma,Homo sapiens,,A,,,U,530,BAO_0000366,CHEMBL618373,22224,,Autocuration,In vitro half life in human plasma,In vitro,9606.0
5293,1969.0,,Plasma,Homo sapiens,,A,,,U,1116,BAO_0000366,CHEMBL618374,22224,,Autocuration,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,9606.0
5294,1969.0,,Plasma,Homo sapiens,,A,,,U,6695,BAO_0000366,CHEMBL618375,22224,,Autocuration,In vitro hydrolysis in human plasma,In vitro,9606.0
5295,1969.0,,Plasma,Homo sapiens,,A,,,U,6695,BAO_0000366,CHEMBL618376,22224,,Autocuration,In vitro hydrolysis in human plasma; no data,In vitro,9606.0
5296,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,10,BAO_0000251,CHEMBL618377,22224,,Autocuration,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,9606.0
5297,1969.0,,Plasma,Homo sapiens,,A,,,U,993,BAO_0000366,CHEMBL618378,22224,,Autocuration,Plasma half life in human,,9606.0
5298,1969.0,,Plasma,Homo sapiens,,A,,,U,15429,BAO_0000366,CHEMBL618379,22224,,Autocuration,Stability after incubation with human plasma (at 37 degree C),,9606.0
5299,1969.0,,Plasma,Homo sapiens,,A,,,U,1675,BAO_0000366,CHEMBL618380,22224,,Autocuration,T1/2 was evaluated in human plasma,,9606.0
5300,1969.0,,Plasma,Homo sapiens,,A,,,U,2209,BAO_0000366,CHEMBL618381,22224,,Autocuration,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,9606.0
5301,1969.0,,Plasma,Homo sapiens,,A,,,U,2209,BAO_0000366,CHEMBL618382,22224,,Autocuration,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,9606.0
5302,,,,Homo sapiens,,A,,,U,5318,BAO_0000019,CHEMBL618383,22224,,Autocuration,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,9606.0
5303,,,,Homo sapiens,,A,,,U,2412,BAO_0000019,CHEMBL618384,22224,,Autocuration,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,9606.0
5304,,,,Homo sapiens,,A,,,U,2412,BAO_0000019,CHEMBL618385,22224,,Autocuration,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,9606.0
5305,1969.0,,Plasma,Homo sapiens,,A,,,U,2906,BAO_0000366,CHEMBL619099,22224,,Autocuration,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,9606.0
5306,1969.0,,Plasma,Homo sapiens,,A,,,U,2906,BAO_0000366,CHEMBL619100,22224,,Autocuration,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,9606.0
5307,,,,Homo sapiens,,A,,,U,5495,BAO_0000019,CHEMBL619101,22224,,Autocuration,Time taken for 50% to be consumed by serum PON1 was determined,,9606.0
5308,,,,Homo sapiens,,A,,,U,5495,BAO_0000019,CHEMBL619102,22224,,Autocuration,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,9606.0
5309,2107.0,,Liver,Homo sapiens,,A,Microsomes,,U,4397,BAO_0000251,CHEMBL619103,22224,,Autocuration,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,9606.0
5310,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL619268,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5311,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL619269,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5312,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL619270,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5313,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL619271,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5314,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL875585,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5315,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL619272,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,10095.0
5316,,786-0,,Homo sapiens,,F,,391.0,N,6058,BAO_0000219,CHEMBL619273,80640,,Intermediate,Compound tested for growth inhibition of renal cancer cell line 786-0,,9606.0
5317,,786-0,,Homo sapiens,,F,,391.0,N,17708,BAO_0000219,CHEMBL619274,80640,,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,9606.0
5318,,786-0,,Homo sapiens,,F,,391.0,N,14017,BAO_0000219,CHEMBL619275,80640,,Expert,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,9606.0
5319,,786-0,,Homo sapiens,,F,,391.0,N,16818,BAO_0000219,CHEMBL619276,80640,,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,9606.0
5320,,786-0,,Homo sapiens,,F,,391.0,N,16818,BAO_0000219,CHEMBL619277,80640,,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,9606.0
5321,,786-0,,Homo sapiens,,F,,391.0,N,16818,BAO_0000219,CHEMBL619278,80640,,Intermediate,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,9606.0
5322,,786-0,,Homo sapiens,,F,,391.0,N,11970,BAO_0000219,CHEMBL619279,80640,,Intermediate,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,9606.0
5323,,786-0,,Homo sapiens,,F,,391.0,N,12400,BAO_0000219,CHEMBL858458,80640,,Intermediate,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,9606.0
5324,,786-0,,Homo sapiens,,F,,391.0,N,12888,BAO_0000219,CHEMBL619280,80640,,Expert,Cytotoxic effect on renal cancer line 786-0,,9606.0
5325,,786-0,,Homo sapiens,,F,,391.0,N,15300,BAO_0000219,CHEMBL619281,80640,,Intermediate,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,9606.0
5326,,786-0,,Homo sapiens,,F,,391.0,N,14769,BAO_0000219,CHEMBL619282,80640,,Intermediate,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,9606.0
5327,,786-0,,Homo sapiens,,F,,391.0,N,15895,BAO_0000219,CHEMBL619283,80640,,Intermediate,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,9606.0
5328,,786-0,,Homo sapiens,,F,,391.0,N,17376,BAO_0000219,CHEMBL619284,80640,,Intermediate,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,9606.0
5329,,786-0,,Homo sapiens,,F,,391.0,N,14882,BAO_0000219,CHEMBL619285,80640,,Intermediate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,9606.0
5330,,786-0,,Homo sapiens,,F,,391.0,N,14882,BAO_0000219,CHEMBL619286,80640,,Intermediate,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,9606.0
5331,,786-0,,Homo sapiens,,F,,391.0,N,15176,BAO_0000219,CHEMBL619287,80640,,Intermediate,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,9606.0
5332,,786-0,,Homo sapiens,,F,,391.0,N,12696,BAO_0000219,CHEMBL857455,80640,,Intermediate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,9606.0
5333,,786-0,,Homo sapiens,,F,,391.0,N,2496,BAO_0000219,CHEMBL883801,80640,,Intermediate,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,9606.0
5334,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619288,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,9606.0
5335,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619289,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,9606.0
5336,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619290,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,9606.0
5337,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619291,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,9606.0
5338,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619292,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,9606.0
5339,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619293,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,9606.0
5340,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619294,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,9606.0
5341,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619295,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,9606.0
5342,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619296,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,9606.0
5343,,791T cell line,,Homo sapiens,,F,,972.0,N,11831,BAO_0000219,CHEMBL619297,80641,,Intermediate,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,9606.0
5344,,786-0,,Homo sapiens,,F,,391.0,N,12782,BAO_0000219,CHEMBL619298,80640,,Intermediate,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,9606.0
5345,,,,,,F,,,U,1229,BAO_0000019,CHEMBL619299,22226,,Intermediate,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,
5346,,RPMI-8226,,Homo sapiens,,F,,741.0,N,15313,BAO_0000219,CHEMBL619300,80433,,Expert,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,9606.0
5347,,RPMI-8226,,Homo sapiens,,F,,741.0,N,15313,BAO_0000219,CHEMBL619301,80433,,Expert,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,9606.0
5348,,RPMI-8226,,Homo sapiens,,F,,741.0,N,11544,BAO_0000219,CHEMBL619302,80433,,Intermediate,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,9606.0
5349,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619303,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9606.0
5350,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619304,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9606.0
5351,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL857706,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9606.0
5352,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619305,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9606.0
5353,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619306,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9606.0
5354,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619307,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9606.0
5355,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619308,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9606.0
5356,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619309,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9606.0
5357,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL619310,80433,,Intermediate,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9606.0
5358,,A498,,Homo sapiens,,F,,624.0,N,14769,BAO_0000219,CHEMBL619311,80021,,Intermediate,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,9606.0
5359,,A498,,Homo sapiens,,F,,624.0,N,15354,BAO_0000219,CHEMBL619312,80021,,Intermediate,Compound was tested for the growth inhibition of A498 renal tumor cell line,,9606.0
5360,,A498,,Homo sapiens,,F,,624.0,N,17445,BAO_0000219,CHEMBL619313,80021,,Intermediate,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,9606.0
5361,,A498,,Homo sapiens,,F,,624.0,N,4337,BAO_0000219,CHEMBL619314,80021,,Intermediate,In vitro inhibitory concentration against renal cancer cell line A498,,9606.0
5362,,A498,,Homo sapiens,,F,,624.0,N,15277,BAO_0000219,CHEMBL619959,80021,,Intermediate,Cytotoxicity against A 498 tumor cell line,,9606.0
5363,,A498,,Homo sapiens,,F,,624.0,N,4812,BAO_0000219,CHEMBL619960,80021,,Intermediate,In vitro antitumor activity against A498 human cancer cell line,,9606.0
5364,,A498,,Homo sapiens,,F,,624.0,N,4812,BAO_0000219,CHEMBL619961,80021,,Intermediate,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,9606.0
5365,,A498,,Homo sapiens,,F,,624.0,N,4995,BAO_0000219,CHEMBL619962,80021,,Intermediate,Inhibitory dose required against A498 human tumor cell lines,,9606.0
5366,,A498,,Homo sapiens,,F,,624.0,N,5847,BAO_0000219,CHEMBL875586,80021,,Intermediate,Anticancer activity against one renal cancer (A498 cell line),,9606.0
5367,,A498,,Homo sapiens,,F,,624.0,N,6557,BAO_0000219,CHEMBL619963,80021,,Intermediate,In vitro cytotoxicity against melanoma A498 cell line,,9606.0
5368,,A498,,Homo sapiens,,F,,624.0,N,2597,BAO_0000219,CHEMBL619964,80021,,Intermediate,Compound was tested for growth inhibitory activity against A498 cell line,,9606.0
5369,,A498,,Homo sapiens,,F,,624.0,N,6058,BAO_0000219,CHEMBL620108,80021,,Intermediate,Compound tested for growth inhibition of renal cancer cell line A498,,9606.0
5370,,A498,,Homo sapiens,,F,,624.0,N,17708,BAO_0000219,CHEMBL620109,80021,,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,9606.0
5371,,A498,,Homo sapiens,,F,,624.0,N,15176,BAO_0000219,CHEMBL620110,80021,,Intermediate,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,9606.0
5372,,A498,,Homo sapiens,,F,,624.0,N,15300,BAO_0000219,CHEMBL620111,80021,,Intermediate,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,9606.0
5373,,A498,,Homo sapiens,,F,,624.0,N,11970,BAO_0000219,CHEMBL620112,80021,,Intermediate,Tested for cytotoxicity against A498 cell lines in renal cancer,,9606.0
5374,,A498,,Homo sapiens,,F,,624.0,N,12400,BAO_0000219,CHEMBL620113,80021,,Intermediate,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,9606.0
5375,,A498,,Homo sapiens,,F,,624.0,N,12888,BAO_0000219,CHEMBL620114,80021,,Expert,Cytotoxic effect on renal cancer lines A498,,9606.0
5376,,A498,,Homo sapiens,,F,,624.0,N,3030,BAO_0000219,CHEMBL620115,80021,,Intermediate,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,9606.0
5377,,A498,,Homo sapiens,,F,,624.0,N,14769,BAO_0000219,CHEMBL620116,80021,,Intermediate,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,9606.0
5378,,A498,,Homo sapiens,,F,,624.0,N,17376,BAO_0000219,CHEMBL620117,80021,,Intermediate,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,9606.0
5379,,A498,,Homo sapiens,,F,,624.0,N,16558,BAO_0000219,CHEMBL620118,80021,,Intermediate,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,9606.0
5380,,A498,,Homo sapiens,,F,,624.0,N,5194,BAO_0000219,CHEMBL620119,80021,,Intermediate,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,9606.0
5381,,A498,,Homo sapiens,,F,,624.0,N,10708,BAO_0000219,CHEMBL620120,80021,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,9606.0
5382,,A549,,Homo sapiens,,F,,646.0,N,16880,BAO_0000219,CHEMBL620121,80682,,Expert,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,9606.0
5383,,A549,,Homo sapiens,,F,,646.0,N,10196,BAO_0000219,CHEMBL620122,80682,,Intermediate,Antitumor activity against A549 human lung carcinoma cell line,,9606.0
5384,,A549,,Homo sapiens,,F,,646.0,N,10196,BAO_0000219,CHEMBL620123,80682,,Intermediate,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,9606.0
5385,,A549,,Homo sapiens,,F,,646.0,N,10196,BAO_0000219,CHEMBL620124,80682,,Intermediate,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,9606.0
5386,,A549,,Homo sapiens,,F,,646.0,N,12083,BAO_0000219,CHEMBL620125,80682,,Intermediate,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,9606.0
5387,,A549,,Homo sapiens,,F,,646.0,N,16464,BAO_0000219,CHEMBL620126,80682,,Expert,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,9606.0
5388,,A549,,Homo sapiens,,F,,646.0,N,16464,BAO_0000219,CHEMBL883027,80682,,Intermediate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5389,,A549,,Homo sapiens,,F,,646.0,N,16470,BAO_0000219,CHEMBL620127,80682,,Expert,In vitro cytotoxic activity against human lung A549 cell line,,9606.0
5390,,A549,,Homo sapiens,,F,,646.0,N,16470,BAO_0000219,CHEMBL620128,80682,,Intermediate,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,9606.0
5391,,A549,,Homo sapiens,,F,,646.0,N,16470,BAO_0000219,CHEMBL620129,80682,,Intermediate,In vitro cytotoxic activity against human lung A549 cell line),,9606.0
5392,,A549,,Homo sapiens,,F,,646.0,N,16470,BAO_0000219,CHEMBL620130,80682,,Intermediate,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,9606.0
5393,,A549,,Homo sapiens,,F,,646.0,N,16582,BAO_0000219,CHEMBL620131,80682,,Expert,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,9606.0
5394,,A549,,Homo sapiens,,F,,646.0,N,15935,BAO_0000219,CHEMBL620132,80682,,Intermediate,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,9606.0
5395,,A549,,Homo sapiens,,F,,646.0,N,15935,BAO_0000219,CHEMBL620133,80682,,Intermediate,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,9606.0
5396,,A549,,Homo sapiens,,F,,646.0,N,16597,BAO_0000219,CHEMBL620134,80682,,Expert,Inhibition of A549 human lung carcinoma cell proliferation,,9606.0
5397,,A549,,Homo sapiens,,F,,646.0,N,17376,BAO_0000219,CHEMBL620135,80682,,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line,,9606.0
5398,,A549,,Homo sapiens,,F,,646.0,N,16496,BAO_0000219,CHEMBL620136,80682,,Intermediate,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,9606.0
5399,,A549,,Homo sapiens,,F,,646.0,N,16152,BAO_0000219,CHEMBL620137,80682,,Intermediate,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,9606.0
5400,,A549,,Homo sapiens,,F,,646.0,N,16152,BAO_0000219,CHEMBL620268,80682,,Intermediate,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,9606.0
5401,,A549,,Homo sapiens,,F,,646.0,N,16464,BAO_0000219,CHEMBL620269,80682,,Intermediate,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5402,,A549,,Homo sapiens,,F,,646.0,N,2288,BAO_0000219,CHEMBL620270,80682,,Intermediate,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,9606.0
5403,,A549,,Homo sapiens,,F,,646.0,N,17350,BAO_0000219,CHEMBL620271,80682,,Intermediate,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,9606.0
5404,,A549,,Homo sapiens,,F,,646.0,N,4090,BAO_0000219,CHEMBL620272,80682,,Expert,Inhibition of A549 cancer cell proliferation,,9606.0
5405,,A549,,Homo sapiens,,F,,646.0,N,4090,BAO_0000219,CHEMBL620273,80682,,Expert,Inhibition of A549 cancer cell proliferation (Not tested),,9606.0
5406,,A549,,Homo sapiens,,F,,646.0,N,17350,BAO_0000219,CHEMBL620274,80682,,Intermediate,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,9606.0
5407,,A549,,Homo sapiens,,F,,646.0,N,4197,BAO_0000219,CHEMBL620275,80682,,Intermediate,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,9606.0
5408,,A549,,Homo sapiens,,F,,646.0,N,17072,BAO_0000219,CHEMBL620276,80682,,Intermediate,Antiproliferative potency determined as inhibitory concentration against A549 cells,,9606.0
5409,,A549,,Homo sapiens,,F,,646.0,N,17072,BAO_0000219,CHEMBL620277,80682,,Intermediate,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,9606.0
5410,,A549,,Homo sapiens,,F,,646.0,N,5194,BAO_0000219,CHEMBL620278,80682,,Intermediate,Cytotoxicity against Renal cell lines A549 was determined,,9606.0
5411,,,,Canis lupus familiaris,,A,,,N,4257,BAO_0000218,CHEMBL620279,50588,,Intermediate,Area under curve was determined in dog after a 3 mg/kg of oral dose,,9615.0
5412,,,,Canis lupus familiaris,,A,,,N,6123,BAO_0000218,CHEMBL620280,50588,,Intermediate,Area under curve was determined in dog after oral administration at 1 mg/kg,,9615.0
5413,,,,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL620281,50588,,Intermediate,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,9615.0
5414,,,,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL620282,50588,,Intermediate,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,9615.0
5415,,,,Canis lupus familiaris,,A,,,N,8833,BAO_0000218,CHEMBL621134,50588,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,9615.0
5416,,,,Canis lupus familiaris,,A,,,N,8833,BAO_0000218,CHEMBL621135,50588,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,9615.0
5417,,,,Canis lupus familiaris,,A,,,N,8833,BAO_0000218,CHEMBL621136,50588,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,9615.0
5418,,,,Canis lupus familiaris,,A,,,N,8833,BAO_0000218,CHEMBL621137,50588,,Intermediate,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,9615.0
5419,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL621138,50588,,Intermediate,Area under plasma concentration time curve in dog upon oral administration,,9615.0
5420,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17650,BAO_0000218,CHEMBL875587,50588,,Intermediate,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,9615.0
5421,,,,Canis lupus familiaris,,A,,,N,1977,BAO_0000218,CHEMBL621139,50588,,Intermediate,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,9615.0
5422,,,,Canis lupus familiaris,,A,,,N,1977,BAO_0000218,CHEMBL621140,50588,,Intermediate,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,9615.0
5423,,,,Canis lupus familiaris,,A,,,N,3132,BAO_0000218,CHEMBL621141,50588,,Intermediate,Area under the curve for the compound was obtained when tested in dog,,9615.0
5424,,,,Canis lupus familiaris,,A,,,N,5473,BAO_0000218,CHEMBL621142,50588,,Intermediate,Area under the curve at a dose of 1 mg/kg,,9615.0
5425,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL621143,50588,,Intermediate,Area under the curve at a dose of 1 mg/kg (oral),,9615.0
5426,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL621144,50588,,Intermediate,Area under the curve at i.v. dose of 0.2 mg/kg,,9615.0
5427,,,,Canis lupus familiaris,,A,,,N,6062,BAO_0000218,CHEMBL621145,50588,,Intermediate,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,9615.0
5428,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL621146,50588,,Intermediate,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,9615.0
5429,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL622567,50588,,Intermediate,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,9615.0
5430,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL622568,50588,,Intermediate,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,9615.0
5431,,,,Canis lupus familiaris,,A,,,N,2877,BAO_0000218,CHEMBL622569,50588,,Intermediate,Compound was evaluated for area under the curve in dog blood.,,9615.0
5432,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL622570,50588,,Intermediate,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,9615.0
5433,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5130,BAO_0000218,CHEMBL622571,50588,,Intermediate,AUC in dog after oral dose (1 mg/kg),,9615.0
5434,,,,Canis lupus familiaris,,A,,,N,6265,BAO_0000218,CHEMBL622572,50588,,Intermediate,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,9615.0
5435,,,,Canis lupus familiaris,,A,,,N,4657,BAO_0000218,CHEMBL622573,50588,,Intermediate,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,9615.0
5436,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL622574,50588,,Intermediate,Pharmacokinetic parameter AUC after intravenous administration to dogs,,9615.0
5437,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL622575,50588,,Intermediate,Pharmacokinetic parameter AUC after oral administration to dogs,,9615.0
5438,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL622576,50588,,Intermediate,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,9615.0
5439,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL622577,50588,,Intermediate,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,9615.0
5440,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL622578,50588,,Intermediate,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,9615.0
5441,,,,Canis lupus familiaris,,A,,,N,6241,BAO_0000218,CHEMBL622579,50588,,Intermediate,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,9615.0
5442,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL622580,50588,,Intermediate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,9615.0
5443,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL622581,50588,,Intermediate,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,9615.0
5444,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL622582,50588,,Intermediate,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,9615.0
5445,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL622583,50588,,Intermediate,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,9615.0
5446,,,,Canis lupus familiaris,,A,,,N,6641,BAO_0000218,CHEMBL622584,50588,,Intermediate,Oral AUCN in dog (dosed at 0.5 mpk iv ),,9615.0
5447,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL622585,50588,,Intermediate,Oral AUCN in dog (dosed at 0.5 mpk iv ),,9615.0
5448,,,,Canis lupus familiaris,,A,,,N,17791,BAO_0000218,CHEMBL622586,50588,,Intermediate,Compound was evaluated for oral bioavailability in dog; 90-100,,9615.0
5449,,,,Canis lupus familiaris,,A,,,N,17655,BAO_0000218,CHEMBL623281,50588,,Intermediate,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,9615.0
5450,,,,Canis lupus familiaris,,A,,,N,17655,BAO_0000218,CHEMBL623282,50588,,Intermediate,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,9615.0
5451,,,,Canis lupus familiaris,,A,,,N,6596,BAO_0000218,CHEMBL623283,50588,,Intermediate,PAPP (membrane permeability) in dog kidney cell monolayer assay,,9615.0
5452,,,,Canis lupus familiaris,,A,,,N,3880,BAO_0000218,CHEMBL623284,50588,,Intermediate,Oral bioavailability in dog,,9615.0
5453,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL623285,50588,,Intermediate,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,9615.0
5454,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17409,BAO_0000218,CHEMBL623463,50588,,Intermediate,Plasma protein binding towards dog plasma at 10 uM,,9615.0
5455,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17409,BAO_0000218,CHEMBL875952,50588,,Intermediate,Plasma protein binding towards dog plasma at 100 uM,,9615.0
5456,,,,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL621705,50588,,Intermediate,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,9615.0
5457,,,,Canis lupus familiaris,,A,,,N,13501,BAO_0000218,CHEMBL621706,50588,,Intermediate,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,9615.0
5458,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL621707,50588,,Intermediate,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,9615.0
5459,,,,Canis lupus familiaris,,A,,,N,15145,BAO_0000218,CHEMBL621708,50588,,Intermediate,Bioavailability in dogs,In vivo,9615.0
5460,,,,Canis lupus familiaris,,A,,,N,4219,BAO_0000218,CHEMBL621709,50588,,Intermediate,Bioavailability,In vivo,9615.0
5461,,,,Canis lupus familiaris,,A,,,N,17538,BAO_0000218,CHEMBL621710,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
5462,,,,Canis lupus familiaris,,A,,,N,17538,BAO_0000218,CHEMBL621711,50588,,Intermediate,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,9615.0
5463,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL621712,50588,,Intermediate,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,9615.0
5464,,,,Canis lupus familiaris,,A,,,N,17650,BAO_0000218,CHEMBL621713,50588,,Intermediate,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,9615.0
5465,,,,Canis lupus familiaris,,A,,,N,3132,BAO_0000218,CHEMBL621714,50588,,Intermediate,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,9615.0
5466,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL621715,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5467,2107.0,,Liver,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623717,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5468,2107.0,,Liver,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623718,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,10095.0
5469,2107.0,,Liver,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623719,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5470,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623720,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5471,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623721,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5472,2385.0,,Muscle tissue,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623722,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5473,2385.0,,Muscle tissue,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623723,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,10095.0
5474,2385.0,,Muscle tissue,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL618543,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5475,2106.0,,Spleen,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL618544,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5476,2106.0,,Spleen,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL875155,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5477,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL618545,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,10095.0
5478,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL618546,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,10095.0
5479,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623529,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5480,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL623530,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,10095.0
5481,,,,Mus sp.,,A,,,U,2413,BAO_0000218,CHEMBL621764,22224,,Autocuration,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,10095.0
5482,,,,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621765,22224,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,9527.0
5483,2037.0,,Cerebellum,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621766,22224,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,9527.0
5484,1870.0,,Frontal cortex,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621767,22224,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,9527.0
5485,,,,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621768,22224,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,9527.0
5486,2435.0,,Striatum,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621769,22224,,Autocuration,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,9527.0
5487,,,,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621770,22224,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,9527.0
5488,2037.0,,Cerebellum,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621771,22224,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,9527.0
5489,1870.0,,Frontal cortex,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621772,22224,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,9527.0
5490,,,,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621773,22224,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,9527.0
5491,2435.0,,Striatum,Cercopithecidae,,A,,,U,17827,BAO_0000019,CHEMBL621774,22224,,Autocuration,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,9527.0
5492,,,,Cercopithecidae,,A,,,U,17791,BAO_0000218,CHEMBL621775,22224,,Autocuration,Compound was evaluated for oral bioavailability in rats,,9527.0
5493,1969.0,,Plasma,Cercopithecidae,,A,,,U,17667,BAO_0000218,CHEMBL621776,22224,,Autocuration,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,9527.0
5494,,,,Cercopithecidae,,A,,,U,17791,BAO_0000019,CHEMBL621777,22224,,Autocuration,Half life period was evaluated in monkey,,9527.0
5495,,,,Cercopithecidae,,A,,,U,110,BAO_0000218,CHEMBL875162,22224,,Autocuration,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,9527.0
5496,1969.0,,Plasma,Mus musculus,,A,,,N,5781,BAO_0000218,CHEMBL621778,50594,,Intermediate,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,10090.0
5497,1969.0,,Plasma,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL621779,50594,,Intermediate,AUC after intraperitoneal administration of 100 mg/kg in mice,,10090.0
5498,1969.0,,Plasma,Mus musculus,,A,,,N,17718,BAO_0000218,CHEMBL622479,50594,,Intermediate,AUC value was determined after oral administration,,10090.0
5499,,,,Mus musculus,,A,,,N,4573,BAO_0000218,CHEMBL622480,50594,,Intermediate,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,10090.0
5500,,,,Mus musculus,,A,,,N,3277,BAO_0000218,CHEMBL622481,50594,,Intermediate,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,10090.0
5501,,,,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL622482,50594,,Intermediate,Area under curve by ioral administration in mouse,,10090.0
5502,,,,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL622483,50594,,Intermediate,Area under curve by iv administration in mouse,,10090.0
5503,,,,Mus musculus,,A,,,N,5951,BAO_0000218,CHEMBL622484,50594,,Intermediate,Area under curve at 0-8 hr in IRC mice after peroral administration,,10090.0
5504,,,,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL622641,50594,,Intermediate,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,10090.0
5505,,,,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL622642,50594,,Intermediate,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,10090.0
5506,,,,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL622643,50594,,Intermediate,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,10090.0
5507,,,,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL622644,50594,,Intermediate,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,10090.0
5508,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL622645,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9606.0
5509,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL622646,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9606.0
5510,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL621238,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9606.0
5511,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL621239,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9606.0
5512,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL621240,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9606.0
5513,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL621241,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9606.0
5514,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL621242,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9606.0
5515,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620350,80433,,Intermediate,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9606.0
5516,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620351,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9606.0
5517,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620352,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9606.0
5518,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620353,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9606.0
5519,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620354,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9606.0
5520,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620355,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9606.0
5521,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620356,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9606.0
5522,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620357,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9606.0
5523,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620358,80433,,Intermediate,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9606.0
5524,,RPMI-8226,,Homo sapiens,,F,,741.0,N,9424,BAO_0000219,CHEMBL620359,80433,,Expert,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,9606.0
5525,,RPMI-8226,,Homo sapiens,,F,,741.0,N,11544,BAO_0000219,CHEMBL620360,80433,,Intermediate,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,9606.0
5526,,RPMI-8226,,Homo sapiens,,F,,741.0,N,17378,BAO_0000219,CHEMBL620361,80433,,Intermediate,Cytotoxicity of compound against 8226/DOX1V cells,,9606.0
5527,,RPMI-8226,,Homo sapiens,,F,,741.0,N,17378,BAO_0000219,CHEMBL620362,80433,,Intermediate,Cytotoxicity of compound against 8226/S cells,,9606.0
5528,,RPMI-8226,,Homo sapiens,,F,,741.0,N,17079,BAO_0000219,CHEMBL620363,80433,,Intermediate,Inhibitory concentration against 8226 myeloma cancer cell line,,9606.0
5529,,RPMI-8226,,Homo sapiens,,F,,741.0,N,17079,BAO_0000219,CHEMBL620364,80433,,Intermediate,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,9606.0
5530,,833K,,Homo sapiens,,F,,854.0,N,13466,BAO_0000219,CHEMBL620365,80647,,Intermediate,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,9606.0
5531,,833K,,Homo sapiens,,F,,854.0,N,13466,BAO_0000219,CHEMBL620366,80647,,Intermediate,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,9606.0
5532,,833K,,Homo sapiens,,F,,854.0,N,2392,BAO_0000219,CHEMBL620367,80647,,Expert,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,9606.0
5533,,833K,,Homo sapiens,,F,,854.0,N,2392,BAO_0000219,CHEMBL620368,80647,,Intermediate,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,9606.0
5534,,,,,,B,,,U,6608,BAO_0000019,CHEMBL620369,22226,,Autocuration,Inhibitory activity against caspase-1,,
5535,,,,Enterococcus faecalis,,B,,,H,10199,BAO_0000357,CHEMBL620370,45,,Autocuration,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,1351.0
5536,,8701-BC,,Homo sapiens,,F,,705.0,N,17749,BAO_0000219,CHEMBL620371,80648,,Intermediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,9606.0
5537,,8701-BC,,Homo sapiens,,F,,705.0,N,17749,BAO_0000219,CHEMBL620372,80648,,Intermediate,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,9606.0
5538,,,,,,F,,,U,1229,BAO_0000019,CHEMBL876492,22226,,Intermediate,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,
5539,,,,,,F,,,U,1229,BAO_0000019,CHEMBL620373,22226,,Intermediate,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,
5540,,,,,,F,,,U,1229,BAO_0000019,CHEMBL620374,22226,,Intermediate,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,
5541,,,,,,B,,,U,6390,BAO_0000019,CHEMBL620375,22226,,Autocuration,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,
5542,,,,Streptococcus pyogenes,,F,,,U,16219,BAO_0000019,CHEMBL857902,22226,,Autocuration,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,1314.0
5543,,,,Streptococcus pyogenes,,F,,,U,16219,BAO_0000019,CHEMBL620376,22226,,Autocuration,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,1314.0
5544,,,,,,B,,,H,17043,BAO_0000357,CHEMBL620377,11922,,Autocuration,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,
5545,,KB ,,Homo sapiens,,F,,324.0,N,6929,BAO_0000219,CHEMBL620378,81115,,Intermediate,Tested for in vitro cytotoxic potency of compound in 9KB assay,,9606.0
5546,,KB ,,Homo sapiens,,A,,324.0,N,6929,BAO_0000219,CHEMBL620379,81115,,Intermediate,Tested for in vitro cytotoxic potency of compound in 9KB assay,,9606.0
5547,,,,Homo sapiens,,F,,,U,7083,BAO_0000219,CHEMBL620380,22226,,Autocuration,In vitro cytotoxicity of compound was tested against 9KB cells.,,9606.0
5548,,9L,,Rattus norvegicus,,F,,392.0,N,12446,BAO_0000219,CHEMBL884006,80653,,Intermediate,Cytotoxic concentration against 9L cells was determined on day 3,,10116.0
5549,,9L,,Rattus norvegicus,,F,,392.0,N,15345,BAO_0000219,CHEMBL620381,80653,,Expert,Tested in vitro for anticancer activity against 9L cells,,10116.0
5550,,9L,,Rattus norvegicus,,F,,392.0,N,15345,BAO_0000219,CHEMBL620382,80653,,Expert,Tested in vitro for anticancer activity against 9L cells; Not determined,,10116.0
5551,,A549,,Homo sapiens,,F,,646.0,N,6301,BAO_0000219,CHEMBL620383,80682,,Intermediate,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,9606.0
5552,,A549,,Homo sapiens,,F,,646.0,N,4833,BAO_0000219,CHEMBL876493,80682,,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,9606.0
5553,,A549,,Homo sapiens,,F,,646.0,N,4833,BAO_0000219,CHEMBL620384,80682,,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,9606.0
5554,,A549,,Homo sapiens,,F,,646.0,N,4833,BAO_0000219,CHEMBL620385,80682,,Intermediate,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,9606.0
5555,,A549,,Homo sapiens,,F,,646.0,N,13330,BAO_0000219,CHEMBL620386,80682,,Expert,Cytotoxicity against human lung carcinoma A549 cell line,,9606.0
5556,,A549,,Homo sapiens,,F,,646.0,D,17517,BAO_0000219,CHEMBL620387,25,,Expert,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,9606.0
5557,,A549,,Homo sapiens,,F,,646.0,D,17517,BAO_0000219,CHEMBL621404,25,,Expert,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,9606.0
5558,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL621405,80682,,Intermediate,"In vitro growth inhibition of A549, lung carcinoma",,9606.0
5559,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL621406,80682,,Intermediate,"In vitro growth inhibition of A549, lung carcinoma.",,9606.0
5560,,A549,,Homo sapiens,,F,,646.0,N,5228,BAO_0000219,CHEMBL621407,80682,,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,9606.0
5561,,A549,,Homo sapiens,,F,,646.0,N,5351,BAO_0000219,CHEMBL621408,80682,,Intermediate,Cytotoxic activity against human lung cancer A549 cell line was determined,,9606.0
5562,,A549,,Homo sapiens,,F,,646.0,N,12198,BAO_0000219,CHEMBL885345,80682,,Expert,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,9606.0
5563,,A549,,Homo sapiens,,F,,646.0,N,13891,BAO_0000219,CHEMBL621409,80682,,Intermediate,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,9606.0
5564,,A549,,Homo sapiens,,F,,646.0,N,5677,BAO_0000219,CHEMBL876034,80682,,Expert,Cytotoxicity in A549 (human carcinoma) cell line.,,9606.0
5565,,A549,,Homo sapiens,,F,,646.0,N,13788,BAO_0000219,CHEMBL621410,80682,,Intermediate,Cytotoxicity on lung carcinoma (A-549) cell line,,9606.0
5566,,A549,,Homo sapiens,,F,,646.0,N,13384,BAO_0000219,CHEMBL621411,80682,,Expert,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,9606.0
5567,,A549,,Homo sapiens,,F,,646.0,N,6726,BAO_0000219,CHEMBL621412,80682,,Intermediate,Effective dose of compound against replication of A549 cell line was evaluated,,9606.0
5568,,A549,,Homo sapiens,,F,,646.0,N,3455,BAO_0000219,CHEMBL621413,80682,,Expert,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,9606.0
5569,,A549,,Homo sapiens,,F,,646.0,N,5726,BAO_0000219,CHEMBL621414,80682,,Intermediate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,9606.0
5570,,A549,,Homo sapiens,,F,,646.0,N,5726,BAO_0000219,CHEMBL621415,80682,,Intermediate,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,9606.0
5571,,A549,,Homo sapiens,,F,,646.0,N,3936,BAO_0000219,CHEMBL621416,80682,,Intermediate,The compound was evaluated for antiproliferative activity against A549 cell line,,9606.0
5572,,A549,,Homo sapiens,,F,,646.0,N,14991,BAO_0000219,CHEMBL621417,80682,,Intermediate,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,9606.0
5573,,A549,,Homo sapiens,,F,,646.0,N,5243,BAO_0000219,CHEMBL621418,80682,,Intermediate,Concentration required for growth inhibition of human lung carcinoma cell line A549,,9606.0
5574,,A549,,Homo sapiens,,F,,646.0,N,12858,BAO_0000219,CHEMBL621419,80682,,Intermediate,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,9606.0
5575,,A549,,Homo sapiens,,F,,646.0,N,6776,BAO_0000219,CHEMBL621420,80682,,Intermediate,Growth inhibition against A549 cell line was evaluated,,9606.0
5576,,A549,,Homo sapiens,,F,,646.0,N,16558,BAO_0000219,CHEMBL875823,80682,,Intermediate,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,9606.0
5577,,A549,,Homo sapiens,,F,,646.0,N,4583,BAO_0000219,CHEMBL621421,80682,,Expert,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,9606.0
5578,,A549,,Homo sapiens,,F,,646.0,N,13514,BAO_0000219,CHEMBL621422,80682,,Intermediate,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,9606.0
5579,,A549,,Homo sapiens,,F,,646.0,N,15166,BAO_0000219,CHEMBL884014,80682,,Expert,Chemosensitivity against DT-diaphorase rich A549 cell lines,,9606.0
5580,,A549,,Homo sapiens,,F,,646.0,N,13873,BAO_0000219,CHEMBL621423,80682,,Intermediate,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,9606.0
5581,,A549,,Homo sapiens,,F,,646.0,N,6447,BAO_0000219,CHEMBL621424,80682,,Expert,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,9606.0
5582,,A549,,Homo sapiens,,F,,646.0,N,2068,BAO_0000219,CHEMBL621425,80682,,Intermediate,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,9606.0
5583,,A549,,Homo sapiens,,F,,646.0,N,1863,BAO_0000219,CHEMBL621426,80682,,Expert,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,9606.0
5584,,A549,,Homo sapiens,,F,,646.0,N,13873,BAO_0000219,CHEMBL621427,80682,,Intermediate,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,9606.0
5585,,A549,,Homo sapiens,,F,,646.0,N,13873,BAO_0000219,CHEMBL621428,80682,,Intermediate,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,9606.0
5586,,A549,,Homo sapiens,,F,,646.0,N,13873,BAO_0000219,CHEMBL621429,80682,,Expert,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,9606.0
5587,,A549,,Homo sapiens,,F,,646.0,N,579,BAO_0000219,CHEMBL621430,80682,,Intermediate,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,9606.0
5588,,A549,,Homo sapiens,,F,,646.0,N,579,BAO_0000219,CHEMBL621431,80682,,Intermediate,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,9606.0
5589,,A549,,Homo sapiens,,F,,646.0,N,4584,BAO_0000219,CHEMBL621432,80682,,Intermediate,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,9606.0
5590,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621433,80682,,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,9606.0
5591,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL875824,80682,,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,9606.0
5592,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621434,80682,,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,9606.0
5593,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621435,80682,,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,9606.0
5594,,A549,,Homo sapiens,,F,,646.0,N,14188,BAO_0000219,CHEMBL621436,80682,,Intermediate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,9606.0
5595,,A549,,Homo sapiens,,F,,646.0,N,14188,BAO_0000219,CHEMBL621437,80682,,Intermediate,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,9606.0
5596,,A549,,Homo sapiens,,F,,646.0,N,15354,BAO_0000219,CHEMBL621438,80682,,Intermediate,Compound was tested for the growth inhibition of A549 lung tumor cell line,,9606.0
5597,,A549,,Homo sapiens,,F,,646.0,N,14253,BAO_0000219,CHEMBL621439,80682,,Expert,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,9606.0
5598,,A549,,Homo sapiens,,F,,646.0,N,13873,BAO_0000219,CHEMBL621440,80682,,Intermediate,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,9606.0
5599,,,,Canis lupus familiaris,,A,,,N,3043,BAO_0000218,CHEMBL621441,50588,,Intermediate,Oral bioavailability in dog (conscious),In vivo,9615.0
5600,,,,Canis lupus familiaris,,A,,,N,3045,BAO_0000218,CHEMBL621442,50588,,Intermediate,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,9615.0
5601,,,,Canis lupus familiaris,,A,,,N,3022,BAO_0000218,CHEMBL621443,50588,,Intermediate,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,9615.0
5602,,,,Canis lupus familiaris,,A,,,N,4453,BAO_0000218,CHEMBL621444,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5603,,,,Canis lupus familiaris,,A,,,N,1696,BAO_0000218,CHEMBL625133,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5604,,,,Canis lupus familiaris,,A,,,N,5045,BAO_0000218,CHEMBL625134,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5605,,,,Canis lupus familiaris,,A,,,N,5356,BAO_0000218,CHEMBL625135,50588,,Intermediate,Oral bioavailability in dog (fasted),In vivo,9615.0
5606,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL625136,50588,,Intermediate,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,9615.0
5607,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL625137,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5608,,,,Canis lupus familiaris,,A,,,N,1475,BAO_0000218,CHEMBL625138,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5609,,,,Canis lupus familiaris,,A,,,N,3788,BAO_0000218,CHEMBL625139,50588,,Intermediate,Percent bioavailability in dog,In vivo,9615.0
5610,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL872264,50588,,Intermediate,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,9615.0
5611,,,,Canis lupus familiaris,,A,,,N,13397,BAO_0000218,CHEMBL625140,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5612,,,,Canis lupus familiaris,,A,,,N,2137,BAO_0000218,CHEMBL624436,50588,,Intermediate,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,9615.0
5613,,,,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL624437,50588,,Intermediate,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,9615.0
5614,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL872261,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
5615,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL624438,50588,,Intermediate,8 hour trough Blood level in dog was measured after administration of compound,,9615.0
5616,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL624439,50588,,Intermediate,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,9615.0
5617,,,,Canis lupus familiaris,,A,,,N,6316,BAO_0000218,CHEMBL624440,50588,,Intermediate,C24 after oral administration at 5 mg/kg,,9615.0
5618,,,,Canis lupus familiaris,,A,,,N,5238,BAO_0000218,CHEMBL624441,50588,,Intermediate,Clearance after oral and iv dosing in dogs,,9615.0
5619,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17796,BAO_0000218,CHEMBL624442,50588,,Intermediate,Clearance of the drug was measured in the plasma of dog,,9615.0
5620,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL624443,50588,,Intermediate,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,9615.0
5621,,,,Canis lupus familiaris,,A,,,N,5654,BAO_0000218,CHEMBL624444,50588,,Intermediate,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,9615.0
5622,,,,Canis lupus familiaris,,A,,,N,6621,BAO_0000218,CHEMBL624445,50588,,Intermediate,Clearance of compound was determined in dogs,In vivo,9615.0
5623,,,,Canis lupus familiaris,,A,,,N,6505,BAO_0000218,CHEMBL624446,50588,,Intermediate,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,9615.0
5624,,,,Canis lupus familiaris,,A,,,N,5802,BAO_0000218,CHEMBL624447,50588,,Intermediate,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,9615.0
5625,,,,Canis lupus familiaris,,A,,,N,17267,BAO_0000218,CHEMBL624448,50588,,Intermediate,Plasma clearance in dog was determined,In vivo,9615.0
5626,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL624449,50588,,Intermediate,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,9615.0
5627,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL624450,50588,,Intermediate,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,9615.0
5628,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL875942,50588,,Intermediate,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,9615.0
5629,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL624451,50588,,Intermediate,Plasma clearance in dogs,In vivo,9615.0
5630,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL624452,50588,,Intermediate,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,9615.0
5631,,,,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL624453,50588,,Intermediate,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,9615.0
5632,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL624454,50588,,Intermediate,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,9615.0
5633,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL624455,50588,,Intermediate,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,9615.0
5634,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL624456,50588,,Intermediate,Plasma administration to dogs,In vivo,9615.0
5635,,,,Canis lupus familiaris,,A,,,N,5505,BAO_0000218,CHEMBL624457,50588,,Intermediate,Plasma clearance was determined,In vivo,9615.0
5636,,,,Canis lupus familiaris,,A,,,N,6215,BAO_0000218,CHEMBL624458,50588,,Intermediate,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,9615.0
5637,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL624459,50588,,Intermediate,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,9615.0
5638,2107.0,,Liver,Homo sapiens,,A,Microsomes,,S,5007,BAO_0000251,CHEMBL624460,102164,,Intermediate,Intrinsic clearance in human liver microsomes,In vitro,9606.0
5639,2107.0,,Liver,Homo sapiens,,A,Microsomes,,S,5007,BAO_0000251,CHEMBL624461,102164,,Intermediate,Intrinsic clearance in human liver microsomes,In vitro,9606.0
5640,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL875943,50588,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,9615.0
5641,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL624462,50588,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,9615.0
5642,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL624463,50588,,Intermediate,Clearance in dog (dose 1 mg/kg i.v.),In vivo,9615.0
5643,,,,Canis lupus familiaris,,A,,,N,6221,BAO_0000218,CHEMBL624464,50588,,Intermediate,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,9615.0
5644,,,,Canis lupus familiaris,,A,,,N,5007,BAO_0000218,CHEMBL624465,50588,,Intermediate,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,9615.0
5645,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL624466,50588,,Intermediate,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,9615.0
5646,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL624467,50588,,Intermediate,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,9615.0
5647,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL624468,50588,,Intermediate,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,9615.0
5648,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL624469,50588,,Intermediate,Plasma clearance was measured in dog,In vivo,9615.0
5649,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL624470,50588,,Intermediate,Plasma clearance was measured in dog,In vivo,9615.0
5650,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL624471,50588,,Intermediate,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,9615.0
5651,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL624472,50588,,Intermediate,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,9615.0
5652,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL622775,50588,,Intermediate,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,9615.0
5653,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL622776,50588,,Intermediate,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,9615.0
5654,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL622777,50588,,Intermediate,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,9615.0
5655,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL622778,50588,,Intermediate,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,9615.0
5656,,,,Canis lupus familiaris,,A,,,N,4368,BAO_0000218,CHEMBL622779,50588,,Intermediate,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,9615.0
5657,,,,Canis lupus familiaris,,A,,,N,4305,BAO_0000218,CHEMBL622780,50588,,Intermediate,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,9615.0
5658,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1918,BAO_0000218,CHEMBL622781,50588,,Intermediate,Clearance value was evaluated in dog plasma,In vivo,9615.0
5659,,,,Canis lupus familiaris,,A,,,N,6005,BAO_0000218,CHEMBL622782,50588,,Intermediate,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,9615.0
5660,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4839,BAO_0000218,CHEMBL622783,50588,,Intermediate,Compound was tested for plasma clearance in dog,In vivo,9615.0
5661,,,,Canis lupus familiaris,,A,,,N,4239,BAO_0000218,CHEMBL622784,50588,,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,9615.0
5662,,,,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL622785,50594,,Intermediate,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,10090.0
5663,,,,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL622786,50594,,Intermediate,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,10090.0
5664,,,,Mus musculus,,A,,,N,5302,BAO_0000218,CHEMBL622787,50594,,Intermediate,Area under curve value in mouse at a dose of 10 mg/kg,,10090.0
5665,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL875949,50594,,Intermediate,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,10090.0
5666,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL622788,50594,,Intermediate,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,10090.0
5667,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622789,50594,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,10090.0
5668,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622790,50594,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,10090.0
5669,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622791,50594,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,10090.0
5670,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622792,50594,,Intermediate,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,10090.0
5671,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL622793,50594,,Intermediate,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,10090.0
5672,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL622794,50594,,Intermediate,Area under curve was determined for the compound at 24 mg/Kg,,10090.0
5673,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL622795,50594,,Intermediate,Area under curve was determined for the compound at 40 mg/Kg,,10090.0
5674,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL621803,50594,,Intermediate,Area under curve was determined for the compound at 5 mg/Kg,,10090.0
5675,,,,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL621804,50594,,Intermediate,Area under the curve for the compound is obtained at dose 25 mg/kg,,10090.0
5676,,,,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL621805,50594,,Intermediate,Area under the curve for the compound was obtained when tested in mouse,,10090.0
5677,,,,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL621806,50594,,Intermediate,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,10090.0
5678,,,,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL621807,50594,,Intermediate,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,10090.0
5679,,,,Mus musculus,,A,,,N,6062,BAO_0000218,CHEMBL621808,50594,,Intermediate,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,10090.0
5680,,,,Mus musculus,,A,,,N,4066,BAO_0000218,CHEMBL621809,50594,,Intermediate,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,10090.0
5681,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL621810,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,10090.0
5682,,,,Mus musculus,,A,,,N,14239,BAO_0000218,CHEMBL875164,50594,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,10090.0
5683,,,,Mus musculus,,A,,,N,14239,BAO_0000218,CHEMBL621811,50594,,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,10090.0
5684,,,,Mus musculus,,A,,,N,4890,BAO_0000218,CHEMBL621812,50594,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,10090.0
5685,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL621813,50594,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,10090.0
5686,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL621814,50594,,Intermediate,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,10090.0
5687,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL621815,50594,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,10090.0
5688,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL621816,50594,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,10090.0
5689,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL621817,50594,,Intermediate,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,10090.0
5690,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL621818,50594,,Intermediate,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,10090.0
5691,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL621819,50594,,Intermediate,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,10090.0
5692,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL621820,50594,,Intermediate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,10090.0
5693,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL621821,50594,,Intermediate,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,10090.0
5694,,,,Mus musculus,,A,,,N,6178,BAO_0000218,CHEMBL621822,50594,,Intermediate,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,10090.0
5695,,,,Mus musculus,,A,,,N,6178,BAO_0000218,CHEMBL619474,50594,,Intermediate,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,10090.0
5696,,,,Mus musculus,,A,,,N,6619,BAO_0000218,CHEMBL619475,50594,,Intermediate,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,10090.0
5697,,,,Mus musculus,,A,,,N,6619,BAO_0000218,CHEMBL619476,50594,,Intermediate,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,10090.0
5698,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL619477,50594,,Intermediate,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,10090.0
5699,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL619478,50594,,Intermediate,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,10090.0
5700,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL619479,50594,,Intermediate,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,10090.0
5701,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL619480,50594,,Intermediate,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,10090.0
5702,,,,Mus musculus,,A,,,N,3192,BAO_0000218,CHEMBL619481,50594,,Intermediate,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,10090.0
5703,,,,Mus musculus,,A,,,N,3192,BAO_0000218,CHEMBL619482,50594,,Intermediate,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,10090.0
5704,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL619483,50594,,Intermediate,Area under the curve was evaluated in mice after intravenous administration,,10090.0
5705,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL619484,50594,,Intermediate,Area under the curve was evaluated in mice after oral administration,,10090.0
5706,1969.0,,Plasma,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619485,50594,,Intermediate,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,10090.0
5707,1969.0,,Plasma,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619486,50594,,Intermediate,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,10090.0
5708,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL619487,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,10090.0
5709,,,,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL619488,50594,,Intermediate,AUMC after intraperitoneal administration of 100 mg/kg in mice,,10090.0
5710,178.0,,Blood,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620106,50594,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,10090.0
5711,,9L,,,,F,,392.0,N,15345,BAO_0000219,CHEMBL620107,80653,,Intermediate,The compound was tested in vitro for anticancer activity against 9L cells,,
5712,,,,Rattus norvegicus,,F,,,U,2181,BAO_0000019,CHEMBL620283,22226,,Autocuration,Anti proliferation activity determined; Weak effect,,10116.0
5713,,,,Rattus norvegicus,,F,,,U,2181,BAO_0000219,CHEMBL875176,22226,,Autocuration,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,10116.0
5714,,,,Rattus norvegicus,,F,,,U,2181,BAO_0000219,CHEMBL620284,22226,,Autocuration,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,10116.0
5715,,,,Rattus norvegicus,,F,,,U,2181,BAO_0000219,CHEMBL623515,22226,,Autocuration,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,10116.0
5716,,,,Mus musculus,,F,,,U,10486,BAO_0000019,CHEMBL623516,22226,,Autocuration,The cytotoxic activity was in vitro tested by 9PS assay method,,10090.0
5717,,,,Mus musculus,,F,,,U,10486,BAO_0000019,CHEMBL623517,22226,,Autocuration,The cytotoxic activity was in vitro tested by 9PS assay method.,,10090.0
5718,,,,,,A,,,U,15508,BAO_0000019,CHEMBL857878,22224,,Autocuration,Partition coefficient (logD6.5),,
5719,,A2780,,Homo sapiens,,F,,478.0,N,5242,BAO_0000219,CHEMBL623518,81034,,Expert,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,9606.0
5720,,A-375,,Homo sapiens,,F,,455.0,N,16167,BAO_0000219,CHEMBL624195,80018,,Intermediate,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,9606.0
5721,,A-431,,Homo sapiens,,F,,500.0,N,4782,BAO_0000219,CHEMBL624196,80852,,Expert,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,9606.0
5722,,A-431,,Homo sapiens,,F,,500.0,D,16093,BAO_0000219,CHEMBL624197,9,,Expert,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,9606.0
5723,,A498,,Homo sapiens,,F,,624.0,N,2596,BAO_0000219,CHEMBL624198,80021,,Intermediate,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,9606.0
5724,,A498,,Homo sapiens,,F,,624.0,N,2596,BAO_0000219,CHEMBL621287,80021,,Intermediate,in vitro cytotoxicity against A 498 cancer cell line,,9606.0
5725,,A498,,Homo sapiens,,F,,624.0,N,3239,BAO_0000219,CHEMBL621288,80021,,Intermediate,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,9606.0
5726,,A498,,Homo sapiens,,F,,624.0,N,1847,BAO_0000219,CHEMBL876496,80021,,Intermediate,Cytotoxic activity against A 498 renal cancer cell lines.,,9606.0
5727,,A498,,Homo sapiens,,F,,624.0,N,10553,BAO_0000219,CHEMBL621289,80021,,Intermediate,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,9606.0
5728,,,,Staphylococcus aureus,,F,,,U,16219,BAO_0000019,CHEMBL621290,22226,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,1280.0
5729,,,,Staphylococcus aureus,,F,,,U,16219,BAO_0000019,CHEMBL621291,22226,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,1280.0
5730,,,,Staphylococcus aureus,,F,,,U,16219,BAO_0000019,CHEMBL621292,22226,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,1280.0
5731,,,,Staphylococcus aureus,,F,,,U,16219,BAO_0000019,CHEMBL621293,22226,,Autocuration,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,1280.0
5732,,A549,,Homo sapiens,,F,,646.0,N,4782,BAO_0000219,CHEMBL621294,80682,,Intermediate,Inhibitory concentration required against A 549 lung cancer cell line,,9606.0
5733,,A549,,Homo sapiens,,F,,646.0,N,11805,BAO_0000219,CHEMBL621295,80682,,Intermediate,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,9606.0
5734,,A549,,Homo sapiens,,F,,646.0,N,11805,BAO_0000219,CHEMBL884007,80682,,Intermediate,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,9606.0
5735,,A549,,Homo sapiens,,F,,646.0,N,2007,BAO_0000219,CHEMBL621296,80682,,Intermediate,In vitro cytotoxicity against lung cancer A 549 cell lines,,9606.0
5736,,A549,,Homo sapiens,,F,,646.0,N,4594,BAO_0000219,CHEMBL621297,80682,,Intermediate,Compound was tested for its cytotoxicity against A 549 cell line,,9606.0
5737,,A549,,Homo sapiens,,F,,646.0,N,6018,BAO_0000219,CHEMBL839828,80682,,Expert,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,9606.0
5738,,A549,,Homo sapiens,,F,,646.0,N,6018,BAO_0000219,CHEMBL620397,80682,,Intermediate,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,9606.0
5739,,A549,,Homo sapiens,,F,,646.0,N,3599,BAO_0000219,CHEMBL620398,80682,,Expert,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,9606.0
5740,,A549,,Homo sapiens,,F,,646.0,N,2551,BAO_0000219,CHEMBL620399,80682,,Intermediate,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,9606.0
5741,,A549,,Homo sapiens,,F,,646.0,N,16132,BAO_0000219,CHEMBL620400,80682,,Expert,In vitro inhibition of A549 (human lung cancer) cell growth.,,9606.0
5742,,A549,,Homo sapiens,,F,,646.0,N,16132,BAO_0000219,CHEMBL620401,80682,,Intermediate,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,9606.0
5743,,A549,,Homo sapiens,,F,,646.0,N,2551,BAO_0000219,CHEMBL620402,80682,,Expert,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,9606.0
5744,,A549,,Homo sapiens,,F,,646.0,N,2551,BAO_0000219,CHEMBL620403,80682,,Expert,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,9606.0
5745,,,,,,F,,,U,11913,BAO_0000218,CHEMBL620404,22226,,Autocuration,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,
5746,,,,,,F,,,H,12621,BAO_0000218,CHEMBL620405,104694,,Autocuration,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,
5747,,,,,,F,,,H,12621,BAO_0000218,CHEMBL620406,104694,,Autocuration,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,
5748,,,,,,F,,,H,12621,BAO_0000218,CHEMBL620407,104694,,Autocuration,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,
5749,,,,,,F,,,H,12621,BAO_0000218,CHEMBL620408,104694,,Autocuration,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,
5750,,,,,,F,,,H,12621,BAO_0000218,CHEMBL620409,104694,,Autocuration,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,
5751,,A498,,Homo sapiens,,F,,624.0,N,3600,BAO_0000219,CHEMBL620410,80021,,Expert,Inhibition of A-498 human Renal cell proliferation,,9606.0
5752,,,,Rattus norvegicus,,F,,,U,1796,BAO_0000019,CHEMBL620411,22226,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,10116.0
5753,,,,Rattus norvegicus,,F,,,U,1796,BAO_0000019,CHEMBL620412,22226,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,10116.0
5754,,,,Rattus norvegicus,,F,,,U,1796,BAO_0000019,CHEMBL876596,22226,,Autocuration,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,10116.0
5755,,A 172,,Homo sapiens,,F,,622.0,N,16464,BAO_0000219,CHEMBL620413,80012,,Expert,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,9606.0
5756,,A 172,,Homo sapiens,,F,,622.0,N,16464,BAO_0000219,CHEMBL620414,80012,,Intermediate,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5757,,A 172,,Homo sapiens,,F,,622.0,N,16464,BAO_0000219,CHEMBL620415,80012,,Intermediate,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5758,,A549,,Homo sapiens,,F,,646.0,N,13617,BAO_0000219,CHEMBL620416,80682,,Expert,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,9606.0
5759,,A549,,Homo sapiens,,F,,646.0,N,4584,BAO_0000219,CHEMBL620417,80682,,Intermediate,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,9606.0
5760,,A549,,Homo sapiens,,F,,646.0,N,13799,BAO_0000219,CHEMBL620418,80682,,Expert,Cytotoxic activity evaluated against A549 tumor cells,,9606.0
5761,,A549,,Homo sapiens,,F,,646.0,N,16726,BAO_0000219,CHEMBL620419,80682,,Intermediate,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,9606.0
5762,,A549,,Homo sapiens,,F,,646.0,N,16109,BAO_0000219,CHEMBL620420,80682,,Intermediate,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,9606.0
5763,,A549,,Homo sapiens,,F,,646.0,N,16109,BAO_0000219,CHEMBL620421,80682,,Intermediate,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,9606.0
5764,,A549,,Homo sapiens,,F,,646.0,N,15474,BAO_0000219,CHEMBL620422,80682,,Intermediate,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,9606.0
5765,,A549,,Homo sapiens,,F,,646.0,N,6851,BAO_0000219,CHEMBL620423,80682,,Intermediate,Cytotoxicity of compound against A549 cell line,,9606.0
5766,,A549,,Homo sapiens,,F,,646.0,N,17534,BAO_0000219,CHEMBL620424,80682,,Expert,Cytotoxicity against human lung cell carcinoma A549 cell line,,9606.0
5767,,A549,,Homo sapiens,,F,,646.0,N,2621,BAO_0000219,CHEMBL620425,80682,,Intermediate,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,9606.0
5768,,A549,,Homo sapiens,,F,,646.0,N,830,BAO_0000219,CHEMBL620426,80682,,Intermediate,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,9606.0
5769,,A549,,Homo sapiens,,F,,646.0,N,14255,BAO_0000219,CHEMBL620427,80682,,Intermediate,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,9606.0
5770,,A549,,Homo sapiens,,F,,646.0,N,14255,BAO_0000219,CHEMBL620428,80682,,Intermediate,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,9606.0
5771,,A549,,Homo sapiens,,F,,646.0,N,1590,BAO_0000219,CHEMBL620429,80682,,Intermediate,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,9606.0
5772,,A549,,Homo sapiens,,F,,646.0,N,6146,BAO_0000219,CHEMBL620430,80682,,Expert,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,9606.0
5773,,A549,,Homo sapiens,,F,,646.0,N,17427,BAO_0000219,CHEMBL839887,80682,,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,9606.0
5774,,A549,,Homo sapiens,,F,,646.0,N,5280,BAO_0000219,CHEMBL620431,80682,,Intermediate,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,9606.0
5775,,A549,,Homo sapiens,,F,,646.0,N,16786,BAO_0000219,CHEMBL884010,80682,,Intermediate,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,9606.0
5776,,A549,,Homo sapiens,,F,,646.0,N,5895,BAO_0000219,CHEMBL620538,80682,,Intermediate,In vitro cytotoxicity against A549 (human lung cancer),,9606.0
5777,,A549,,Homo sapiens,,F,,646.0,N,14297,BAO_0000219,CHEMBL620539,80682,,Expert,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,9606.0
5778,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL623373,80682,,Intermediate,In vivo antiproliferative activity against A549 cell line,,9606.0
5779,,A549,,Homo sapiens,,F,,646.0,N,14368,BAO_0000219,CHEMBL623374,80682,,Intermediate,Inhibition of non-small-cell lung adenocarcinoma (A549),,9606.0
5780,,A549,,Homo sapiens,,F,,646.0,N,14368,BAO_0000219,CHEMBL623375,80682,,Intermediate,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,9606.0
5781,,A549,,Homo sapiens,,F,,646.0,N,14254,BAO_0000219,CHEMBL623376,80682,,Intermediate,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,9606.0
5782,,A549,,Homo sapiens,,F,,646.0,N,15897,BAO_0000219,CHEMBL623377,80682,,Intermediate,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,9606.0
5783,,A549,,Homo sapiens,,F,,646.0,N,13866,BAO_0000219,CHEMBL623378,80682,,Intermediate,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,9606.0
5784,,A549,,Homo sapiens,,F,,646.0,N,13370,BAO_0000219,CHEMBL623379,80682,,Intermediate,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,9606.0
5785,,A549,,Homo sapiens,,F,,646.0,N,4862,BAO_0000219,CHEMBL623380,80682,,Intermediate,Inhibitory activity against A549 lung cancer cell line,,9606.0
5786,,A549,,Homo sapiens,,F,,646.0,N,4862,BAO_0000219,CHEMBL623381,80682,,Intermediate,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,9606.0
5787,,A549,,Homo sapiens,,F,,646.0,N,4862,BAO_0000219,CHEMBL623382,80682,,Intermediate,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,9606.0
5788,,A549,,Homo sapiens,,F,,646.0,N,15970,BAO_0000219,CHEMBL623383,80682,,Intermediate,Inhibitory concentration against A549 (lung cancer) cell line,,9606.0
5789,,A549,,Homo sapiens,,F,,646.0,N,17713,BAO_0000219,CHEMBL623384,80682,,Expert,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,9606.0
5790,,A549,,Homo sapiens,,F,,646.0,N,4833,BAO_0000219,CHEMBL623385,80682,,Intermediate,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,9606.0
5791,,A549,,Homo sapiens,,F,,646.0,N,13736,BAO_0000219,CHEMBL623386,80682,,Expert,Activity against A549 cancer cell line.,,9606.0
5792,,A549,,Homo sapiens,,F,,646.0,N,4312,BAO_0000219,CHEMBL884105,80682,,Intermediate,The compound was evaluated for cytotoxicity against A549 cell line,,9606.0
5793,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL623387,80682,,Intermediate,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,9606.0
5794,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621568,80682,,Intermediate,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,9606.0
5795,,A549,,Homo sapiens,,F,,646.0,N,14717,BAO_0000219,CHEMBL621569,80682,,Intermediate,Growth inhibitory activity was measured for human A549 tumor cell line.,,9606.0
5796,,A549,,Homo sapiens,,F,,646.0,N,4634,BAO_0000219,CHEMBL621570,80682,,Intermediate,Inhibitory activity against A549 lung cancer cell line,,9606.0
5797,,A549,,Homo sapiens,,F,,646.0,N,1149,BAO_0000219,CHEMBL621571,80682,,Intermediate,Inhibitory activity against A549 cell line; inactive,,9606.0
5798,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621572,80682,,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,9606.0
5799,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621573,80682,,Expert,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,9606.0
5800,,A549,,Homo sapiens,,F,,646.0,N,5421,BAO_0000219,CHEMBL621574,80682,,Intermediate,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,9606.0
5801,,A549,,Homo sapiens,,F,,646.0,N,3320,BAO_0000219,CHEMBL621575,80682,,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,9606.0
5802,,A549,,Homo sapiens,,F,,646.0,N,3320,BAO_0000219,CHEMBL621576,80682,,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,9606.0
5803,,A549,,Homo sapiens,,F,,646.0,N,3320,BAO_0000219,CHEMBL621577,80682,,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,9606.0
5804,,A549,,Homo sapiens,,F,,646.0,N,3320,BAO_0000219,CHEMBL621578,80682,,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,9606.0
5805,,A549,,Homo sapiens,,F,,646.0,N,3320,BAO_0000219,CHEMBL621579,80682,,Intermediate,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,9606.0
5806,,A549,,Homo sapiens,,F,,646.0,N,5726,BAO_0000219,CHEMBL621580,80682,,Intermediate,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,9606.0
5807,,,,Canis lupus familiaris,,A,,,N,17800,BAO_0000218,CHEMBL621581,50588,,Intermediate,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,9615.0
5808,,,,Canis lupus familiaris,,A,,,N,5985,BAO_0000218,CHEMBL621582,50588,,Intermediate,Plasma clearance was measured in dog,In vivo,9615.0
5809,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621583,50588,,Intermediate,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,9615.0
5810,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621584,50588,,Intermediate,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,9615.0
5811,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4839,BAO_0000218,CHEMBL621585,50588,,Intermediate,Tested for plasma clearance in dog,In vivo,9615.0
5812,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL621586,50588,,Intermediate,The compound was tested for clearance in dog plasma.,In vivo,9615.0
5813,,,,Canis lupus familiaris,,A,,,N,4838,BAO_0000218,CHEMBL875835,50588,,Intermediate,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,9615.0
5814,,,,Canis lupus familiaris,,A,,,N,4137,BAO_0000218,CHEMBL621587,50588,,Intermediate,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,9615.0
5815,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5017,BAO_0000218,CHEMBL621588,50588,,Intermediate,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,9615.0
5816,2107.0,,Liver,Canis lupus familiaris,,A,Microsomes,,N,17538,BAO_0000218,CHEMBL621589,50588,,Intermediate,In vitro clearance in dog liver microsomes,In vitro,9615.0
5817,,,,Canis lupus familiaris,,A,,,N,6161,BAO_0000218,CHEMBL621590,50588,,Intermediate,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,9615.0
5818,,,,Canis lupus familiaris,,A,,,N,6161,BAO_0000218,CHEMBL621591,50588,,Intermediate,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,9615.0
5819,,,,Canis lupus familiaris,,A,,,N,1696,BAO_0000218,CHEMBL621592,50588,,Intermediate,Plasma clearance in dog,In vivo,9615.0
5820,,,,Canis lupus familiaris,,A,,,N,6762,BAO_0000218,CHEMBL621593,50588,,Intermediate,Clearance rate in dog,In vivo,9615.0
5821,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5932,BAO_0000218,CHEMBL621594,50588,,Intermediate,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,9615.0
5822,,,,Canis lupus familiaris,,A,,,N,6305,BAO_0000218,CHEMBL621595,50588,,Intermediate,Clearance in dogs,In vivo,9615.0
5823,,,,Canis lupus familiaris,,A,,,N,4942,BAO_0000218,CHEMBL621596,50588,,Intermediate,Plasma clearance in dogs,In vivo,9615.0
5824,,,,Canis lupus familiaris,,A,,,N,4219,BAO_0000218,CHEMBL621597,50588,,Intermediate,Plasma clearance was determined,In vivo,9615.0
5825,,,,Canis lupus familiaris,,A,,,N,17853,BAO_0000218,CHEMBL621598,50588,,Intermediate,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,9615.0
5826,,,,Canis lupus familiaris,,A,,,N,4514,BAO_0000218,CHEMBL621599,50588,,Intermediate,Plasma clearance in Beagle dogs,In vivo,9615.0
5827,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL875836,50588,,Intermediate,Plasma clearance (Clp) in dog,In vivo,9615.0
5828,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL621600,50588,,Intermediate,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,9615.0
5829,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL621601,50588,,Intermediate,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,9615.0
5830,,,,Canis lupus familiaris,,A,,,N,6062,BAO_0000218,CHEMBL618474,50588,,Intermediate,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,9615.0
5831,,,,Canis lupus familiaris,,A,,,N,6821,BAO_0000218,CHEMBL618475,50588,,Intermediate,Plasma clearance of compound was determined in dog,In vivo,9615.0
5832,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL624524,50588,,Intermediate,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,9615.0
5833,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL624525,50588,,Intermediate,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,9615.0
5834,,,,Canis lupus familiaris,,A,,,N,5374,BAO_0000218,CHEMBL624526,50588,,Intermediate,Plasma clearance in dog was determined,In vivo,9615.0
5835,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL624527,50588,,Intermediate,Plasma clearance was calculated in dog,In vivo,9615.0
5836,,,,Canis lupus familiaris,,A,,,N,4727,BAO_0000218,CHEMBL624528,50588,,Intermediate,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,9615.0
5837,,,,Canis lupus familiaris,,A,,,N,5145,BAO_0000218,CHEMBL624529,50588,,Intermediate,Plasma clearance in dog,In vivo,9615.0
5838,,,,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL624530,50588,,Intermediate,Plasma clearance in dog,In vivo,9615.0
5839,,,,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL624531,50588,,Intermediate,Plasma clearance in dog; Unable to calculate,In vivo,9615.0
5840,,,,Canis lupus familiaris,,A,,,N,5145,BAO_0000218,CHEMBL624532,50588,,Intermediate,Plasma clearance in rhesus monkey,In vivo,9615.0
5841,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL624533,50588,,Intermediate,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,9615.0
5842,,,,Canis lupus familiaris,,A,,,N,6641,BAO_0000218,CHEMBL624534,50588,,Intermediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
5843,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL624535,50588,,Intermediate,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
5844,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL624536,50588,,Intermediate,Plasma clearance was evaluated in dog,In vivo,9615.0
5845,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL624537,50588,,Intermediate,Plasma clearance was evaluated in dog; Not tested,In vivo,9615.0
5846,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL624538,50588,,Intermediate,Plasma clearance was evaluated in rhesus,In vivo,9615.0
5847,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL624539,50588,,Intermediate,Plasma clearance was evaluated in rhesus; Not tested,In vivo,9615.0
5848,,,,Canis lupus familiaris,,A,,,N,4257,BAO_0000218,CHEMBL624540,50588,,Intermediate,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,9615.0
5849,,,,Canis lupus familiaris,,A,,,N,6679,BAO_0000218,CHEMBL624541,50588,,Intermediate,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,9615.0
5850,,,,Canis lupus familiaris,,A,,,N,5546,BAO_0000218,CHEMBL624542,50588,,Intermediate,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,9615.0
5851,,,,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL624543,50588,,Intermediate,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
5852,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL624544,50588,,Intermediate,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,9615.0
5853,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6316,BAO_0000218,CHEMBL624545,50588,,Intermediate,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,9615.0
5854,,,,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL624546,50588,,Intermediate,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,9615.0
5855,,,,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL875957,50588,,Intermediate,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,9615.0
5856,,,,Canis lupus familiaris,,A,,,N,5802,BAO_0000218,CHEMBL624547,50588,,Intermediate,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,9615.0
5857,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL624548,50588,,Intermediate,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,9615.0
5858,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL624549,50588,,Intermediate,Cmax in dog after administration of 1 mg/kg iv,In vivo,9615.0
5859,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL624550,50588,,Intermediate,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,9615.0
5860,,,,Canis lupus familiaris,,A,,,N,6505,BAO_0000218,CHEMBL621613,50588,,Intermediate,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,9615.0
5861,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL621614,50588,,Intermediate,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,9615.0
5862,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL623431,50588,,Intermediate,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,9615.0
5863,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL623432,50588,,Intermediate,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,9615.0
5864,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL623433,50588,,Intermediate,Cmax after 0.3 mg/kg po administration in dog,In vivo,9615.0
5865,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL623434,50588,,Intermediate,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,9615.0
5866,,,,Canis lupus familiaris,,A,,,N,6123,BAO_0000218,CHEMBL623435,50588,,Intermediate,Cmax in dog after oral administration at 1 mg/kg,In vivo,9615.0
5867,,,,Canis lupus familiaris,,A,,,N,6123,BAO_0000218,CHEMBL623436,50588,,Intermediate,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,9615.0
5868,,,,Canis lupus familiaris,,A,,,N,6757,BAO_0000218,CHEMBL875958,50588,,Intermediate,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,9615.0
5869,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL623437,50588,,Intermediate,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,9615.0
5870,178.0,,Blood,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623438,50594,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5871,178.0,,Blood,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623439,50594,,Intermediate,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5872,10000001.0,,Bone,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623440,50594,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5873,10000001.0,,Bone,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623441,50594,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5874,10000001.0,,Bone,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623442,50594,,Intermediate,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5875,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623469,50594,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5876,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623470,50594,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5877,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623471,50594,,Intermediate,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5878,948.0,,Heart,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623472,50594,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5879,948.0,,Heart,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623473,50594,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5880,948.0,,Heart,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623474,50594,,Intermediate,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5881,2113.0,,Kidney,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623475,50594,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5882,2113.0,,Kidney,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623476,50594,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5883,2113.0,,Kidney,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL623477,50594,,Intermediate,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5884,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621896,50594,,Intermediate,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5885,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621897,50594,,Intermediate,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5886,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621898,50594,,Intermediate,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5887,2107.0,,Liver,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621899,50594,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5888,2107.0,,Liver,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621900,50594,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5889,2107.0,,Liver,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621901,50594,,Intermediate,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5890,2048.0,,Lung,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621902,50594,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5891,2048.0,,Lung,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL621903,50594,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5892,2048.0,,Lung,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL622587,50594,,Intermediate,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5893,2385.0,,Muscle tissue,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620285,50594,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5894,2385.0,,Muscle tissue,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL875285,50594,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5895,2385.0,,Muscle tissue,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620286,50594,,Intermediate,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5896,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620287,50594,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5897,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620288,50594,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5898,,,,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620289,50594,,Intermediate,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5899,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620290,50594,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5900,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620291,50594,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5901,160.0,,Intestine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620292,50594,,Intermediate,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5902,2106.0,,Spleen,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620293,50594,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5903,2106.0,,Spleen,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL620294,50594,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5904,2106.0,,Spleen,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL618614,50594,,Intermediate,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5905,945.0,,Stomach,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL618615,50594,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
5906,945.0,,Stomach,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL618616,50594,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
5907,,A 172,,Homo sapiens,,F,,622.0,N,2036,BAO_0000219,CHEMBL618617,80012,,Expert,Cytotoxicity against A-172 human tumor cell lines,,9606.0
5908,,A 172,,Homo sapiens,,F,,622.0,N,2357,BAO_0000219,CHEMBL618618,80012,,Intermediate,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,9606.0
5909,,A204,,Homo sapiens,,F,,623.0,N,1457,BAO_0000219,CHEMBL618619,80014,,Intermediate,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,9606.0
5910,,A2780,,Homo sapiens,,F,,478.0,N,4379,BAO_0000219,CHEMBL618620,81034,,Intermediate,Tested for antiproliferative activity against A-2780 tumoral cell line,,9606.0
5911,,A-375,,Homo sapiens,,F,,455.0,N,1093,BAO_0000219,CHEMBL618621,80018,,Intermediate,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,9606.0
5912,,A-375,,Homo sapiens,,F,,455.0,N,12152,BAO_0000219,CHEMBL618622,80018,,Intermediate,Tested in vitro against A-375 cell line human melanoma,,9606.0
5913,,A-427,,Homo sapiens,,F,,797.0,N,16464,BAO_0000219,CHEMBL618623,80019,,Expert,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,9606.0
5914,,A-427,,Homo sapiens,,F,,797.0,N,16464,BAO_0000219,CHEMBL618624,80019,,Intermediate,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5915,,A-427,,Homo sapiens,,F,,797.0,N,16582,BAO_0000219,CHEMBL618625,80019,,Expert,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,9606.0
5916,,A-427,,Homo sapiens,,F,,797.0,N,16464,BAO_0000219,CHEMBL618626,80019,,Intermediate,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,9606.0
5917,,A-427,,Homo sapiens,,F,,797.0,N,10413,BAO_0000219,CHEMBL618627,80019,,Intermediate,Antitumor activity on A-427 lung carcinoma cell lines,,9606.0
5918,,A-427,,Homo sapiens,,F,,797.0,N,6418,BAO_0000219,CHEMBL618628,80019,,Intermediate,Cytotoxic activity against human A-427 lung tumor cell line,,9606.0
5919,,A-427,,Homo sapiens,,F,,797.0,N,17134,BAO_0000219,CHEMBL618629,80019,,Expert,In vitro antitumor effects against human A-427 cell lines.,,9606.0
5920,,A-427,,Homo sapiens,,F,,797.0,N,16132,BAO_0000219,CHEMBL618630,80019,,Expert,In vitro inhibition of A-427 (human lung cancer) cell growth.,,9606.0
5921,,A-427,,Homo sapiens,,F,,797.0,N,16132,BAO_0000219,CHEMBL618631,80019,,Intermediate,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,9606.0
5922,,A-427,,Homo sapiens,,F,,797.0,N,16780,BAO_0000219,CHEMBL618632,80019,,Intermediate,Cytotoxic activity of compound against A-427 lung human tumor cell line,,9606.0
5923,,A-431,,Homo sapiens,,F,,500.0,N,4085,BAO_0000219,CHEMBL618633,80852,,Expert,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,9606.0
5924,,A498,,Homo sapiens,,F,,624.0,N,1276,BAO_0000219,CHEMBL619315,80021,,Intermediate,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,9606.0
5925,,A498,,Homo sapiens,,F,,624.0,N,3498,BAO_0000219,CHEMBL619316,80021,,Expert,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,9606.0
5926,,A498,,Homo sapiens,,F,,624.0,N,1169,BAO_0000219,CHEMBL619317,80021,,Intermediate,Cytotoxicity against human kidney carcinoma A-498cell lines,,9606.0
5927,,A498,,Homo sapiens,,F,,624.0,N,4450,BAO_0000219,CHEMBL619318,80021,,Intermediate,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,9606.0
5928,,A498,,Homo sapiens,,F,,624.0,N,3311,BAO_0000219,CHEMBL619319,80021,,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,9606.0
5929,,A498,,Homo sapiens,,F,,624.0,N,4461,BAO_0000219,CHEMBL619739,80021,,Intermediate,Antitumor cytotoxic activity against A-498 cell line was determined,,9606.0
5930,,A498,,Homo sapiens,,F,,624.0,N,3311,BAO_0000219,CHEMBL619740,80021,,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,9606.0
5931,,A498,,Homo sapiens,,F,,624.0,N,3311,BAO_0000219,CHEMBL883158,80021,,Intermediate,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,9606.0
5932,,A498,,Homo sapiens,,F,,624.0,N,1457,BAO_0000219,CHEMBL884012,80021,,Intermediate,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,9606.0
5933,,A498,,Homo sapiens,,F,,624.0,N,3664,BAO_0000219,CHEMBL619741,80021,,Intermediate,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,9606.0
5934,,A498,,Homo sapiens,,F,,624.0,N,15895,BAO_0000219,CHEMBL619742,80021,,Intermediate,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,9606.0
5935,,A549,,Homo sapiens,,F,,646.0,N,11843,BAO_0000219,CHEMBL876610,80682,,Intermediate,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,9606.0
5936,,A549,,Homo sapiens,,F,,646.0,N,11843,BAO_0000219,CHEMBL619743,80682,,Intermediate,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,9606.0
5937,,A549,,Homo sapiens,,F,,646.0,N,17705,BAO_0000219,CHEMBL619744,80682,,Intermediate,In vitro antiproliferative activity against human A-549 NSCL cell line,,9606.0
5938,,A549,,Homo sapiens,,F,,646.0,N,17705,BAO_0000219,CHEMBL619745,80682,,Intermediate,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,9606.0
5939,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL619746,80682,,Intermediate,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,9606.0
5940,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL619747,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,9606.0
5941,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL619748,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,9606.0
5942,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL619749,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,9606.0
5943,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL619750,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,9606.0
5944,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL624014,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,9606.0
5945,,A549,,Homo sapiens,,F,,646.0,N,4369,BAO_0000219,CHEMBL624015,80682,,Intermediate,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,9606.0
5946,,A549,,Homo sapiens,,F,,646.0,N,4787,BAO_0000219,CHEMBL885344,80682,,Expert,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,9606.0
5947,,A549,,Homo sapiens,,F,,646.0,N,4787,BAO_0000219,CHEMBL623224,80682,,Intermediate,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,9606.0
5948,,A549,,Homo sapiens,,F,,646.0,N,6513,BAO_0000219,CHEMBL623225,80682,,Intermediate,Cytotoxic activity against A-549 cell line,,9606.0
5949,,A549,,Homo sapiens,,F,,646.0,N,6690,BAO_0000219,CHEMBL622698,80682,,Intermediate,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,9606.0
5950,,A549,,Homo sapiens,,F,,646.0,N,6690,BAO_0000219,CHEMBL622699,80682,,Intermediate,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,9606.0
5951,,A549,,Homo sapiens,,F,,646.0,N,12263,BAO_0000219,CHEMBL622700,80682,,Expert,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,9606.0
5952,,A549,,Homo sapiens,,F,,646.0,N,1054,BAO_0000219,CHEMBL622701,80682,,Intermediate,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,9606.0
5953,,A549,,Homo sapiens,,F,,646.0,N,1359,BAO_0000219,CHEMBL622702,80682,,Intermediate,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,9606.0
5954,,A549,,Homo sapiens,,F,,646.0,N,3547,BAO_0000219,CHEMBL622703,80682,,Intermediate,Cytotoxic activity against human lung carcinoma (A-549) cell line,,9606.0
5955,,A549,,Homo sapiens,,F,,646.0,N,5771,BAO_0000219,CHEMBL622704,80682,,Expert,Cytotoxic activity towards A-549 cells,,9606.0
5956,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL622705,80682,,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.",,9606.0
5957,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL622706,80682,,Intermediate,"In vitro percent inhibition of A549, lung carcinoma",,9606.0
5958,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL622707,80682,,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.",,9606.0
5959,,A549,,Homo sapiens,,F,,646.0,N,14425,BAO_0000219,CHEMBL622708,80682,,Intermediate,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,9606.0
5960,,A549,,Homo sapiens,,F,,646.0,N,5280,BAO_0000219,CHEMBL622709,80682,,Intermediate,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,9606.0
5961,,A549,,Homo sapiens,,F,,646.0,N,15176,BAO_0000219,CHEMBL622710,80682,,Intermediate,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,9606.0
5962,,A549,,Homo sapiens,,F,,646.0,N,15300,BAO_0000219,CHEMBL622711,80682,,Intermediate,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,9606.0
5963,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL622712,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,9606.0
5964,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL622713,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,9606.0
5965,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL622714,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,9606.0
5966,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL622715,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,9606.0
5967,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000218,CHEMBL622716,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,9606.0
5968,,A549,,Homo sapiens,,F,,646.0,N,17824,BAO_0000219,CHEMBL622717,80682,,Intermediate,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,9606.0
5969,,A549,,Homo sapiens,,F,,646.0,N,17528,BAO_0000218,CHEMBL622718,80682,,Intermediate,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,9606.0
5970,,A549,,Homo sapiens,,F,,646.0,N,6870,BAO_0000219,CHEMBL622719,80682,,Expert,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,9606.0
5971,,A549,,Homo sapiens,,F,,646.0,N,6870,BAO_0000219,CHEMBL622720,80682,,Intermediate,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,9606.0
5972,,A549,,Homo sapiens,,F,,646.0,N,6870,BAO_0000219,CHEMBL622721,80682,,Intermediate,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,9606.0
5973,,A549,,Homo sapiens,,F,,646.0,N,6870,BAO_0000219,CHEMBL622722,80682,,Intermediate,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,9606.0
5974,,A549,,Homo sapiens,,F,,646.0,N,16726,BAO_0000219,CHEMBL876030,80682,,Intermediate,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,9606.0
5975,,A549,,Homo sapiens,,F,,646.0,N,6170,BAO_0000219,CHEMBL620206,80682,,Intermediate,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,9606.0
5976,,A549,,Homo sapiens,,F,,646.0,N,6583,BAO_0000219,CHEMBL620207,80682,,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,9606.0
5977,,A549,,Homo sapiens,,F,,646.0,N,6583,BAO_0000219,CHEMBL620208,80682,,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,9606.0
5978,,A549,,Homo sapiens,,F,,646.0,N,6583,BAO_0000219,CHEMBL620209,80682,,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,9606.0
5979,,A549,,Homo sapiens,,F,,646.0,N,6583,BAO_0000219,CHEMBL620210,80682,,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,9606.0
5980,,A549,,Homo sapiens,,F,,646.0,N,6583,BAO_0000219,CHEMBL621639,80682,,Expert,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,9606.0
5981,,A549,,Homo sapiens,,F,,646.0,N,17321,BAO_0000219,CHEMBL621640,80682,,Intermediate,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,9606.0
5982,,A549,,Homo sapiens,,F,,646.0,N,17528,BAO_0000219,CHEMBL621641,80682,,Expert,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,9606.0
5983,,A549,,Homo sapiens,,F,,646.0,N,12888,BAO_0000219,CHEMBL621642,80682,,Expert,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,9606.0
5984,,A549,,Homo sapiens,,F,,646.0,N,4312,BAO_0000219,CHEMBL621643,80682,,Intermediate,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,9606.0
5985,,A549,,Homo sapiens,,F,,646.0,N,4312,BAO_0000219,CHEMBL621644,80682,,Intermediate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,9606.0
5986,,A549,,Homo sapiens,,F,,646.0,N,4312,BAO_0000219,CHEMBL621645,80682,,Intermediate,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,9606.0
5987,,A549,,Mus musculus,,F,,646.0,N,17737,BAO_0000219,CHEMBL621646,80682,,Intermediate,In vitro antiproliferative activity against A549 cell line,,10090.0
5988,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621647,80682,,Intermediate,Synergism with indomethacin in A549 cells,,
5989,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621648,80682,,Intermediate,Synergism with tolmetin in A549 cells,,
5990,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621649,80682,,Intermediate,Synergism with sulindac in A549 cells,,
5991,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621650,80682,,Intermediate,Antagonism of indomethacin in A549 cells,,
5992,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621651,80682,,Intermediate,Antagonism of sulindac in A549 cells,,
5993,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621652,80682,,Intermediate,Antagonism of tolmetin in A549 cells,,
5994,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621653,80682,,Intermediate,Synergism with indomethacin in A549 cells,,
5995,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621654,80682,,Intermediate,Synergism with sulindac in A549 cells,,
5996,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL621655,80682,,Intermediate,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,
5997,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL621656,50588,,Intermediate,Cmax value after 30 mg/kg po dose in Dogs,In vivo,9615.0
5998,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL621657,50588,,Intermediate,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,9615.0
5999,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL621658,50588,,Intermediate,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,9615.0
6000,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL621659,50588,,Intermediate,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,9615.0
6001,,,,Canis lupus familiaris,,A,,,N,5944,BAO_0000218,CHEMBL621660,50588,,Intermediate,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,9615.0
6002,,,,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL621661,50588,,Intermediate,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,9615.0
6003,,,,Canis lupus familiaris,,A,,,N,6241,BAO_0000218,CHEMBL621662,50588,,Intermediate,Cmax value in dog,In vivo,9615.0
6004,,,,Canis lupus familiaris,,A,,,N,6241,BAO_0000218,CHEMBL621663,50588,,Intermediate,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,9615.0
6005,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL621664,50588,,Intermediate,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,9615.0
6006,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1806,BAO_0000218,CHEMBL621665,50588,,Intermediate,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,9615.0
6007,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1806,BAO_0000218,CHEMBL621666,50588,,Intermediate,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,9615.0
6008,,,,Canis lupus familiaris,,A,,,N,1021,BAO_0000218,CHEMBL621667,50588,,Intermediate,Concentration maxima after oral dosing in dogs,In vivo,9615.0
6009,,,,Canis lupus familiaris,,A,,,N,1021,BAO_0000218,CHEMBL876738,50588,,Intermediate,Concentration maxima after oral dosing in dogs; not available,In vivo,9615.0
6010,,,,Canis lupus familiaris,,A,,,N,1021,BAO_0000218,CHEMBL621668,50588,,Intermediate,Concentration maxima after oral dosing in dogs; not available,In vivo,9615.0
6011,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL621669,50588,,Intermediate,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,9615.0
6012,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL621670,50588,,Intermediate,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,9615.0
6013,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL621671,50588,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,9615.0
6014,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL622360,50588,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,9615.0
6015,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL622361,50588,,Intermediate,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,9615.0
6016,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5130,BAO_0000218,CHEMBL622362,50588,,Intermediate,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,9615.0
6017,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3249,BAO_0000218,CHEMBL622363,50588,,Intermediate,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,9615.0
6018,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5473,BAO_0000218,CHEMBL622364,50588,,Intermediate,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,9615.0
6019,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL622365,50588,,Intermediate,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,9615.0
6020,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4657,BAO_0000218,CHEMBL622533,50588,,Intermediate,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,9615.0
6021,,,,Canis lupus familiaris,,A,,,N,3031,BAO_0000218,CHEMBL622534,50588,,Intermediate,Maximum concentration of compound in dog was evaluated.,In vivo,9615.0
6022,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL622535,50588,,Intermediate,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,9615.0
6023,,,,Canis lupus familiaris,,A,,,N,4186,BAO_0000218,CHEMBL876739,50588,,Intermediate,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,9615.0
6024,,,,Canis lupus familiaris,,A,,,N,5007,BAO_0000218,CHEMBL622536,50588,,Intermediate,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,9615.0
6025,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3132,BAO_0000218,CHEMBL622537,50588,,Intermediate,Maximum concentration obtained in dog plasma was determined,In vivo,9615.0
6026,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL622538,50588,,Intermediate,Maximum concentration was determined,In vivo,9615.0
6027,,,,Canis lupus familiaris,,A,,,N,4727,BAO_0000218,CHEMBL627867,50588,,Intermediate,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,9615.0
6028,,,,Canis lupus familiaris,,A,,,N,1916,BAO_0000218,CHEMBL627868,50588,,Intermediate,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,9615.0
6029,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1918,BAO_0000218,CHEMBL627869,50588,,Intermediate,Maximum concentration was evaluated in dog plasma,In vivo,9615.0
6030,,,,Canis lupus familiaris,,A,,,N,3045,BAO_0000218,CHEMBL627870,50588,,Intermediate,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,9615.0
6031,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL627871,50588,,Intermediate,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,9615.0
6032,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL627872,50588,,Intermediate,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,9615.0
6033,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,933,BAO_0000218,CHEMBL627873,50588,,Intermediate,Maximum plasma concentration in dog,In vivo,9615.0
6034,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL627874,50588,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,9615.0
6035,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL627875,50588,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,9615.0
6036,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL627876,50588,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,9615.0
6037,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL627877,50588,,Intermediate,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,9615.0
6038,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL627878,50588,,Intermediate,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
6039,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL627879,50588,,Intermediate,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,9615.0
6040,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL875355,50588,,Intermediate,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
6041,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL627880,50588,,Intermediate,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
6042,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL627881,50588,,Intermediate,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,9615.0
6043,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17650,BAO_0000218,CHEMBL627882,50588,,Intermediate,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,9615.0
6044,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6679,BAO_0000218,CHEMBL627883,50588,,Intermediate,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,9615.0
6045,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5356,BAO_0000218,CHEMBL628526,50588,,Intermediate,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,9615.0
6046,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5356,BAO_0000218,CHEMBL628527,50588,,Intermediate,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,9615.0
6047,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL628528,50588,,Intermediate,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,9615.0
6048,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL628529,50588,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,9615.0
6049,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL628530,50588,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,9615.0
6050,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL625243,50588,,Intermediate,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,9615.0
6051,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL625244,50588,,Expert,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,9615.0
6052,,,,Canis lupus familiaris,,A,,,N,4368,BAO_0000218,CHEMBL625245,50588,,Intermediate,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,9615.0
6053,,,,Canis lupus familiaris,,A,,,N,6265,BAO_0000218,CHEMBL625246,50588,,Intermediate,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,9615.0
6054,945.0,,Stomach,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL625247,50594,,Intermediate,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,10090.0
6055,1088.0,,Urine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL625248,50594,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,10090.0
6056,1088.0,,Urine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL625249,50594,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,10090.0
6057,1088.0,,Urine,Mus musculus,,A,,,N,7767,BAO_0000218,CHEMBL625250,50594,,Intermediate,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,10090.0
6058,,,,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL625251,50594,,Intermediate,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,10090.0
6059,,,,Mus musculus,,A,,,N,17811,BAO_0000218,CHEMBL875356,50594,,Intermediate,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,10090.0
6060,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625252,50594,,Intermediate,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,10090.0
6061,178.0,,Blood,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625253,50594,,Intermediate,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,10090.0
6062,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625254,50594,,Intermediate,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,10090.0
6063,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625255,50594,,Intermediate,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,10090.0
6064,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625256,50594,,Intermediate,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,10090.0
6065,178.0,,Blood,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625257,50594,,Intermediate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,10090.0
6066,178.0,,Blood,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625258,50594,,Intermediate,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,10090.0
6067,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625259,50594,,Intermediate,Compound was evaluated for washout rate in mice (Radiolabeled compound),,10090.0
6068,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625260,50594,,Intermediate,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,10090.0
6069,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625261,50594,,Intermediate,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,10090.0
6070,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL625262,50594,,Intermediate,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,10090.0
6071,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL622639,50594,,Intermediate,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,10090.0
6072,,,,Mus musculus,,A,,,N,17257,BAO_0000218,CHEMBL622640,50594,,Intermediate,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,10090.0
6073,,,,Mus musculus,,A,,,N,17257,BAO_0000218,CHEMBL622812,50594,,Intermediate,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,10090.0
6074,,,,Mus musculus,,A,,,N,17257,BAO_0000218,CHEMBL622813,50594,,Intermediate,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,10090.0
6075,,,,Mus musculus,,A,,,N,17257,BAO_0000218,CHEMBL622814,50594,,Intermediate,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,10090.0
6076,,,,Mus musculus,,A,,,N,17827,BAO_0000218,CHEMBL622815,50594,,Intermediate,Time at maximum activity in mice (Radiolabeled compound),,10090.0
6077,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL625342,50594,,Intermediate,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,10090.0
6078,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL625343,50594,,Intermediate,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,10090.0
6079,,,,Mus musculus,,A,,,N,17409,BAO_0000218,CHEMBL877591,50594,,Intermediate,Binding towards mouse plasma protein at 10 uM,,10090.0
6080,,,,Mus musculus,,A,,,N,17409,BAO_0000218,CHEMBL625344,50594,,Intermediate,Binding towards mouse plasma protein at 100 uM,,10090.0
6081,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL625345,50594,,Intermediate,Bioavailability was evaluated in mice after intravenous administration,In vivo,10090.0
6082,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL625346,50594,,Intermediate,Bioavailability was evaluated in mice after oral administration,In vivo,10090.0
6083,,,,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL625347,50594,,Intermediate,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,10090.0
6084,,,,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL625348,50594,,Intermediate,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,10090.0
6085,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL625349,50594,,Intermediate,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,10090.0
6086,,,,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL625350,50594,,Intermediate,Oral bioavailability in mouse,In vivo,10090.0
6087,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL882952,50594,,Intermediate,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,10090.0
6088,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL625351,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6089,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL625352,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6090,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL877592,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6091,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL625353,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6092,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL625354,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6093,955.0,,Brain,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL626019,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6094,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL626020,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6095,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL626021,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6096,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL626022,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6097,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL626192,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6098,,A549,,Homo sapiens,,F,,646.0,N,1276,BAO_0000219,CHEMBL626193,80682,,Intermediate,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,9606.0
6099,,A549,,Homo sapiens,,F,,646.0,N,3498,BAO_0000219,CHEMBL626194,80682,,Expert,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,9606.0
6100,,A549,,Homo sapiens,,F,,646.0,N,1169,BAO_0000219,CHEMBL626195,80682,,Intermediate,Cytotoxicity against human lung carcinoma A-549 cell lines,,9606.0
6101,,A549,,Homo sapiens,,F,,646.0,N,4450,BAO_0000219,CHEMBL626196,80682,,Intermediate,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,9606.0
6102,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626197,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549,,9606.0
6103,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626198,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,9606.0
6104,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626199,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,9606.0
6105,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626200,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,9606.0
6106,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626201,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,9606.0
6107,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626202,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,9606.0
6108,,A549,,Homo sapiens,,F,,646.0,N,358,BAO_0000219,CHEMBL626203,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,9606.0
6109,,A549,,Homo sapiens,,F,,646.0,N,15167,BAO_0000219,CHEMBL626204,80682,,Intermediate,In vitro cytotoxicity against A-549 human lung cancer cells,,9606.0
6110,,A549,,Homo sapiens,,F,,646.0,N,4139,BAO_0000219,CHEMBL624701,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,9606.0
6111,,A549,,Homo sapiens,,F,,646.0,N,833,BAO_0000219,CHEMBL624702,80682,,Intermediate,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,9606.0
6112,,A549,,Homo sapiens,,F,,646.0,N,15718,BAO_0000219,CHEMBL624703,80682,,Expert,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,9606.0
6113,,A549,,Homo sapiens,,F,,646.0,N,12373,BAO_0000219,CHEMBL624704,80682,,Intermediate,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,9606.0
6114,,A549,,Homo sapiens,,F,,646.0,N,637,BAO_0000219,CHEMBL624705,80682,,Intermediate,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,9606.0
6115,,A549,,Homo sapiens,,F,,646.0,N,14867,BAO_0000219,CHEMBL624706,80682,,Expert,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,9606.0
6116,,A549,,Homo sapiens,,F,,646.0,N,4461,BAO_0000219,CHEMBL624707,80682,,Intermediate,Antitumor cytotoxic activity against A-549 cell line was determined,,9606.0
6117,,A549,,Homo sapiens,,F,,646.0,N,5406,BAO_0000219,CHEMBL624708,80682,,Intermediate,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,9606.0
6118,,A549,,Homo sapiens,,F,,646.0,N,4457,BAO_0000219,CHEMBL624709,80682,,Intermediate,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,9606.0
6119,,A549,,Homo sapiens,,F,,646.0,N,1386,BAO_0000219,CHEMBL884107,80682,,Expert,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,9606.0
6120,,A549,,Homo sapiens,,F,,646.0,N,3265,BAO_0000219,CHEMBL624710,80682,,Intermediate,Antitumoral activity was assayed against A-549 cell line,,9606.0
6121,,A549,,Homo sapiens,,F,,646.0,N,2359,BAO_0000219,CHEMBL624711,80682,,Intermediate,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,9606.0
6122,,A549,,Homo sapiens,,F,,646.0,N,4457,BAO_0000219,CHEMBL624712,80682,,Intermediate,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,9606.0
6123,,A549,,Homo sapiens,,F,,646.0,N,12454,BAO_0000219,CHEMBL624713,80682,,Expert,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,9606.0
6124,,A549,,Homo sapiens,,F,,646.0,N,1481,BAO_0000219,CHEMBL624714,80682,,Intermediate,Compound was tested for inhibition of cell growth of A-549 cells,,9606.0
6125,,A549,,Homo sapiens,,F,,646.0,N,1750,BAO_0000219,CHEMBL624715,80682,,Intermediate,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,9606.0
6126,,A549,,Homo sapiens,,F,,646.0,N,5065,BAO_0000219,CHEMBL624716,80682,,Intermediate,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,9606.0
6127,,A549,,Homo sapiens,,F,,646.0,N,808,BAO_0000219,CHEMBL619505,80682,,Expert,In vitro cytotoxicity against A549-human lung carcinoma cells.,,9606.0
6128,,A549,,Homo sapiens,,F,,646.0,N,16364,BAO_0000219,CHEMBL619506,80682,,Expert,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,9606.0
6129,,A549,,Homo sapiens,,F,,646.0,N,1847,BAO_0000219,CHEMBL619507,80682,,Intermediate,Cytotoxic activity against A-549 cell lines.,,9606.0
6130,,A549,,Homo sapiens,,F,,646.0,N,1747,BAO_0000219,CHEMBL619508,80682,,Expert,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,9606.0
6131,,A549,,Homo sapiens,,F,,646.0,N,1003,BAO_0000219,CHEMBL619509,80682,,Intermediate,Cytotoxicity against human A549 non small cell lung cell lines,,9606.0
6132,,A549,,Homo sapiens,,F,,646.0,N,15313,BAO_0000219,CHEMBL619510,80682,,Expert,Inhibition of cell growth in (A-549) lung cell line,,9606.0
6133,,A549,,Homo sapiens,,F,,646.0,N,3122,BAO_0000219,CHEMBL619511,80682,,Intermediate,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,9606.0
6134,,A549,,Homo sapiens,,F,,646.0,N,16049,BAO_0000219,CHEMBL619512,80682,,Intermediate,In vitro antitumor activity against A-549 tumor cells.,,9606.0
6135,,A549,,Homo sapiens,,F,,646.0,N,17134,BAO_0000219,CHEMBL619513,80682,,Expert,In vitro antitumor effects against human A-549 cell lines.,,9606.0
6136,,A549,,Homo sapiens,,F,,646.0,N,6406,BAO_0000219,CHEMBL619514,80682,,Intermediate,In vitro cytotoxic activity of compound against A-549 cell line,,9606.0
6137,,A549,,Homo sapiens,,F,,646.0,N,627,BAO_0000219,CHEMBL619515,80682,,Intermediate,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,9606.0
6138,,A549,,Homo sapiens,,F,,646.0,N,12307,BAO_0000219,CHEMBL619516,80682,,Intermediate,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,9606.0
6139,,A549,,Homo sapiens,,F,,646.0,N,17861,BAO_0000219,CHEMBL884005,80682,,Intermediate,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,9606.0
6140,,A549,,Homo sapiens,,F,,646.0,N,6682,BAO_0000219,CHEMBL619517,80682,,Expert,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,9606.0
6141,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL619518,80682,,Intermediate,Inhibitory concentration of compound against A-549 cell line,,9606.0
6142,,A549,,Homo sapiens,,F,,646.0,N,2454,BAO_0000219,CHEMBL619519,80682,,Intermediate,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,9606.0
6143,,A549,,Homo sapiens,,F,,646.0,N,14709,BAO_0000219,CHEMBL876489,80682,,Intermediate,cytotoxic activity against leukemia (A-549) cancer cell line,,9606.0
6144,,A549,,Homo sapiens,,F,,646.0,N,15718,BAO_0000219,CHEMBL619520,80682,,Expert,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,9606.0
6145,,A549,,Homo sapiens,,F,,646.0,N,15718,BAO_0000219,CHEMBL619521,80682,,Intermediate,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,9606.0
6146,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL619522,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,9606.0
6147,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL619523,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,9606.0
6148,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL619524,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,9606.0
6149,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL619525,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,9606.0
6150,,A549,,,,F,,646.0,N,6630,BAO_0000219,CHEMBL619526,80682,,Intermediate,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,
6151,,A549,,Homo sapiens,,F,,646.0,N,16726,BAO_0000219,CHEMBL619527,80682,,Intermediate,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,9606.0
6152,,A549,,Homo sapiens,,F,,646.0,N,17846,BAO_0000219,CHEMBL619528,80682,,Intermediate,Cytotoxicity against A549 cells; No cytotoxicity,,9606.0
6153,,A549,,Homo sapiens,,F,,646.0,N,3415,BAO_0000219,CHEMBL619529,80682,,Expert,Cytotoxicity against human lung carcinoma (A549) cell lines,,9606.0
6154,,A549,,Homo sapiens,,F,,646.0,N,3415,BAO_0000219,CHEMBL619530,80682,,Expert,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,9606.0
6155,,A549,,Homo sapiens,,F,,646.0,N,5609,BAO_0000219,CHEMBL876490,80682,,Intermediate,In vitro anticancer activity against human lung (A549) cell line,,9606.0
6156,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619531,80682,,Intermediate,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,9606.0
6157,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619532,80682,,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,9606.0
6158,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619533,80682,,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,9606.0
6159,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619534,80682,,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,9606.0
6160,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL620164,80682,,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,9606.0
6161,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL620165,80682,,Intermediate,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,9606.0
6162,,A549,,Homo sapiens,,F,,646.0,N,16295,BAO_0000219,CHEMBL620166,80682,,Expert,Inhibition of A549 human lung tumor cell proliferation,,9606.0
6163,,A549,,Homo sapiens,,F,,646.0,N,16825,BAO_0000219,CHEMBL620167,80682,,Intermediate,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,9606.0
6164,,A549,,Homo sapiens,,F,,646.0,N,3439,BAO_0000219,CHEMBL620168,80682,,Expert,In vitro cytotoxicity against human tumor cell line A549,,9606.0
6165,,A549,,Homo sapiens,,F,,646.0,N,10870,BAO_0000219,CHEMBL620338,80682,,Intermediate,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,9606.0
6166,,A549,,Homo sapiens,,F,,646.0,N,4845,BAO_0000219,CHEMBL620339,80682,,Intermediate,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,9606.0
6167,,A549,,Homo sapiens,,F,,646.0,N,5822,BAO_0000219,CHEMBL620340,80682,,Intermediate,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,9606.0
6168,,A549,,Homo sapiens,,F,,646.0,N,5822,BAO_0000219,CHEMBL620341,80682,,Intermediate,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,9606.0
6169,,A549,,Homo sapiens,,F,,646.0,N,5822,BAO_0000219,CHEMBL876491,80682,,Intermediate,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,9606.0
6170,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL620342,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,9606.0
6171,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL620343,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,9606.0
6172,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL620344,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,9606.0
6173,,A549,,Homo sapiens,,F,,646.0,N,5609,BAO_0000219,CHEMBL620345,80682,,Intermediate,In vitro anticancer activity against human lung (A549) cell line,,9606.0
6174,,A549,,Homo sapiens,,F,,646.0,N,4644,BAO_0000219,CHEMBL620346,80682,,Intermediate,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,9606.0
6175,,A549,,Homo sapiens,,F,,646.0,N,4644,BAO_0000219,CHEMBL620347,80682,,Intermediate,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,9606.0
6176,,A549,,Homo sapiens,,F,,646.0,N,4644,BAO_0000219,CHEMBL620348,80682,,Intermediate,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,9606.0
6177,,A549,,Homo sapiens,,F,,646.0,N,4644,BAO_0000219,CHEMBL620349,80682,,Intermediate,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,9606.0
6178,,A549,,Homo sapiens,,F,,646.0,N,5822,BAO_0000219,CHEMBL618667,80682,,Intermediate,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,9606.0
6179,,A549,,Homo sapiens,,F,,646.0,N,3415,BAO_0000219,CHEMBL618668,80682,,Expert,Percentage inhibition of human lung carcinoma (A549) cell lines,,9606.0
6180,,A549,,Homo sapiens,,F,,646.0,N,16726,BAO_0000219,CHEMBL876031,80682,,Intermediate,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,9606.0
6181,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL618759,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,9606.0
6182,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL618760,80682,,Intermediate,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,9606.0
6183,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619000,80682,,Intermediate,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,9606.0
6184,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619001,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,9606.0
6185,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619002,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,9606.0
6186,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619003,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,9606.0
6187,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619597,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,9606.0
6188,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619598,80682,,Intermediate,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,9606.0
6189,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619599,80682,,Intermediate,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,9606.0
6190,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619600,80682,,Intermediate,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,9606.0
6191,,A549,,Homo sapiens,,F,,646.0,N,16726,BAO_0000219,CHEMBL619601,80682,,Intermediate,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,9606.0
6192,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619602,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,9606.0
6193,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619603,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,9606.0
6194,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619604,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,9606.0
6195,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619605,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,9606.0
6196,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL619606,50588,,Intermediate,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,9615.0
6197,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL876032,50588,,Intermediate,Pharmacokinetic activity (Cmax) in dog,In vivo,9615.0
6198,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL619607,50588,,Intermediate,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,9615.0
6199,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL619608,50588,,Intermediate,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,9615.0
6200,,,,Canis lupus familiaris,,A,,,N,6251,BAO_0000218,CHEMBL619609,50588,,Intermediate,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,9615.0
6201,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5932,BAO_0000218,CHEMBL619610,50588,,Intermediate,Cmax in dog plasma after 30mg/kg oral dose,In vivo,9615.0
6202,178.0,,Blood,Canis lupus familiaris,,A,,,N,4273,BAO_0000218,CHEMBL619611,50588,,Intermediate,Tested for the peak blood level in dog,In vivo,9615.0
6203,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL619612,50588,,Intermediate,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,9615.0
6204,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL619613,50588,,Intermediate,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,9615.0
6205,178.0,,Blood,Canis lupus familiaris,,A,,,N,6221,BAO_0000218,CHEMBL619614,50588,,Intermediate,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,9615.0
6206,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL619615,50588,,Intermediate,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,9615.0
6207,,,,Canis lupus familiaris,,A,,,N,167,BAO_0000218,CHEMBL619616,50588,,Intermediate,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,9615.0
6208,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6241,BAO_0000218,CHEMBL619617,50588,,Intermediate,Final plasma concentration in dogs after oral administration at 1 mg/kg,,9615.0
6209,,,,Canis lupus familiaris,,A,,,N,344,BAO_0000218,CHEMBL619618,50588,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,9615.0
6210,,,,Canis lupus familiaris,,A,,,N,344,BAO_0000218,CHEMBL876033,50588,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,9615.0
6211,,,,Canis lupus familiaris,,A,,,N,344,BAO_0000218,CHEMBL619619,50588,,Intermediate,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,9615.0
6212,,,,Canis lupus familiaris,,A,,,N,2189,BAO_0000218,CHEMBL619620,50588,,Intermediate,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,9615.0
6213,1088.0,,Urine,Canis lupus familiaris,,A,,,N,2189,BAO_0000218,CHEMBL619621,50588,,Intermediate,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,9615.0
6214,1088.0,,Urine,Canis lupus familiaris,,A,,,N,2189,BAO_0000218,CHEMBL619622,50588,,Intermediate,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,9615.0
6215,1088.0,,Urine,Canis lupus familiaris,,A,,,N,2189,BAO_0000218,CHEMBL618874,50588,,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,9615.0
6216,,,,Canis lupus familiaris,,A,,,N,4257,BAO_0000218,CHEMBL618875,50588,,Intermediate,Absolute bioavailability was evaluated in dog,In vivo,9615.0
6217,,,,Canis lupus familiaris,,A,,,N,6221,BAO_0000218,CHEMBL618876,50588,,Intermediate,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,9615.0
6218,,,,Canis lupus familiaris,,A,,,N,6215,BAO_0000218,CHEMBL618877,50588,,Intermediate,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,9615.0
6219,,,,Canis lupus familiaris,,A,,,N,17267,BAO_0000218,CHEMBL618878,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6220,,,,Canis lupus familiaris,,A,,,N,6621,BAO_0000218,CHEMBL618879,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6221,,,,Canis lupus familiaris,,A,,,N,3854,BAO_0000218,CHEMBL618880,50588,,Intermediate,Bioavailability after intravenous administration in dogs,In vivo,9615.0
6222,,,,Canis lupus familiaris,,A,,,N,3854,BAO_0000218,CHEMBL618881,50588,,Intermediate,Bioavailability after peroral administration in dogs,In vivo,9615.0
6223,,,,Canis lupus familiaris,,A,,,N,5007,BAO_0000218,CHEMBL618882,50588,,Intermediate,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,9615.0
6224,,,,Canis lupus familiaris,,A,,,N,4333,BAO_0000218,CHEMBL624226,50588,,Intermediate,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,9615.0
6225,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,4333,BAO_0000218,CHEMBL624227,50588,,Intermediate,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,9615.0
6226,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL624228,50588,,Intermediate,Bioavailability,In vivo,9615.0
6227,,,,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL624229,50588,,Intermediate,Bioavailability,In vivo,9615.0
6228,,,,Canis lupus familiaris,,A,,,N,4368,BAO_0000218,CHEMBL624230,50588,,Intermediate,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,9615.0
6229,,,,Canis lupus familiaris,,A,,,N,3771,BAO_0000218,CHEMBL624231,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6230,,,,Canis lupus familiaris,,A,,,N,4953,BAO_0000218,CHEMBL624232,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6231,,,,Canis lupus familiaris,,A,,,N,5064,BAO_0000218,CHEMBL625127,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6232,,,,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL625128,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6233,,,,Canis lupus familiaris,,A,,,N,17796,BAO_0000218,CHEMBL621675,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6234,,,,Canis lupus familiaris,,A,,,N,17853,BAO_0000218,CHEMBL621676,50588,,Intermediate,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,9615.0
6235,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL621677,50588,,Intermediate,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,9615.0
6236,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL621678,50588,,Intermediate,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,9615.0
6237,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL621679,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6238,,,,Canis lupus familiaris,,A,,,N,16365,BAO_0000218,CHEMBL621680,50588,,Intermediate,Bioavailability was evaluated after oral administration in dog,In vivo,9615.0
6239,,,,Canis lupus familiaris,,A,,,N,1916,BAO_0000218,CHEMBL621681,50588,,Intermediate,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,9615.0
6240,,,,Canis lupus familiaris,,A,,,N,1918,BAO_0000218,CHEMBL876740,50588,,Intermediate,Bioavailability was evaluated in dog,In vivo,9615.0
6241,,,,Canis lupus familiaris,,A,,,N,4239,BAO_0000218,CHEMBL621682,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6242,,,,Canis lupus familiaris,,A,,,N,6505,BAO_0000218,CHEMBL621683,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6243,,,,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL621684,50588,,Intermediate,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,9615.0
6244,,,,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL621685,50588,,Intermediate,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,9615.0
6245,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL621686,50588,,Intermediate,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,9615.0
6246,,,,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL621687,50588,,Intermediate,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
6247,,,,Canis lupus familiaris,,A,,,N,6005,BAO_0000218,CHEMBL621688,50588,,Intermediate,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,9615.0
6248,,,,Canis lupus familiaris,,A,,,N,17804,BAO_0000218,CHEMBL621689,50588,,Intermediate,Bioavailability of compound in dog was determined after peroral administration,In vivo,9615.0
6249,,,,Canis lupus familiaris,,A,,,N,3184,BAO_0000218,CHEMBL621690,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6250,,,,Canis lupus familiaris,,A,,,N,1806,BAO_0000218,CHEMBL621691,50588,,Intermediate,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,9615.0
6251,,,,Canis lupus familiaris,,A,,,N,1806,BAO_0000218,CHEMBL875941,50588,,Intermediate,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,9615.0
6252,,,,Canis lupus familiaris,,A,,,N,1806,BAO_0000218,CHEMBL621692,50588,,Intermediate,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,9615.0
6253,,,,Canis lupus familiaris,,A,,,N,4839,BAO_0000218,CHEMBL621693,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6254,,,,Canis lupus familiaris,,A,,,N,5017,BAO_0000218,CHEMBL621694,50588,,Intermediate,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,9615.0
6255,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL621695,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6256,948.0,,Heart,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL621696,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6257,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL621697,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6258,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL621698,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6259,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623420,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6260,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623421,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6261,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623422,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6262,2113.0,,Kidney,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623423,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6263,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623424,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6264,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623425,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6265,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623426,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6266,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623427,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6267,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623428,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6268,2107.0,,Liver,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL875947,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6269,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623429,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6270,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL623430,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6271,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL622588,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6272,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL622589,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6273,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL622751,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6274,2048.0,,Lung,Mus musculus,,A,,,N,846,BAO_0000218,CHEMBL622752,50594,,Intermediate,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,10090.0
6275,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622753,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,10090.0
6276,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622647,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,10090.0
6277,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL875163,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,10090.0
6278,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622648,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,10090.0
6279,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622649,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,10090.0
6280,955.0,CCRF S-180,Brain,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622650,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,10090.0
6281,955.0,CCRF S-180,Brain,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622651,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,10090.0
6282,955.0,CCRF S-180,Brain,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622652,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,10090.0
6283,955.0,CCRF S-180,Brain,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622653,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,10090.0
6284,955.0,CCRF S-180,Brain,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622654,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,10090.0
6285,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622655,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,10090.0
6286,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622656,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,10090.0
6287,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622657,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,10090.0
6288,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622658,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,10090.0
6289,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL622659,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,10090.0
6290,2113.0,CCRF S-180,Kidney,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624630,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,10090.0
6291,2113.0,CCRF S-180,Kidney,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624631,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,10090.0
6292,2113.0,CCRF S-180,Kidney,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624632,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,10090.0
6293,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL624633,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,9606.0
6294,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL624634,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,9606.0
6295,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL624635,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,9606.0
6296,,A549,,Homo sapiens,,F,,646.0,N,17130,BAO_0000219,CHEMBL624636,80682,,Intermediate,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,9606.0
6297,,A549,,Homo sapiens,,F,,646.0,N,3263,BAO_0000219,CHEMBL857055,80682,,Expert,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,9606.0
6298,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624637,80682,,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,9606.0
6299,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624638,80682,,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,9606.0
6300,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL874366,80682,,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,9606.0
6301,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624639,80682,,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,9606.0
6302,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624640,80682,,Expert,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,9606.0
6303,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624641,80682,,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,9606.0
6304,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624642,80682,,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,9606.0
6305,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624643,80682,,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,9606.0
6306,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624644,80682,,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,9606.0
6307,,A549,,Homo sapiens,,F,,646.0,N,6663,BAO_0000219,CHEMBL624645,80682,,Intermediate,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,9606.0
6308,,A549,,Homo sapiens,,F,,646.0,N,3983,BAO_0000219,CHEMBL619445,80682,,Intermediate,The compound was evaluated for its cytotoxic potency against A-549 cell line,,9606.0
6309,,A549,,Homo sapiens,,F,,646.0,N,11141,BAO_0000219,CHEMBL839886,80682,,Expert,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,9606.0
6310,,A549,,Homo sapiens,,F,,646.0,N,5076,BAO_0000219,CHEMBL619446,80682,,Intermediate,Cytotoxic activity of compound against A-549 tumor cell line.,,9606.0
6311,,A549,,Homo sapiens,,F,,646.0,N,3311,BAO_0000219,CHEMBL619447,80682,,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,9606.0
6312,,A549,,Homo sapiens,,F,,646.0,N,3311,BAO_0000219,CHEMBL619448,80682,,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,9606.0
6313,,A549,,Homo sapiens,,F,,646.0,N,3311,BAO_0000219,CHEMBL619449,80682,,Intermediate,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,9606.0
6314,,A549,,Homo sapiens,,F,,646.0,N,5076,BAO_0000219,CHEMBL619450,80682,,Intermediate,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,9606.0
6315,,A549,,Homo sapiens,,F,,646.0,N,4150,BAO_0000219,CHEMBL619451,80682,,Intermediate,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,9606.0
6316,,A549,,Homo sapiens,,F,,646.0,N,2150,BAO_0000219,CHEMBL619452,80682,,Expert,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,9606.0
6317,,A549,,Homo sapiens,,F,,646.0,N,4644,BAO_0000219,CHEMBL619453,80682,,Intermediate,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,9606.0
6318,,A549,,Homo sapiens,,F,,646.0,N,263,BAO_0000219,CHEMBL874367,80682,,Intermediate,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,9606.0
6319,,A549,,Homo sapiens,,F,,646.0,N,11333,BAO_0000219,CHEMBL619454,80682,,Intermediate,Cytotoxic concentration against A-549 tumor cells.,,9606.0
6320,,A549,,Homo sapiens,,F,,646.0,N,11333,BAO_0000219,CHEMBL619455,80682,,Intermediate,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,9606.0
6321,,A549,,Homo sapiens,,F,,646.0,N,15895,BAO_0000219,CHEMBL619456,80682,,Intermediate,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,9606.0
6322,,,,Acinetobacter baumannii,,F,,,N,16677,BAO_0000218,CHEMBL619457,50191,,Expert,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,470.0
6323,,,,Acinetobacter calcoaceticus,,F,,,N,10624,BAO_0000218,CHEMBL619458,50192,,Intermediate,Activity against Acinetobacter calcoaceticus (AC54),,471.0
6324,,,,Aspergillus flavus,,F,,,N,16717,BAO_0000218,CHEMBL619459,50274,,Expert,In vitro antifungal activity against Aspergillus flavus CM74,,5059.0
6325,,,,Aspergillus flavus,,F,,,N,16717,BAO_0000218,CHEMBL619460,50274,,Expert,In vitro antifungal activity against Aspergillus flavus CM74,,5059.0
6326,,,,Aspergillus fumigatus,,F,,,N,5513,BAO_0000218,CHEMBL619461,50416,,Intermediate,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,746128.0
6327,,,,Aspergillus fumigatus,,F,,,N,15962,BAO_0000218,CHEMBL619462,50416,,Intermediate,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,746128.0
6328,,,,Aspergillus fumigatus,,F,,,N,15962,BAO_0000218,CHEMBL620388,50416,,Intermediate,Antimicrobial activity against Aspergillus fumigatus (MIC),,746128.0
6329,,,,Aspergillus fumigatus,,F,,,N,15962,BAO_0000218,CHEMBL620389,50416,,Intermediate,Antimicrobial activity against Aspergillus fumigatus (MIC),,746128.0
6330,,,,Aspergillus fumigatus,,F,,,N,15962,BAO_0000218,CHEMBL620390,50416,,Intermediate,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,746128.0
6331,,,,Aspergillus fumigatus,,F,,,N,16717,BAO_0000218,CHEMBL620391,50416,,Expert,In vitro antifungal activity against Aspergillus fumigatus 48238E,,746128.0
6332,,,,Aspergillus fumigatus,,F,,,N,16717,BAO_0000218,CHEMBL621073,50416,,Expert,In vitro antifungal activity against Aspergillus fumigatus 48238E,,746128.0
6333,,,,Actinomyces naeslundii,,F,,,N,8117,BAO_0000218,CHEMBL621074,50296,,Intermediate,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,1655.0
6334,,,,Actinomyces viscosus,,F,,,N,8117,BAO_0000218,CHEMBL621075,50366,,Intermediate,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,1656.0
6335,,,,Acanthocheilonema viteae,,F,,,N,15472,BAO_0000218,CHEMBL619554,50535,,Intermediate,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,6277.0
6336,,,,Acanthocheilonema viteae,,F,,,N,15472,BAO_0000218,CHEMBL619555,50535,,Intermediate,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,6277.0
6337,,,,Aggregatibacter actinomycetemcomitans,,F,,,N,16443,BAO_0000218,CHEMBL619556,50169,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,714.0
6338,,,,Aggregatibacter actinomycetemcomitans,,F,,,N,16443,BAO_0000218,CHEMBL619557,50169,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,714.0
6339,,,,Aggregatibacter actinomycetemcomitans,,F,,,N,16443,BAO_0000218,CHEMBL619558,50169,,Intermediate,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,714.0
6340,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619559,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,9606.0
6341,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619560,80682,,Intermediate,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,9606.0
6342,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL619561,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,9606.0
6343,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL619562,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,9606.0
6344,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL619563,80682,,Intermediate,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,9606.0
6345,,A549,,Homo sapiens,,F,,646.0,N,16381,BAO_0000219,CHEMBL857457,80682,,Intermediate,GI values against A549 cells (lung cancer),,9606.0
6346,,A549,,Homo sapiens,,F,,646.0,N,17206,BAO_0000219,CHEMBL619564,80682,,Intermediate,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,9606.0
6347,,A549,,Homo sapiens,,F,,646.0,N,16325,BAO_0000219,CHEMBL619565,80682,,Intermediate,Inhibitory activity against A549 human adenocarcinoma,,9606.0
6348,,A549,,Homo sapiens,,F,,646.0,N,10708,BAO_0000218,CHEMBL619566,80682,,Intermediate,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,9606.0
6349,,A549,,Homo sapiens,,F,,646.0,N,10708,BAO_0000218,CHEMBL619567,80682,,Intermediate,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,9606.0
6350,,A549,,Homo sapiens,,F,,646.0,N,17376,BAO_0000219,CHEMBL619568,80682,,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line,,9606.0
6351,,A549,,Homo sapiens,,F,,646.0,N,17376,BAO_0000219,CHEMBL619569,80682,,Intermediate,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,9606.0
6352,,A549,,Homo sapiens,,F,,646.0,N,17488,BAO_0000219,CHEMBL619570,80682,,Intermediate,Cytotoxicity against human A549 lung cells,,9606.0
6353,,A549,,Homo sapiens,,F,,646.0,N,17404,BAO_0000218,CHEMBL619571,80682,,Intermediate,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,9606.0
6354,,A549,,Homo sapiens,,F,,646.0,N,10958,BAO_0000219,CHEMBL619572,80682,,Expert,Growth inhibition of A549 (human lung carcinoma) cell line.,,9606.0
6355,,A549,,Homo sapiens,,F,,646.0,N,17099,BAO_0000219,CHEMBL619573,80682,,Expert,Effective dose required for inhibitory activity against A549 human tumor cell line.,,9606.0
6356,,A549,,Homo sapiens,,F,,646.0,N,17099,BAO_0000219,CHEMBL619574,80682,,Intermediate,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,9606.0
6357,,A549,,Homo sapiens,,F,,646.0,N,4096,BAO_0000219,CHEMBL619575,80682,,Intermediate,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,9606.0
6358,,A549,,Homo sapiens,,F,,646.0,N,4096,BAO_0000219,CHEMBL619576,80682,,Expert,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,9606.0
6359,,A549,,Homo sapiens,,F,,646.0,N,4096,BAO_0000219,CHEMBL619577,80682,,Intermediate,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,9606.0
6360,,A549,,Homo sapiens,,F,,646.0,N,2525,BAO_0000219,CHEMBL619578,80682,,Intermediate,In vitro inhibitory activity against A549 tumor cell culture,,9606.0
6361,,A549,,Homo sapiens,,F,,646.0,N,2525,BAO_0000219,CHEMBL884009,80682,,Intermediate,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,9606.0
6362,,A549,,Homo sapiens,,F,,646.0,N,5302,BAO_0000219,CHEMBL619579,80682,,Intermediate,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,9606.0
6363,,A549,,Homo sapiens,,F,,646.0,N,16325,BAO_0000219,CHEMBL619580,80682,,Intermediate,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,9606.0
6364,,A549,,Homo sapiens,,F,,646.0,N,16939,BAO_0000219,CHEMBL619581,80682,,Intermediate,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,9606.0
6365,,A549,,Homo sapiens,,F,,646.0,N,17229,BAO_0000219,CHEMBL619582,80682,,Intermediate,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,9606.0
6366,,A549,,Homo sapiens,,F,,646.0,N,17380,BAO_0000219,CHEMBL619583,80682,,Intermediate,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,9606.0
6367,,A549,,Homo sapiens,,F,,646.0,N,17380,BAO_0000219,CHEMBL876502,80682,,Intermediate,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,9606.0
6368,,A549,,Homo sapiens,,F,,646.0,N,1903,BAO_0000219,CHEMBL619584,80682,,Intermediate,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,9606.0
6369,,A549,,Homo sapiens,,F,,646.0,N,3838,BAO_0000219,CHEMBL619585,80682,,Intermediate,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,9606.0
6370,,A549,,Homo sapiens,,F,,646.0,N,14696,BAO_0000219,CHEMBL619586,80682,,Intermediate,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,9606.0
6371,,A549,,Homo sapiens,,F,,646.0,N,3838,BAO_0000219,CHEMBL619587,80682,,Intermediate,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,9606.0
6372,,A549,,Homo sapiens,,F,,646.0,N,1522,BAO_0000219,CHEMBL619588,80682,,Intermediate,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,9606.0
6373,,A549,,Homo sapiens,,F,,646.0,N,12400,BAO_0000219,CHEMBL619589,80682,,Intermediate,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,9606.0
6374,,A549,,Homo sapiens,,F,,646.0,N,14696,BAO_0000219,CHEMBL619590,80682,,Intermediate,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,9606.0
6375,,A549,,Homo sapiens,,F,,646.0,N,14769,BAO_0000219,CHEMBL619591,80682,,Intermediate,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,9606.0
6376,,A549,,Homo sapiens,,F,,646.0,N,14696,BAO_0000219,CHEMBL619592,80682,,Intermediate,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,9606.0
6377,,A549,,Homo sapiens,,F,,646.0,N,1888,BAO_0000219,CHEMBL619593,80682,,Intermediate,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,9606.0
6378,,A549,,Homo sapiens,,F,,646.0,N,12016,BAO_0000219,CHEMBL620217,80682,,Intermediate,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,9606.0
6379,,A549,,Homo sapiens,,F,,646.0,N,6058,BAO_0000219,CHEMBL620218,80682,,Intermediate,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,9606.0
6380,,A549,,Homo sapiens,,F,,646.0,N,17708,BAO_0000219,CHEMBL620219,80682,,Intermediate,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,9606.0
6381,,A549,,Homo sapiens,,F,,646.0,N,12301,BAO_0000219,CHEMBL620220,80682,,Intermediate,Antitumor activity against A549/ATCC cell line,,9606.0
6382,,A549,,Homo sapiens,,F,,646.0,N,11970,BAO_0000219,CHEMBL625141,80682,,Intermediate,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,9606.0
6383,,A549,,Homo sapiens,,F,,646.0,N,11818,BAO_0000219,CHEMBL625142,80682,,Expert,In vitro cytotoxicity against A549/ATCC cell line.,,9606.0
6384,,A549,,Homo sapiens,,F,,646.0,N,12400,BAO_0000219,CHEMBL625143,80682,,Intermediate,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,9606.0
6385,,A549,,Homo sapiens,,F,,646.0,N,3381,BAO_0000219,CHEMBL625144,80682,,Intermediate,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,9606.0
6386,,A549,,Homo sapiens,,F,,646.0,N,17376,BAO_0000219,CHEMBL622474,80682,,Intermediate,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,9606.0
6387,,A549,,Homo sapiens,,F,,646.0,N,10708,BAO_0000219,CHEMBL884104,80682,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,9606.0
6388,,,,Homo sapiens,,F,,,U,2964,BAO_0000219,CHEMBL622475,22226,,Autocuration,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,9606.0
6389,,,,Canis lupus familiaris,,A,,,U,5005,BAO_0000218,CHEMBL622476,22224,,Intermediate,Compound was tested for oral bioavailability in dogs,In vivo,9615.0
6390,,,,Canis lupus familiaris,,A,,,N,6229,BAO_0000218,CHEMBL875831,50588,,Intermediate,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,9615.0
6391,,,,Canis lupus familiaris,,A,,,N,6229,BAO_0000218,CHEMBL622477,50588,,Intermediate,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,9615.0
6392,,,,Canis lupus familiaris,,A,,,N,5374,BAO_0000218,CHEMBL622478,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6393,,,,Canis lupus familiaris,,A,,,N,5374,BAO_0000218,CHEMBL623172,50588,,Intermediate,Compound was tested for the oral bioavailability in dog; No availability,In vivo,9615.0
6394,,,,Canis lupus familiaris,,A,,,N,6265,BAO_0000218,CHEMBL623173,50588,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),In vivo,9615.0
6395,,,,Canis lupus familiaris,,A,,,N,5654,BAO_0000218,CHEMBL623174,50588,,Intermediate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,9615.0
6396,,,,Canis lupus familiaris,,A,,,N,5654,BAO_0000218,CHEMBL623175,50588,,Intermediate,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,9615.0
6397,,,,Canis lupus familiaris,,A,,,N,16456,BAO_0000218,CHEMBL623340,50588,,Intermediate,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,9615.0
6398,,,,Canis lupus familiaris,,A,,,N,5302,BAO_0000218,CHEMBL623341,50588,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),In vivo,9615.0
6399,,,,Canis lupus familiaris,,A,,,N,3624,BAO_0000218,CHEMBL623342,50588,,Intermediate,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,9615.0
6400,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL623343,50588,,Intermediate,Oral bioavailability of active FTIs in dogs,In vivo,9615.0
6401,,,,Canis lupus familiaris,,A,,,N,5802,BAO_0000218,CHEMBL623344,50588,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,9615.0
6402,,,,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL623345,50588,,Expert,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,9615.0
6403,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL875832,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6404,,,,Canis lupus familiaris,,A,,,N,6762,BAO_0000218,CHEMBL623346,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6405,,,,Canis lupus familiaris,,A,,,N,6821,BAO_0000218,CHEMBL623347,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6406,,,,Canis lupus familiaris,,A,,,N,6821,BAO_0000218,CHEMBL623348,50588,,Intermediate,Oral bioavailability of compound was determined in dog; Not tested,In vivo,9615.0
6407,,,,Canis lupus familiaris,,A,,,N,5210,BAO_0000218,CHEMBL623349,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6408,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL623350,50588,,Intermediate,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,9615.0
6409,,,,Canis lupus familiaris,,A,,,N,761,BAO_0000218,CHEMBL623351,50588,,Intermediate,Oral bioavailability,In vivo,9615.0
6410,,,,Canis lupus familiaris,,A,,,N,761,BAO_0000218,CHEMBL623352,50588,,Intermediate,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,9615.0
6411,,,,Canis lupus familiaris,,A,,,N,761,BAO_0000218,CHEMBL623353,50588,,Intermediate,Oral bioavailability administered in solution in rats,In vivo,9615.0
6412,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL875833,50588,,Intermediate,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,9615.0
6413,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL623354,50588,,Intermediate,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,9615.0
6414,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL623355,50588,,Intermediate,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,9615.0
6415,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL623356,50588,,Intermediate,Oral bioavailability in Dog; ND = not determined,In vivo,9615.0
6416,,,,Canis lupus familiaris,,A,,,N,3352,BAO_0000218,CHEMBL623357,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6417,,,,Canis lupus familiaris,,A,,,N,6168,BAO_0000218,CHEMBL623358,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6418,,,,Canis lupus familiaris,,A,,,N,5988,BAO_0000218,CHEMBL623359,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6419,,,,Canis lupus familiaris,,A,,,N,4942,BAO_0000218,CHEMBL623360,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6420,,,,Canis lupus familiaris,,A,,,N,4942,BAO_0000218,CHEMBL623361,50588,,Intermediate,Oral bioavailability in dogs; No data,In vivo,9615.0
6421,,,,Canis lupus familiaris,,A,,,N,14541,BAO_0000218,CHEMBL623362,50588,,Intermediate,Oral bioavailability measured in dogs,In vivo,9615.0
6422,,,,Canis lupus familiaris,,A,,,N,4449,BAO_0000218,CHEMBL623363,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6423,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL623364,50588,,Intermediate,Oral bioavailability was calculated in dog,In vivo,9615.0
6424,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL875834,50588,,Intermediate,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,9615.0
6425,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL623365,50588,,Intermediate,Oral bioavailability in dog (i.v. dosing),In vivo,9615.0
6426,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL623366,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6427,,,,Canis lupus familiaris,,A,,,N,5546,BAO_0000218,CHEMBL623367,50588,,Intermediate,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,9615.0
6428,,,,Canis lupus familiaris,,A,,,N,4514,BAO_0000218,CHEMBL623368,50588,,Intermediate,Oral bioavailability in Beagle dogs,In vivo,9615.0
6429,,,,Canis lupus familiaris,,A,,,N,3624,BAO_0000218,CHEMBL623369,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6430,,,,Canis lupus familiaris,,A,,,N,3854,BAO_0000218,CHEMBL623370,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6431,,,,Canis lupus familiaris,,A,,,N,5836,BAO_0000218,CHEMBL623371,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6432,,,,Canis lupus familiaris,,A,,,N,5940,BAO_0000218,CHEMBL623372,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6433,,,,Canis lupus familiaris,,A,,,N,6168,BAO_0000218,CHEMBL621351,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6434,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL621352,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6435,,,,Canis lupus familiaris,,A,,,N,6251,BAO_0000218,CHEMBL621353,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6436,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL621354,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6437,,,,Canis lupus familiaris,,A,,,N,6647,BAO_0000218,CHEMBL621355,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6438,,,,Canis lupus familiaris,,A,,,N,5940,BAO_0000218,CHEMBL621356,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6439,,,,Canis lupus familiaris,,A,,,N,933,BAO_0000218,CHEMBL621357,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6440,,,,Canis lupus familiaris,,A,,,N,5210,BAO_0000218,CHEMBL621358,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6441,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL621359,50588,,Intermediate,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,9615.0
6442,,,,Canis lupus familiaris,,A,,,N,6641,BAO_0000218,CHEMBL621360,50588,,Intermediate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,9615.0
6443,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL621361,50588,,Intermediate,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,9615.0
6444,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL621362,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6445,,,,Canis lupus familiaris,,A,,,N,5985,BAO_0000218,CHEMBL621363,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6446,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL621364,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6447,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621166,50588,,Intermediate,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,9615.0
6448,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621167,50588,,Intermediate,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,9615.0
6449,,,,Canis lupus familiaris,,A,,,N,6305,BAO_0000218,CHEMBL621168,50588,,Intermediate,Oral bioavailability (F) in dogs,In vivo,9615.0
6450,,,,Canis lupus familiaris,,A,,,N,5210,BAO_0000218,CHEMBL621169,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6451,,,,Canis lupus familiaris,,A,,,N,5238,BAO_0000218,CHEMBL875950,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6452,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL621170,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
6453,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL621171,50588,,Intermediate,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,9615.0
6454,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL621172,50588,,Intermediate,Oral bioavailability in dog (dose 5 mg/kg),In vivo,9615.0
6455,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL621173,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
6456,2113.0,CCRF S-180,Kidney,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621174,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,10090.0
6457,2113.0,CCRF S-180,Kidney,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621175,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,10090.0
6458,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621176,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,10090.0
6459,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621177,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,10090.0
6460,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621178,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,10090.0
6461,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621179,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,10090.0
6462,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621180,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,10090.0
6463,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL875951,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,10090.0
6464,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621181,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,10090.0
6465,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621182,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,10090.0
6466,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621183,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,10090.0
6467,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621184,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,10090.0
6468,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621185,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,10090.0
6469,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621186,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,10090.0
6470,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621187,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,10090.0
6471,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621188,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,10090.0
6472,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621189,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,10090.0
6473,2106.0,CCRF S-180,Spleen,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621190,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,10090.0
6474,2106.0,CCRF S-180,Spleen,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL618520,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,10090.0
6475,2106.0,CCRF S-180,Spleen,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621739,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,10090.0
6476,2106.0,CCRF S-180,Spleen,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621740,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,10090.0
6477,2106.0,CCRF S-180,Spleen,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621741,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,10090.0
6478,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621742,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,10090.0
6479,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621743,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,10090.0
6480,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621744,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,10090.0
6481,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621745,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,10090.0
6482,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621746,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,10090.0
6483,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621747,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,10090.0
6484,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621748,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,10090.0
6485,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621749,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,10090.0
6486,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621750,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,10090.0
6487,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621751,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,10090.0
6488,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621752,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,10090.0
6489,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621753,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,10090.0
6490,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL875955,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,10090.0
6491,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621754,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,10090.0
6492,948.0,CCRF S-180,Heart,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621755,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,10090.0
6493,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL621756,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,10090.0
6494,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624199,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,10090.0
6495,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624200,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,10090.0
6496,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624375,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,10090.0
6497,2107.0,CCRF S-180,Liver,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624376,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,10090.0
6498,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624377,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,10090.0
6499,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624378,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,10090.0
6500,,,,aeinetobacter anitrotap,,F,,,N,12269,BAO_0000218,CHEMBL857901,50067,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,107673.0
6501,,,,Acinetobacter calcoaceticus subsp. anitratus,,F,,,N,12269,BAO_0000218,CHEMBL875274,50067,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,107673.0
6502,,,,Acinetobacter calcoaceticus subsp. anitratus,,F,,,N,12269,BAO_0000218,CHEMBL624379,50067,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,107673.0
6503,,,,aeinetobacter anitrotap,,F,,,N,12269,BAO_0000218,CHEMBL624380,50067,,Intermediate,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,107673.0
6504,,,,Acinetobacter calcoaceticus,,F,,,N,10624,BAO_0000218,CHEMBL624381,50192,,Intermediate,Activity against Acinetobacter calcoaceticus (AC54),,471.0
6505,,,,Anolis carolinensis,,F,,,N,17216,BAO_0000218,CHEMBL624382,50714,,Intermediate,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,28377.0
6506,,,,Anolis carolinensis,,F,,,N,17216,BAO_0000218,CHEMBL624383,50714,,Intermediate,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,28377.0
6507,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624384,50296,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii 631,,1655.0
6508,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624385,50296,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii B74,,1655.0
6509,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624386,50296,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,1655.0
6510,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624387,50296,,Intermediate,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,1655.0
6511,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624388,50296,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii 631,,1655.0
6512,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624389,50296,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii N/9,,1655.0
6513,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL624390,50296,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii B74,,1655.0
6514,,,,Actinomyces naeslundii,,F,,,N,9560,BAO_0000218,CHEMBL875275,50296,,Intermediate,Plaque bactericidal index against Actinomyces naeslundii N/3,,1655.0
6515,,,,Artemia salina,,F,,,N,114,BAO_0000218,CHEMBL624391,50056,,Intermediate,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,85549.0
6516,,,,Artemia salina,,F,,,N,114,BAO_0000218,CHEMBL623636,50056,,Intermediate,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,85549.0
6517,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623637,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,6253.0
6518,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623638,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,6253.0
6519,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623639,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,6253.0
6520,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623640,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,6253.0
6521,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623641,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,6253.0
6522,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623642,50532,,Intermediate,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,6253.0
6523,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623643,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,6253.0
6524,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623644,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,6253.0
6525,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623645,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,6253.0
6526,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623646,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,6253.0
6527,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623647,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,6253.0
6528,,,,Ascaris suum,,F,,,N,10841,BAO_0000218,CHEMBL623648,50532,,Intermediate,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,6253.0
6529,,,,Actinomyces viscosus,,F,,,N,8117,BAO_0000218,CHEMBL623649,50366,,Intermediate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,1656.0
6530,,,,Actinomyces viscosus,,F,,,N,8117,BAO_0000218,CHEMBL623650,50366,,Intermediate,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,1656.0
6531,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623651,50366,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,1656.0
6532,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623652,50366,,Expert,Chlorohexidine coefficient for Actinomyces viscosus M-100,,1656.0
6533,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623653,50366,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus M-626,,1656.0
6534,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623654,50366,,Intermediate,Chlorohexidine coefficient for Actinomyces viscosus T14V,,1656.0
6535,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623655,50366,,Intermediate,Plaque bactericidal index against Actinomyces viscosus 8A06,,1656.0
6536,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623656,50366,,Intermediate,Plaque bactericidal index against Actinomyces viscosus M-100,,1656.0
6537,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623657,50366,,Expert,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,1656.0
6538,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623658,50366,,Intermediate,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,1656.0
6539,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623659,50366,,Intermediate,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,1656.0
6540,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623660,50366,,Intermediate,Plaque bactericidal index against Actinomyces viscosus 626,,1656.0
6541,,,,Actinomyces viscosus,,F,,,N,9560,BAO_0000218,CHEMBL623661,50366,,Intermediate,Plaque bactericidal index against Actinomyces viscosus T14V,,1656.0
6542,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL875281,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,6277.0
6543,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL623662,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,6277.0
6544,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL623663,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,6277.0
6545,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL623664,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,6277.0
6546,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL623665,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,6277.0
6547,,A673,,Homo sapiens,,F,,165.0,N,10708,BAO_0000219,CHEMBL621856,80023,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,9606.0
6548,,A704,,Homo sapiens,,F,,645.0,N,10708,BAO_0000219,CHEMBL620432,80661,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,9606.0
6549,,,,Rattus norvegicus,,F,,,U,416,BAO_0000219,CHEMBL620433,22226,,Autocuration,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,10116.0
6550,,A9,,Mus musculus,,F,,625.0,N,14354,BAO_0000219,CHEMBL620434,80024,,Intermediate,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,10090.0
6551,,A9,,Mus musculus,,F,,625.0,N,14354,BAO_0000219,CHEMBL620435,80024,,Intermediate,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,10090.0
6552,,A9,,Homo sapiens,,F,,625.0,N,5116,BAO_0000219,CHEMBL620436,80024,,Intermediate,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,9606.0
6553,,A9,,Homo sapiens,,F,,625.0,N,5116,BAO_0000219,CHEMBL876597,80024,,Intermediate,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,9606.0
6554,,Human ovarian carcinoma cell line,,Homo sapiens,,F,,874.0,N,15694,BAO_0000219,CHEMBL620437,81037,,Expert,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,9606.0
6555,,A9,,Mus musculus,,F,,625.0,N,13038,BAO_0000219,CHEMBL620438,80024,,Expert,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,10090.0
6556,,A9,,Mus musculus,,F,,625.0,N,13038,BAO_0000219,CHEMBL620439,80024,,Expert,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,10090.0
6557,,A9,,Mus musculus,,F,,625.0,N,10923,BAO_0000219,CHEMBL619657,80024,,Expert,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,10090.0
6558,,A9,,Mus musculus,,F,,625.0,N,10923,BAO_0000219,CHEMBL619658,80024,,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,10090.0
6559,,A9,,Mus musculus,,F,,625.0,N,10923,BAO_0000219,CHEMBL619659,80024,,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,10090.0
6560,,,,,,F,,,H,10923,BAO_0000019,CHEMBL619660,10649,,Expert,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,
6561,,A9,,Mus musculus,,F,,625.0,N,10923,BAO_0000219,CHEMBL619661,80024,,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,10090.0
6562,,A9,,Mus musculus,,F,,625.0,N,10923,BAO_0000219,CHEMBL619662,80024,,Intermediate,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,10090.0
6563,,AA6,,Cricetulus griseus,,F,,975.0,N,8158,BAO_0000219,CHEMBL619663,80663,,Intermediate,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,10029.0
6564,,,,Homo sapiens,,F,,,U,15494,BAO_0000219,CHEMBL619664,22226,,Autocuration,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,9606.0
6565,,,,Homo sapiens,,F,,,U,15494,BAO_0000219,CHEMBL619665,22226,,Autocuration,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,9606.0
6566,,AA5,,Homo sapiens,,F,,974.0,N,12348,BAO_0000219,CHEMBL883244,80662,,Intermediate,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,9606.0
6567,,AA5,,Homo sapiens,,F,,974.0,N,12348,BAO_0000219,CHEMBL884011,80662,,Intermediate,Cytotoxicity was measured against AA5/HIV-1(IIIB),,9606.0
6568,,AA5,,Homo sapiens,,F,,974.0,N,2726,BAO_0000219,CHEMBL619666,80662,,Intermediate,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,9606.0
6569,,U-937,,Homo sapiens,,F,,379.0,N,2726,BAO_0000219,CHEMBL619667,80566,,Intermediate,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,9606.0
6570,,UV4,,Cricetulus griseus,,F,,274.0,N,10747,BAO_0000219,CHEMBL619668,80578,,Intermediate,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,10029.0
6571,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,11005,BAO_0000219,CHEMBL619669,80089,,Expert,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,10029.0
6572,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL876608,80089,,Intermediate,Average intracellular compound concentration when the hypoxic SER=1.6,,10029.0
6573,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL619670,80089,,Intermediate,Average intracellular compound concentration when the hypoxic SER=1.6.,,10029.0
6574,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL619671,80089,,Intermediate,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,10029.0
6575,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL619672,80089,,Intermediate,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,10029.0
6576,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL619673,80089,,Intermediate,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,10029.0
6577,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13436,BAO_0000219,CHEMBL619674,80089,,Intermediate,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,10029.0
6578,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13435,BAO_0000219,CHEMBL619675,80089,,Intermediate,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,10029.0
6579,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13302,BAO_0000219,CHEMBL619676,80089,,Intermediate,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,10029.0
6580,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL619677,80089,,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,10029.0
6581,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12687,BAO_0000219,CHEMBL619678,80089,,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,10029.0
6582,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12687,BAO_0000219,CHEMBL619679,80089,,Intermediate,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,10029.0
6583,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12878,BAO_0000219,CHEMBL619680,80089,,Expert,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,10029.0
6584,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12878,BAO_0000219,CHEMBL621457,80089,,Intermediate,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,10029.0
6585,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,14367,BAO_0000219,CHEMBL876609,80089,,Expert,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,10029.0
6586,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,14367,BAO_0000219,CHEMBL621458,80089,,Intermediate,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,10029.0
6587,,CHO-AA8,,hampster,,F,,185.0,N,12398,BAO_0000219,CHEMBL621459,80089,,Expert,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,36483.0
6588,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12878,BAO_0000219,CHEMBL621460,80089,,Expert,Aerobic growth inhibition in Chinese hamster cell line AA8,,10029.0
6589,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13820,BAO_0000219,CHEMBL621461,80089,,Expert,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,10029.0
6590,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13436,BAO_0000219,CHEMBL621462,80089,,Expert,Inhibition of growth under aerobic conditions in AA8 cells,,10029.0
6591,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL621463,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
6592,,,,Canis lupus familiaris,,A,,,N,5711,BAO_0000218,CHEMBL621464,50588,,Intermediate,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,9615.0
6593,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL621465,50588,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),In vivo,9615.0
6594,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL621466,50588,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),In vivo,9615.0
6595,,,,Canis lupus familiaris,,A,,,N,17800,BAO_0000218,CHEMBL621467,50588,,Intermediate,Oral bioavailability in dog (mongrel),In vivo,9615.0
6596,,,,Canis lupus familiaris,,A,,,N,3994,BAO_0000218,CHEMBL621468,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
6597,,,,Canis lupus familiaris,,F,,,N,3994,BAO_0000218,CHEMBL876734,50588,,Intermediate,Oral bioavailability in dog (dose 10 mg/kg),In vivo,9615.0
6598,,,,Canis lupus familiaris,,A,,,N,5145,BAO_0000218,CHEMBL618476,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6599,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL618477,50588,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,9615.0
6600,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL618478,50588,,Intermediate,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,9615.0
6601,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL618479,50588,,Intermediate,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,9615.0
6602,,,,Canis lupus familiaris,,A,,,N,4273,BAO_0000218,CHEMBL618480,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6603,,,,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL618481,50588,,Intermediate,Bioavailability in dog (dose 3-10 mg/kg),In vivo,9615.0
6604,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL618482,50588,,Intermediate,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,9615.0
6605,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL618483,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6606,,,,Canis lupus familiaris,,A,,,N,3880,BAO_0000218,CHEMBL618484,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6607,,,,Canis lupus familiaris,,A,,,N,4838,BAO_0000218,CHEMBL618485,50588,,Intermediate,Bioavailability in dog,In vivo,9615.0
6608,,,,Canis lupus familiaris,,A,,,N,15600,BAO_0000218,CHEMBL618486,50588,,Intermediate,oral bioavailability was measured in dogs,In vivo,9615.0
6609,,,,Canis lupus familiaris,,A,,,N,17248,BAO_0000218,CHEMBL618487,50588,,Intermediate,Compound was tested for plasma protein binding in dog; Not determined,,9615.0
6610,,,,Canis lupus familiaris,,A,,,N,17248,BAO_0000218,CHEMBL618488,50588,,Intermediate,Compound was tested for plasma protein binding of dog,,9615.0
6611,,,,Canis lupus familiaris,,A,,,N,17248,BAO_0000218,CHEMBL876735,50588,,Intermediate,Compound was tested for plasma protein binding of dog; Not determined,,9615.0
6612,,,,Canis lupus familiaris,,A,,,N,17443,BAO_0000218,CHEMBL618489,50588,,Intermediate,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,9615.0
6613,,,,Canis lupus familiaris,,A,,,N,4186,BAO_0000218,CHEMBL618490,50588,,Intermediate,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,9615.0
6614,,,,Canis lupus familiaris,,A,,,N,3749,BAO_0000218,CHEMBL618491,50588,,Intermediate,Half life was determined,,9615.0
6615,,,,Canis lupus familiaris,,A,,,N,3249,BAO_0000218,CHEMBL618492,50588,,Intermediate,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,9615.0
6616,,,,Canis lupus familiaris,,A,,,N,3022,BAO_0000218,CHEMBL873354,50588,,Intermediate,Half life was evaluated in dog,,9615.0
6617,,,,Canis lupus familiaris,,A,,,N,3749,BAO_0000218,CHEMBL618493,50588,,Intermediate,Half life was determined,,9615.0
6618,,,,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618494,50588,,Intermediate,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6619,948.0,,Heart,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618495,50588,,Intermediate,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6620,2113.0,,Kidney,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618496,50588,,Intermediate,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6621,2107.0,,Liver,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618497,50588,,Intermediate,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6622,2048.0,,Lung,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618498,50588,,Intermediate,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6623,2106.0,,Spleen,Canis lupus familiaris,,A,,,N,2517,BAO_0000218,CHEMBL618499,50588,,Intermediate,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,9615.0
6624,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL876736,50588,,Intermediate,LogP in dog,,9615.0
6625,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL618500,50588,,Intermediate,Partition coefficient (logP),,9615.0
6626,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL857831,50588,,Intermediate,Partition coefficient in dog,,9615.0
6627,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL618501,50588,,Intermediate,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,9615.0
6628,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL618502,50588,,Intermediate,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,9615.0
6629,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL618503,50588,,Intermediate,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,9615.0
6630,,,,Canis lupus familiaris,,A,,,N,14294,BAO_0000218,CHEMBL618504,50588,,Intermediate,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,9615.0
6631,,,,Canis lupus familiaris,,A,,,N,14294,BAO_0000218,CHEMBL618505,50588,,Intermediate,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,9615.0
6632,,,,Canis lupus familiaris,,A,,,N,14294,BAO_0000218,CHEMBL618506,50588,,Intermediate,Metabolism of compound in dog S9 microsomes; Trace,,9615.0
6633,2107.0,,Liver,Canis lupus familiaris,,A,,,N,6251,BAO_0000218,CHEMBL618507,50588,,Intermediate,In vitro metabolic potential in dog liver microsomes,,9615.0
6634,,,,Canis lupus familiaris,,A,,,N,3748,BAO_0000218,CHEMBL876737,50588,,Intermediate,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,9615.0
6635,,,,Canis lupus familiaris,,A,,,N,2713,BAO_0000218,CHEMBL618508,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6636,,,,Canis lupus familiaris,,A,,,N,6512,BAO_0000218,CHEMBL618509,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6637,,,,Canis lupus familiaris,,A,,,N,6679,BAO_0000218,CHEMBL618510,50588,,Intermediate,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,9615.0
6638,,,,Canis lupus familiaris,,A,,,N,3749,BAO_0000218,CHEMBL618511,50588,,Intermediate,The compound was tested for bioavailability in dogs,In vivo,9615.0
6639,,,,Canis lupus familiaris,,A,,,N,3749,BAO_0000218,CHEMBL618512,50588,,Intermediate,The compound was tested for oral bioavailability in dogs,In vivo,9615.0
6640,,,,Canis lupus familiaris,,A,,,N,6742,BAO_0000218,CHEMBL618513,50588,,Intermediate,Oral bioavailability in dog,In vivo,9615.0
6641,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL618514,50588,,Intermediate,Compound was tested for percent protein binding (PB) in dog,,9615.0
6642,,,,Canis lupus familiaris,,A,,,N,6874,BAO_0000218,CHEMBL620052,50588,,Intermediate,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,9615.0
6643,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,2877,BAO_0000218,CHEMBL620053,50588,,Intermediate,Compound was evaluated for plasma clearance.,In vivo,9615.0
6644,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL620054,50588,,Intermediate,The compound was tested for plasma clearance in dog,In vivo,9615.0
6645,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL620055,50588,,Intermediate,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,9615.0
6646,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL620056,50588,,Intermediate,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,9615.0
6647,2107.0,,Liver,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL620057,50588,,Intermediate,In vitro relative rate of metabolism was determined in dog liver microsomes,,9615.0
6648,,,,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL618939,50588,,Intermediate,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,9615.0
6649,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL618940,50588,,Intermediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,9615.0
6650,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL618941,50588,,Intermediate,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,9615.0
6651,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624473,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,10090.0
6652,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624474,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,10090.0
6653,2048.0,CCRF S-180,Lung,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624475,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,10090.0
6654,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL624476,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,10090.0
6655,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL623478,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,10090.0
6656,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL623479,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,10090.0
6657,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL623480,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,10090.0
6658,,CCRF S-180,,Mus musculus,,A,,42.0,N,6599,BAO_0000218,CHEMBL623481,50594,,Intermediate,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,10090.0
6659,955.0,,Brain,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623482,50594,,Intermediate,C2 in brain of mice at the oral dose of 50 mg/kg,,10090.0
6660,2113.0,,Kidney,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623483,50594,,Intermediate,C2 in kidney of mice at the oral dose of 50 mg/kg,,10090.0
6661,2107.0,,Liver,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623484,50594,,Intermediate,C2 in liver of mice at the oral dose of 50 mg/kg,,10090.0
6662,2048.0,,Lung,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623485,50594,,Intermediate,C2 in lungs of mice at the oral dose of 50 mg/kg,,10090.0
6663,2106.0,,Spleen,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623486,50594,,Intermediate,C2 in spleen of mice at the oral dose of 50 mg/kg,,10090.0
6664,,,,Mus musculus,,A,,,N,17852,BAO_0000218,CHEMBL623487,50594,,Intermediate,Plasma clearance in mouse,In vivo,10090.0
6665,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL623488,50594,,Intermediate,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,10090.0
6666,,,,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL623489,50594,,Intermediate,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,10090.0
6667,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL875157,50594,,Intermediate,Clearance was evaluated in mice after intravenous administration,In vivo,10090.0
6668,,,,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL623490,50594,,Intermediate,Clearance was evaluated in mice after oral administration,In vivo,10090.0
6669,,,,Mus musculus,,A,,,N,4239,BAO_0000218,CHEMBL623491,50594,,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,10090.0
6670,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL623492,50594,,Intermediate,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,10090.0
6671,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL623493,50594,,Intermediate,Plasma clearance of at 24 mg/Kg,In vivo,10090.0
6672,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL623494,50594,,Intermediate,Plasma clearance at 24 mg/Kg,In vivo,10090.0
6673,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL623495,50594,,Intermediate,Plasma clearance at 5 mg/Kg,In vivo,10090.0
6674,,,,Mus musculus,,A,,,N,5727,BAO_0000218,CHEMBL623496,50594,,Intermediate,Plasma clearance in mice,In vivo,10090.0
6675,,,,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL623497,50594,,Intermediate,Plasma clearance value upon iv administration in mouse,In vivo,10090.0
6676,1969.0,,Plasma,Mus musculus,,A,,,N,5980,BAO_0000218,CHEMBL623498,50594,,Intermediate,Total plasma clearance in mice,In vivo,10090.0
6677,,,,Mus musculus,,A,,,N,17592,BAO_0000218,CHEMBL623499,50594,,Intermediate,Clearance in mouse,In vivo,10090.0
6678,,,,Mus musculus,,A,,,N,17718,BAO_0000218,CHEMBL623500,50594,,Intermediate,Clearance value was determined,In vivo,10090.0
6679,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL623501,50594,,Intermediate,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
6680,,,,,,P,,,U,17384,BAO_0000100,CHEMBL875158,22229,,Intermediate,Calculated partition coefficient (clogP),,
6681,,,,Mus musculus,,A,,,N,6062,BAO_0000218,CHEMBL623502,50594,,Intermediate,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,10090.0
6682,,,,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL623503,50594,,Intermediate,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,10090.0
6683,,,,Mus musculus,,A,,,N,6348,BAO_0000218,CHEMBL623504,50594,,Intermediate,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,10090.0
6684,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL623505,50594,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,10090.0
6685,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL623506,50594,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,10090.0
6686,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL623507,50594,,Intermediate,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,10090.0
6687,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL623508,50594,,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,10090.0
6688,,,,Mus musculus,,A,,,N,5781,BAO_0000218,CHEMBL623509,50594,,Intermediate,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,10090.0
6689,,,,Mus musculus,,A,,,N,17764,BAO_0000218,CHEMBL875159,50594,,Intermediate,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,10090.0
6690,955.0,,Brain,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623510,50594,,Intermediate,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,10090.0
6691,2113.0,,Kidney,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623511,50594,,Intermediate,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,10090.0
6692,2107.0,,Liver,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623512,50594,,Intermediate,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,10090.0
6693,2048.0,,Lung,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL623513,50594,,Intermediate,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,10090.0
6694,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL623514,50594,,Intermediate,Cmax in mice at 18 uM/kg i.p. administration,In vivo,10090.0
6695,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622609,50594,,Intermediate,Cmax in mice at 23 uM/kg i.v. administration,In vivo,10090.0
6696,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL622610,50594,,Intermediate,Cmax in mice at 24 uM/kg i.p. administration,In vivo,10090.0
6697,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL621823,50594,,Intermediate,Cmax in mice at 25 uM/kg i.p. administration,In vivo,10090.0
6698,,,,Mus musculus,,F,,,N,17764,BAO_0000218,CHEMBL621824,50594,,Intermediate,Cmax in mice at 26 uM/kg i.p. administration,In vivo,10090.0
6699,2106.0,,Spleen,Mus musculus,,A,,,N,17641,BAO_0000218,CHEMBL621825,50594,,Intermediate,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,10090.0
6700,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL621826,50594,,Intermediate,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,10090.0
6701,,,,Mus musculus,,A,,,N,16597,BAO_0000218,CHEMBL621827,50594,,Intermediate,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,10090.0
6702,,,,Mus musculus,,A,,,N,5727,BAO_0000218,CHEMBL621828,50594,,Intermediate,Cmax value was determined,In vivo,10090.0
6703,,,,Mus musculus,,A,,,N,5951,BAO_0000218,CHEMBL621829,50594,,Intermediate,Cmax value in IRC mice,In vivo,10090.0
6704,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL621830,50594,,Intermediate,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,10090.0
6705,,,,Mus musculus,,A,,,N,5506,BAO_0000218,CHEMBL621831,50594,,Intermediate,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,10090.0
6706,1969.0,,Plasma,Mus musculus,,A,,,N,14239,BAO_0000218,CHEMBL621832,50594,,Intermediate,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,10090.0
6707,1969.0,,Plasma,Mus musculus,,A,,,N,4890,BAO_0000218,CHEMBL624579,50594,,Intermediate,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,10090.0
6708,,,,Mus musculus,,A,,,N,429,BAO_0000218,CHEMBL624580,50594,,Intermediate,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,10090.0
6709,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL624581,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,6277.0
6710,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL624582,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,6277.0
6711,,,,Acanthocheilonema viteae,,F,,,N,10986,BAO_0000218,CHEMBL624583,50535,,Intermediate,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,6277.0
6712,,A-375,,Homo sapiens,,F,,455.0,N,13227,BAO_0000219,CHEMBL624584,80018,,Intermediate,Inhibitory activity against human tumor cell line A0375 melanoma.,,9606.0
6713,,,,Rattus norvegicus,,B,Brain membranes,,D,4481,BAO_0000249,CHEMBL624585,12512,,Expert,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,10116.0
6714,,,,Homo sapiens,,F,,,D,16931,BAO_0000019,CHEMBL875165,114,,Expert,Forskolin-induced cAMP production at human A1 adenosine receptor,,9606.0
6715,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619490,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,
6716,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619491,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,
6717,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619492,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,
6718,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619493,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,
6719,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619494,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,
6720,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619495,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,
6721,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619496,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,
6722,,CHO,,Homo sapiens,,F,,449.0,D,3850,BAO_0000219,CHEMBL619497,114,,Expert,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,9606.0
6723,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619498,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,
6724,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619499,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,
6725,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619500,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,
6726,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619501,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,
6727,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619502,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,
6728,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619503,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,
6729,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL619504,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6730,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL621298,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,
6731,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL621299,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,
6732,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL621300,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,
6733,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL621301,114,,Autocuration,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,
6734,,CHO,,,,F,,449.0,H,3850,BAO_0000219,CHEMBL621302,114,,Expert,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6735,,A10,,Oryctolagus cuniculus,,F,,164.0,N,12680,BAO_0000219,CHEMBL621303,80013,,Intermediate,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,9986.0
6736,,A10,,Rattus norvegicus,,F,,164.0,U,1313,BAO_0000219,CHEMBL621304,22226,,Autocuration,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,10116.0
6737,,A10,,Rattus norvegicus,,F,,164.0,U,1313,BAO_0000219,CHEMBL621305,22226,,Autocuration,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,10116.0
6738,,A10,,Rattus norvegicus,,F,,164.0,N,17567,BAO_0000219,CHEMBL621306,80013,,Intermediate,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,10116.0
6739,,A10,,Rattus norvegicus,,F,,164.0,N,17567,BAO_0000219,CHEMBL618444,80013,,Intermediate,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,10116.0
6740,,A10,,Rattus norvegicus,,F,,164.0,N,11819,BAO_0000219,CHEMBL618445,80013,,Intermediate,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,10116.0
6741,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13436,BAO_0000219,CHEMBL618446,80089,,Intermediate,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,10029.0
6742,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL618447,80089,,Intermediate,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,10029.0
6743,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12651,BAO_0000219,CHEMBL618448,80089,,Intermediate,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,10029.0
6744,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13300,BAO_0000219,CHEMBL618449,80089,,Intermediate,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,10029.0
6745,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,15296,BAO_0000219,CHEMBL618637,80089,,Intermediate,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,10029.0
6746,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,15328,BAO_0000219,CHEMBL618638,80089,,Intermediate,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,10029.0
6747,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13302,BAO_0000219,CHEMBL618639,80089,,Intermediate,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,10029.0
6748,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,14367,BAO_0000219,CHEMBL618640,80089,,Expert,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,10029.0
6749,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,17002,BAO_0000219,CHEMBL618641,80089,,Expert,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,10029.0
6750,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13436,BAO_0000219,CHEMBL618642,80089,,Intermediate,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,10029.0
6751,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,13435,BAO_0000219,CHEMBL618643,80089,,Intermediate,Inhibitory activity against aerobic growth of AA8 cells.,,10029.0
6752,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,10503,BAO_0000219,CHEMBL884013,80089,,Intermediate,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10029.0
6753,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,10503,BAO_0000219,CHEMBL622723,80089,,Expert,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10029.0
6754,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,10503,BAO_0000219,CHEMBL622724,80089,,Intermediate,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10029.0
6755,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,15090,BAO_0000219,CHEMBL622725,80089,,Expert,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,10029.0
6756,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,10368,BAO_0000219,CHEMBL622726,80089,,Expert,Cytotoxicity against AA8 cell line,,10029.0
6757,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12651,BAO_0000219,CHEMBL622727,80089,,Intermediate,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,10029.0
6758,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12687,BAO_0000219,CHEMBL622728,80089,,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,10029.0
6759,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,12687,BAO_0000219,CHEMBL622729,80089,,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,10029.0
6760,,CHO-AA8,,Cricetulus griseus,,A,,185.0,N,12687,BAO_0000219,CHEMBL622730,80089,,Intermediate,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,10029.0
6761,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,1890,BAO_0000219,CHEMBL622731,80089,,Intermediate,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,10029.0
6762,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,10747,BAO_0000219,CHEMBL622732,80089,,Intermediate,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10029.0
6763,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,10747,BAO_0000219,CHEMBL622733,80089,,Intermediate,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10029.0
6764,,,,Cricetulus griseus,,F,,,U,11616,BAO_0000218,CHEMBL622734,22224,,Autocuration,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,10029.0
6765,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,11616,BAO_0000219,CHEMBL622735,80089,,Expert,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,10029.0
6766,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL618746,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,10029.0
6767,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL618747,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,10029.0
6768,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL620540,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,10029.0
6769,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL620541,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,10029.0
6770,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL620542,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,10029.0
6771,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL620543,22224,,Autocuration,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,10029.0
6772,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,3471,BAO_0000219,CHEMBL618832,22224,,Autocuration,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,10029.0
6773,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,11616,BAO_0000219,CHEMBL618833,80089,,Expert,Concentration required to reduce AA8 cell survival by 10%,,10029.0
6774,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,2656,BAO_0000219,CHEMBL618834,22224,,Autocuration,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,10029.0
6775,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL618835,22224,,Autocuration,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10029.0
6776,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL618836,22224,,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10029.0
6777,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL618837,22224,,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,10029.0
6778,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL618838,22224,,Autocuration,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,10029.0
6779,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,16156,BAO_0000219,CHEMBL618839,22224,,Autocuration,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,10029.0
6780,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,2656,BAO_0000219,CHEMBL618840,22224,,Autocuration,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,10029.0
6781,,,,Cricetulus griseus,,F,,,U,11005,BAO_0000019,CHEMBL618841,22224,,Autocuration,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,10029.0
6782,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,11942,BAO_0000219,CHEMBL618842,22224,,Autocuration,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,10029.0
6783,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,2128,BAO_0000219,CHEMBL618843,22224,,Autocuration,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,10029.0
6784,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL618844,50588,,Intermediate,Half life period after 15 mg/kg iv dose in Dogs,In vivo,9615.0
6785,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL618845,50588,,Intermediate,Half life period after 30 mg/kg po dose in Dogs,In vivo,9615.0
6786,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL618846,50588,,Intermediate,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,9615.0
6787,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL618847,50588,,Intermediate,Half life was measured in dog after oral 17b administration,In vivo,9615.0
6788,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL618848,50588,,Intermediate,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,9615.0
6789,,,,Canis lupus familiaris,,A,,,N,9579,BAO_0000218,CHEMBL618849,50588,,Intermediate,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,9615.0
6790,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL618850,50588,,Intermediate,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,9615.0
6791,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL618851,50588,,Intermediate,Tmax value after 30 mg/kg po dose in Dogs,In vivo,9615.0
6792,,,,Canis lupus familiaris,,A,,,N,3184,BAO_0000218,CHEMBL873815,50588,,Intermediate,Compound was evaluated for its half life when administered intravenously in dog,In vivo,9615.0
6793,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5017,BAO_0000218,CHEMBL618852,50588,,Intermediate,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,9615.0
6794,,,,Canis lupus familiaris,,A,,,N,6821,BAO_0000218,CHEMBL618853,50588,,Intermediate,Elimination Half-life of compound was determined in dog,,9615.0
6795,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL618854,50588,,Intermediate,Half life of compound in dog following oral administration,In vivo,9615.0
6796,,,,Canis lupus familiaris,,A,,,N,17267,BAO_0000218,CHEMBL618855,50588,,Intermediate,Half life of compound was determined in dog,,9615.0
6797,178.0,,Blood,Canis lupus familiaris,,A,,,N,4727,BAO_0000218,CHEMBL618856,50588,,Intermediate,Half life of compound was determined in dog blood,,9615.0
6798,,,,Canis lupus familiaris,,A,,,N,5238,BAO_0000218,CHEMBL875827,50588,,Intermediate,Half life after oral and iv dosing in dogs,In vivo,9615.0
6799,,,,Canis lupus familiaris,,A,,,N,4942,BAO_0000218,CHEMBL618857,50588,,Intermediate,Half life in dogs in hours,,9615.0
6800,,,,Canis lupus familiaris,,A,,,N,6505,BAO_0000218,CHEMBL618858,50588,,Intermediate,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,9615.0
6801,,,,Canis lupus familiaris,,A,,,N,5130,BAO_0000218,CHEMBL618859,50588,,Intermediate,t1/2 in dog after oral dose (1 mg/kg),In vivo,9615.0
6802,,,,Canis lupus familiaris,,A,,,N,1475,BAO_0000218,CHEMBL618860,50588,,Intermediate,Half life was evaluated in dog,,9615.0
6803,,,,Canis lupus familiaris,,A,,,N,17804,BAO_0000218,CHEMBL618861,50588,,Intermediate,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,9615.0
6804,,,,Canis lupus familiaris,,A,,,N,17804,BAO_0000218,CHEMBL622539,50588,,Intermediate,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,9615.0
6805,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL622540,50588,,Intermediate,Half life period (10 mg/kg) was determined in dog,In vivo,9615.0
6806,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL873803,50588,,Intermediate,Half life period (10 mg/kg) was determined in dog,In vivo,9615.0
6807,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL873804,50588,,Intermediate,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,9615.0
6808,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL624311,50588,,Intermediate,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,9615.0
6809,,,,Canis lupus familiaris,,A,,,N,6084,BAO_0000218,CHEMBL624312,50588,,Intermediate,Half life period in dog,,9615.0
6810,,,,Canis lupus familiaris,,A,,,N,6241,BAO_0000218,CHEMBL624313,50588,,Intermediate,Half life period in dogs after oral administration at 1 mg/kg,In vivo,9615.0
6811,,,,Canis lupus familiaris,,A,,,N,1916,BAO_0000218,CHEMBL624314,50588,,Intermediate,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,9615.0
6812,,,,Canis lupus familiaris,,A,,,N,6621,BAO_0000218,CHEMBL624315,50588,,Intermediate,Half-life of compound was determined in dogs,,9615.0
6813,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1696,BAO_0000218,CHEMBL624316,50588,,Intermediate,Half-life in dog plasma,,9615.0
6814,,,,Canis lupus familiaris,,A,,,N,17800,BAO_0000218,CHEMBL624317,50588,,Intermediate,Half-life in mongrel dogs was determined,,9615.0
6815,,,,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL624318,50588,,Intermediate,Half-life in dog upon oral administration,In vivo,9615.0
6816,,,,Canis lupus familiaris,,A,,,N,17657,BAO_0000218,CHEMBL624319,50588,,Intermediate,Half-life in dog upon oral administration; Unable to calculate,In vivo,9615.0
6817,,,,Canis lupus familiaris,,A,,,N,4239,BAO_0000218,CHEMBL624496,50588,,Intermediate,Half-life was measured in dog,,9615.0
6818,,,,Canis lupus familiaris,,A,,,N,5985,BAO_0000218,CHEMBL624497,50588,,Intermediate,Half-life was measured in dog,,9615.0
6819,,,,Canis lupus familiaris,,A,,,N,9932,BAO_0000218,CHEMBL624498,50588,,Intermediate,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,9615.0
6820,,,,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL624499,50588,,Intermediate,Oral half life was determined,In vivo,9615.0
6821,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL624500,50588,,Intermediate,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,9615.0
6822,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1475,BAO_0000218,CHEMBL624501,50588,,Intermediate,Plasma half life was evaluated,,9615.0
6823,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1475,BAO_0000218,CHEMBL623666,50588,,Intermediate,Plasma half life was evaluated in Dog,,9615.0
6824,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1475,BAO_0000218,CHEMBL623667,50588,,Intermediate,Plasma half life was evaluated in dog,,9615.0
6825,,,,Canis lupus familiaris,,A,,,N,6316,BAO_0000218,CHEMBL623668,50588,,Intermediate,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,9615.0
6826,,,,Canis lupus familiaris,,A,,,N,4883,BAO_0000218,CHEMBL623669,50588,,Intermediate,Tested for the half life value in dog,,9615.0
6827,,,,Canis lupus familiaris,,A,,,N,4727,BAO_0000218,CHEMBL623670,50588,,Intermediate,Maximum time at the dose of 2 mg/kg in dog,In vivo,9615.0
6828,,,,Canis lupus familiaris,,A,,,N,1916,BAO_0000218,CHEMBL623671,50588,,Intermediate,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,9615.0
6829,178.0,,Blood,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL875945,50588,,Intermediate,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
6830,178.0,,Blood,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL623672,50588,,Intermediate,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
6831,,,,Canis lupus familiaris,,A,,,N,6265,BAO_0000218,CHEMBL623673,50588,,Intermediate,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,9615.0
6832,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL623674,50588,,Intermediate,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,9615.0
6833,,,,Canis lupus familiaris,,A,,,N,5983,BAO_0000218,CHEMBL623675,50588,,Intermediate,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,9615.0
6834,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL872526,50588,,Intermediate,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,9615.0
6835,,,,Canis lupus familiaris,,A,,,N,5313,BAO_0000218,CHEMBL623676,50588,,Intermediate,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,9615.0
6836,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,17650,BAO_0000218,CHEMBL623677,50588,,Intermediate,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,9615.0
6837,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL623678,50588,,Intermediate,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,9615.0
6838,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,933,BAO_0000218,CHEMBL623679,50588,,Intermediate,Time taken for maximum plasma concentration in dog,,9615.0
6839,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL623680,50588,,Intermediate,Time to reach Cmax after oral administration to dogs,In vivo,9615.0
6840,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL623681,50588,,Intermediate,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
6841,,,,Canis lupus familiaris,,A,,,N,6316,BAO_0000218,CHEMBL623682,50588,,Intermediate,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,9615.0
6842,,,,Canis lupus familiaris,,A,,,N,6215,BAO_0000218,CHEMBL623683,50588,,Intermediate,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,9615.0
6843,,,,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL623684,50588,,Expert,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,9615.0
6844,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL622745,50588,,Intermediate,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,9615.0
6845,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL622746,50588,,Intermediate,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,9615.0
6846,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL622747,50594,,Intermediate,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,10090.0
6847,,,,Mus musculus,,A,,,N,5969,BAO_0000218,CHEMBL622748,50594,,Intermediate,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,10090.0
6848,,,,Mus musculus,,A,,,N,4573,BAO_0000218,CHEMBL622749,50594,,Intermediate,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,10090.0
6849,1969.0,,Plasma,Mus musculus,,A,,,N,3277,BAO_0000218,CHEMBL622750,50594,,Intermediate,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,10090.0
6850,1969.0,,Plasma,Mus musculus,,A,,,N,17734,BAO_0000218,CHEMBL623411,50594,,Intermediate,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,10090.0
6851,1969.0,,Plasma,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL875946,50594,,Intermediate,Maximum concentration obtained in mouse plasma was determined,In vivo,10090.0
6852,1969.0,,Plasma,Mus musculus,,A,,,N,3132,BAO_0000218,CHEMBL623412,50594,,Intermediate,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,10090.0
6853,1969.0,,Plasma,Mus musculus,,A,,,N,6348,BAO_0000218,CHEMBL623413,50594,,Intermediate,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,10090.0
6854,1969.0,,Plasma,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL623414,50594,,Intermediate,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,10090.0
6855,1969.0,,Plasma,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL623415,50594,,Intermediate,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,10090.0
6856,1969.0,,Plasma,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL623416,50594,,Intermediate,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,10090.0
6857,1969.0,,Plasma,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL623417,50594,,Intermediate,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,10090.0
6858,1969.0,,Plasma,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL623418,50594,,Intermediate,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,10090.0
6859,1969.0,,Plasma,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL623419,50594,,Intermediate,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,10090.0
6860,,,,Mus musculus,,A,,,N,4066,BAO_0000218,CHEMBL622816,50594,,Intermediate,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,10090.0
6861,,,,Mus musculus,,A,,,N,6178,BAO_0000218,CHEMBL623313,50594,,Intermediate,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,10090.0
6862,,,,Mus musculus,,A,,,N,6178,BAO_0000218,CHEMBL623314,50594,,Intermediate,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,10090.0
6863,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL876788,50594,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,10090.0
6864,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL623315,50594,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,10090.0
6865,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL623316,50594,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,10090.0
6866,,,,Mus musculus,,A,,,N,3760,BAO_0000218,CHEMBL623317,50594,,Intermediate,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,10090.0
6868,,,,Mus musculus,,A,,,N,5961,BAO_0000218,CHEMBL623319,50594,,Intermediate,Cmax in male mice after 2 mg/kg oral dose,In vivo,10090.0
6869,,,,Mus musculus,,A,,,N,6137,BAO_0000218,CHEMBL623320,50594,,Intermediate,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,10090.0
6870,,,,Mus musculus,,A,,,N,3802,BAO_0000218,CHEMBL623321,50594,,Intermediate,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,10090.0
6871,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623322,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,10090.0
6872,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623323,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,10090.0
6873,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623324,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,10090.0
6874,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623325,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,10090.0
6875,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623326,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,10090.0
6876,,,,Mus musculus,,A,,,N,3535,BAO_0000218,CHEMBL623327,50594,,Intermediate,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,10090.0
6877,1969.0,,Plasma,Mus musculus,,A,,,N,2862,BAO_0000218,CHEMBL623328,50594,,Intermediate,Maximum concentration in plasma upon oral administration in mouse,,10090.0
6878,1969.0,,Plasma,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL623329,50594,,Intermediate,Maximum plasma concentration was evaluated in mice after oral administration,,10090.0
6879,1969.0,,Plasma,Mus musculus,,A,,,N,2675,BAO_0000218,CHEMBL623330,50594,,Intermediate,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,10090.0
6880,,,,Mus musculus,,A,,,N,5399,BAO_0000218,CHEMBL876789,50594,,Intermediate,Dose at which the compound induced fecal excretion in mice,,10090.0
6893,,A10,,Rattus norvegicus,,F,,164.0,N,11819,BAO_0000219,CHEMBL623333,80013,,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,10116.0
6894,,A10,,Rattus norvegicus,,F,,164.0,N,11819,BAO_0000219,CHEMBL623334,80013,,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,10116.0
6895,,A10,,Rattus norvegicus,,F,,164.0,N,11819,BAO_0000219,CHEMBL627536,80013,,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,10116.0
6896,,A10,,Rattus norvegicus,,F,,164.0,N,11819,BAO_0000219,CHEMBL627537,80013,,Expert,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,10116.0
6897,,A10,,Rattus norvegicus,,F,,164.0,N,16361,BAO_0000219,CHEMBL627538,80013,,Intermediate,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,10116.0
6898,,A121,,Homo sapiens,,F,,393.0,N,2288,BAO_0000219,CHEMBL884106,80655,,Intermediate,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,9606.0
6899,,A121,,Homo sapiens,,F,,393.0,N,10404,BAO_0000219,CHEMBL625294,80655,,Intermediate,Anticancer activity against human ovarian carcinoma A121 cells,,9606.0
6900,,A121,,Homo sapiens,,F,,393.0,N,14790,BAO_0000219,CHEMBL625295,80655,,Intermediate,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,9606.0
6901,,A121,,Homo sapiens,,F,,393.0,N,14790,BAO_0000219,CHEMBL625296,80655,,Intermediate,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,9606.0
6902,,A121,,Homo sapiens,,F,,393.0,N,14253,BAO_0000219,CHEMBL625297,80655,,Expert,Growth inhibition of human ovarian carcinoma (A121) cell line,,9606.0
6903,,A121,,Homo sapiens,,F,,393.0,N,13617,BAO_0000219,CHEMBL625298,80655,,Expert,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,9606.0
6904,,A121,,Homo sapiens,,F,,393.0,N,1003,BAO_0000219,CHEMBL625960,80655,,Intermediate,Cytotoxicity against human A121 ovarian cells,,9606.0
6905,,A121,,Homo sapiens,,F,,393.0,N,830,BAO_0000219,CHEMBL625961,80655,,Intermediate,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,9606.0
6906,,A121,,Homo sapiens,,F,,393.0,N,12307,BAO_0000219,CHEMBL625962,80655,,Intermediate,In vitro cytotoxicity against human ovarian carcinoma A21,,9606.0
6907,,A121,,Homo sapiens,,F,,393.0,N,14254,BAO_0000219,CHEMBL624717,80655,,Intermediate,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,9606.0
6908,,A121,,Homo sapiens,,F,,393.0,N,13370,BAO_0000219,CHEMBL624718,80655,,Intermediate,Inhibitory activity of compound against human A121 ovarian cell line.,,9606.0
6909,,A121,,Homo sapiens,,F,,393.0,N,14790,BAO_0000219,CHEMBL624719,80655,,Intermediate,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,9606.0
6910,,A121,,Homo sapiens,,F,,393.0,N,3614,BAO_0000219,CHEMBL624720,80655,,Intermediate,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,9606.0
6911,,A 172,,Homo sapiens,,F,,622.0,N,2664,BAO_0000219,CHEMBL624721,80012,,Intermediate,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,9606.0
6912,,A 172,,Homo sapiens,,F,,622.0,N,2037,BAO_0000219,CHEMBL624722,80012,,Expert,In vitro cytotoxicity against A172 human tumor cell lines.,,9606.0
6913,,A 172,,Homo sapiens,,F,,622.0,N,14539,BAO_0000219,CHEMBL877597,80012,,Intermediate,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,9606.0
6914,,A 172,,Homo sapiens,,F,,622.0,N,2836,BAO_0000219,CHEMBL624723,80012,,Intermediate,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,9606.0
6915,,A 172,,Homo sapiens,,F,,622.0,N,10708,BAO_0000219,CHEMBL624724,80012,,Intermediate,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,9606.0
6916,,,,Canis lupus familiaris,,B,,,H,8975,BAO_0000224,CHEMBL624725,104729,,Autocuration,Association constant against A2 adenosine receptor,,9615.0
6917,,A2,,fish,,F,,1085.0,N,7645,BAO_0000219,CHEMBL624726,80656,,Intermediate,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,
6918,,,,Rattus norvegicus,,B,,,D,11377,BAO_0000224,CHEMBL857535,104713,,Autocuration,Ratio of Ki for adenosine A2 and A1 receptor binding,,10116.0
6919,,A204,,Homo sapiens,,F,,623.0,N,13528,BAO_0000219,CHEMBL624727,80014,,Expert,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,9606.0
6920,,A204,,Homo sapiens,,F,,623.0,N,10160,BAO_0000219,CHEMBL624728,80014,,Expert,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,9606.0
6921,,A2058,,Homo sapiens,,F,,404.0,N,15144,BAO_0000219,CHEMBL624729,80015,,Intermediate,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,9606.0
6922,,A253 cell line,,Homo sapiens,,F,,973.0,N,13160,BAO_0000219,CHEMBL624730,80657,,Intermediate,Growth inhibition against Human squamous cell line(A 253),,9606.0
6923,,A253 cell line,,Homo sapiens,,F,,973.0,N,12898,BAO_0000219,CHEMBL624731,80657,,Intermediate,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,9606.0
6924,,A253 cell line,,Homo sapiens,,F,,973.0,N,13069,BAO_0000219,CHEMBL624732,80657,,Intermediate,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,9606.0
6925,,A253 cell line,,Homo sapiens,,F,,973.0,N,15984,BAO_0000219,CHEMBL883245,80657,,Intermediate,Growth inhibition of A253 cell lines.,,9606.0
6926,,A253 cell line,,Homo sapiens,,F,,973.0,N,15564,BAO_0000219,CHEMBL624733,80657,,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,9606.0
6927,,A253 cell line,,Homo sapiens,,F,,973.0,N,15564,BAO_0000219,CHEMBL624734,80657,,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,9606.0
6928,,A253 cell line,,Homo sapiens,,F,,973.0,N,15564,BAO_0000219,CHEMBL624735,80657,,Intermediate,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,9606.0
6929,,A2780,,Homo sapiens,,F,,478.0,N,4720,BAO_0000219,CHEMBL621780,81034,,Intermediate,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,9606.0
6930,,A2780,,Homo sapiens,,F,,478.0,N,16112,BAO_0000219,CHEMBL877598,81034,,Intermediate,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,9606.0
6931,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000219,CHEMBL621781,81034,,Expert,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,9606.0
6932,,A2780,,Homo sapiens,,F,,478.0,N,16378,BAO_0000219,CHEMBL621782,81034,,Intermediate,Cytotoxicity against human cancer cell lines A2780 (ovarian),,9606.0
6933,,A2780,,Homo sapiens,,F,,478.0,N,16085,BAO_0000219,CHEMBL621783,81034,,Expert,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,9606.0
6934,,A2780,,Homo sapiens,,F,,478.0,N,16317,BAO_0000219,CHEMBL621784,81034,,Intermediate,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,9606.0
6935,,A2780,,Homo sapiens,,F,,478.0,N,15748,BAO_0000219,CHEMBL621785,81034,,Intermediate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,9606.0
6936,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000219,CHEMBL621968,81034,,Expert,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,9606.0
6937,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000219,CHEMBL621969,81034,,Expert,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,9606.0
6938,,A2780,,Homo sapiens,,F,,478.0,N,16597,BAO_0000219,CHEMBL621970,81034,,Expert,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,9606.0
6939,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL621971,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,9606.0
6940,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL621972,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,9606.0
6941,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL884108,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,9606.0
6942,,,,Cricetulus griseus,,F,,,U,15296,BAO_0000019,CHEMBL623826,22224,,Autocuration,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,10029.0
6943,,CHO-AA8,,Cricetulus griseus,,A,,185.0,U,10251,BAO_0000219,CHEMBL623827,22224,,Autocuration,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,10029.0
6944,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10251,BAO_0000219,CHEMBL623828,22224,,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,10029.0
6945,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10251,BAO_0000219,CHEMBL623829,22224,,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,10029.0
6946,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10251,BAO_0000219,CHEMBL623830,22224,,Autocuration,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,10029.0
6947,,,,Cricetulus griseus,,F,,,U,11858,BAO_0000019,CHEMBL623831,22224,,Autocuration,Growth inhibition against CHO-derived cell line AA8,,10029.0
6948,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,11858,BAO_0000219,CHEMBL623832,22224,,Autocuration,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,10029.0
6949,,CHO-AA8,,hampster,,F,,185.0,N,11616,BAO_0000219,CHEMBL623833,80089,,Expert,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,36483.0
6950,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,11616,BAO_0000219,CHEMBL623834,80089,,Expert,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,10029.0
6951,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL623835,22224,,Autocuration,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,10029.0
6952,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,11396,BAO_0000219,CHEMBL623836,22224,,Autocuration,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,10029.0
6953,,CHO-AA8,,Cricetulus griseus,,F,,185.0,U,10518,BAO_0000219,CHEMBL623837,22224,,Autocuration,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,10029.0
6954,,CHO-AA8,,Cricetulus griseus,,F,,185.0,N,11616,BAO_0000219,CHEMBL623838,80089,,Expert,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,10029.0
6955,,,,,,F,,,H,14837,BAO_0000019,CHEMBL623839,12675,,Autocuration,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,
6956,,,,,,F,,,H,14837,BAO_0000019,CHEMBL623840,12675,,Autocuration,Number of binding sites (n) of isolated serum protein AAG,,
6957,,,,,,B,,,M,16037,BAO_0000225,CHEMBL623841,22222,,Intermediate,Association constant for binding to AATT duplex,,
6958,,ABAE,,Homo sapiens,,F,,416.0,N,16597,BAO_0000219,CHEMBL623842,100090,,Expert,Inhibition of ABAE human fibroblast cell proliferation,,9606.0
6959,,AC755,,Mus musculus,,F,,1064.0,N,8831,BAO_0000218,CHEMBL623843,80668,,Intermediate,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,10090.0
6960,,,,Oryctolagus cuniculus,,F,,,D,13419,BAO_0000218,CHEMBL618669,102444,,Expert,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,9986.0
6961,,,,Oryctolagus cuniculus,,F,,,D,13419,BAO_0000218,CHEMBL618670,102444,,Expert,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,9986.0
6962,,,,,,B,,,H,15778,BAO_0000357,CHEMBL618671,69,,Autocuration,Inhibitory activity against angiotensin-converting enzyme (ACE).,,
6963,,,,,,B,,,H,15778,BAO_0000357,CHEMBL618672,69,,Autocuration,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,
6964,,ACH-2 cell line,,Homo sapiens,,F,,978.0,N,12988,BAO_0000219,CHEMBL618673,80669,,Intermediate,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,9606.0
6965,,ACH-2 cell line,,Homo sapiens,,F,,978.0,N,12988,BAO_0000219,CHEMBL618674,80669,,Intermediate,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,9606.0
6966,,T cell line,,Human immunodeficiency virus 1,,F,,998.0,U,12988,BAO_0000219,CHEMBL618675,22224,,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,11676.0
6967,,T cell line,,Human immunodeficiency virus 1,,F,,998.0,U,12988,BAO_0000219,CHEMBL618676,22224,,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,11676.0
6968,,T cell line,,Human immunodeficiency virus 1,,F,,998.0,U,12988,BAO_0000219,CHEMBL618677,22224,,Autocuration,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,11676.0
6969,,ACHN,,Homo sapiens,,F,,626.0,N,11843,BAO_0000219,CHEMBL618678,80025,,Intermediate,Inhibition of growth of renal cancer ACHN cell line,,9606.0
6970,,ACHN,,Homo sapiens,,F,,626.0,N,16939,BAO_0000219,CHEMBL618679,80025,,Intermediate,Inhibition of growth of ACHN renal cancer cell line,,9606.0
6971,,ACHN,,Homo sapiens,,F,,626.0,N,4782,BAO_0000219,CHEMBL618680,80025,,Intermediate,Inhibitory concentration required against ACHN renal cancer cell line,,9606.0
6972,,ACHN,,Homo sapiens,,F,,626.0,N,6310,BAO_0000219,CHEMBL618681,80025,,Expert,Concentration required to inhibit growth of human renal (ACHN) cell line,,9606.0
6973,,ACHN,,Homo sapiens,,F,,626.0,N,6310,BAO_0000219,CHEMBL618682,80025,,Intermediate,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,9606.0
6974,,ACHN,,Homo sapiens,,F,,626.0,N,12858,BAO_0000219,CHEMBL618683,80025,,Intermediate,Cytotoxic activity against ACHN Renal cancer cell line,,9606.0
6975,,ACHN,,Homo sapiens,,F,,626.0,N,17380,BAO_0000219,CHEMBL618684,80025,,Intermediate,Cytotoxicity evaluation against ACHN renal cancer cells,,9606.0
6976,,ACHN,,Homo sapiens,,F,,626.0,N,5858,BAO_0000219,CHEMBL618685,80025,,Intermediate,In vitro antitumor activity against human renal ACHN cell line,,9606.0
6977,,ACHN,,Homo sapiens,,F,,626.0,N,3838,BAO_0000219,CHEMBL876499,80025,,Intermediate,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,9606.0
6978,,ACHN,,Homo sapiens,,F,,626.0,N,3838,BAO_0000219,CHEMBL618686,80025,,Intermediate,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,9606.0
6979,,ACHN,,Homo sapiens,,F,,626.0,N,5406,BAO_0000219,CHEMBL618687,80025,,Intermediate,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,9606.0
6980,,ACHN,,Homo sapiens,,F,,626.0,N,4071,BAO_0000219,CHEMBL618688,80025,,Intermediate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,9606.0
6981,,ACHN,,Homo sapiens,,F,,626.0,N,4071,BAO_0000219,CHEMBL618689,80025,,Expert,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,9606.0
6982,,ACHN,,Homo sapiens,,F,,626.0,N,4071,BAO_0000219,CHEMBL618690,80025,,Intermediate,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,9606.0
6983,,ACHN,,Homo sapiens,,F,,626.0,N,15002,BAO_0000219,CHEMBL618691,80025,,Intermediate,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,9606.0
6984,,ACHN,,Homo sapiens,,F,,626.0,N,14769,BAO_0000219,CHEMBL619373,80025,,Intermediate,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,9606.0
6985,,ACHN,,Homo sapiens,,F,,626.0,N,13958,BAO_0000219,CHEMBL884008,80025,,Intermediate,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,9606.0
6986,,ACHN,,Homo sapiens,,F,,626.0,N,1665,BAO_0000219,CHEMBL619374,80025,,Intermediate,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,9606.0
6987,,ACHN,,Homo sapiens,,F,,626.0,N,15354,BAO_0000219,CHEMBL619375,80025,,Intermediate,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,9606.0
6988,,ACHN,,Homo sapiens,,F,,626.0,N,15354,BAO_0000219,CHEMBL619376,80025,,Intermediate,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,9606.0
6989,,ACHN,,Homo sapiens,,F,,626.0,N,13978,BAO_0000219,CHEMBL619377,80025,,Intermediate,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,9606.0
6990,,ACHN,,Homo sapiens,,F,,626.0,N,6798,BAO_0000219,CHEMBL619378,80025,,Intermediate,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,9606.0
6991,,,,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL872527,50588,,Intermediate,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,9615.0
6992,,,,Canis lupus familiaris,,A,,,N,9932,BAO_0000218,CHEMBL876500,50588,,Intermediate,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,9615.0
6993,,,,Canis lupus familiaris,,A,,,N,5546,BAO_0000218,CHEMBL619379,50588,,Intermediate,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,9615.0
6994,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL619538,50588,,Intermediate,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,9615.0
6995,,,,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL619539,50588,,Intermediate,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,9615.0
6996,,,,Canis lupus familiaris,,A,,,N,4257,BAO_0000218,CHEMBL619540,50588,,Intermediate,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,9615.0
6997,,,,Canis lupus familiaris,,A,,,N,4305,BAO_0000218,CHEMBL619541,50588,,Intermediate,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,9615.0
6998,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL619542,50588,,Intermediate,Volume of distribution was evaluated in dog,In vivo,9615.0
6999,,,,Canis lupus familiaris,,A,,,N,6062,BAO_0000218,CHEMBL619543,50588,,Intermediate,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,9615.0
7000,,,,Canis lupus familiaris,,A,,,N,3598,BAO_0000218,CHEMBL619544,50588,,Expert,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,9615.0
7001,,,,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL619545,50588,,Intermediate,The compound was tested for volume of distribution in dog,In vivo,9615.0
7002,,,,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL619546,50588,,Intermediate,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,9615.0
7003,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL619547,50588,,Intermediate,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,9615.0
7004,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL619548,50588,,Intermediate,Vd in dog,In vivo,9615.0
7005,,,,Canis lupus familiaris,,A,,,N,4219,BAO_0000218,CHEMBL619549,50588,,Intermediate,Volume distribution was determined,In vivo,9615.0
7006,,,,Canis lupus familiaris,,A,,,N,1696,BAO_0000218,CHEMBL619550,50588,,Intermediate,Volume of distribution in dog,In vivo,9615.0
7007,,,,Canis lupus familiaris,,A,,,N,5542,BAO_0000218,CHEMBL876501,50588,,Intermediate,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,9615.0
7008,,,,Canis lupus familiaris,,A,,,N,5199,BAO_0000218,CHEMBL619551,50588,,Intermediate,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,9615.0
7009,,,,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL619552,50588,,Intermediate,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
7010,,,,Canis lupus familiaris,,A,,,N,4727,BAO_0000218,CHEMBL619553,50588,,Intermediate,Volume distribution at the dose of 2 mg/kg in dog,In vivo,9615.0
7011,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL618722,50588,,Intermediate,Steady state volume of distribution was determined,In vivo,9615.0
7012,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL618723,50588,,Intermediate,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,9615.0
7013,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL618724,50588,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,9615.0
7014,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL618725,50588,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,9615.0
7015,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL618726,50588,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,9615.0
7016,,,,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL618727,50588,,Intermediate,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,9615.0
7017,,,,Canis lupus familiaris,,A,,,N,4239,BAO_0000218,CHEMBL624233,50588,,Intermediate,Pharmacokinetic property (vdss) was measured in dog,In vivo,9615.0
7018,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL624234,50588,,Intermediate,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,9615.0
7019,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL624235,50588,,Intermediate,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,9615.0
7020,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL624236,50588,,Intermediate,Volume displacement was calculated in dog,In vivo,9615.0
7021,,,,Canis lupus familiaris,,A,,,N,5654,BAO_0000218,CHEMBL624237,50588,,Intermediate,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,9615.0
7022,,,,Canis lupus familiaris,,A,,,N,5505,BAO_0000218,CHEMBL624238,50588,,Intermediate,Volume distribution constant was determined,In vivo,9615.0
7023,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL624239,50588,,Intermediate,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,9615.0
7024,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL875829,50588,,Intermediate,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,9615.0
7025,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL624240,50588,,Intermediate,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,9615.0
7026,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL624241,50588,,Intermediate,Volume distribution (Vdss) was measured in dog,In vivo,9615.0
7027,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL624242,50588,,Intermediate,Volume distribution (Vdss) was measured in dog,In vivo,9615.0
7028,,,,Canis lupus familiaris,,A,,,N,6679,BAO_0000218,CHEMBL624243,50588,,Intermediate,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,9615.0
7029,,,,Canis lupus familiaris,,A,,,N,5145,BAO_0000218,CHEMBL624244,50588,,Intermediate,Volume of distribution in steady state was determined in dog,In vivo,9615.0
7030,,,,Canis lupus familiaris,,A,,,N,6821,BAO_0000218,CHEMBL624245,50588,,Intermediate,Volume of distribution of compound was determined in dog,In vivo,9615.0
7031,,,,Canis lupus familiaris,,A,,,N,4137,BAO_0000218,CHEMBL624246,50588,,Intermediate,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,9615.0
7032,,,,Canis lupus familiaris,,A,,,N,5334,BAO_0000218,CHEMBL624247,50588,,Intermediate,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,9615.0
7033,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL624248,50588,,Intermediate,Volume of distribution (Vdss) was measured in dog,In vivo,9615.0
7034,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL624249,50588,,Intermediate,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,9615.0
7035,,,,Canis lupus familiaris,,A,,,N,6641,BAO_0000218,CHEMBL624250,50588,,Intermediate,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
7036,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL624251,50588,,Intermediate,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
7037,,,,Canis lupus familiaris,,A,,,N,11659,BAO_0000218,CHEMBL624252,50588,,Intermediate,Maximum rate of depolarization of the upstroke of the action potential,,9615.0
7038,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL624253,50588,,Intermediate,Steady state volume distribution in dog,In vivo,9615.0
7039,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL624950,50588,,Intermediate,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,9615.0
7040,,,,Canis lupus familiaris,,A,,,N,1466,BAO_0000218,CHEMBL624951,50588,,Intermediate,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,9615.0
7041,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL875830,50588,,Intermediate,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,9615.0
7042,,,,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL624952,50588,,Intermediate,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,9615.0
7043,,,,Canis lupus familiaris,,A,,,N,17764,BAO_0000218,CHEMBL624953,50588,,Intermediate,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,9615.0
7044,,,,Canis lupus familiaris,,A,,,N,6215,BAO_0000218,CHEMBL624954,50588,,Intermediate,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,9615.0
7045,,,,Canis lupus familiaris,,A,,,N,6505,BAO_0000218,CHEMBL624955,50588,,Intermediate,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,9615.0
7046,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL624956,50588,,Intermediate,Vss was determined,,9615.0
7047,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL625129,50588,,Intermediate,Vss in dog,,9615.0
7048,,,,Canis lupus familiaris,,A,,,N,6062,BAO_0000218,CHEMBL625130,50588,,Intermediate,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,9615.0
7049,,,,Canis lupus familiaris,,A,,,N,4942,BAO_0000218,CHEMBL625131,50588,,Intermediate,Volume distribution in dogs,In vivo,9615.0
7050,,,,Canis lupus familiaris,,A,,,N,17796,BAO_0000218,CHEMBL625132,50588,,Intermediate,Volume of distribution in dog,In vivo,9615.0
7051,,,,Canis lupus familiaris,,A,,,N,4883,BAO_0000218,CHEMBL872263,50588,,Intermediate,Tested for the oral bioavailability in dog,In vivo,9615.0
7060,,,,Mus musculus,,A,,,N,17837,BAO_0000218,CHEMBL624336,50594,,Intermediate,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,10090.0
7061,,,,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL624337,50594,,Intermediate,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,10090.0
7062,,,,Mus musculus,,A,,,N,17729,BAO_0000218,CHEMBL624338,50594,,Intermediate,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,10090.0
7063,,,,Mus musculus,,A,,,N,4239,BAO_0000218,CHEMBL624339,50594,,Intermediate,Bioavailability was measured in mouse,In vivo,10090.0
7064,,,,Mus musculus,,A,,,N,17592,BAO_0000218,CHEMBL624340,50594,,Intermediate,Bioavailability in mouse,In vivo,10090.0
7065,,,,Mus musculus,,A,,,N,6348,BAO_0000218,CHEMBL624341,50594,,Intermediate,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,10090.0
7066,,,,Mus musculus,,A,,,N,2801,BAO_0000218,CHEMBL624342,50594,,Intermediate,Bioavailability in mouse,In vivo,10090.0
7067,,,,Mus musculus,,A,,,N,2801,BAO_0000218,CHEMBL624343,50594,,Intermediate,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,10090.0
7068,,,,Mus musculus,,A,,,N,17718,BAO_0000218,CHEMBL624344,50594,,Intermediate,Oral bioavailability in mouse,In vivo,10090.0
7069,,,,Mus musculus,,A,,,N,5727,BAO_0000218,CHEMBL624345,50594,,Intermediate,Oral availability at 50 mg/kg po in male mice,In vivo,10090.0
7070,,,,Mus musculus,,A,,,N,5302,BAO_0000218,CHEMBL624346,50594,,Intermediate,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,10090.0
7071,,,,Mus musculus,,A,,,N,3598,BAO_0000218,CHEMBL624347,50594,,Expert,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,10090.0
7072,,,,Mus musculus,,A,,,N,5961,BAO_0000218,CHEMBL624348,50594,,Intermediate,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,10090.0
7074,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL622754,50594,,Intermediate,Oral bioavailability in mouse,In vivo,10090.0
7075,,,,Mus musculus,,A,,,N,6091,BAO_0000218,CHEMBL622755,50594,,Intermediate,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,10090.0
7076,,,,Mus musculus,,A,,,N,5711,BAO_0000218,CHEMBL622756,50594,,Intermediate,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,10090.0
7077,,,,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL622757,50594,,Intermediate,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,10090.0
7078,,,,Mus musculus,,A,,,N,17728,BAO_0000218,CHEMBL622758,50594,,Intermediate,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,10090.0
7079,,,,Mus musculus,,A,,,N,3802,BAO_0000218,CHEMBL622759,50594,,Intermediate,Tested for bioavailability of the compound,In vivo,10090.0
7080,,,,Mus musculus,,A,,,N,3802,BAO_0000218,CHEMBL622760,50594,,Intermediate,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,10090.0
7081,1969.0,,Plasma,Mus musculus,,A,,,N,14029,BAO_0000218,CHEMBL622761,50594,,Intermediate,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,10090.0
7082,1969.0,,Plasma,Mus musculus,,A,,,N,14029,BAO_0000218,CHEMBL622762,50594,,Intermediate,The plasma half life of compound was determined on heparin prepared by human plasma. ,,10090.0
7083,1969.0,,Plasma,Mus musculus,,A,,,N,14029,BAO_0000218,CHEMBL622763,50594,,Intermediate,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,10090.0
7084,1969.0,,Plasma,Mus musculus,,A,,,N,14029,BAO_0000218,CHEMBL622764,50594,,Intermediate,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,10090.0
7085,1969.0,,Plasma,Mus musculus,,A,,,N,14029,BAO_0000218,CHEMBL622765,50594,,Intermediate,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,10090.0
7086,,,,Mus musculus,,F,,,N,17753,BAO_0000218,CHEMBL622766,50594,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,10090.0
7087,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL622767,50594,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,10090.0
7088,,,,Mus musculus,,A,,,N,17753,BAO_0000218,CHEMBL622768,50594,,Intermediate,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,10090.0
7089,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL875948,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7090,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622769,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7091,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622770,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7092,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622771,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7093,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622772,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7094,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622773,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7095,178.0,,Blood,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL622774,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7096,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621725,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7097,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621726,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10090.0
7098,,A2780,,Homo sapiens,,F,,478.0,N,15608,BAO_0000219,CHEMBL621727,81034,,Intermediate,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,9606.0
7099,,A2780,,Homo sapiens,,F,,478.0,N,3290,BAO_0000219,CHEMBL622413,81034,,Expert,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,9606.0
7100,,A2780,,Homo sapiens,,F,,478.0,N,2859,BAO_0000219,CHEMBL622414,81034,,Intermediate,Compound was evaluated for cytotoxicity against A2780 cell line,,9606.0
7101,,A2780,,Homo sapiens,,F,,478.0,N,15688,BAO_0000219,CHEMBL622415,81034,,Expert,Inhibition of A2780 cell clonogenic assay,,9606.0
7102,,A2780,,Homo sapiens,,F,,478.0,N,5642,BAO_0000219,CHEMBL884001,81034,,Expert,Cytotoxic effect on ovarian cancer cell line (A2780),,9606.0
7103,,A2780,,Homo sapiens,,F,,478.0,N,6633,BAO_0000219,CHEMBL622416,81034,,Intermediate,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,9606.0
7104,,A2780,,Homo sapiens,,F,,478.0,N,3906,BAO_0000219,CHEMBL622417,81034,,Intermediate,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,9606.0
7105,,A2780,,Homo sapiens,,F,,478.0,N,6788,BAO_0000219,CHEMBL622590,81034,,Expert,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,9606.0
7106,,A2780,,Homo sapiens,,F,,478.0,N,17582,BAO_0000219,CHEMBL622591,81034,,Expert,Antiproliferative activity against human A2780 cells,,9606.0
7107,,A2780,,Homo sapiens,,F,,478.0,N,17764,BAO_0000219,CHEMBL622592,81034,,Expert,Inhibition of human A2780 cell proliferation,,9606.0
7108,,A2780,,Homo sapiens,,F,,478.0,N,17764,BAO_0000219,CHEMBL622593,81034,,Expert,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,9606.0
7109,,A2780,,Homo sapiens,,F,,478.0,N,17764,BAO_0000219,CHEMBL622594,81034,,Expert,Inhibition of human A2780 cell proliferation (No data),,9606.0
7110,,A2780,,Homo sapiens,,F,,478.0,N,2815,BAO_0000219,CHEMBL622595,81034,,Intermediate,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,9606.0
7111,,A2780,,Homo sapiens,,F,,478.0,N,16930,BAO_0000219,CHEMBL622596,81034,,Intermediate,Compound was evaluated against human Ovarian carcinoma cell line A2780,,9606.0
7112,,A2780,,Homo sapiens,,F,,478.0,N,17777,BAO_0000219,CHEMBL622597,81034,,Expert,Growth inhibition against A2780 wild-type ovarian cell lines,,9606.0
7113,,A2780,,Homo sapiens,,F,,478.0,N,17777,BAO_0000219,CHEMBL622598,81034,,Intermediate,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,9606.0
7114,,,,Homo sapiens,,F,,,D,16936,BAO_0000019,CHEMBL622599,104766,,Autocuration,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,9606.0
7115,,A2780,,Homo sapiens,,F,,478.0,N,13759,BAO_0000219,CHEMBL622600,81034,,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,9606.0
7116,,A2780,,Homo sapiens,,F,,478.0,N,13759,BAO_0000219,CHEMBL622601,81034,,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,9606.0
7117,,A2780,,Homo sapiens,,F,,478.0,N,13759,BAO_0000219,CHEMBL622602,81034,,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,9606.0
7118,,A2780,,Homo sapiens,,F,,478.0,N,13759,BAO_0000219,CHEMBL622603,81034,,Intermediate,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,9606.0
7119,,A2780,,Homo sapiens,,F,,478.0,N,15292,BAO_0000219,CHEMBL622604,81034,,Intermediate,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,9606.0
7120,,A2780,,Homo sapiens,,F,,478.0,N,15292,BAO_0000219,CHEMBL622605,81034,,Intermediate,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,9606.0
7121,,A2780,,Homo sapiens,,F,,478.0,N,15069,BAO_0000219,CHEMBL622606,81034,,Expert,In vitro inhibition of human ovarian cell line A2780,,9606.0
7122,,A2780,,Homo sapiens,,F,,478.0,N,15069,BAO_0000219,CHEMBL619463,81034,,Expert,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,9606.0
7123,,A2780,,Homo sapiens,,F,,478.0,N,14073,BAO_0000219,CHEMBL619464,81034,,Intermediate,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,9606.0
7124,,A2780,,Homo sapiens,,F,,478.0,N,14553,BAO_0000219,CHEMBL619465,81034,,Expert,Concentration required to inhibit A2780-cell growth by 50%,,9606.0
7125,,A2780,,Homo sapiens,,F,,478.0,N,13040,BAO_0000219,CHEMBL619466,81034,,Expert,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,9606.0
7126,,A2780,,Homo sapiens,,F,,478.0,N,6891,BAO_0000219,CHEMBL619467,81034,,Expert,Cytotoxic effect on human ovarian (A2780) cancer cell line,,9606.0
7127,,A2780,,Homo sapiens,,F,,478.0,N,15569,BAO_0000219,CHEMBL619468,81034,,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,9606.0
7128,,A2780,,Homo sapiens,,F,,478.0,N,14190,BAO_0000219,CHEMBL619469,81034,,Expert,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,9606.0
7129,,A2780,,Homo sapiens,,F,,478.0,N,15014,BAO_0000219,CHEMBL619470,81034,,Expert,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,9606.0
7130,,A2780,,Homo sapiens,,F,,478.0,N,15014,BAO_0000219,CHEMBL619471,81034,,Intermediate,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,9606.0
7131,,A2780,,Homo sapiens,,F,,478.0,N,17496,BAO_0000219,CHEMBL619472,81034,,Intermediate,Cytotoxicity against human ovarian carcinoma A2780 cell line,,9606.0
7132,,A2780,,Homo sapiens,,F,,478.0,N,13617,BAO_0000219,CHEMBL619473,81034,,Intermediate,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,9606.0
7133,,A2780,,Homo sapiens,,F,,478.0,N,13617,BAO_0000219,CHEMBL874368,81034,,Intermediate,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,9606.0
7134,,A2780,,Homo sapiens,,F,,478.0,N,13617,BAO_0000219,CHEMBL884003,81034,,Intermediate,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,9606.0
7135,,A2780,,Homo sapiens,,F,,478.0,N,13617,BAO_0000219,CHEMBL622690,81034,,Intermediate,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,9606.0
7136,,A2780,,Homo sapiens,,F,,478.0,N,17672,BAO_0000219,CHEMBL622691,81034,,Intermediate,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,9606.0
7137,,A2780,,Homo sapiens,,F,,478.0,N,4544,BAO_0000219,CHEMBL622692,81034,,Intermediate,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,9606.0
7138,,A2780,,Homo sapiens,,F,,478.0,N,4544,BAO_0000219,CHEMBL623406,81034,,Intermediate,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,9606.0
7139,,A2780,,Homo sapiens,,F,,478.0,N,16317,BAO_0000219,CHEMBL884004,81034,,Intermediate,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,9606.0
7140,,A2780,,Homo sapiens,,F,,478.0,N,15099,BAO_0000219,CHEMBL623407,81034,,Intermediate,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,9606.0
7141,,A2780,,Homo sapiens,,F,,478.0,N,13978,BAO_0000219,CHEMBL623408,81034,,Intermediate,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,9606.0
7142,,A2780,,Homo sapiens,,F,,478.0,N,12989,BAO_0000219,CHEMBL623409,81034,,Expert,In vitro antitumor activity against A2780 cell line.,,9606.0
7143,,A2780,,Homo sapiens,,F,,478.0,N,5574,BAO_0000219,CHEMBL623410,81034,,Intermediate,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,9606.0
7144,,A2780,,Homo sapiens,,F,,478.0,N,13528,BAO_0000219,CHEMBL623576,81034,,Expert,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,9606.0
7145,,ACHN,,Homo sapiens,,F,,626.0,N,12782,BAO_0000219,CHEMBL623577,80025,,Intermediate,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,9606.0
7146,,ACHN,,Homo sapiens,,F,,626.0,N,14255,BAO_0000219,CHEMBL623578,80025,,Intermediate,The IC50 value was measured on ACHN cell line in renal tumor type.,,9606.0
7147,,ACHN,,Homo sapiens,,F,,626.0,N,16364,BAO_0000219,CHEMBL623579,80025,,Intermediate,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,9606.0
7148,,ACHN,,Homo sapiens,,F,,626.0,N,17376,BAO_0000219,CHEMBL623580,80025,,Expert,In vitro lethal concentration against most sensitive ACHN cell line,,9606.0
7149,,ACHN,,Homo sapiens,,F,,626.0,N,12016,BAO_0000219,CHEMBL623581,80025,,Intermediate,Tested for cytotoxic activity against renal cancer ACHN cell line,,9606.0
7150,,ACHN,,Homo sapiens,,F,,626.0,N,6058,BAO_0000219,CHEMBL857456,80025,,Intermediate,Compound tested for growth inhibition of renal cancer cell line ACHN,,9606.0
7151,,ACHN,,Homo sapiens,,F,,626.0,N,17708,BAO_0000219,CHEMBL623582,80025,,Intermediate,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,9606.0
7152,,ACHN,,Homo sapiens,,F,,626.0,N,15176,BAO_0000219,CHEMBL623583,80025,,Intermediate,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,9606.0
7153,,ACHN,,Homo sapiens,,F,,626.0,N,2806,BAO_0000219,CHEMBL623584,80025,,Intermediate,In vitro anticancer activity against ACHN renal cancer cell line,,9606.0
7154,,ACHN,,Homo sapiens,,F,,626.0,N,15300,BAO_0000219,CHEMBL623585,80025,,Intermediate,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,9606.0
7155,,ACHN,,Homo sapiens,,F,,626.0,N,16364,BAO_0000219,CHEMBL623586,80025,,Intermediate,Percent selectivity was evaluated in renal ACHN cell lines,,9606.0
7156,,ACHN,,Homo sapiens,,F,,626.0,N,13859,BAO_0000219,CHEMBL623587,80025,,Intermediate,In vitro inhibitory activity against renal ACHN cancer cell line,,9606.0
7157,,ACHN,,Homo sapiens,,F,,626.0,N,11970,BAO_0000219,CHEMBL875279,80025,,Intermediate,Tested for cytotoxicity against ACHN cell lines in renal cancer,,9606.0
7158,,ACHN,,Homo sapiens,,F,,626.0,N,2450,BAO_0000219,CHEMBL623588,80025,,Intermediate,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,9606.0
7159,,ACHN,,Homo sapiens,,F,,626.0,N,12696,BAO_0000219,CHEMBL623589,80025,,Intermediate,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,9606.0
7160,,ACHN,,Homo sapiens,,F,,626.0,N,12400,BAO_0000219,CHEMBL623590,80025,,Intermediate,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,9606.0
7161,,ACHN,,Homo sapiens,,F,,626.0,N,12888,BAO_0000219,CHEMBL623591,80025,,Expert,Cytotoxic effect on renal cancer line ACHN,,9606.0
7162,,ACHN,,Homo sapiens,,F,,626.0,N,3156,BAO_0000219,CHEMBL623592,80025,,Intermediate,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,9606.0
7163,,ACHN,,Homo sapiens,,F,,626.0,N,3381,BAO_0000219,CHEMBL623593,80025,,Intermediate,In vitro inhibition of Renal Cancer ACHN cell lines,,9606.0
7164,,ACHN,,Homo sapiens,,F,,626.0,N,16747,BAO_0000219,CHEMBL623594,80025,,Intermediate,Antitumor activity against human renal adenocarcinoma ACHN cells,,9606.0
7165,,ACHN,,Homo sapiens,,F,,626.0,N,16748,BAO_0000219,CHEMBL621833,80025,,Expert,Antitumor activity against human renal adenocarcinoma ACHN cells.,,9606.0
7166,,ACHN,,Homo sapiens,,F,,626.0,N,12062,BAO_0000219,CHEMBL621834,80025,,Intermediate,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,9606.0
7167,,ACHN,,Homo sapiens,,F,,626.0,N,14769,BAO_0000219,CHEMBL621835,80025,,Intermediate,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,9606.0
7168,,ACHN,,Homo sapiens,,F,,626.0,N,15895,BAO_0000219,CHEMBL621836,80025,,Intermediate,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,9606.0
7169,,ACHN,,Homo sapiens,,F,,626.0,N,17376,BAO_0000219,CHEMBL621837,80025,,Intermediate,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,9606.0
7170,,ACHN,,Homo sapiens,,F,,626.0,N,14882,BAO_0000219,CHEMBL875280,80025,,Intermediate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,9606.0
7171,,ACHN,,Homo sapiens,,F,,626.0,N,14882,BAO_0000219,CHEMBL621838,80025,,Intermediate,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,9606.0
7172,,ACHN,,Homo sapiens,,F,,626.0,N,15661,BAO_0000219,CHEMBL621839,80025,,Intermediate,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,9606.0
7173,,,,,,A,,,U,9680,BAO_0000019,CHEMBL621840,22224,,Autocuration,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,
7174,,,,,,F,,,H,14579,BAO_0000019,CHEMBL621841,10647,,Autocuration,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,
7175,,HEL,,Cytomegalovirus,,F,,468.0,N,17290,BAO_0000218,CHEMBL622979,50529,,Expert,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,10358.0
7176,,,,Cytomegalovirus,,F,,,N,17290,BAO_0000218,CHEMBL876595,50529,,Intermediate,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,10358.0
7177,,,,,,B,,,H,15891,BAO_0000357,CHEMBL620221,12159,,Autocuration,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,
7178,,,,,,B,,,H,15890,BAO_0000357,CHEMBL620222,12159,,Autocuration,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,
7179,,ADDP cell line,,Bos taurus,,F,,979.0,N,3801,BAO_0000219,CHEMBL620506,80670,,Intermediate,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,9913.0
7180,,ADJ/PC6,,Mus musculus,,F,,980.0,N,9222,BAO_0000219,CHEMBL620507,80671,,Intermediate,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,10090.0
7181,,ADJ/PC6,,Mus musculus,,F,,980.0,N,9222,BAO_0000219,CHEMBL620508,80671,,Intermediate,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,10090.0
7182,,ADJ/PC6,,Mus musculus,,F,,980.0,N,7257,BAO_0000219,CHEMBL620509,80671,,Intermediate,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,10090.0
7183,,ADJ/PC6,,Mus musculus,,F,,980.0,N,7257,BAO_0000219,CHEMBL620510,80671,,Intermediate,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,10090.0
7184,,ADJ/PC6,,Mus musculus,,A,,980.0,N,7257,BAO_0000219,CHEMBL620511,80671,,Intermediate,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,10090.0
7185,,ADJ/PC6,,Mus musculus,,F,,980.0,N,8084,BAO_0000219,CHEMBL620512,80671,,Intermediate,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,10090.0
7186,,,,Mus musculus,,F,,,U,14943,BAO_0000019,CHEMBL620513,22224,,Autocuration,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,10090.0
7187,,,,Mus musculus,,F,,,U,14943,BAO_0000019,CHEMBL620514,22224,,Autocuration,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,10090.0
7188,,,,Mus musculus,,F,,,U,14943,BAO_0000019,CHEMBL620515,22224,,Autocuration,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,10090.0
7189,,,,Bacillus subtilis,,A,,,U,10524,BAO_0000218,CHEMBL620516,22224,,Autocuration,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,1423.0
7190,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL620517,50588,,Intermediate,AUC value in dog after IV administration at a dose of 5 mg/kg,,9615.0
7191,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL620518,50588,,Intermediate,AUC value in dog after oral administration at a dose of 5 mg/kg,,9615.0
7192,,,,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL620519,50588,,Intermediate,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,9615.0
7193,,,,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL621386,50588,,Intermediate,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,9615.0
7194,,,,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL621387,50588,,Intermediate,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,9615.0
7195,,,,Canis lupus familiaris,,A,,,N,3184,BAO_0000218,CHEMBL621388,50588,,Intermediate,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,9615.0
7196,,,,Canis lupus familiaris,,A,,,N,16456,BAO_0000218,CHEMBL621389,50588,,Intermediate,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,9615.0
7197,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL621390,50588,,Intermediate,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,9615.0
7198,,,,,,P,,,U,4219,BAO_0000100,CHEMBL621391,22229,,Intermediate,Calculated partition coefficient (clogP),,
7199,,,,Canis lupus familiaris,,A,,,N,3748,BAO_0000218,CHEMBL621392,50588,,Intermediate,Half life in dog,,9615.0
7200,,,,Canis lupus familiaris,,A,,,N,3132,BAO_0000218,CHEMBL621393,50588,,Intermediate,Time taken for EC90 was determined when tested in dog,,9615.0
7201,,,,Canis lupus familiaris,,A,,,N,4219,BAO_0000218,CHEMBL621394,50588,,Intermediate,Half life (iv) was determined,,9615.0
7202,2107.0,,Liver,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL621395,50588,,Intermediate,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,9615.0
7203,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL621396,50588,,Intermediate,Area under the curve was calculated in dog after iv administration,,9615.0
7204,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL621397,50588,,Intermediate,Area under the curve was calculated in dog after peroral administration,,9615.0
7205,,,,Canis lupus familiaris,,A,,,N,17853,BAO_0000218,CHEMBL621398,50588,,Intermediate,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,9615.0
7206,,,,Canis lupus familiaris,,A,,,N,3639,BAO_0000218,CHEMBL618818,50588,,Intermediate,pKa was evaluated in dog,,9615.0
7207,,,,Canis lupus familiaris,,A,,,N,14541,BAO_0000218,CHEMBL618819,50588,,Intermediate,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,9615.0
7208,,,,Canis lupus familiaris,,A,,,N,16456,BAO_0000218,CHEMBL618820,50588,,Intermediate,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,9615.0
7209,,,,Canis lupus familiaris,,A,,,N,16456,BAO_0000218,CHEMBL873810,50588,,Intermediate,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,9615.0
7210,,,,Canis lupus familiaris,,A,,,N,2652,BAO_0000218,CHEMBL876606,50588,,Intermediate,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,9615.0
7211,,,,Canis lupus familiaris,,A,,,N,3624,BAO_0000218,CHEMBL618821,50588,,Intermediate,Compound was evaluated for the half-life (t 1/2) in hours,,9615.0
7212,178.0,,Blood,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL618822,50588,,Intermediate,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
7213,178.0,,Blood,Canis lupus familiaris,,A,,,N,1337,BAO_0000218,CHEMBL618823,50588,,Intermediate,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,9615.0
7214,,,,Canis lupus familiaris,,A,,,N,4709,BAO_0000218,CHEMBL618824,50588,,Intermediate,Half life after intravenous administration of 1 mg/kg in dog,In vivo,9615.0
7215,,,,Canis lupus familiaris,,A,,,N,15660,BAO_0000218,CHEMBL618825,50588,,Intermediate,Half life was measured in dog,,9615.0
7216,,,,Canis lupus familiaris,,A,,,N,5302,BAO_0000218,CHEMBL618826,50588,,Intermediate,Half life period in dog after 5 mg/kg dose,In vivo,9615.0
7217,,,,Canis lupus familiaris,,A,,,N,17791,BAO_0000218,CHEMBL618827,50588,,Intermediate,Half life period was evaluated in dog; 4-4.8,,9615.0
7218,,,,Canis lupus familiaris,,A,,,N,6348,BAO_0000218,CHEMBL618828,50588,,Intermediate,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,9615.0
7219,,,,Canis lupus familiaris,,A,,,N,4257,BAO_0000218,CHEMBL618829,50588,,Intermediate,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,9615.0
7220,,,,Canis lupus familiaris,,A,,,N,3771,BAO_0000218,CHEMBL618830,50588,,Intermediate,Half-life was determined,,9615.0
7221,,,,Canis lupus familiaris,,A,,,N,6305,BAO_0000218,CHEMBL618831,50588,,Intermediate,Half life in dogs,,9615.0
7222,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,13501,BAO_0000218,CHEMBL619489,50588,,Intermediate,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,9615.0
7223,,,,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL619649,50588,,Intermediate,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,9615.0
7224,,,,Canis lupus familiaris,,A,,,N,3045,BAO_0000218,CHEMBL876607,50588,,Intermediate,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,9615.0
7225,,,,Canis lupus familiaris,,A,,,N,3043,BAO_0000218,CHEMBL619650,50588,,Intermediate,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,9615.0
7226,,,,Canis lupus familiaris,,A,,,N,4839,BAO_0000218,CHEMBL619651,50588,,Intermediate,Compound was tested for half life in dog,,9615.0
7227,,,,Canis lupus familiaris,,A,,,N,4839,BAO_0000218,CHEMBL619652,50588,,Intermediate,Compound was tested for its half life in dog,,9615.0
7228,,,,Canis lupus familiaris,,A,,,N,5802,BAO_0000218,CHEMBL619653,50588,,Intermediate,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,9615.0
7229,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL619654,50588,,Intermediate,Half life of compound in dog was determined,,9615.0
7230,,,,Canis lupus familiaris,,A,,,N,4219,BAO_0000218,CHEMBL619655,50588,,Intermediate,Half life (iv) was determined,In vivo,9615.0
7231,178.0,,Blood,Canis lupus familiaris,,A,,,N,13966,BAO_0000218,CHEMBL619656,50588,,Intermediate,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,9615.0
7232,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3994,BAO_0000218,CHEMBL873812,50588,,Intermediate,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,9615.0
7233,1969.0,,Plasma,Canis lupus familiaris,,F,,,N,3994,BAO_0000218,CHEMBL621365,50588,,Intermediate,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,9615.0
7234,,,,Canis lupus familiaris,,A,,,N,4453,BAO_0000218,CHEMBL621366,50588,,Intermediate,Half life in dog,,9615.0
7235,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL621367,50588,,Intermediate,Half life in dog plasma,,9615.0
7236,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL621368,50588,,Intermediate,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,9615.0
7237,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,6535,BAO_0000218,CHEMBL621369,50588,,Intermediate,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,9615.0
7238,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,3132,BAO_0000218,CHEMBL621370,50588,,Intermediate,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,9615.0
7239,,,,Canis lupus familiaris,,A,,,N,5374,BAO_0000218,CHEMBL621371,50588,,Intermediate,Half life in dog was determined,,9615.0
7240,,,,Canis lupus familiaris,,A,,,N,5007,BAO_0000218,CHEMBL621372,50588,,Intermediate,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,9615.0
7241,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,16907,BAO_0000218,CHEMBL621373,50588,,Intermediate,Half life upon exposure to human plasma,,9615.0
7242,,,,Canis lupus familiaris,,A,,,N,6057,BAO_0000218,CHEMBL621374,50588,,Intermediate,Half life was calculated in dog,,9615.0
7243,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL621375,50588,,Intermediate,Half life was determined,,9615.0
7244,,,,Canis lupus familiaris,,A,,,N,5473,BAO_0000218,CHEMBL621376,50588,,Intermediate,Half life was determined,,9615.0
7245,,,,Canis lupus familiaris,,A,,,N,4368,BAO_0000218,CHEMBL619624,50588,,Intermediate,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,9615.0
7246,,,,Canis lupus familiaris,,A,,,N,6448,BAO_0000218,CHEMBL875840,50588,,Intermediate,Half life in dog,,9615.0
7247,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL619625,50588,,Intermediate,Half life in dog after intra venous administration of the compound,,9615.0
7248,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL619626,50588,,Intermediate,Half life in dog after intra venous administration of the compound; ND means Not determined,,9615.0
7249,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL619627,50588,,Intermediate,Half life in dog after po administration of the compound,In vivo,9615.0
7250,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL873817,50588,,Intermediate,Half life in dog after po administration of the compound; ND means Not determined,In vivo,9615.0
7251,,,,Canis lupus familiaris,,A,,,N,6265,BAO_0000218,CHEMBL619628,50588,,Intermediate,Half life in dog at the single oral dose of 1 mg/kg,In vivo,9615.0
7252,,,,Canis lupus familiaris,,A,,,N,5006,BAO_0000218,CHEMBL619629,50588,,Intermediate,Half life in dogs,,9615.0
7253,,,,Canis lupus familiaris,,A,,,N,5356,BAO_0000218,CHEMBL619630,50588,,Intermediate,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,9615.0
7254,,,,Canis lupus familiaris,,A,,,N,405,BAO_0000218,CHEMBL619631,50588,,Intermediate,Half life in rat,,9615.0
7255,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL619632,50588,,Intermediate,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,9615.0
7256,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619633,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7257,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL875841,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7258,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619634,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7259,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619635,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7260,10000001.0,,Bone,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619636,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7261,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619637,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7262,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619638,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7263,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619639,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7264,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619640,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7265,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619641,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7266,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619642,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7267,10000004.0,,Gut,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619643,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7268,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL619644,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7269,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621112,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7270,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621113,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7271,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621114,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7272,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621115,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7273,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621116,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7274,948.0,,Heart,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621117,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7275,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621118,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7276,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621119,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10090.0
7277,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621120,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7278,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621757,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7279,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621758,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7280,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621759,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7281,2113.0,,Kidney,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621760,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7282,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621761,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7283,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621762,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7284,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL621763,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7285,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624502,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7286,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624503,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7287,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624504,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7288,2107.0,,Liver,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624505,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7289,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624506,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7290,,A2780,,Homo sapiens,,F,,478.0,N,5895,BAO_0000219,CHEMBL624507,81034,,Intermediate,In vitro cytotoxicity against A2780 (human ovarian cancer),,9606.0
7291,,A2780,,Homo sapiens,,F,,478.0,N,6338,BAO_0000219,CHEMBL624508,81034,,Intermediate,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,9606.0
7292,,A2780,,Homo sapiens,,F,,478.0,N,15163,BAO_0000219,CHEMBL624509,81034,,Intermediate,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,9606.0
7293,,A2780,,Homo sapiens,,F,,478.0,N,15163,BAO_0000219,CHEMBL624510,81034,,Intermediate,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,9606.0
7294,,A2780,,Homo sapiens,,F,,478.0,N,15000,BAO_0000219,CHEMBL875956,81034,,Expert,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,9606.0
7295,,A2780,,Homo sapiens,,F,,478.0,N,15000,BAO_0000219,CHEMBL839885,81034,,Expert,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,9606.0
7296,,A2780,,Homo sapiens,,F,,478.0,N,14729,BAO_0000219,CHEMBL624511,81034,,Expert,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,9606.0
7297,,A2780,,Homo sapiens,,F,,478.0,N,17270,BAO_0000219,CHEMBL624512,81034,,Intermediate,In vitro cytotoxicity against A2780 cell line,,9606.0
7298,,A2780,,Homo sapiens,,F,,478.0,N,5685,BAO_0000219,CHEMBL624513,81034,,Intermediate,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,9606.0
7299,,A2780,,Homo sapiens,,F,,478.0,N,3563,BAO_0000219,CHEMBL624514,81034,,Intermediate,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,9606.0
7300,,A2780,,Homo sapiens,,F,,478.0,N,17753,BAO_0000218,CHEMBL618547,81034,,Intermediate,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,9606.0
7301,,A2780,,Homo sapiens,,F,,478.0,N,16317,BAO_0000219,CHEMBL618548,81034,,Intermediate,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,9606.0
7302,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL618549,81034,,Intermediate,Inhibition of tubulin polymerization in analogy of ca.,,9606.0
7303,,A2780,,Homo sapiens,,F,,478.0,N,3801,BAO_0000219,CHEMBL618550,81034,,Intermediate,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,9606.0
7304,,A2780,,Homo sapiens,,F,,478.0,N,6181,BAO_0000219,CHEMBL618551,81034,,Expert,Cytotoxic effect in ovarian cancer cell line (A2780),,9606.0
7305,,A2780,,Homo sapiens,,F,,478.0,N,5318,BAO_0000219,CHEMBL618552,81034,,Intermediate,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,9606.0
7306,,A2780,,Homo sapiens,,F,,478.0,N,4840,BAO_0000219,CHEMBL618553,81034,,Intermediate,Tested for the cytotoxicity in A2780 ovarian cell line,,9606.0
7307,,A2780,,Homo sapiens,,F,,478.0,N,15748,BAO_0000219,CHEMBL618554,81034,,Intermediate,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,9606.0
7308,,A2780,,Homo sapiens,,F,,478.0,N,15748,BAO_0000219,CHEMBL618555,81034,,Intermediate,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,9606.0
7309,,A2780cisR,,,,F,,481.0,N,15748,BAO_0000219,CHEMBL618556,80017,,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,
7310,,A2780cisR,,,,F,,481.0,N,15748,BAO_0000219,CHEMBL618557,80017,,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,
7311,,A2780cisR,,,,F,,481.0,N,15748,BAO_0000219,CHEMBL618558,80017,,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,
7312,,A2780cisR,,,,F,,481.0,N,15748,BAO_0000219,CHEMBL618559,80017,,Intermediate,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,
7313,,A2780,,Homo sapiens,,F,,478.0,N,17753,BAO_0000218,CHEMBL618560,81034,,Intermediate,In vivo log of cells killed after administration of compound in A2780 cell line,,9606.0
7314,,A2780,,Homo sapiens,,F,,478.0,N,17753,BAO_0000218,CHEMBL618561,81034,,Intermediate,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,9606.0
7315,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL618562,81034,,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,9606.0
7316,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL618563,81034,,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,9606.0
7317,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL618564,81034,,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,9606.0
7318,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL618565,81034,,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,9606.0
7319,,A2780,,Homo sapiens,,F,,478.0,N,17528,BAO_0000218,CHEMBL618566,81034,,Intermediate,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,9606.0
7320,,A2780,,Homo sapiens,,F,,478.0,N,6633,BAO_0000219,CHEMBL618567,81034,,Intermediate,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,9606.0
7321,,A2780,,Homo sapiens,,F,,478.0,N,15000,BAO_0000219,CHEMBL618568,81034,,Expert,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,9606.0
7322,,A2780,,Homo sapiens,,F,,478.0,N,17528,BAO_0000219,CHEMBL618569,81034,,Expert,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,9606.0
7323,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621857,81034,,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,9606.0
7324,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621858,81034,,Intermediate,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,9606.0
7325,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621859,81034,,Intermediate,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,9606.0
7326,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621860,81034,,Intermediate,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,9606.0
7327,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621861,81034,,Intermediate,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,9606.0
7328,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621862,81034,,Expert,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,9606.0
7329,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621863,81034,,Intermediate,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,9606.0
7330,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621864,81034,,Intermediate,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,9606.0
7331,,A2780,,Homo sapiens,,F,,478.0,N,16936,BAO_0000219,CHEMBL621865,81034,,Intermediate,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,9606.0
7332,,A2780,,Mus musculus,,F,,478.0,N,17737,BAO_0000219,CHEMBL621866,81034,,Intermediate,In vitro antiproliferative activity against A2780 cell line,,10090.0
7333,,A2780,,Mus musculus,,F,,478.0,N,17764,BAO_0000219,CHEMBL621867,81034,,Expert,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,10090.0
7334,,A2780,,Homo sapiens,,F,,478.0,N,3830,BAO_0000219,CHEMBL621868,81034,,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,9606.0
7335,,A2780,,Homo sapiens,,F,,478.0,N,3829,BAO_0000219,CHEMBL875282,81034,,Intermediate,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,9606.0
7336,,,,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL621869,50588,,Intermediate,Vc value in dog after IV administration at a dose of 5 mg/kg,,9615.0
7337,,,,Canis lupus familiaris,,A,,,N,3546,BAO_0000218,CHEMBL621870,50588,,Intermediate,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,9615.0
7338,,,,Cercopithecidae,,A,,,U,5668,BAO_0000019,CHEMBL621871,22224,,Autocuration,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,9527.0
7339,1969.0,,Plasma,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL621243,22224,,Autocuration,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
7340,1969.0,,Plasma,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL621244,22224,,Autocuration,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,9527.0
7341,,,,Macaca fascicularis,,A,,,U,4256,BAO_0000218,CHEMBL621245,22224,,Autocuration,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,9541.0
7342,,,,Macaca fascicularis,,A,,,U,4256,BAO_0000218,CHEMBL621246,22224,,Autocuration,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,9541.0
7343,,,,Macaca fascicularis,,A,,,U,4256,BAO_0000218,CHEMBL621247,22224,,Autocuration,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,9541.0
7344,,,,Rattus norvegicus,,A,,,U,4256,BAO_0000218,CHEMBL618386,22224,,Autocuration,Oral Bioavailability in rat,In vivo,10116.0
7345,,,,Cercopithecidae,,A,,,U,1916,BAO_0000218,CHEMBL618387,22224,,Autocuration,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,9527.0
7346,,,,Cercopithecidae,,A,,,U,5302,BAO_0000218,CHEMBL618388,22224,,Autocuration,Area under curve value in monkey at a dose of 5 mg/kg,,9527.0
7347,,,,Cercopithecidae,,A,,,U,4257,BAO_0000218,CHEMBL618389,22224,,Autocuration,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,9527.0
7348,,,,Cercopithecidae,,A,,,U,5355,BAO_0000019,CHEMBL618574,22224,,Autocuration,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,9527.0
7349,,,,Cercopithecidae,,A,,,U,5355,BAO_0000019,CHEMBL618575,22224,,Autocuration,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,9527.0
7350,,,,Cercopithecidae,,A,,,U,5355,BAO_0000019,CHEMBL618576,22224,,Autocuration,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,9527.0
7351,,,,Cercopithecidae,,A,,,U,6078,BAO_0000218,CHEMBL618577,22224,,Autocuration,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,9527.0
7352,,,,Cercopithecidae,,A,,,U,6078,BAO_0000218,CHEMBL876487,22224,,Autocuration,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,9527.0
7353,,,,Cercopithecidae,,A,,,U,6062,BAO_0000218,CHEMBL618578,22224,,Autocuration,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,9527.0
7354,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL618579,22224,,Autocuration,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,9527.0
7355,,,,Cercopithecidae,,A,,,U,2661,BAO_0000019,CHEMBL618580,22224,,Autocuration,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,9527.0
7356,,,,Cercopithecidae,,A,,,U,5394,BAO_0000218,CHEMBL618581,22224,,Autocuration,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,9527.0
7357,,,,Cercopithecidae,,A,,,U,4397,BAO_0000218,CHEMBL618582,22224,,Autocuration,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,9527.0
7358,,,,Cercopithecidae,,A,,,U,17509,BAO_0000218,CHEMBL618583,22224,,Autocuration,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,9527.0
7359,,,,Cercopithecidae,,A,,,U,17509,BAO_0000218,CHEMBL618584,22224,,Autocuration,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,9527.0
7360,,,,Cercopithecidae,,A,,,U,6641,BAO_0000218,CHEMBL618585,22224,,Autocuration,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,9527.0
7361,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL618586,22224,,Autocuration,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,9527.0
7362,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL618587,22224,,Autocuration,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,9527.0
7363,,,,Cercopithecidae,,A,,,U,3443,BAO_0000218,CHEMBL618588,22224,,Autocuration,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,9527.0
7364,,,,Cercopithecidae,,A,,,U,17409,BAO_0000019,CHEMBL618589,22224,,Autocuration,Binding towards monkey plasma protein at 10 uM,,9527.0
7365,,,,Cercopithecidae,,A,,,U,17409,BAO_0000019,CHEMBL618590,22224,,Autocuration,Binding towards monkey plasma protein at 100 uM,,9527.0
7366,,,,Cercopithecidae,,A,,,U,1052,BAO_0000218,CHEMBL872262,22224,,Autocuration,Apparent bioavailability in squirrel monkey was determined,In vivo,9527.0
7367,,,,Cercopithecidae,,A,,,U,13501,BAO_0000218,CHEMBL618591,22224,,Autocuration,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,9527.0
7368,,,,monkey,,A,,,U,17509,BAO_0000218,CHEMBL618592,22224,,Autocuration,Bioavailability in monkey (dose 2 mg/kg),In vivo,9443.0
7369,,,,Cercopithecidae,,A,,,U,5394,BAO_0000218,CHEMBL876488,22224,,Autocuration,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,9527.0
7370,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL618593,22224,,Autocuration,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,9527.0
7371,,,,monkey,,A,,,U,11219,BAO_0000218,CHEMBL618594,22224,,Autocuration,Bioavailability in monkey (i.d. dosing),In vivo,9443.0
7372,,,,Cercopithecidae,,A,,,U,3045,BAO_0000218,CHEMBL618595,22224,,Autocuration,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,9527.0
7373,,,,Cercopithecidae,,A,,,U,17796,BAO_0000019,CHEMBL621469,22224,,Autocuration,Clearance of the drug was measured in cynomolgus,,9527.0
7374,,,,Cercopithecidae,,A,,,U,1399,BAO_0000218,CHEMBL621470,22224,,Autocuration,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,9527.0
7375,,,,Cercopithecidae,,A,,,U,2661,BAO_0000218,CHEMBL621471,22224,,Autocuration,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,9527.0
7376,1969.0,,Plasma,Macaca mulatta,,A,,,U,5005,BAO_0000218,CHEMBL621472,22224,,Autocuration,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,9544.0
7377,,,,Cercopithecidae,,A,,,U,17267,BAO_0000218,CHEMBL621473,22224,,Autocuration,Plasma clearance in rhesus monkey was determined,In vivo,9527.0
7378,,,,Cercopithecidae,,A,,,U,6535,BAO_0000218,CHEMBL621474,22224,,Autocuration,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,9527.0
7379,,,,Cercopithecidae,,A,,,U,5922,BAO_0000218,CHEMBL621475,22224,,Autocuration,Plasma clearance in cynomolgus monkey,In vivo,9527.0
7380,,,,Cercopithecidae,,A,,,U,6221,BAO_0000218,CHEMBL621476,22224,,Autocuration,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,9527.0
7381,,,,Cercopithecidae,,A,,,U,5668,BAO_0000218,CHEMBL624290,22224,,Autocuration,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,9527.0
7382,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL624291,22224,,Autocuration,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,9527.0
7383,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL624292,22224,,Autocuration,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,9527.0
7384,,,,Cercopithecidae,,A,,,U,5355,BAO_0000218,CHEMBL624293,22224,,Autocuration,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,9527.0
7385,,,,Cercopithecidae,,A,,,U,4578,BAO_0000218,CHEMBL624294,22224,,Autocuration,Tested for Clearance upon iv administration to african green monkey,In vivo,9527.0
7386,,,,Cercopithecidae,,A,,,U,17592,BAO_0000218,CHEMBL624295,22224,,Autocuration,Clearance in monkey,In vivo,9527.0
7387,,,,Canis lupus familiaris,,A,,,N,6641,BAO_0000218,CHEMBL624296,50588,,Intermediate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
7388,,,,Canis lupus familiaris,,A,,,N,6642,BAO_0000218,CHEMBL624297,50588,,Intermediate,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,9615.0
7389,,,,Canis lupus familiaris,,A,,,N,16367,BAO_0000218,CHEMBL624298,50588,,Intermediate,Half life was evaluated after intravenous administration to dogs,In vivo,9615.0
7390,,,,Canis lupus familiaris,,A,,,N,5472,BAO_0000218,CHEMBL624299,50588,,Intermediate,Half life was evaluated in dog,,9615.0
7391,,,,Canis lupus familiaris,,A,,,N,5474,BAO_0000218,CHEMBL624300,50588,,Intermediate,Half life was evaluated in dog,,9615.0
7392,,,,Canis lupus familiaris,,A,,,N,5654,BAO_0000218,CHEMBL624301,50588,,Intermediate,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,9615.0
7393,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL624302,50588,,Intermediate,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,9615.0
7394,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL876026,50588,,Intermediate,Half life period after intravenous administration in dog,In vivo,9615.0
7395,,,,Canis lupus familiaris,,A,,,N,6221,BAO_0000218,CHEMBL624303,50588,,Intermediate,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,9615.0
7396,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL624304,50588,,Intermediate,Half life period at a dose of 1 uM/kg in dog was determined,,9615.0
7397,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL624305,50588,,Intermediate,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,9615.0
7398,,,,Canis lupus familiaris,,A,,,N,5668,BAO_0000218,CHEMBL624306,50588,,Intermediate,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,9615.0
7399,,,,Canis lupus familiaris,,A,,,N,3854,BAO_0000218,CHEMBL624307,50588,,Intermediate,Half life period was determined,,9615.0
7400,,,,Canis lupus familiaris,,A,,,N,5505,BAO_0000218,CHEMBL624308,50588,,Intermediate,Half life period was determined,,9615.0
7401,,,,Canis lupus familiaris,,A,,,N,6251,BAO_0000218,CHEMBL624309,50588,,Intermediate,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,9615.0
7402,,,,Canis lupus familiaris,,A,,,N,1918,BAO_0000218,CHEMBL624310,50588,,Intermediate,Half life period was evaluated in dog,,9615.0
7403,,,,Canis lupus familiaris,,A,,,N,5546,BAO_0000218,CHEMBL625003,50588,,Intermediate,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,9615.0
7404,,,,Canis lupus familiaris,,A,,,N,4809,BAO_0000218,CHEMBL625004,50588,,Intermediate,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,9615.0
7405,,,,Canis lupus familiaris,,A,,,N,6215,BAO_0000218,CHEMBL625005,50588,,Intermediate,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,9615.0
7406,,,,Canis lupus familiaris,,A,,,N,4527,BAO_0000218,CHEMBL873813,50588,,Intermediate,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,9615.0
7407,,,,Canis lupus familiaris,,A,,,N,17594,BAO_0000218,CHEMBL625006,50588,,Intermediate,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,9615.0
7408,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL625007,50588,,Intermediate,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,9615.0
7409,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL876027,50588,,Intermediate,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,9615.0
7410,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL625008,50588,,Intermediate,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,9615.0
7411,,,,Canis lupus familiaris,,A,,,N,17839,BAO_0000218,CHEMBL625009,50588,,Intermediate,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,9615.0
7412,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,5210,BAO_0000218,CHEMBL625010,50588,,Intermediate,Half-life of compound in plasma of dog was determined,,9615.0
7413,,,,Canis lupus familiaris,,A,,,N,5210,BAO_0000218,CHEMBL625011,50588,,Intermediate,Half-life of compound was determined in dogs,,9615.0
7414,,,,Canis lupus familiaris,,A,,,N,2959,BAO_0000218,CHEMBL621553,50588,,Intermediate,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,9615.0
7415,,,,Canis lupus familiaris,,A,,,N,4137,BAO_0000218,CHEMBL621554,50588,,Intermediate,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,9615.0
7416,,,,Canis lupus familiaris,,A,,,N,5064,BAO_0000218,CHEMBL621555,50588,,Intermediate,Half-life in Dog,,9615.0
7417,,,,Canis lupus familiaris,,A,,,N,5147,BAO_0000218,CHEMBL621556,50588,,Intermediate,Half-life in Dog,,9615.0
7418,,,,Canis lupus familiaris,,A,,,N,5145,BAO_0000218,CHEMBL621557,50588,,Intermediate,Half-life in dog,,9615.0
7419,,,,Canis lupus familiaris,,A,,,N,6123,BAO_0000218,CHEMBL621558,50588,,Intermediate,Half-life in dog after oral administration at 1 mg/kg,In vivo,9615.0
7420,,,,Canis lupus familiaris,,A,,,N,6123,BAO_0000218,CHEMBL621559,50588,,Intermediate,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,9615.0
7421,,,,Canis lupus familiaris,,A,,,N,4333,BAO_0000218,CHEMBL621560,50588,,Intermediate,Half-life in dogs,,9615.0
7422,,,,Canis lupus familiaris,,A,,,N,4333,BAO_0000218,CHEMBL876028,50588,,Intermediate,Half-life in dogs; ND indicates not determined,,9615.0
7423,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL621561,50588,,Intermediate,Half-life in plasma of dog,,9615.0
7424,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,12500,BAO_0000218,CHEMBL621562,50588,,Intermediate,Half-life in plasma of dog at dose of 3-10 mgkg,,9615.0
7425,,,,Canis lupus familiaris,,A,,,N,6005,BAO_0000218,CHEMBL621563,50588,,Intermediate,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,9615.0
7426,,,,Canis lupus familiaris,,A,,,N,6062,BAO_0000218,CHEMBL621564,50588,,Intermediate,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,9615.0
7427,,,,Canis lupus familiaris,,A,,,N,17650,BAO_0000218,CHEMBL621565,50588,,Intermediate,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,9615.0
7428,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621566,50588,,Intermediate,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,9615.0
7429,,,,Canis lupus familiaris,,A,,,N,5530,BAO_0000218,CHEMBL621567,50588,,Intermediate,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,9615.0
7430,,,,Canis lupus familiaris,,A,,,N,5600,BAO_0000218,CHEMBL622978,50588,,Intermediate,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,9615.0
7431,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL873814,50588,,Intermediate,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,9615.0
7432,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL623219,50588,,Intermediate,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,9615.0
7433,,,,Canis lupus familiaris,,A,,,N,6039,BAO_0000218,CHEMBL624477,50588,,Intermediate,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,9615.0
7434,,,,Canis lupus familiaris,,A,,,N,6227,BAO_0000218,CHEMBL624478,50588,,Intermediate,t1/2 in dog,,9615.0
7435,,,,Canis lupus familiaris,,A,,,N,14541,BAO_0000218,CHEMBL624479,50588,,Intermediate,Half-life period measured in dogs,,9615.0
7436,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL624480,50588,,Intermediate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,9615.0
7437,,,,Canis lupus familiaris,,A,,,N,4521,BAO_0000218,CHEMBL623595,50588,,Intermediate,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,9615.0
7438,,,,Canis lupus familiaris,,A,,,N,6679,BAO_0000218,CHEMBL623596,50588,,Intermediate,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,9615.0
7439,1969.0,,Plasma,Canis lupus familiaris,,A,,,N,1116,BAO_0000218,CHEMBL623597,50588,,Intermediate,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,9615.0
7440,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL623598,50588,,Intermediate,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,9615.0
7441,,,,Canis lupus familiaris,,A,,,N,5444,BAO_0000218,CHEMBL623599,50588,,Intermediate,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,9615.0
7442,,,,Canis lupus familiaris,,A,,,N,17853,BAO_0000218,CHEMBL623600,50588,,Intermediate,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,9615.0
7443,,,,Canis lupus familiaris,,A,,,N,4353,BAO_0000218,CHEMBL623601,50588,,Intermediate,Oral bioavailability in dog (dose 5 uM/kg),In vivo,9615.0
7444,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL623602,50588,,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,9615.0
7445,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL623603,50588,,Intermediate,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,9615.0
7446,,,,Canis lupus familiaris,,A,,,N,16452,BAO_0000218,CHEMBL623604,50588,,Intermediate,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,9615.0
7447,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623605,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10090.0
7448,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623606,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7449,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623607,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7450,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623608,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7451,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623609,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7452,2048.0,,Lung,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623610,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7453,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623611,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7454,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623612,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10090.0
7455,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623613,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7456,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623614,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7457,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623615,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7458,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623616,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7459,2385.0,,Muscle tissue,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623617,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7460,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL875944,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7461,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623618,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7462,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623619,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7463,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623620,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7464,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623621,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7465,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623622,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7466,14.0,,Zone of skin,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623623,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7467,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL623624,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7468,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618521,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7469,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618522,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7470,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618523,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7471,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618524,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7472,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL618525,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7473,2106.0,,Spleen,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624586,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7474,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624587,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10090.0
7475,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624588,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10090.0
7476,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624589,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10090.0
7477,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624590,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10090.0
7478,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624591,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10090.0
7479,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624592,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10090.0
7480,945.0,,Stomach,Mus musculus,,A,,,N,10107,BAO_0000218,CHEMBL624593,50594,,Intermediate,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10090.0
7481,,,,Rattus norvegicus,,A,,,N,4689,BAO_0000218,CHEMBL624594,50597,,Intermediate,Oral bioavailability in rat,In vivo,10116.0
7482,,,,Rattus norvegicus,,A,,,N,4950,BAO_0000218,CHEMBL624595,50597,,Intermediate,Tested for the bioavailability in rat,In vivo,10116.0
7483,,,,Rattus norvegicus,,A,,,N,5328,BAO_0000218,CHEMBL624596,50597,,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,10116.0
7484,,,,Rattus norvegicus,,A,,,N,406,BAO_0000218,CHEMBL624597,50597,,Intermediate,Bioavailability in rat,In vivo,10116.0
7485,,,,Rattus norvegicus,,A,,,N,12500,BAO_0000218,CHEMBL624598,50597,,Intermediate,Bioavailability in rat,In vivo,10116.0
7486,,,,Rattus norvegicus,,A,,,N,12500,BAO_0000218,CHEMBL624599,50597,,Intermediate,Bioavailability in rat (dose 3-10 mg/kg),In vivo,10116.0
7487,,,,Rattus norvegicus,,A,,,N,5247,BAO_0000218,CHEMBL875166,50597,,Intermediate,Bioavailability in rat,In vivo,10116.0
7488,1969.0,,Plasma,Rattus norvegicus,,A,,,N,4186,BAO_0000218,CHEMBL624600,50597,,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,10116.0
7489,1969.0,,Plasma,Rattus norvegicus,,A,,,N,4186,BAO_0000218,CHEMBL624601,50597,,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,10116.0
7490,,,,Rattus norvegicus,,A,,,N,6647,BAO_0000218,CHEMBL624602,50597,,Intermediate,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,10116.0
7491,,,,Rattus norvegicus,,A,,,N,6484,BAO_0000218,CHEMBL624603,50597,,Intermediate,Half life was determined,,10116.0
7492,,,,Rattus norvegicus,,A,,,N,3249,BAO_0000218,CHEMBL624604,50597,,Intermediate,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,10116.0
7493,1969.0,,Plasma,Rattus norvegicus,,A,,,N,6281,BAO_0000218,CHEMBL624605,50597,,Intermediate,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,10116.0
7494,,,,Rattus norvegicus,,A,,,N,3307,BAO_0000218,CHEMBL624606,50597,,Intermediate,Half life in rats,,10116.0
7495,178.0,,Blood,Rattus norvegicus,,A,,,N,12058,BAO_0000218,CHEMBL624607,50597,,Intermediate,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,10116.0
7496,,,,Rattus norvegicus,,A,,,N,8833,BAO_0000218,CHEMBL624608,50597,,Intermediate,Hill coefficient of the compound,,10116.0
7497,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624609,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,10116.0
7498,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624610,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,10116.0
7499,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624611,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,10116.0
7500,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624612,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,10116.0
7501,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL875167,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,10116.0
7502,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624613,50597,,Intermediate,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,10116.0
7503,178.0,,Blood,Rattus norvegicus,,A,,,N,3193,BAO_0000218,CHEMBL624614,50597,,Intermediate,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,10116.0
7504,,,,Rattus norvegicus,,A,,,N,5960,BAO_0000218,CHEMBL624392,50597,,Intermediate,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,10116.0
7505,955.0,,Brain,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624393,50597,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7506,955.0,,Brain,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624394,50597,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7507,955.0,,Brain,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624395,50597,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7508,955.0,,Brain,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624396,50597,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7509,955.0,,Brain,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624397,50597,,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7510,2046.0,,Thyroid gland,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624398,50597,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7511,2046.0,,Thyroid gland,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624399,50597,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7512,2046.0,,Thyroid gland,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624400,50597,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7513,2046.0,,Thyroid gland,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624401,50597,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7514,2046.0,,Thyroid gland,Rattus norvegicus,,A,,,N,13950,BAO_0000218,CHEMBL624402,50597,,Intermediate,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,10116.0
7515,178.0,,Blood,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624403,50597,,Intermediate,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,10116.0
7516,178.0,,Blood,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624404,50597,,Intermediate,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,10116.0
7517,178.0,,Blood,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624405,50597,,Intermediate,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,10116.0
7518,10000001.0,,Bone,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624406,50597,,Intermediate,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,10116.0
7519,10000001.0,,Bone,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624407,50597,,Intermediate,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,10116.0
7520,10000001.0,,Bone,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL624408,50597,,Intermediate,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,10116.0
7521,948.0,,Heart,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL618644,50597,,Intermediate,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,10116.0
7522,948.0,,Heart,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL618645,50597,,Intermediate,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,10116.0
7523,948.0,,Heart,Rattus norvegicus,,A,,,N,9866,BAO_0000218,CHEMBL618646,50597,,Intermediate,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,10116.0
